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Purpose of Project: Gut dysfunction in children in resource-poor environments is well 
documented. The precipitant of this dysfunction is unknown. However, infections, nonspecific 
inflammation, malabsorption, and leakiness of mucosa are frequently incriminated as processes 
that underlie this dysfunction. Major consequences of this dysfunction have been postulated, the 
most critical of which is poor growth, especially stunting. The study of gut dysfunction in children 
would have as its ultimate goal the prevention of growth consequences. In this project, we have 
collated literature published between 2000 and 2010, with the purpose of guiding near-term 
research into the causes and pathophysiology of enteric dysfunction. In particular, we have 
attempted to identify biomarkers with which to detect this dysfunction. 
Rationale for seeking biomarkers: Theoretically, tissue from the small bowel, the organ of 
greatest interest, could shed light on the underlying pathophysiology. However, analyzing this 
tissue poses challenges. These challenges include the practicalities of gaining access to this 
organ, incomplete confidence regarding sampling strategies to pursue, risk of sampling error, 
and the yet-to-be-determined value of the information that would be obtained. Thus, the more 
readily obtained and potentially more informative biomarkers found in stool or blood could 
feasibly advance the field.  
Methods: A systematic literature review was performed by trained research analysts, two 
physicians, and two epidemiologists. Materials were collated in a master, highly inclusive 
database of publications relevant to environmental enteric dysfunction (EED) in children in 
resource-poor settings. This process was undertaken for two reasons. First, because search 
terms sensitive and specific for “enteropathy” and “enteric dysfunction” are not well indexed in 
literature databases (including PubMed), we had to create a resource with which to find data 




related to the topic. Development of an internal library was the most efficient preparation for 
multiple interrogations, including those seeking to identify publications relevant to the following 
systematic review question, which is a main focus of this book: 
What biomarkers or diagnostic tests have been used to identify, or have been shown to 
be associated with, mucosal dysfunction of the small intestine or host inflammation in 
children less than five years of age from developing-country settings? 
Findings: 67,903 unique references were obtained from PubMed, Embase, Global Health and 
World Health Organization (WHO) Regional Libraries (1980-2010). 9,675 of these publications 
met EED Library inclusion criteria and 374 between 2000 and 2010 were potentially relevant to 
the systematic review question. Of these, 77 met the review inclusion criteria. 
Each relevant publication was thoroughly and systematically reviewed and summarized in 
evidence table format. Biomarkers were categorized as being relevant to one of eight processes 
that could underlie, be associated with, or reflect enteric function/dysfunction in children: (1) 
absorption; (2) porosity/permeability; (3) digestion; (4) intestinal inflammation and/or intestinal 
immune activation; (5) systemic inflammation and/or systemic immune activation; (6) microbial 
drivers; (7) nonspecific intestinal injury, and (8) non-small intestinal organ function. A meta- 
analysis of pooled data from these publications was not possible because of the heterogeneity 
of study populations and methods, non-standardized information portrayal, scant attempts to 
correlate biomarkers to intestinal pathology (and where this was attempted, correlation was 
lacking), small population sizes, and limited relation of biomarkers with outcomes of interest, 
i.e., stunting. However, the data do strongly suggest the presence of broad categories of 
intestinal dysfunction, and imply a high prevalence of poorly functioning guts, in children in 
resource-poor environments. It is quite likely that a panel of biomarkers reflecting multiple 




Conclusions: Our novel search and EED construction methodology effectively identified a 
diffusely defined and poorly indexed (in the literature)—but nevertheless important—public 
health problem. Our EED Library format permits efficient information retrieval for multiple EED-
related inquiries and the methodology can be applied to other health issues that face similar 
definition and search/retrieval issues.  
Using this comprehensive data collation and extraction system, we found no evidence of a 
globally applicable, simple, single-purpose biomarker that reliably correlates with intestinal 
dysfunction in children or to growth faltering mediated by such a lesion. The studies that are 
available were often not performed with this goal in mind. However, there is a large body of 
evidence that enteric dysfunction in children is highly prevalent in resource-poor settings, and 
that this dysfunction could be an important, and potentially remediable, cause of stunting. 
Therefore, we urge that future research on biomarkers in human populations be pursued. We 
also urge that future work adheres to the following principles: 
1. Assess function-related candidate biomarkers. 
2. Relate the biomarker data to consequential outcomes. 
3. Rigorously describe the study design and methodology underlying the data produced. 
4. Provide robust data repositories. Employ best practices publication guidelines, such as 
those endorsed by the Consolidated Standards of Reporting Trials (CONSORT) system 
including the Standards for Reporting of Diagnostic Accuracy (STARD) Initiative. 
5. Consider indices of enteric dysfunction, incorporating “stacking” multiple biomarkers 
representing diverse pathophysiologic processes, potentially also including non-
laboratory test derived clinical characteristics. 
6. Explore invasive, field-adaptable, host assessments (e.g., saliva, transcutaneous), even 
if technology needs to be developed or adapted. 
Chapter 1. Environmental Enteric 
Dysfunction (EED) Background 
1.1 EED History and Overview 
For many years it has been known that the digestive system, and in particular the small 
bowel, of people who reside in poor regions do not function well. The first English language 
description of this disorder was written by William Hillary in the mid-1700s. His case series of 
malabsorption in European expatriates in Barbados [2] (reviewed by Booth [3]) also reported 
glossitis (most likely caused by concomitant folate deficiency) and diarrhea. Over a century 
later, Patrick Manson re-described this disorder, again focusing on expatriates in the Dutch 
West Indies, and used the term tropical “Sprouw,” from a Dutch word describing what was 
almost certainly celiac disease (gluten-sensitive enteropathy) in Europe [4]. The onset of this 
malady in previously healthy Europeans residing in the tropics, and reports of epidemic 
malabsorption in Allied troops in Southern Asia during the Second World War [5, 6], gave rise to 
the concept of gut lesions caused by “environmental” factors. Therefore, this enteropathy was 
modeled as an acquired, likely infectious, problem [7]. This acquired/environmental concept was 
reinforced by secular variances in the incidence of tropical malabsorption syndromes, 
alternately referred to as tropical enteropathy (TE), in areas previously endemic for this disorder 
[8, 9]. 
The early descriptions of tropical enteropathy did not define the true extent of the 
problem. Most notably, these initial reports focused on adults. The realization that children were 
affected by what was probably the same disorder was delayed. Second, while various causes of 
this intestinal dysfunction have been postulated, the definitive cause or causes remain(s) 
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elusive. Indeed, interest and investigation into the problem itself waxes and wanes with 
discoveries of new enteric pathogens. This has implications for our systematic review of the 
problem. For example, giardiasis would be a lead candidate as a cause of tropical enteropathy 
in view of the chronicity of the illnesses it can cause, and the ability of Giardia to injure the 
mucosa of the small bowel. However, Giardia lamblia was not widely accepted as a human 
pathogen until the 1970s. Hence, prior investigations would have discounted this agent as being 
a cause of enteropathy. Third, there have been regional differences in the reported incidence of 
tropical enteropathy. Early communications suggested that individuals in Africa were seemingly 
less affected than were individuals in other areas, and that many cases of adult malabsorption 
were attributed to biliary and pancreatic disorders [10]. However, more recent reports suggest 
that Africans are, indeed, susceptible to tropical enteropathy [11-15]. Also, diagnosis in early 
studies was made by varying methodologies, including those based on response to empiric 
treatments (antibiotics, antiparasitics, micronutrients) and repatriation to countries in which 
tropical enteropathy is not endemic; it is often unclear from which intervention(s) responders 
benefitted. Finally, enteric dysfunction in resource-poor settings has often eluded, and continues 
to elude, useful definition. Instead, we are forced to rely on histopathologic findings from the 
small bowel, and these findings are variably specific. These abnormalities include villous 
blunting, increased crypt:villous ratios, and presence of intraepithelial lymphocytes (IEL). 
However, the reliance on biopsies skews disease detection and data acquisition towards adults 
who more frequently undergo invasive testing [16]. These definitional issues continue to hinder 
advancement in the field, and to impose challenges in identifying useful biomarkers. 
The nomenclature used to describe the entity of interest has shifted in response to 
ongoing efforts to better understand and describe the disease. As early as 1984, the term 
“environmental enteropathy” was used synonymously with “tropical enteropathy” [17], although 
not commonly until 2004 [18]. Most recently, "environmental enteric dysfunction" (EED) has 
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been suggested as nomenclature for the entity of interest [16]. We adopt this term in this book 
as it provides specificity with regards to the origin of intestinal dysfunction (i.e., environmental 
opposed to genetic or other factors) and focuses on functional alterations of consequence [19]. 
The term EED refers to functional shortcomings of the gut with and/or without histological 
correlates, and obviates the need to rely on the histology inferred by the term “enteropathy"1. 
We acknowledge that EED might differ in disease burden, etiology, and effects in children and 
adults in different regions. However, independent of case definition or underlying criteria, 
suboptimal intestinal function in children in resource-poor environments is common, and it is 
important to determine its true incidence, spectrum of host injury, mechanisms of 
pathophysiology, diagnostic ascertainment, clinical consequences, and mitigation via 
interventions whether prevention or treatment. Therefore, it is now time to measure the extent of 
this dysfunction and its consequences. To do so, we need to consider the technology that will 
be required to investigate the problem. 
1.2 An Old Problem Requiring New Knowledge 
There is a compelling need for research on enteric dysfunction in children in resource-
poor environments, but scientific advancement in the field has been, in fact, quite modest. The 
Web of Science (formerly ISI Web of Knowledge) demonstrates a paucity of publications related 
to EED (Figure 1).  
                                                     
1 Strictly speaking, the “-pathy” suffix is from the Greek word for disease or suffering, but in many 
connotations refers to histopathologically defined disorders. 
3
Figure 1. List of plausibly relevant literature from 1980 to 2010. 
A search of Thomson Reuters Web of Science™ ALL Databases Collection1 on 27 August 
2014, spanning 1980-2010 and using any of the following search terms: "tropical enteropathy", 
"environmental enteropathy", "tropical sprue", "environmental enteric dysfunction", "tropical 
malabsorption syndrome", or "tropical malabsorption." Topic was used for the query, with the 
phrase enclosed in quotation marks. Search filters for language or document type were not 
applied. 
 
The lack of progress on EED contrasts with recent dramatic advances in mortality 
reduction caused by acute enteric infections. The annual number of deaths attributed to 
diarrhea among children under five years of age fell from an estimated 4.6 million in 1980 [20] to 
about 700,000 in 2011 [21]. Most of the mortality reduction in the latter two decades of the past 
century was likely a result of refinements in, and/or increased use of, oral rehydration 
                                                     
1 Searches were conducted using the Thomson Reuters Web of Science™ ALL Databases Collection and 
reflect only the data as indexed by the database. Publication data may be incomplete. The Thomson 
Reuters Web of Science™ ALL Databases Collection consisted of Inspec® (1898-present), MEDLINE® 
(1950-present), SciELO Citation Index (1997-present), Science Citation Index Expanded (1970-present), 




















therapy(ORT) [22, 23]. Globally, current ORT coverage rates are moderate and have stabilized 
over the past decade [24]; more recent reductions in diarrhea-related mortality likely stem from 
general improvements in socioeconomic development, nutrition, and water/sanitation 
infrastructure [25]. Coverage rates for access to improved water sources, particularly in urban 
settings, are on track to meet international development goals [26]. However, access to 
adequate quantities of water, water of sufficient quality for drinking, and improved sanitation 
facilities are limited and only slowly improving [26-28]; the same lack of progress applies to 
hand hygiene prevalences [29]. Improved water sources, sanitation, and hygiene can avert 58% 
of childhood diarrhea-related deaths in low- and middle-income countries [27]. A 34% reduction 
in risk of diarrheal disease has been demonstrated with interventions to improve water quality, 
and a 28% reduction in diarrheal disease has been observed with improvements in sanitation, 
particularly sewer interventions [30]. Promotion of hand hygiene with soap is estimated to 
contribute to a 23% reduction in diarrheal disease risk [29]. 
Treatment with zinc can reduce the duration and severity of acute episodes of diarrhea 
and reduce the risk of future episodes [31-33]. Since 2004, zinc has been a recommended 
therapeutic for children suffering from diarrheal episodes in resource-limited settings. Safe and 
effective rotavirus vaccines are now available and recommended for widespread use [34-36]. 
Coverage rates for these relatively “new” interventions are low, but their implementation is 
accelerating. Major advances might also be on the horizon in the form of effective cholera, 
typhoid, Shigella, and enterotoxigenic Escherichia coli (ETEC) vaccines [37-39]. 
Despite reductions in mortality risk associated with acute diarrhea, enteric infections 
remain prevalent. Over 1.7 billion episodes of diarrhea occur among children under five years of 
age each year [21] and incidence rates have not changed markedly in the past several decades 
[40]. Repeated episodes of infection in the developing gut are probably deleterious [41]. 
Expanded implementation of prevention and treatment measures could further diminish diarrhea 
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mortality and could additionally reduce morbidity and disease burden. However, these advances 
against acute enteric infections now raise the relative importance of chronic intestinal 
dysfunction as a hindrance to optimal childhood health [42]. 
However, this problem is much more complex: emphasis on acute enteric infection fails 
to address the consequences of recurrent, persistent, and chronic diarrhea, as well as the long-
term consequences of diarrhea on stunting and on disability-adjusted life years. Also, a new 
variety of agents, in particular enteroaggregative Escherichia coli, and Cryptosporidia spp., 
which each require special technologies to identify, have recently and repeatedly been 
associated with persistent diarrhea and stunting. Additionally, several epidemiologic studies 
suggested that the frequency of episodes of acute diarrhea impairs long-term health in 
populations outside Brazil [18, 43, 44]. In view of the successes of oral rehydration and the 
rotavirus vaccine, it was reasonable to assume that the problem of enteric infections in children 
would be solved. Moreover, simple infrastructural management strategies, particularly the 
provision of appropriate village waste containment facilities [45] were determined to be 
important protective measures against chronic diarrhea. We now recognize that enteric 
inflammation is a determinant of stunting and long-term gastrointestinal dysfunction, even 
independent of the presence of the more easily enumerable episodes of diarrhea [45]. 
The renewed interest in EED is aptly timed for many different reasons. As noted above, 
we are in an era in which we know how to treat and prevent acute diarrhea. Therefore, chronic 
intestinal injury and inflammation now pose larger proportional threats to population and 
childhood well-being. Also, translational research has created new proteomic, metabolomic, and 
genomic technology with which to study human pathophysiology. The value of re-examining and 
expanding diagnostic capabilities is two-fold. First, such efforts will shed light on incidence rates 
within communities and assess factors associated with differences in disease rates in various 
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populations. Second, such tools might accurately identify children at risk of developing EED, 
who have EED (at its various clinical stages), and as a way to monitor treatment for EED.  
We recognize that other priorities compete with EED for resources in the field of child 
health. First, there is the imperative to continue to reduce mortality from acute diarrhea. Indeed, 
the Child Health and Nutrition Research Initiative of the Global Forum for Health Research 
methodology de-emphasized research on chronic enteric conditions in favor of implementing 
available strategies to continue to reduce acute childhood diarrhea mortality [46, 47]. That 
analysis was weighted towards interventions that could be implemented by 2015 to meet 
Millennium Development Goals. EED intervention studies require longer investigation periods 
than do disorders with known etiologies and outcomes that are apparent in the short term. For 
example, the pathophysiology of EED is not well understood, technologies sufficient to assess 
the process in individual hosts or within populations are not broadly available, and interventions 
to mitigate consequences of clinical importance are not yet established. Work to understand and 
control EED should be viewed as complementing, rather than competing with, continued efforts 
to reduce the burden of acute enteric illnesses. It was with this concept in mind that we 
embarked on our review of the EED literature, with a goal of providing a platform on which 
future EED efforts, especially those related to biomarkers and diagnostics, could be built.  
1.3 Pathophysiologic Processes and Consequences 
of EED 
The gut is an organ that is central to health and development. Healthy intestinal 
functioning optimizes childhood physical and intellectual well-being and development, and 
enables children to achieve adult stature. Several lines of evidence indicate that suboptimal 
functioning of the human gut, manifesting as EED, leads to poor health for children in resource-
poor settings. First, investigators in Fortaleza, Brazil have demonstrated that episodes of 
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recurrent or persistent diarrhea are major determinants of childhood growth impairment [48], 
and subsequent reduced growth and intellectual capacity at school entrance [49, 50]. These 
investigations were seminal because they provided a new metric for calculating the burden of 
enteric-related disease other than counting deaths or numbers of episodes of loose stools. This 
is also important because stunting can be associated with subclinical intestinal inflammation [15, 
51]. 
Multiple aspects of intestinal pathophysiology contribute to poor health, growth and 
development (Figure 2) and physiologic derangements in these processes are deleterious 
(Figure 3). First, injured intestinal mucosa absorbs nutrients poorly [52] and represents one 
potential EED-mediated growth-failure pathway [15, 53]. Chronic intestinal inflammation is very 
common in the tropics [54] and can damage intestinal epithelial integrity and disrupt tight 
junctions, resulting in intestinal permeability defects. Multiple studies demonstrate increased 
intestinal porosity in children in the tropics [15, 44, 55-58]. Increased intestinal permeability can, 
in turn, lead to translocation or the nonphysiologic uptake of intestinal luminal contents, 
including microbes and microbial products, into the bloodstream [59]. Microbial translocation 
can, in turn, mediate systemic inflammation as can chronic intestinal inflammation. Stunting is 
often associated with subclinical intestinal inflammation [15, 51]. Systemic inflammation can 
penalize growth by interrupting bone growth potential, release of growth hormone binding 
proteins at the level of the liver [60], suppressing appetite, and increasing metabolic 
requirements [61]. Such mechanistic attribution remains hypothetical at this juncture. 
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Figure 2. The vicious cycle of intestinal dysfunction, infectious disease susceptibility, 
poor growth, and development. 
NCDs= non-communicable diseases. WaSH=water, sanitation and hygiene. EED= 
environmental enteric dysfunction.  
 
Adapted from Denno DM [62], Guerrant RL, et al. [63] and Mata L [64].   
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Figure 3. EED-related pathophysiological processes result in stunting and/or growth 
shortfall. 
Growth can be affected by disturbances in a variety of intestinal and other physiologic 
processes resulting from EED. GH=growth hormone. 
 
 
The first several years of childhood represent a critical period that influences life-long 
nutritional and health status and human potential [65]. Stunting is an especially important cause 
of adverse consequences in resource-poor regions, and stunting that occurs in the first two 
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years of life is particularly consequential [48, 66-72]. Childhood stunting is associated with 
cognitive impairment, poor school performance, and reduced adult capacity [73-76]. Clinical 
complications of childhood stunting also include predisposition to obesity and diabetes and 
other chronic diseases in later adulthood—a double burden increasingly afflicting populations in 
resource-limited settings [65]. Moreover, undernutrition contributes to over one-third of 
childhood deaths [77]. 
Poor nutrition among girls can have a particularly profound effect on future reproductive 
and fetal/neonatal health. For example, maternal stunting can be a risk factor for obstructed 
labor, stillbirth, and neonatal mortality [78]. Furthermore, maternal anthropometry also 
influences future generational growth, morbidity and mortality [79].  
Dysfunctional guts can hinder the efficacy of oral vaccinations and absorption of 
medications. This may pose a threat to oral enteric vaccine strategies and absorption of 
medications for chronic infections such as tuberculosis and HIV/AIDS [80]. Indeed, failure of oral 
polio vaccine to induce protective immunity in children at risk is a major challenge to disease 
eradication [81].  
Increasing dietary nutrient provision does not necessarily or completely resolve growth 
failure in resource-poor settings [82]. Gut function is an important antecedent to healthy human 
growth and development. Strategies are needed to ascertain gut inflammation, increased 
permeability, and decreased absorption. Strategies are also needed to measure and address 
the persistence, progression, and resolution of these types of dysfunction. Chronic intestinal 
inflammation and inability to absorb nutrients may be the most actionable manifestations of 
enteric dysfunction in children. Intervention studies to mitigate EED will require appropriate, 
robust and reproducible methods to identify children with intestinal dysfunction, ideally before 
penalties to growth and development accrue.  
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A coordinated effort to control EED in children in resource-poor regions could markedly 
reduce childhood undernutrition, poor development, and mortality. In the past decade, we have 
seen an explosion in our understanding and abilities to diagnose an analogous disorder, i.e., 
celiac disease, which has histopathologic similarities to EED. We have learned the genetic and 
environmental, i.e., dietary, risk factors for celiac disease, and also determined that this disorder 
is not confined to individuals of northern European ancestry, as previously thought. 
Furthermore, the diagnosis and management of celiac disease, including partial mitigation of 
growth consequences, has advanced, at least in high-income countries. Similar data are 
emerging regarding the more challenging disorders of inflammatory bowel disease, i.e., Crohn’s 
disease and ulcerative colitis [83]. We can apply lessons learned from these chronic intestinal 
inflammatory states to the study of EED.  
There is reason to be optimistic about renewed research and development relevant to 
EED. Emerging technologies can interrogate human processes and microbial populations to an 
extent not predicted even a few years ago. These technologies can shed new light on EED, an 
entity that has traditionally required tissue for diagnosis. 
1.4 The Role of Biomarkers and Diagnostics in EED 
Much as pioneering studies on mechanisms of intestinal secretion in cholera [84] formed 
the basis for giving oral rehydration solution to children with diarrhea worldwide, it is critical to 
identify the mechanisms underlying intestinal dysfunction in children in resource-poor areas. 
Beyond searches for specific etiologic pathogens or nutritional deficiencies, biomarkers and 
diagnostics will need to be broadly considered in favor of pursuing a better understanding of 
EED as a disorder. “Discovery” efforts will be needed to generate sufficient information to move 
forward.  
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Broad-based research is urgently needed to invigorate the field. For example, multi-
dimensional assessments of individuals and populations will be necessary to measure intestinal 
dysfunction, and identify factors that precipitate and perpetuate EED. We believe that the utility 
of biomarkers in EED needs to extend beyond the concept of diagnostics. Diagnostics, as most 
commonly used to assess the human gut, usually seek specific pathogens, or belong to a 
limited panel of tests of gut inflammation and/or absorptive function. It is likely that rigorous and 
systematic analyses of EED require a better understanding of the microbial population in the gut 
and detailed assessments of intestinal inflammation, absorption, permeability, translocation, and 
subsequent systemic inflammatory cascade as well as the precipitants and consequences of 
EED, such as nutrient deficiencies. As such, we sought to systematically search, review and 
portray the existing diagnostics/biomarkers literature related to EED as a basis of knowledge to 
leverage further investigation. 
1.5 Scientific Basis for this Review 
In view of increasing understanding of the role of gut health and function in promoting 
overall health and development in childhood and beyond, it is logical to catalyze efforts to 
accurately identify and predict children with EED and to refine the sensitivity and specificity of 
promising biomarkers. While a single marker with optimal operating characteristics would be a 
welcome tool, it is unlikely that a single test can be used worldwide to detect and predict EED 
with the necessary precision. A panel of tests, perhaps in conjunction with clinical 
characteristics, may be necessary, akin to the Jones criteria used to diagnose acute rheumatic 
fever.  
Currently, there is no consensus on the best way to measure intestinal function either 
invasively or noninvasively. Additionally, there is no evidence that the entities of interest, i.e., 
intestinal inflammation and/or poor function associated with stunting, are caused by a single 
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etiology or that a common pathogenesis underlies all cases. Also, we do not know if intestinal 
inflammation precedes growth failure, if the disorder might actually begin in utero, or if any 
therapies can reliably and uniformly restore linear growth. Nonetheless, there is now consensus 
that stunted children are not only at risk for unhealthy consequences during childhood, they are 
more likely than their non-stunted peers to develop chronic disorders that extend into adulthood, 
including obesity, type II diabetes, and hypertension [85, 86]. Clearly there is a need to reassess 
whether existing markers of intestinal dysfunction can better define the disorder of interest, and 
anticipate its development in children. We therefore attempted to first identify the current state of 
the knowledge, then delineate gaps in that knowledge, and, finally, sought to determine which 
tests might have the most utility. 
Table 1. Spectrum of etiologies, outcomes, and biomarkers/diagnostics in EED. 
These lists of causes, results, and techniques to identify EED were used to define manuscripts 
of potential interest in the list generated by the search terms. 
Potential drivers (causes) of EED Pathogens, food insecurity, immune activation, specific 
nutrient deficiencies, environmental hygiene 
Potential consequences of EED Recurrent diarrhea, persistent diarrhea, intestinal 
inflammation with and without diarrhea, stunting 
Possible biomarkers/diagnostics of 
EED 
Biopsies, sugar clearance tests (measuring absorption 
and permeability of the gut), breath hydrogen tests, 
nutrient challenge tests, fecal analyses for leakage or 
non-absorption, serologic analyses for inflammation or 
evidence of gut permeability 
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Chapter 2. Methodology: Building the EED 
Library and Undertaking a Systematic 
Review of EED Biomarkers/Diagnostics 
2.1 EED: A Broad Field, Many Unanswered 
Questions 
First, in collaboration with experts in the field, we developed a set of questions that 
would be of primary importance to better understand and control EED. The scope was broad 
and included environmental, nutritional, and other factors that might underlie EED, as well as 
information related to EED pathogenesis. We framed these questions within six “topic areas” 
(Table 2). We used these questions to guide our systematic literature search, seeking to identify 
all references that could contribute to answering them. Prior to searching the literature for 
relevant EED references, a search of the Cochrane Database of Systematic Reviews found no 
Cochrane Reviews related to EED.  
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Table 2. Topic areas and questions. 
The left column lists inclusive but circumscribed areas of relevance to EED, and the right 
column presents questions relevant to each topic area. These formed the basis for the literature 
search terms (Appendix 1). 
Topic area Questions 
I. Epidemiology 
of EED 
What is the burden of disease represented by EED? 
 
What is the prevalence of EED (including as measured by tests of gut 
dysfunction or inflammation)? 
 
1. What proportion of stunted/malnourished children have EED (as 
measured by gut dysfunction/inflammation or infection with specific 











of acquisition of 
EED, 
malnutrition 
What exposures/variables are associated with EED (including as measured 
by tests of gut dysfunction or inflammation) or malnutrition/stunting? What 
are the effect sizes (e.g., relative risk (RR), odd ratio (OR)) of the 
associations? What are the causal pathways/mechanisms? Exclude 
exposures related to food security/caloric density. Include:  
 
3. Is infection with specific enteric pathogens (e.g., subsets of 
diarrheagenic E. coli, Cryptosporidium, Giardia) associated with EED 
or malnutrition/stunting? 
4. Are recurrent acute enteric infections/recurrent episodes of diarrhea 
associated with EED or malnutrition/stunting? 
5. Are persistent or chronic enteric infections/persistent diarrheal 
episodes associated with EED or malnutrition/stunting? 
6. Is exposure to/ingestion of fecal microbial populations (e.g., in 
settings with lack of access to improved sanitation) associated with 
EED or malnutrition/stunting? 
7. Are other diseases/conditions including infections not predominantly 
enteric in origin/manifestation (e.g., HIV, tuberculosis, malaria) 
associated with EED or malnutrition/stunting? 
8. Are environmental (e.g., water, sanitation, hygiene) factors 
associated with EED or malnutrition/stunting?  
9. Are social (e.g., socioeconomic status (SES), household 
characteristics) or geographic (e.g., rural/urban) factors associated 
with EED or malnutrition/stunting?  
10. Are genetic factors associated with EED or malnutrition/stunting? 
11. Are specific foods or nutrients (e.g., micronutrients (MNs), lack of 
specific foods or nutrients, or specific feeding practices associated 
with EED or malnutrition/stunting? 
12. Are maternal factors (e.g., anemia in pregnancy, maternal short 
stature) associated with EED or malnutrition/stunting? 
13. Is low birth weight (LBW) or small for gestational age (SGA) 
associated with EED or malnutrition/stunting? 
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Topic area Questions 
14. Are microbially contaminated foods/lack of food safety or 
contaminated bottles, feeding utensils, etc. associated with EED or 
malnutrition/stunting? 
15. Is malnutrition a risk factor for EED? 
16. Other 





with, risk factor 





What outcomes are associated with EED (including as measured by gut 
dysfunction or inflammation or infection with specific microbes or identifiable 
microbial populations)?  
 
17. Is EED a risk factor for malnutrition/stunting? 
18. Is EED a risk factor for MN deficiencies—either multiple deficiencies 
or isolated deficiencies (including zinc, vitamin A, iron, vitamin D, 
folate, vitamin B12)?  
19. Is EED a risk factor for overnutrition (including overweight and 
obesity), especially later in childhood/adulthood? 
20. Is EED a risk factor for subsequent enteric infections/diarrheal illness, 
either in general or as caused by specific pathogens? 
21. Is EED a risk factor for decreased oral vaccine efficacy or oral drug 
efficacy? 









24. What diagnostic tools or biomarkers are available to assess for EED 
or malnutrition1? What biomarkers are manifest during the EED 
clinical state that could be utilized to develop a diagnostic test? 
Subquestions:  
24a. How sensitive and specific is the test/biomarker in identifying the 
child with EED compared to villous blunting with crypt hyperplasia on 
histologic examination of small bowel biopsy intestinal biopsy? In the 
absence of comparison to histology, how does the test/marker 
compare to other diagnostic tests of gut function/dysfunction 
including permeability, inflammation, or nutrient uptake? 
 
24b. Does the marker or diagnostic allow grading of disease severity 
or gut dysfunction? 
 
24c. Is the diagnostic or biomarker field-friendly? 
 
24d. What are the costs associated with the diagnostic/marker? 
25. Other 
V. EED Clinical 
course, patho-
physiology 
26. What is the clinical course of EED (e.g., clinical symptoms, signs and 
laboratory findings)? What are the underlying mechanisms/pathways 
of these clinical changes? 
27. What nutritional changes/abnormalities occur in EED including 
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Topic area Questions 
energy metabolism, MN uptake, bioavailability and metabolism? 








What interventions can prevent, treat or mitigate EED (including as 
measured by tests of gut dysfunction or inflammation) or 
stunting/malnutrition? What is the effect2 of interventions in reducing 
prevalence of EED or malnutrition among children (compared to no 
intervention or placebo intervention)? What is the effect of interventions on 
treating or mitigating the impact of EED (outcomes could include diminished 
gut inflammation, diminished microbial content in host guts, improved gut 
function) or stunting/malnutrition (outcomes could include improved linear 
growth or weight gain) among individual children? For each treatment 
intervention identified, what is the effect in impacting outcomes compared to 
no intervention or placebo intervention3? 
 
Exclude interventions related to increased calorie intake or food security. 
Interventions include: 
 
Population-based interventions among asymptomatic children in 
developing-country settings: 
 
30. Zinc, vitamin A, folic acid, vitamin B12 supplementation or 
fortification4 (or supplementation or fortification with other MNs or with 
multiple MNs) 
31. Interventions related to breastfeeding 
32. Nutritional interventions such as introduction of or increased 
consumption of certain foods, including weaning or complementary 
foods 
33. Feeding practices (e.g., responsive feeding practices among 
caretakers) 
34. Improved food safety (e.g., boiling eating utensils, improved food 
storage and reheating) 
35. Improved water, sanitation, hygiene 
36. Prebiotics, probiotics 
37. Maternal interventions (e.g., prenatal iron/folate supplements in 
pregnancy and examination of impact on EED or malnutrition in 
offspring) 
38. Health services interventions (e.g., implementation of growth 
monitoring programs, cash transfers in return for care-seeking) 
39. Other 
Interventions to prevent EED implemented among children in 
developing-country settings with specific symptoms (e.g., diarrhea): 
 
40. Zinc, vitamin A, folic acid, vitamin B12, or other MNs (e.g., for 
treatment of diarrhea) 
41. Prebiotics, probiotics (e.g., for treatment diarrhea) 
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Topic area Questions 
42. Management/treatment of other conditions (e.g., antitubercular 
agents, tuberculosis, antiretrovirals for HIV, antimalarials to treat 
malaria infections, intermittent preventive treatment of malaria)  
43. Other 
Among children identified/diagnosed as having EED or malnutrition: 
44. Treatment with specific MNs including: iron, zinc, vitamin A, vitamin 
D, folic acid, vitamin B12 
45. Treatment with multiple MN preparations (e.g., Sprinkles) 
46. Treatment with antibiotics 
47. Treatment with probiotics 
48. Nutritional interventions such as introduction or increased 
consumption of specific foods; ready-to-use therapeutic or 
supplementary foods; related nutritional therapeutics 
49. Feeding practices (e.g., responsive feeding practices among 
caretakers) 
50. Other 
1 Not including measures of physical growth (e.g., height, weight, mid upper arm circumference), indices 
calculated from measures of physical growth (e.g., body surface area), or use of growth charts or growth 
standards. 
2 Including any potential harms identified with the intervention. Furthermore, cost information should be 
captured where available. 
3 Where possible, also identify the best stage in the EED clinical spectrum in which to intervene and at 
which stage does therapeutic effect have the greatest impact on outcomes compared to other stages?  
4 Supplementation defined as administration of MNs to a population subgroup based on age or other life 
cycle factors. E.g., prenatal vitamins, giving 6-36 month-olds vitamin A capsule every six months. 
Fortification defined as adding MNs to food staples such as the addition of folate to flour. 
 
A “wide-net” broadly inclusive systematic search strategy was considered necessary at 
project inception in order to capture sufficient references of relevance for four reasons: (1) a 
wide scope and breadth of questions were deemed of interest for potential systematic 
investigation; (2) we believed that there would likely be modified or derivative questions after the 
initial review was performed; (3) EED has a broad, indistinct, and historically variable definition; 
and (4) specific search terms for EED, ED or even enteropathy do not exist in the medical and 
health databases. Because the effort involved in searching for articles solely related to one EED 
systematic review question would only be marginally more compared to searching more broadly 
for articles to address a wide range of EED-related questions, we opted for an infrastructure that 
could produce a systematic review product efficiently and expediently. 
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2.2 Constructing a Systematic Search Strategy: 
Optimizing Sensitivity 
We devised a systematic and comprehensive search, extraction, and analysis strategy. 
Our overall procedure is depicted in Figure 4. We now describe the process components. 
The first step was the construction of a comprehensive, systematic search strategy. We 
developed individual search strategies for each database with the assistance of a research 
librarian at the World Health Organization in Geneva. We devised a two-step search strategy 
that was extensive due to the broadly defined nature of EED and the lack of robust indexing of 
search terms across databases (as described above) (Appendix 1). In the first step, we used 
broad terms to capture all references related to EED, including similar or identical disorders 
(‘tropical enteropathy’, ‘environmental enteropathy’, ‘tropical sprue’, ‘tropical malabsorption 
syndrome’, and ‘malabsorption’, ’enteropathy’, or ‘intestinal dysfunction’ in the tropics). At first 
pass, we included any age group and any setting (e.g., returned travelers), because these 
publications could conceivably contain data that provide some understanding of aspects of 
EED. We were also interested in other enteropathies among children under five years of age 
in developing countries, such as celiac disease or Crohn’s disease, because these disorders 
might have been misdiagnosed EED, or because tests employed could be relevant to EED in 
children at risk in resource-poor areas of the world.  
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Figure 4. EED systematic review processes flow chart. 
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As the second step, we identified references about malnutrition or nutritional status (as 
measured by anthropometrics) among children under five years of age in developing countries. 
The goal was to identify scenarios where EED is an intermediary: nutritional status as an 
outcome of enteric dysfunction, biochemical or radiologic biomarkers/diagnostics of nutritional 
status, or interventions to prevent or treat malnutrition. For nutritional outcomes, we limited our 
search to effects on anthropometric indices (e.g., height-for-age, weight-for-age, weight-for-
height, mid-upper arm circumference, and growth velocity). We excluded articles strictly about 
prevalence or incidence of malnutrition (i.e., containing no information about risk factors 
associated with nutritional status), articles about non-EED outcomes of malnutrition/nutritional 
status, and articles examining the utility of anthropometric measures. 
Next, we constructed search strategies to query the most relevant medical and health 
databases: PubMed (http://www.ncbi.nlm.nih.gov/pubmed/), Embase 
(http://www.embase.com/), Global Health (database published by Centre for Agriculture and 
Biosciences International (CABI)), and the WHO regional databases. We included Global Health 
and the WHO databases because of their higher proportions of articles from resource-poor 
regions, which are often not published in journals that are indexed in PubMed and Embase. 
Additionally, the WHO regional databases contain much “gray” literature from government and 
nongovernmental organizations that could have been of relevance.  
To ensure that our search adequately identified relevant references, we developed a test 
set of references obtained by identifying 20 key EED references in collaboration with two 
external advisors with content expertise (Appendix 2). 
We sought to retain as many relevant references in our search results as possible, while 
minimizing extraneous and irrelevant information. To maintain specificity, we filtered the 
references for data from developing countries, tropical settings, or indigenous populations. 
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However, universal use of this filter resulted in test EED references being missed. We were, 
however, able to use the filter on the malnutrition search strategy without losing relevant 
articles. We were able to apply another filter to restrict malnutrition articles to those related to 
children. We did not restrict language or year of publication. After these modifications to our 
search strategy, 18 of the 20 test references were captured. To detect the remaining two 
articles, we would have needed to use a strategy that yielded a ten-fold increase in the number 
of articles returned in the search. On further scrutiny, this problem was caused by a lack of 
sensitive index terms for one article [87] and lack of child terms for the other [57] (Appendix 2). 
We accepted this compromise, recognizing that the “snowball” technique (described below) 
would increase our search sensitivity.  
With our approach, we were able to interrogate the literature on a topic that is both 
poorly defined and poorly indexed. Our comprehensive, rigorously evaluated, and reproducible 
methodology can be utilized as a systematic search model approach for other topics that are 
similarly broad and/or diffusely defined or cataloged, for which standard systematic search 
techniques would be insufficient and imprecise.  
2.3 Reference Volume Mitigation  
The systematic search, completed June 2010, identified a total of 85,334 references 
(after identifying and removing references that were duplicated within the four databases that 
were searched), dating back to 1910 (discussed further in Results section). This overwhelming 
volume of potentially relevant literature was unexpected, and we briefly considered using only 
references from recent review articles on the topic. This was not possible, however, because no 
previous systematic reviews had been published with which to identify biomarkers that could be 
used to prevent and treat, or to guide rehabilitation from, intestinal dysfunction in children in 
resource-limited countries. Some reviews [8, 45, 88-93] either focused on adults or on narrow 
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components of the problems, and not diagnostic strategies. Hence, this “look back” literature 
review strategy would not have yielded the information we were seeking.  
We next considered two options relevant to processing the ca. 85,000 titles. The first 
option was to scrutinize this very long list with only one or two questions in mind, and vote on 
each as presumptive “include” or “exclude” related only to the limited inquiry, and ignore all 
irrelevant topic areas and corresponding questions (“limited-use scrutiny”). The second option 
was to build an EED Library with references with notation of its relevance to any of the potential 
topic area(s) and questions (“future use scrutiny”). The third option was to scrutinize each 
reference, and then note the relevance only at the topic level, and not identify the specific 
questions that each reference might address. Table 3 summarizes the advantages and 
disadvantages of each approach. 
After careful consideration, we decided to use a “modified future use” approach, i.e., 
examine each reference for its relevance to each of the six target areas, but not drill down to the 
question level. However, we left questions available to the analysts as guides to the potential 
utility of each document. We recognized that this approach entailed more analyst labor, i.e., 
approximately 200 additional person hours (assuming two readings of each listing) compared to 
the first strategy in Table 3 (these estimates are limited to the review of the reference lists). 
However, the hours of effort per question potentially answered would be considerably fewer, 
when considering that the comprehensive scoring would encompass topic areas that include a 
total of 49 potentially useful questions.  
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Table 3. Summary of analysis options. 
Advantages and disadvantages of comprehensive versus targeted analysis of literature 
produced by search terms are portrayed.  
2.4 Building the EED Library  
The initial list of approximately 85,000 references from the processes described above 
contained the following information from the databases searched: title, authors, journal, and to 
varying extents, abstracts. We exported the references from PubMed, EMBASE and Global 
Health into EndNote software (ca. 81,000); this was not possible with the references from the 
WHO Regional libraries (ca. 4,000) because of the format in which these references were 
exported from the search engine.  
Strategy Advantages Disadvantages 
1. Targeted (“single use”) 
scrutiny of 85,000 
references (focus on only 
1 or 2 possible uses 
of/questions for 
database) 
Reduced time per reference, 
based on an estimate of 0.75 
hour for 1 analyst to scrutinize 
200 references, and all 
references are independently 
reviewed by two analysts, for 
a total of 637 person hours 
Cannot be used for more than 
a very limited number of 
questions (estimated 2 at 
most)  
2. Broad (“future use”) 
scrutiny (focus on all 
possible topic areas, and 
denote particular 
questions) 
Diminishes need to repeat 
scrutiny of references, and 
generates candidate 
documents for all potential 
topic areas and questions 
Extended time per reference 
compared to strategy 1 
(based on an estimate of 1.75 
hours for 1 analyst to 
scrutinize 200 references, and 
all references are reviewed by 
two analysts), for a total of 
1488 hours 
3. Broad (“modified future 
use”) scrutiny (focus on 
all possible topic areas, 
but do not denote 
particular questions) 
Diminishes need to repeat 
scrutiny of references, and 
generates candidate 
documents for all potential 
topic areas, but not questions 
Extended time per reference 
compared to strategy 1 
(based on an estimate of 1.25 
hours for 1 analyst to 
scrutinize 200 references, and 
all references are reviewed by 
two analysts), for a total of 
1,063 person hours 
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References from all of these sources were reviewed by research analyst (RA) pairs 
comprised of individuals trained in epidemiology or nutritional sciences, and who received 
extensive training in our protocol for inclusion/exclusion of studies.  
Per standard systematic review methodology, each reference (title, keywords, and 
abstract when available) was reviewed by two analysts to determine inclusion status for the 
EED Library. Dual review reduces bias and inaccuracies in the systematic review process. The 
principal investigators (DMD and PIT) initially piloted the Library inclusion process, until 100% 
concordance was achieved upon independent review of 1,300 consecutive references. A series 
of training sessions to convey the goals of the project, along with a protocol with which to 
determine inclusion of a reference in the EED Library, were provided to the team of RAs. Verbal 
and written instructions were conveyed to the analysts (Table 4), and a schematic regarding 
articles to include, and under what category, was also provided (Figure 5).  
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Table 4. Summary of EED Library inclusion/exclusion instructions to research analysts.  
Each analyst was instructed in the scope of interest of the EED Library, and how to code, tag 
and label data related to each reference included in the EED Library.  
 
A reference was included if it pertained to any of the following conditions: 
• Environmental Enteric Dysfunction 
• Tropical Enteropathy 
• Tropical Sprue 
• Environmental Enteropathy 
• Tropical Malabsorption Syndrome  
• Malabsorption/Enteropathy/Enteric Dysfunction in resource-limited settings 
 
Any age group and any setting (e.g., travelers) were eligible for this filter step. 
References about other enteropathies were included only if among children under five in 
developing countries (e.g., celiac disease, inflammatory bowel disease (IBD)). 
Nutrition-related articles were included if: 
• Malnutrition or nutritional status (as measured by anthropometrics) among children 
under five in developing country was an outcome  
• The study pertained to biochemical diagnostics or biomarkers or radiographic or 
other imaging among children under five in a developing country  
• The study used interventions to prevent or treat malnutrition, even if the outcome 
was something other than change in nutritional status or prevalence of malnutrition. 
Interventions were eligible only if they started among children under five years, 
even if outcomes were measured at a later age. 
 
 
A separate category of inclusion captured relevant reviews; this was defined broadly to include 
review articles, meta-analyses, editorials, commentaries, compendia or conference 
proceedings, letters, books, or book chapters. 
 
Exclusions: 
• prevalence, incidence, etc. of malnutrition if there was no information about factors 
(other than caloric insufficiency/food insecurity) associated with nutritional status 
• outcomes specifically due to malnutrition/nutritional status 







Further delineation of relevance to our systematic review 
Topic areas: 
I. Epidemiology of EED 
II. EED or malnutrition as an outcome 
Any associations, risk factors, protective factors, causes of acquisition of EED, 
malnutrition (except for food insecurity/inadequate calories associated with malnutrition). 
III. EED as an exposure 
EED as an association with, risk factor for, or cause of subsequent other child health 
problems. 
IV. Assessment, biomarkers, and diagnostics of EED or malnutrition 
V. EED clinical course, pathophysiology 
VI. EED or malnutrition interventions 
 
Relevant studies included in the EED Library: 
• Exposures, risk factors, protective factors, host factors, prevention or treatment 
interventions (other than those related to caloric density or food security), and their 
impact on EED or malnutrition outcomes. 
• Diagnostic tests or biomarkers related to, or to assess for, EED or malnutrition. 
• Interventions (other than those related to caloric density or food security) to prevent or 
treat malnutrition in children under five years, even if the outcome was something other 
than change in prevalence of malnutrition or change in nutritional status of individual 
children. Outcomes could include, for example, change in case fatality rate. Outcomes 
measured beyond five years were also included. 
• Prevalence, clinical course, and pathophysiology of EED. 
 
References we excluded from the EED Library: 
• Malnutrition as a risk factor for other morbidities/outcomes (e.g., malnutrition as a risk 
factor for pneumonia, stunting as a risk factor for obesity or mortality in adulthood, 
malnutrition as a risk factor for childhood mortality) unless the outcome was EED (e.g., 
malnutrition as a risk factor for poor intestinal function was included)  
• Malnutrition prevalence studies--unless they also examined risk factors for malnutrition 
or were intervention studies where change in prevalence of malnutrition is an outcome. 
• Measures/indices of physical growth such as growth charts or use of new indices 





Figure 5. EED Library inclusion schematic.  
Analysts used this as a guide in determining which references should be included in the EED 
Library.  
 
Feedback on nuances of the inclusion protocol was communicated to the analysts on a 
regular basis for the duration of the project. Table 5 contains samples of such guidance.  
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 Table 5. Additional EED Library inclusion/exclusion guidance and tips. 
The EED category was intentionally defined broadly. The term environmental enteric 
dysfunction (EED) has several potential equivalents in the literature, including tropical 
enteropathy, environmental enteropathy, tropical sprue, and tropical malabsorption syndrome. 
We also included references about enteric dysfunction and any other enteropathy impacting 
children in developing countries. These enteric conditions included kwashiorkor enteropathy, 
HIV enteropathy, tuberculosis enteropathy, celiac disease, inflammatory bowel disease, and 
other enteropathies, assuming they occurred in a developing-country setting. 
References were included even if our outcomes of interest were not the study's primary focus. 
If the title or abstract clearly indicated that the outcome was acute diarrhea, acute gastroenteritis 
or an acute enteric infection, we excluded it. If the reference noted they specifically examined 
persistent or chronic diarrhea as an outcome, it was included. Even if the main outcome studied 
was acute diarrhea, the reference was included if it examined EED or persistent/chronic 
diarrhea as a "minor" outcome. If an outcome of "diarrhea" was not specified as either acute or 
persistent/chronic, we assumed the article referred to acute diarrhea and we excluded it. 
References about acute diarrhea were included when they examined the impact of acute 
diarrheal illness or acute gastroenteritis on EED or malnutrition.  
References about children with IBD or celiac disease originating in a developing country were 
included (but excluded if the study was conducted in a developed country). Even though the 
origin of IBD and celiac disease is distinct from EED, we included it from developing-country 
settings for two reasons:  
 a. Celiac disease or IBD in developing countries may truly be misdiagnosed EED, a fact 
we will be better able to judge when reading the study methodology. 
 b. We are attempting to look at enteric dysfunction in developing settings more broadly 
and with fresh perspectives, to allow new observations of underlying patterns. 
While enteropathy is not always a manifestation of tuberculosis, HIV, or kwashiorkor, if a study 
in a developing country discussed enteric dysfunction or enteropathy related to these 
conditions, we included it. 
We excluded studies that reported prevalence of infection with a specific pathogen. If a study 
examined a pathogen's association with EED or other outcomes of interest as previously 
specified, then we included it.  
We focused on small intestine pathology; therefore, we excluded studies looking at 
gastric/colonic pathology unless they also examined outcomes pertaining to the small intestine. 
References about gastrointestinal problems that are not EED-related were excluded; a non-
exhaustive list of commonly encountered conditions not included in our review includes:  
• Appendicitis 
• Blind loop syndrome 
• Colonic atresia 
• Duodenal atresia 
• Dyspepsia 
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• Hemolytic uremic syndrome 
• Henoch-Schonlein purpura 
• Hirschsprung's disease 
• Intestinal obstruction  
• Intussusception 
• Irritable bowel syndrome 
• Malrotation 
• Necrotizing enterocolitis 
• Perirectal abscess 
• Peritonitis 
• Primary bile acid malabsorption 
• Pseudomembranous colitis 
• Rectal prolapse 
• Short bowel syndrome 
• Volvulus 
 
We included studies examining potential risk/protective factors for stunting, wasting or other 
forms of malnutrition, except those related to food security or caloric density. We excluded 
studies where any type of malnutrition was considered the exposure, unless EED was an 
outcome. 
Articles examining factors associated with anthropometric/growth outcomes were included even 
if not related to malnutrition. We did not include articles that solely examined the outcomes of 
overweight and obesity (unless related to EED), but studies of changes in growth status among 
children under five in developing countries were included. We excluded anthropometric data 
collected for the purpose of evaluating national statistics (e.g., in relation to WHO child growth 
standards) and studies of malnutrition or nutritional status prevalence unless the studies also 
looked at risk or protective factors associated with EED.  
Growth outcomes among children with common chronic infectious diseases such as HIV or 
hepatitis were considered outcomes of interest. 
We included any potential risk or protective factors for EED, malnutrition, or other outcomes of 
interest, even if they are not necessarily directly related to gut dysfunction, e.g., poverty, 
domestic violence, maternal anemia, small for gestational age (SGA), or low birth weight (LBW). 
We excluded studies where SGA or LBW was the study outcome, however.  
We included genetic risk factors for EED, malnutrition, or another related outcome of interest as 
long the study was conducted in a developing-country setting.  
Many studies contain relevant information about children under five even though they are not 
restricted to— or even focusing on— that age group. If any children under five were included, 
we included the reference. 
If a relevant study was conducted in a year when the study country was on the developing 
country list, it was included. 
We excluded case reports (or in vitro lab or animal model studies) even if relevant to EED. 
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The analysts were provided guidelines on inclusion and exclusion criteria. They were 
further instructed to: include only references from work performed in low- and middle-income 
countries (per World Bank definitions during the time that the data in the reference were 
collected) or among marginalized or indigenous populations in developed countries (e.g., 
Aboriginal Australian children) [94, 95]; to include references related to EED or conditions 
identical to or very consistent with EED (e.g., environmental enteropathy, tropical enteropathy, 
persistent diarrhea) among any age group in a setting of interest, and references related to 
other enteropathies or to nutritional conditions of interest among children under five years of age 
in a setting of interest.  
The refinements in the inclusion/exclusion instructions regarding other enteropathies 
were implemented because there is accumulating evidence that celiac disease is not confined 
to individuals of northern European descent residing in industrialized countries, but is instead a 
worldwide problem, including in regions in which EED is endemic, such as South Asia [96]. 
Second, there is increasing recognition of inflammatory bowel diseases (i.e., Crohn’s disease 
and ulcerative colitis) in these regions [97], though most cases of intestinal inflammation in 
these populations are not related to idiopathic inflammatory bowel diseases in children under 
five years of age. Third, we wished to include references on malnutrition and nutritional status 
where EED could act as an intermediary while excluding references that examined other 
aspects of malnutrition. For example, while food insecurity commonly affects populations at risk 
for EED, studies of nutritional deficits by themselves, including surveys of such deficiencies, 
were designated to be beyond the scope of our project. In another example, iron deficiency can 
be caused by a multitude of factors including defective absorptive capacity in the small bowel. 
To capture only the references relating to intestinal absorptive function, we excluded references 
if iron deficiency was studied outside the context of intestinal uptake assessment or another 
process related to EED.  
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Progressing in reverse chronological order, virtually all references between 1980 and 
2010 were evaluated as to whether or not they should be included or excluded from the EED 
Library, or whether or not additional information from the full text (particularly when the abstract 
was not initially available from the medical/health databases searched) was needed to make the 
determination. If included in the Library, references were assigned tags as to whether the 
reference contained information about: 1) enteropathy or enteric function/dysfunction, 2) 
nutritional status or malnutrition, and/or 3) enteric microbes. By using the topic areas and tags, 
we could then formulate queries to apply to our EED Library to identify articles potentially 
relevant to specific review questions that are contained in Table 2 or identified in the future. 
Additionally, topic areas (Table 2) covered in each reference were noted, as well as an 
indication whether the reference was a review or otherwise did not present primary data.  
Each reference published between 1980 and 2010 was reviewed for inclusion by two 
analysts according to the written guidelines and instructions. A principal investigator or lead 
analyst reviewed all references for which the analysts were discordant on Library inclusion, topic 
area, or other determinations, and provided final decisions. Furthermore, to verify that 
systematic errors did not occur in the exclusion of references, a random subset of references 
excluded by both analysts was scrutinized by a lead analyst. Percent error rate for this subset 
was calculated. 
The kappa statistic was used to evaluate reliability of individual analyst responses 
against final inclusion/exclusion determinations. Interpretation of kappa was performed using 
the following guidelines as described by Koepsell and Weiss [98]: agreement of >0.80 was 
deemed excellent, 0.61-0.80 substantial, 0.41-0.60 moderate, 0.21-0.40 fair, 0.00-0.20 slight, 
and <0.00 poor.  
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Chapter 3. EED Library as a Basis for 
Systematic Reviews 
3.1 Defining Systematic Review Question Priorities 
Evidence related to any topic area and addressing questions raised in Table 2 has 
potential to move the EED field forward. While an argument could be made to pursue any of the 
topic areas/questions, we had to define a starting question to address and had to develop a 
prioritization scheme given the importance of many of the topic areas/questions. Descriptive 
epidemiology (topic area I in Table 2), for example, would certainly be useful to gauge the scope 
of the problem, but would probably not produce useful recommendations. We considered 
developing a review that considered EED as a dependent variable (i.e., an outcome) of 
processes and risk factors (topic area II in Table 2). Such a characterization might be used to 
develop preventive interventions for EED. We next formulated a model of EED as an event that 
causes many injuries in the host (topic area III in Table 2), such as stunting and micronutrient 
deficiencies. A review based on this model could be considered an analysis of its consequences 
by focusing on host injuries and population impact. Biomarkers of EED as a subject for review 
(topic area IV in Table 2) could provide a compendium of tools that could be used to detect 
EED, and possibly to shed light on its origin. Consideration was additionally given to reporting 
the clinical course and pathophysiology of EED (topic area V in Table 2), to summarize the state 
of knowledge about cellular and organ processes that underlie its disease course. Finally, we 
considered reviewing existing treatment or prevention interventions for EED (topic area VI in 
Table 2).  
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To provide direction for our initial efforts, we decided that it was important to select areas 
in which a sufficient body of data is likely to exist. An additional attribute for a useful review is 
that the resulting analysis can be used for disease control.  
With these considerations in mind, we narrowed the set to four lead questions:  
1. What is the evidence that EED is caused by (an) identifiable pathogen(s), 
microbial populations, environmental or other identifiable factors? 
2. What is the evidence that EED can be prevented by any interventions? 
3. What is the evidence that EED can be noninvasively diagnosed? 
4. What is the evidence regarding efficacy/effectiveness of treatment 
interventions for EED? 
Based on deliberations amongst the co-authors, and engagement with the Bill & Melinda 
Gates Foundation, as well as discussions at the Gut Integrity Workshop held in Seattle, 
Washington in December 2010, we focused on noninvasive diagnosis of EED as a priority 
systematic review question. 
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3.2 Determining Relevance to the Systematic 
Review 
We carefully considered the specifics of the review question and framed the question for 
consistency with the Population Intervention Comparison Outcome (PICO) framework for 
systematic review questions [99]: 
What biomarkers or diagnostic tests1 have been used to identify or have been shown to 
be associated with mucosal dysfunction of the small intestine2 or host inflammation3 in 
children under five years of age from developing-country settings4? 
For the purpose of this systematic review question, dysfunction was defined as 
manifestation of increased small intestinal permeability, decreased absorption of nutrients, 
enteric inflammation, or abnormal enterocyte metabolism or cell function. These conditions 
could be present in children with environmental enteric dysfunction based on histology or 
persistent diarrhea or those with malnutrition, or who were clinically asymptomatic. Evaluation of 
asymptomatic or “normal” subjects without overt clinical evidence of enteric dysfunction or those 
with acute diarrhea was of interest as long as they were evaluated for tests of mucosal small 
intestinal dysfunction (e.g., endoscopy, histology, or markers of permeability or absorption from 
serum, urine, or stool) or they were being tested in the same study as children with persistent 
diarrhea. Gastrointestinal dysfunction or enteropathy related to celiac disease, cow's milk 
protein allergy (CMPA), inflammatory bowel disease, or cystic fibrosis, as well as primary 
                                                     
1 Assessments of host biological materials or imaging assessments (e.g. radiologic) of the host. 
2 Including increased small intestinal permeability, decreased absorption of nutrients, enteric 
inflammation, or abnormal enterocyte metabolism or cell function among those with enteropathy (e.g. 
environmental enteric dysfunction (EED) based on histology or persistent diarrhea) or children with 
malnutrition or clinically asymptomatic children.  
3 Laboratory confirmed generalized or tissue inflammation, but not necessarily specifically measuring gut-
specific inflammation, e.g. C-reactive protein (CRP), IL-6. 
4 Defined as low or middle income country as determined by World Bank or among marginalized or 
indigenous populations in a developed country. 
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immunodeficiency disorders (e.g., X-linked agammaglobulinemia, common variable 
immunodeficiency, IgA deficiency, IgG subclass deficiency) were excluded from this systematic 
review.  
Studies that used tests or markers specifically related to small intestinal mucosal 
function (except for the aforementioned excluded specific enteropathies) among children under 
five years of age from a developing country setting were included. These tests include biopsy, 
tests of nutrient absorption (e.g., iron absorption), tests of gut permeability and/or absorption 
(e.g., D-xylose, lactulose:mannitol ratio [L:M]), and stool markers (e.g., fecal fat, reducing 
substances). Articles describing tests or markers of systemic inflammation that can be affected 
by mucosal intestinal function (e.g., IL-6, C-reactive protein (CRP), blood counts) were also 
included as long as they were conducted: a) among children with EED or enteric dysfunction 
consistent with EED (e.g., those with persistent diarrhea and without an excluded enteropathy), 
b) among acute diarrhea or asymptomatic patients in a study that compared results to subjects 
with a small intestinal mucosal disorder of interest, or c) in association with a test of mucosal 
small intestinal function. Articles that were limited to tests of micronutrient status, celiac or 
CMPA disease-specific tests, or tests for specific pathogens were excluded from the systematic 
review.  
We decided to restrict this analysis to articles published between 2000 and 2010 in the 
interest of producing an expedited analysis of a well-defined literature set. We retain the ability 
to apply this methodology to the literature identified for prior intervals. We also performed an 
assessment of 10 references chosen at random that were published between 1990 and 1999 to 
determine the scope of additional information that an analysis of the literature prior to our 
restricted time block might provide (Appendix 3). Of the 10 articles, only one had a sample size 
of 100 or more subjects under five years of age. Overall, these articles do not lend substantial or 
novel data to content already derived from the 2000-2010 analysis. 
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We acknowledge that delving back to prior decades could provide additional informative 
data. This is especially true because much study regarding EED occurred in the 1970s and 
1980s and waned in the subsequent decades, and because technology is not evolving rapidly in 
this field. However, secular trends in socioeconomic, environmental, nutritional, and disease 
conditions as well as improvements in laboratory, epidemiologic, and biostatical methods 
complicate comparison of data across studies from different time periods. Also, earlier studies 
focused on adults. 
The team included analysts knowledgeable in German, French, Spanish, Italian, and 
Portuguese; thus, we were able to thoroughly dissect articles in these languages. References in 
other languages were excluded as we were not able to translate other languages in detail 
sufficient for the purposes of thorough extraction and analysis.  
A summary of inclusion/exclusion criteria and of the instructions given to analysts is 
provided in Table 6. 
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Table 6. Guidelines for systematic review inclusion/exclusion determination and data 
extraction.  
Biomarkers and Diagnostics Systematic Review Question: 
What biomarkers or diagnostic tests1 have been used to identify or have been shown to be 
associated with mucosal dysfunction2 of the small intestine or host inflammation3 in children 
under five years of age from developing-country settings4? 
1 Assessments of host biological materials or imaging (e.g., radiologic) assessments of the host.  
2 Dysfunction can be related to increased small intestinal permeability, decreased absorption of 
nutrients, enteric inflammation, or abnormal enterocyte metabolism or cell function among those 
with enteropathy (e.g., EED based on histology, persistent diarrhea) or children with malnutrition 
or clinically asymptomatic children.  
3 Laboratory-confirmed generalized or tissue inflammation, but not necessarily specifically 
measuring gut-specific inflammation (e.g. CRP, IL-6). 
4 Developing-country setting is defined as a low- or middle-income country (as classified by 
World Bank) or among indigenous populations in a developed country. 
 
Excludable conditions (non-EED enteropathies) 
Celiac disease, IBD, CMPA, cystic fibrosis (CF) (diagnosed by abnormal sweat test), as well as 
primary immunodeficiency disorders (e.g., X-Linked agammaglobulinemia, common variable 
immunodeficiency, IgA deficiency, IgG subclass deficiency) were not conditions of interest for 
this review unless the following circumstances existed:  
1. The study had controls or other subjects of interest who underwent diagnostic tests that 
are of interest to us (see "Category I Tests," below). 
2. The condition (i.e., celiac disease, CMPA, IBD) did not meet our systematic review 
criteria for defining or diagnosing that condition. In other words, these disorders may have been 
incorrectly diagnosed and could actually have been an enteric dysfunction of interest.  
 
Asymptomatic children and children with acute diarrhea:  
 
Evaluation of asymptomatic or ‘normal’ subjects without overt clinical evidence of enteropathy or 
those with acute diarrhea was pertinent to our review as long as the included tests of mucosal 
small intestinal dysfunction (e.g., endoscopy, histology, or serum, urine, or stool markers of 
permeability or absorption). We were not interested in asymptomatic children or those with 
acute diarrhea if tested for only systemic markers, unless they were tested in the same study as 
children with EED or persistent diarrhea (PD). We were interested in the comparison of 
systemic tests in patients who are asymptomatic and/or have acute diarrhea vs. PD. For 
example, if a systemic marker was measured in subjects who were asymptomatic or had acute 
diarrhea, we did not include these data. However, if these tests were also performed in a PD 
group, then we included the data from all of these subjects— acute diarrhea, PD, and 
asymptomatic subjects— taking care to separate findings by these categories.  
We did not include references about children who presented with abdominal pain, vomiting, 
anemia, rectal bleeding, gastroesophageal reflux, etc., unless they reported to have also had 
EED, tropical enteropathy (TE), environmental enteropathy (EE), PD, malabsorption, or other 
symptoms suggesting small intestinal mucosal dysfunction.  
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Tests to Include: 
Tests specific to intestinal dysfunction: We included biomarkers and diagnostic tests specifically 
related to small intestinal mucosal function if other inclusion criteria were met (i.e., age under 5, 
developing-country setting, etc.). We included these types of tests:  
• Endoscopy 
• Intestinal biopsy or lavage 
• Lactose/sucrose load test 
Tests of nutrient absorption (not static blood levels; see Excludable Diagnostic Tests, below), 
such as the following: 
• B12 absorption 
• Iron absorption 
• Calcium absorption 
• 13C sucrose or hydrogen breath test (HBT) 
Urine markers of gut permeability or absorption: 
• D-xylose 
• Creatinine, fraction excretion 
• Lactulose, fraction excretion 
• Sucrose, fraction excretion 
• Sucralose, fraction excretion 
• Mannitol, fraction excretion 
• L:M (lactulose:mannitol) ratio 
• Sucrose:lactulose ratio 
• Sucralose:lactulose ratio 
• Urea:creatinine ratio 
• Lactose:creatinine ratio 
Any stool markers (except those testing for specific micro-organisms; see Excludable Diagnostic 
Tests, below), such as the following:  
• Alpha-1-antitrypsin 
• Calprotectin 





• Reducing substances 
• Leukocytes (i.e., white blood cells (WBCs) by microscopy 
• Occult blood testing (including guiac) 
• Red blood cells (RBCs) by microscopy 
Systemic, Non-specific Tests: Many biomarkers and diagnostic tests, including the below list of 
systemic markers of inflammation, can be impacted by mucosal intestinal function, but they can 
also be impacted by other non-gastrointestinal disorders.  
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For these tests, we only included if one or more of the following conditions were met: 
1. They were conducted among patients with a mucosal small intestinal disorder of interest 
(e.g., EED, PD, or among asymptomatic or acute diarrhea subjects in a study that also 
examined subjects with mucosal small intestinal disorder of interest).   
2. The tests were reported in relation to a test of mucosal small intestinal function (see list 
above).  
Examples of systemic, non-specific tests are the following: 
• Hemoglobin (HGB), hematocrit (HCT) (blood cell counts) 
• Total serum proteins and other serum proteins such as albumin, pre-albumin 
• Serum lipids and lipoproteins 
• Liver function tests (e.g., alanine transaminase) 
• Urine sodium (Na) 
• Urine pH 
• Systemic inflammatory markers such as: 
• C-reactive protein (CRP) 
• Erythrocyte sedimentation rate (ESR) 
• Tumor necrosis factor (TNF) 
• Interleukin-6 (IL-6) 
• Interferon-gamma (IFN-gamma) 
• Alpha-1-acid glycoprotein (AGP) 
• Serum immunoglobulins 
• Immune cell subsets 
• Ferritin 
Algorithm for our inclusion/exclusion decisions on tests/markers: 
1. Was the test performed on children under five years in a developing-country setting? If 
no, exclude. If yes, continue. 
2. Is the test on the list of excludable tests? If yes, exclude. If no, continue. 
3. Is the test potentially related to small intestinal mucosal function? If no, exclude. If yes, 
continue. 
4. Is the test specific for small intestinal mucosal function? If yes, include and extract data. 
If no, continue. 
5. Is the test a more general test that could be related to dysfunction of other organ 
systems? If no, exclude. If yes, continue. 
6. Was the test assessed among children with mucosal small intestinal dysfunction or 
among children who have been assessed for mucosal small intestinal dysfunction? If no, 




 3.3 Acquisition of References and Copyright Fair 
Use Compliance 
References potentially relevant to the systematic review were determined by querying 
the EED Library Access database. The query identified references tagged as explicitly EED-
related and relevant to or possibly relevant to topic area IV (i.e., diagnostic tests and 
biomarkers).  
Starting in reverse chronological order, full texts of references that were identified as 
potentially relevant to the systematic review were obtained as Portable Document Format files 
(PDFs) and deposited into a central repository on Google Drive. 
We maintained compliance with Fair Use obligations of U.S. Copyright Law, 
watermarking all PDFs and making the Google Drive repository available only to team 
members. Furthermore, analysts who performed data extraction indicated their compliance with 
fair use when logging into the data entry system, via a checkbox that stated “I agree to use this 
article according to US copyright law.”  
3.4 Documenting Relevance to the Systematic 
Review 
Two principal investigators (DMD, PIT) and/or lead analysts (ZCN, KMV) reviewed 
discordant decisions made by research analysts (RAs) to determine relevance of references to 
the systematic review according to written guidelines (Table 6). In addition, a subset of 
concordant decisions (with an emphasis on excluded references) was reviewed for quality 
control.  
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 After the systematic search of the EED Library, we employed the "snowball technique" to 
identify further articles relevant to the systematic review. The snowball technique involves 
review of bibliographies of references determined as relevant to the systematic review, and 
cited articles were cross-checked against the EED Library. If not already included in the Library, 
the article was evaluated for inclusion in the Library and the systematic review. 
3.5 Data Extraction for the Systematic Review 
For data extraction, presentation, and analysis, we utilized the REDCap (Research 
Electronic Data Capture) system (http://project-redcap.org/). REDCap is a secure, web-based 
application for construction and management of online surveys and databases from multiple 
users [100]. A sample REDCap template for data extracted from systematic review references 
can be found in Appendix 4. 
After inclusion/exclusion decisions for the review were finalized, six analysts extracted 
data from studies into REDCap. The analysts were provided written guidelines on the type of 
data to be extracted (Table 6). Conference call training sessions were employed to reinforce 
guidelines and to address questions. Analysts were instructed to extract data on relevant facets 
including: study objectives, outcome of relevance to review question, setting, study design, 
subject description, case definition for subjects of interest, age groups and age range, study 
population, sample size for review question, biomarkers or diagnostic tests, test conditions and 
specifications, and results, as well as provide their impression of the evidence quality and a 
study synopsis. Extracted data were reviewed for accuracy and completeness by lead analysts, 
who made edits as needed and provided feedback to the RAs to increase efficiency and 
accuracy.  
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 We exported specific fields of data from REDCap, facilitating analyses and data 
presentation in evidence table format. From these characterizations, we portrayed the spectrum 
of responses in quantitative and free-text formats as needed. 
It is important to note that the EED Library, with references from PubMed, EMBASE, 
Global Health, and WHO Regional databases that were published between 1980 and 2010, 
remains available for research relevant to enteric dysfunction in children in resource-poor 
environments.  
3.6 EED Library: Search Results Overview 
The systematic search of PubMed, Embase, WHO Regional, and Global Health 
databases yielded 85,334 references of potential relevance to the EED Library. 17,431 
references that were published before 1980 have not been assessed for inclusion in the Library. 
67,903 references published between 1980 and 2010 are depicted in Figure 6. A small portion 
of this set was not reviewed because full text was necessary for determination, but was not 
available (i.e., we were unable to retrieve 89 articles published between 2000 and 2010). 
66,541 references were dual-reviewed against EED Library inclusion criteria with 9,669 
admitted to the project Library. Fifteen percent of those included were reviews, commentaries, 
abstract proceedings, books, or editorials, and the remainder were references with primary data. 
To conserve project resources, approximately 1,350 articles from the original systematic search 
that were published before 2000 were not reviewed for library inclusion.  
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 Figure 6. Flowchart of project procedure results. 
 
3.7 Quality Control 
Accuracy and completeness in coding inclusion/exclusion and labels, tags, and topic 
areas by analysts were closely monitored. Means for the percent of inaccurate exclusion and 
inclusion and for kappa statistics were weighted based on the number of reference 
spreadsheets reviewed by each analyst. The overall inaccurate exclusion and inclusion rates 
were 2.2% and 2.7%, respectively. The kappa average for the group of analysts was 0.76, 
which is considered to be in the "substantial concordance" range [98]. In addition, 1,200 
references that were concordantly excluded by two analysts were reviewed by a lead analyst; 
the exclusion error rate for these references was 0.5% (Table 7).  
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 Table 7. Accuracy rates for inclusion and exclusion. 
Concordance/discordance between analysts and study investigators on an evaluation set of 















     
A 5.2 3.4 0.46 1800 
B 0.9 3.2 0.83 11400 
C 2.9 0.9 0.78 2000 
D 1.9 2.9 0.78 7800 
E 2.9 1.3 0.74 6400 
F 5.8 6.4 0.50 600 
G 6.4 3.7 0.61 200 
H 2.9 3.3 0.75 600 
I 4.2 6.5 0.67 800 
J 3.3 0.7 0.79 600 

















 2.2 2.7 0.76 0.5 % 
 
3.8 EED Library Status 
Twenty percent of all of the references derived from our initial systematic search of the 
PubMed, Embase, and Global Health databases were published between 2006 and 2010. The 
discordance between the abundance of references that we found in our search and the paucity 
of references found in the ISI query suggest that relevant literature is indexed with search terms 
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 that are neither sensitive nor specific. The inclusive approach using terms that broadened the 
scope of papers identified was therefore warranted, even though such broadening obligated the 
inclusion of over 85,000 references.  
Furthermore, careful documentation of our search terms allows reproducibility despite 
the complex nature of our strategy. The search strategy can be replicated and resultant 
references run through our project procedures to update the Library at any time. In addition, the 
search strategy designed for this project can be modified if related searches are needed.  
The EED Library, as derived from PubMed, EMBASE, Global Health and WHO Regional 
databases and published between 1980 and 2010, was designed to be a resource for scientists, 
public health and clinical practitioners working on a variety of EED investigations. In fact, we 
have interrogated our EED Library for several groups of researchers in the field:  
1. Dr. David Rudnick at Washington University in St. Louis requested assistance in 
his work on liver function and growth in resource-limited settings, and we queried 
the database as regards the role of aflatoxin and growth as reflected in the 
literature.  
2. We provided a list of references from the last decade that reported use of 
biopsies among children in resource-limited settings to Dr. James Lavery‘s team 
in Toronto to assist in their examination of ethical considerations of invasive and 
noninvasive assessments of what they termed "tropical enteropathy/enteric 
enteropathy." 
3. We provided data from our database to Dr. Gerald Keusch’s team (which 
includes co-authors Drs. Denno and Tarr) who were building a working definition 
of EED.  
4. The master evidence table was made available to all of the participants of the Bill 
and Melinda Gates Foundation Grand Challenges Gut Function Biomarker 
Shaping Meeting in London in June 2012. 
5. We performed a pilot project for the Bill and Melinda Gates Foundation to 
determine the number of studies in the EED database that involved interventions. 
We further determined how many of these were clinical trials vs. treatment 
studies, categorized the interventions, and tallied the number of studies per 
category. 
The EED Library can be searched using the codes, labels and tags that our Research 
Analyst team assigned to EED Library records. Continued assembly of literature post-2010 
would add value if the database is to be further utilized to address other queries. 
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 Chapter 4. Systematic Review of EED 
Biomarkers/Diagnostic Tests: Results 
Synopsis 
4.1 Biomarkers and Diagnostics Systematic Search 
Results 
The query of our EED Library to identify references potentially relevant to the systematic 
review produced 361 citations for the time period between 2000 and 2010. The "snowball" 
technique identified 13 additional potentially relevant publications that were not found through 
the original systematic search. Thirty-three of the 374 potentially relevant publications were in 
languages other than those that we included for this review—English, French, German, Italian, 
Portuguese, and Spanish (Table 8).  
Table 8. Breakdown of publications in excluded languages of potential relevance to the 
systematic review. 
Language Number potentially relevant 
Number sufficiently reviewed 
and excluded for reasons other 
than language 
Arabic 1 0 
Chinese 3 1 
Croatian 2 2 
Czech 2 1 
Norwegian 1 0 
Polish 14 10 
Russian 9 6 
Turkish 1 1 
Totals 33 21 
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 However, we were able to determine (via translation and/or English language abstract) 
that 21 of the 33 did not meet our other systematic review inclusion criteria. We were unable to 
sufficiently translate the remaining 12 papers to determine their relevance or, if they were 
relevant, to extract data. These papers were in Arabic (n=1), Chinese (n=2), Czech (n=1), 
Norwegian (n=1), Polish (n=4), and Russian (n=3). Two-hundred and fifty publications were 
eliminated for various reasons, including their focus on celiac disease, cow’s milk protein 
allergy, or inflammatory bowel disease; lack of at least three subjects of interest under five years 
of age; or they did not assess biomarkers or diagnostic tests related to small intestinal function 
or inflammation. One potentially relevant article was thought to be pertinent to the systematic 
review based on the abstract, and another article required full text for further determination; 
however, the full texts for these two articles could not be found. 
An additional 12 references were highly considered for inclusion, but ultimately excluded 
from the review for reasons including insufficient subjects in the specified age range, inadequate 
relevant data on appropriately-aged subjects, or uncertainty about the setting in which the study 
was performed (Appendix 5).  
We identified 20 review articles with content that addressed or discussed material of 
relevance to our systematic review question (Appendix 6); however, we identified no systematic 
review that had been conducted on biomarkers or diagnostic tests related to EED.  
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 4.2 Characteristics of References Included in the 
Systematic Review 
The remaining 77 references included in the systematic review (Table 9) describe 
research that was performed in 22 different countries. Figure 7 maps the sites where the studies 
were performed.  
Table 9. Articles pertinent to the systematic review. 
These were determined to be the publications of interest between 2000 and 2010. 
Alcantara CS, et al. Interleukin-8, tumor necrosis factor-alpha, and lactoferrin in immunocompetent hosts with 
experimental and Brazilian children with acquired cryptosporidiosis. 2003. [101] 
Alves GM, et al. Nutritional status and breath hydrogen test with lactose and lactulose in Terena Indian 
children. 2002. [102] 
Amadi B, et al. Reduced production of sulfated glycosaminoglycans occurs in Zambian children with 
kwashiorkor but not marasmus. 2009. [103] 
Azim T, et al. Immune response of Bangladeshi children with AD who subsequently have persistent diarrhea. 
2000. [104] 
Bhatnagar S, et al. Celiac disease with mild to moderate histological changes is a common cause of chronic 
diarrhea in Indian children. 2005. [105] 
Bitarakwate E, et al. Serum zinc status of children with persistent diarrhoea admitted to the diarrhoea 
management unit of Mulago Hospital, Uganda. 2003. [106] 
Bukhari AS, et al. DNA damage and plasma homocysteine levels are associated with serum metabolites and 
mineral constituents' profiles in children with persistent diarrhea. 2010. [107] 
Bushen OY, et al. Heavy cryptosporidial infections in children in northeast Brazil: comparison of 
Cryptosporidium hominis and Cryptosporidium parvum. 2007. [108] 
Bustos M, et al. Disaccharidase deficiency in Bolivian children with persistent diarrhea. 2003. [109] 
Campbell DI, et al. Intestinal inflammation measured by fecal neopterin in Gambian children with enteropathy: 
association with growth failure, Giardia lamblia, and intestinal permeability. 2004. [15] 
Campbell DI, et al. Growth faltering in rural Gambian infants is associated with impaired small intestinal barrier 
function, leading to endotoxemia and systemic inflammation. 2003. [110] 
Campbell DI, et al. Chronic T cell-mediated enteropathy in rural west African children: relationship with 
nutritional status and small bowel function. 2003. [111] 
Campbell DI, et al. Age-related association of small intestinal mucosal enteropathy with nutritional status in 
rural Gambian children. 2002. [112] 
Chen P, et al. Association of vitamin A and zinc status with altered intestinal permeability: analyses of cohort 
data from northeastern Brazil. 2003. [113] 
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 Clark TD, et al. Risk factors and cumulative incidence of anaemia among human immunodeficiency virus-
infected children in Uganda. 2002. [114] 
Darboe MK, et al. Effectiveness of an early supplementation scheme of high-dose vitamin A versus standard 
WHO protocol in Gambian mothers and infants: a randomised controlled trial. 2007. [115] 
Dini E, et al. Sudan III and steatocrit in the detection of fecal fat in malnourished children. 2002. [116] 
El Mouzan MI, et al. Endoscopic duodenal biopsy in children. 2006. [117] 
Fagundes-Neto U, et al. Studies of the small bowel surface by scanning electron microscopy in infants with 
persistent diarrhea. 2000. [118] 
Filteau SM, et al. The effect of antenatal vitamin A and (beta)-carotene supplementation on gut integrity of 
infants of HIV-infected South African women. 2001. [119] 
Galpin L, et al. Effect of Lactobacillus GG on intestinal integrity in Malawian children at risk of tropical 
enteropathy. 2005. [120] 
Gandolfi L, et al. Antiendomysial antibody test reliability in children with frequent diarrhea and malnutrition: is it 
celiac disease? 2001. [121] 
Goto R, et al. Impact of anti-Giardia and anthelminthic treatment on infant growth and intestinal permeability in 
rural Bangladesh: a randomised double-blind controlled study. 2008. [122] 
Goto R, et al. Impact of intestinal permeability, inflammation status and parasitic infections on infant growth 
faltering in rural Bangladesh. 2008. [123] 
Goto R, et al. Poor intestinal permeability in mildly stunted Nepali children: Associations with weaning practices 
and Giardia lamblia infection. 2002. [124] 
Haase A, et al. Dual sugar permeability testing in diarrheal disease. 2000. [125] 
Hafeez A, et al. An audit of pediatric upper gastrointestinal endoscopies. 2000. [126] 
Jain S, et al. Fecal occult blood screening in children with severe malnutrition. 2007. [127] 
Kapoor L, et al. Giardiasis--clinical and diagnostic perspective. 2001. [128] 
Kapoor S, et al. Detecting protein losing enteropathy by Tc-99m dextran scintigraphy: A novel experience. 
2002. [129] 
Kirkpatrick BD, et al. Serum mannose-binding lectin deficiency is associated with cryptosporidiosis in young 
Haitian children. 2006. [130] 
Kirkpatrick BD, et al. Childhood cryptosporidiosis is associated with a persistent systemic inflammatory 
response. 2006. [131] 
Kirkpatrick BD, et al. Cryptosporidiosis stimulates an inflammatory intestinal response in malnourished Haitian 
children. 2002. [132] 
Kohli A, et al. Giardia duodenalis assemblage, clinical presentation and markers of intestinal inflammation in 
Brazilian children. 2008. [133] 
Kukuruzovic R, et al. Increased nitric oxide production in AD is associated with abnormal gut permeability, 
hypokalemia and malnutrition in tropical Australian aboriginal children. 2003. [43] 
Kukuruzovic R, et al. Milk formulas in acute gastroenteritis and malnutrition: a randomized trial. 2002. [134] 
Kukuruzovic R, et al. Small bowel intestinal permeability in Australian aboriginal children. 2002. [58] 
Laadhar L, et al. Determination of anti-transglutaminase antibodies in the diagnosis of celiac disease in 
children: results of a five year prospective study. 2004. [135] 
Leite CA, et al. Functional, microbiological and morphological intestinal findings among human 
immunodeficiency virus infected children. 2006. [136] 
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 Lima AA, et al. Effects of vitamin A supplementation on intestinal barrier function, growth, total parasitic, and 
specific Giardia spp infections in Brazilian children: a prospective randomized, double-blind, placebo-controlled 
trial. 2010. [137] 
Lima AA, et al. Intestinal barrier function and weight gain in malnourished children taking glutamine 
supplemented enteral formula. 2005. [138] 
Lima NL, et al. Wasting and intestinal barrier function in children taking alanyl-glutamine-supplemented enteral 
formula. 2007. [139] 
Long KZ, et al. The effect of vitamin A supplementation on the intestinal immune response in Mexican children 
is modified by pathogen infections and diarrhea. 2006. [140] 
López de Romaña D, et al. Longitudinal measurements of zinc absorption in Peruvian children consuming 
wheat products fortified with iron only or iron and 1 of 2 amounts of zinc. 2005. [141] 
Mahmud MA, et al. Sociodemographic, environmental and clinical risk factors for developing persistent diarrhea 
among infants in a rural community of Egypt. 2001. [142] 
Mahmud MA, et al. Increased fecal IgE among infants in a rural community of Egypt: an analysis of associated 
risk factors. 2001. [143] 
Manary ML, et al. Zinc homeostasis in Malawian children consuming a high-phytate, maize-based diet. 2002. 
[144] 
Mishra OP, et al. Endoscopic and histopathological evaluation of preschool children with chronic diarrhea. 
2001. [145] 
Mittal SK, et al. Tropical Sprue in North Indian Children. 2001. [146] 
Moya-Camarena SY, et al. Effects of asymptomatic Giardia intestinalis infection on carbohydrate absorption in 
well-nourished Mexican children. 2002. [147] 
Murphy JL, et al. Maldigestion and malabsorption of dietary lipid during severe childhood malnutrition. 2002. 
[148] 
Murphy JL, et al. Gastrointestinal handling and metabolic disposal of 13C-labelled tripalmitin during 
rehabilitation from childhood malnutrition. 2001. [149] 
Nichols B, et al. Contribution of villous atrophy to reduced intestinal maltase in infants with malnutrition. 2000. 
[53] 
Northrop-Clewes CA, et al. Anthelmintic treatment of rural Bangladeshi children: effect on host physiology, 
growth, and biochemical status. 2001. [150] 
Panter-Brick C, et al. Pathways leading to early growth faltering: An investigation into the importance of 
mucosal damage and immunostimulation in different socio-economic groups in Nepal. 2009. [151] 
Perin NM, et al. Intestinal absorption of D-xylose in children infected with the human immunodeficiency virus. 
2001. [152] 
Pires AL, et al. Digital morphometric and stereologic analysis of small intestinal mucosa in well-nourished and 
malnourished children with persistent diarrhea. 2003. [153] 
Poddar U, et al. Is tissue transglutaminase autoantibody the best for diagnosing celiac disease in children of 
developing countries? 2008. [154] 
Poddar U, et al. Celiac disease in India: Are they true cases of celiac disease? 2002. [155] 
Quadro L, et al. Retinol and retinol-binding protein: gut integrity and circulating immunoglobulins. 2000. [156] 
Rabbani GH, et al. Green banana and pectin improve small intestinal permeability and reduce fluid loss in 
Bangladeshi children with persistent diarrhea. 2004. [157] 
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 Rabbani GH, et al. Increased nitrite and nitrate concentrations in sera and urine of patients with cholera or 
shigellosis. 2001. [158] 
Ritchie BK, et al. 13C-sucrose breath test: novel use of a noninvasive biomarker of environmental gut health. 
2009. [159] 
Rollins NC, et al. Feeding mode, intestinal permeability, and neopterin excretion: A longitudinal study in infants 
of HIV-infected South African women. 2001. [160] 
Rollins NC, et al. Vitamin A supplementation of South African children with diarrhea: optimum timing for 
improving biochemical and clinical recovery and subsequent vitamin A status. 2000. [161] 
Samie A, et al. Cryptosporidium species: preliminary descriptions of the prevalence and genotype distribution 
among school children and hospital patients in the Venda region, Limpopo Province, South Africa. 2006. [162] 
Sarker SA, et al. Helicobacter pylori infection, iron absorption, and gastric acid secretion in Bangladeshi 
children. 2004. [163] 
Sheng XY, et al. Major variables of zinc homeostasis in Chinese toddlers. 2006. [164] 
Sherwani K, et al. Prevalence of iron deficiency anemia in chronic diarrhoea and celiac disease - A western UP 
experience. 2008. [165] 
Soliman SM, et al. Role of micronutrient mixture in acute and persistent diarrhea in infants and its impact on 
nutritional status. 2003. [166] 
Tassara O, et al. Gastrointestinal diseases in children infected with the human immunodeficiency virus. 2003. 
[167] 
Thurnham DI, et al. Innate immunity, gut integrity, and vitamin A in Gambian and Indian infants. 2000. [168] 
Trehan I, et al. A randomized, double-blind, placebo-controlled trial of rifaximin, a nonabsorbable antibiotic, in 
the treatment of tropical enteropathy. 2009. [13] 
Vieira MM, et al. Carotenoids, retinol, and intestinal barrier function in children from northeastern Brazil. 2008. 
[169] 
Williams EA, et al. A double-blind, placebo-controlled, glutamine-supplementation trial in growth-faltering 
Gambian infants. 2007. [170]  
Willumsen JF, et al. Subclinical mastitis as a risk factor for mother-infant HIV transmission. 2000. [171] 
Zhang Y, et al. Lactulose-mannitol intestinal permeability test in children with diarrhea caused by rotavirus and 























*One of the studies attributed only to The Gambia in this map had two study locations: The Gambia and India.
Figure 7. Geographic mapping of study sites 
Number of studies by country included in the systematic review. 
 Aggregated characteristics of the included studies are presented in Table 10. Details of 
the data from each article are reported in the Evidence Table of all studies included in the 
review (Appendix 7 ). Data are also presented in individual Evidence Tables based on category 
of biomarker (Evidence Tables 1-8). It is important to note that we only include data from articles 
that pertain to our review question. No identified study was explicitly designed to assess the 
accuracy of the diagnostic tests or biomarkers that they employed among children in 
developing-country settings. While this does not detract from their intrinsic value, it does pose 
an additional challenge to our goal of evaluating diagnostics for EED. For example, we did not 
find data pertaining specifically to standard measures of diagnostic test evaluation, such as 
positive or negative predictive values, or receiver operating characteristic curves. We assessed 
the use of the biomarkers as they were employed and extracted data relevant to the markers 
themselves, even if these data were not the primary focus of the studies.  
Table 10. Overview of studies. 
Characteristics of studies are provided and demonstrate broad-based nature of current and 
recent data.  
Study sites by WHO regions, countries: Number of studies 
WPRO: China (1), Australia (5) 
AMRO: Brazil (16), Haiti (3), Mexico (2), Peru (2),  
  Venezuela (1), Chile (1), Bolivia (1), Jamaica (2) 
AFRO: Zambia (1), Malawi (3), The Gambia (6),  
  South Africa (5), Uganda (2) 
EMRO: Saudi Arabia (1), Pakistan (2), Egypt (3), Tunisia (1) 
SEARO: India (10), Bangladesh (7), Nepal (2) 


















 Study durations: Time period for subject enrollment 
Median: 502 days 
Range: 28 days – 17 years  
Not specified: 27 studies 
Publication Lag: Time from study enrollment to publication 
Median: 4 years  
Range: 1 year – 15 years  
Not specified: 37 studies 




Urban slum1: 7 
Study designs: Number of studies 
Case-controls: 25 
Longitudinal cohort: 14  
Randomized controlled trial: 16  
Cross-sectional: 12  
Case-series: 10 
 
Sample size of subjects of interest: Number of subjects in all studies combined 
Total: 7730    
Interquartile Range: 104 
Median: 75    
Range: 3-318 
Age range of subjects investigated in all studies combined  
Range: birth-88 years  
Subjects of interest to this review under five years of age: Number of subjects all studies combined 
Total: 54192     
Interquartile range: 119 
Median: 71     
Range: 3-306 
Presenting conditions of study subjects of interest at the time of recruitment: Number of studies3 
Acute Diarrhea: 27 
Persistent Diarrhea: 30 
Infection with specific enteric pathogens: 28 
   Cryptosporidium (8) 
   Giardia (11) 
   Helminths (4) 
   Helicobacter pylori (3) 
   Other (13) 
Malnutrition: 45 
Infected with HIV or Tuberculosis: 9 
Healthy / asymptomatic: 40 
Other: 18 
                                                     
1 This comprises any study noted as being conducted in a slum, shantytown, or urban squatter settlement. 
2 Excluding 22 studies that do not specify subjects <4 and 5 years. 
3 Number >77 because some studies included more than one condition or test. 
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Lactulose:rhamnose ratio (L:R): 5  
α-1-acid glycoprotein: 4 
CRP: 5 
Red blood cell indices (e.g., Mean 
corpuscular volume): 4 
WBC: 4 
Total protein: 3 
D-xylose: 2  
Transferrin (saturation): 2  
α-1-antichymotrypsin: 2 
Cytokines: 1 
Immune function assays: 1 
Mannose-binding lectin: 1  
Nitric oxide: 1 
Oxidative stress markers, DNA 
   damage to lymphocytes, liver  
   enzymes, thyroid hormones: 1 




13C lipid breath test: 1 
13C sucrose breath test: 1  
Hydrogen breath test  
  Lactose: 2 
  Lactulose: 1 
  Xylose: 1 
 
Urine (32) 
Lactulose:mannitol (L:M): 255  
Radiolabeled zinc or lipid    
  challenge: 3 
Neopterin: 2 
Nitric oxide: 2 
Sucrose:lactulose ratio: 26 
D-xylose: 1 
Lactose:lactulose ratio: 17 
Lactulose:rhamnose (L:R): 1  
Sucralose:lactulose ratio: 18 
  
Stool (24) 
Lactoferrin: 9  
Leukocytes: 4 
Cytokines: 5 
Fecal fat: 3  
Radiolabeled zinc or lipid   
  challenge: 4 
Reducing substances: 4  
Occult blood/RBCs by    






Small intestinal aspirates (2) 
Concentrations of  
  immunoglobulins (Ig) IgA, IgG,  
  and IgM: 1 
Microbial concentrations: 1 
 
 




Small intestinal tissue (18) 
Histopathology: 17 
Disaccharidases: 2 
Protein and inflammatory  
  markers: 2 
Messenger RNA abundances: 1 
 
 
Site not specified (2) 
D-xylose: 2 
For studies that included small intestinal biopsy, characteristics specific to biopsy results: 
 
Total subjects of interest: 996 
 
Subjects of interest under five years of age: 8 studies specified   
  (n=311), 10 did not specify 
 
Site of small intestinal biopsy: Number of studies 
- Duodenum: 11  
- Jejunum or ileum: 4 
- Not specified: 3 
 
Esophagus or stomach also biopsied: 1 
Large intestine or rectum also biopsied: 2 
                                                     
4 Number >77 because some studies included more than one condition or test. 
5 18 of the 25 studies include fractional excretion of the individual components. 
6 Includes fractional excretion of the individual components. 
7 Includes fractional excretion of the individual components; there was also one study that measured lactose 
excretion individually without relationship to another sugar. 
8 Includes fractional excretion of the individual components. 
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Comparison of biomarkers to histopathology: Number of studies 
Yes: 3 studies compared extra-intestinal tissue markers to 
histopathology: D-xylose (2)9; Fecal fat (1); L:M (1)10 
 
Yes: 3 studies compared endoscopic visualization or intestinal 
tissue markers to histopathology: Intestinal maltase activity and 
various intestinal mRNA abundances (1), endoscopic gross 
visualization (1), scanning electron microscopy (compared to 
light microscopy) (1) 
 
No: 71 studies 
Comparison of extra-intestinal tissue biomarkers to other extra-intestinal tissue biomarkers: Number of 
studies 
Yes: 12 studies11 comparing:  
L:M vs. albumin (1), Immunoglobulins (2), Alpha-1-acid 
glycoprotein AGP (1), Endotoxin and IgG endotoxin core 
antibody (1) Fecal neopterin (1); Lactose and Lactose:lactulose 
(1) 
 
Serum L:R vs. urinary L:R (1), sucrose breath test (1), urinary 
nitric oxide (1), serum lactose (1), reducing substances (1), red 
cell indices (1) 
Fecal lactoferrin vs. TNF-α receptor I (1), Urinary 
lactose:creatinine vs. hemoglobin (1); Urinary nitrites vs. stool 
reducing substances (1); Serum nitrites vs. WBC (1) 
 
No: 65 studies 
                                                     
9 One study compared D-xylose as well as fecal fat.  
10 This study compared the lactulose:mannitol ratio (L:M) to morphometric analysis of biopsy tissue. 
11 Number of comparisons listed is >12 because some studies included more than one comparison. 
 
We calculated that in the 77 papers analyzed, a total of 5,410 children under five years 
of age were studied for any biomarker plausibly related to EED, and an additional 2,311 children 
were studied, among whom the number of subjects aged under five years could not be 
determined (Table 10). More than 50 different biomarkers were studied. These biomarkers were 
obtained by study of urine, stool, blood, breath, and intestinal tissue. Eighteen studies examined 
the histopathology of biopsied intestinal tissue, but only three studies compared intestinal 
histopathology to non-intestinal tissue biomarkers (D-xylose; fecal fat; urinary L:M [111, 136, 
155]). One additional study compared results of intestinal tissue markers (maltase activity and 
intestinal mRNA abundances for various markers) to histopathology [53]. Notably, few small 
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 bowel biopsies (the “gold standard” diagnostic) among children under five years of age in 
developing-country settings are included in this cohort of studies from the past eleven years. 
Indeed, small bowel biopsies from only 311 children under five years of age in eight studies 
were reported, and an additional 685 children in 10 other studies had small bowel biopsies but 
the number of those who were under five years of age could not be determined.  
We were also interested in the lag time between study enrollment and publication, and 
examined a subset of the first 24 articles relevant to the systematic review. Table 11 provides 
intervals between enrollment, study start and close, study duration, and year of publication for a 
subset of the first 24 articles that we reviewed. There were, in general, long delays in cohort 
enrollment and dissemination of primary data (up to 19 years, and often over a decade).  
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Table 11. Study timing analysis. 
Dates of publication, enrollment, and performance of a subset of publications. Seven of 24 
studies did not specify study time interval. 
Publication 
Year Study enrollment years Range of study intervals 
2006 
Aug 1994-May 1995 
1991-2002 
30 days – date not specified 
1993-2002 
Not specified 
9 months – date not specified 




Sept 2001-October 2004 
2001-2004 July 2003-November 2004 
5 years – date not specified 
2008 
June 2003-February 2004 
1989-2004 
June 2003-April 2004 
Jan 2000-Dec 2002 
Not specified 
Aug 1989-Apr 1993 (current study 2004) 
July 2000-Aug 2001 
2009 
3 days- date not specified 
1998-2007 
Date not specified 









4.3 Classification of Biomarkers and Diagnostic 
Tests  
The “job description” of the small bowel can be reduced to a circumscribed set of tasks: 
break down specific nutrients using enzymes in the intestinal lining or by micellization of 
lipophilic substances; extract nutrients from food; exclude the food components that have no 
nutritive value and propel them distally for elimination; retain (i.e., not leak into the gut) 
molecules used (and often synthesized) by the host; and resist microbial breach of the barrier. 
Hence, the intestinal mucosa serves as a specialized transporting organ as well as a physical, 
physiologic, and antimicrobial interface between the host and the environment which in this 
case consists of ingested food and water, but also other potentially highly contaminated 
materials (e.g., soil) [173], given the oral-motor activities of infants and toddlers. The cells and 
submucosa that line the small bowel are, therefore, critical for assimilation of nutrients, 
maintenance of structural integrity, and protection against microbial assault. In injury, 
substances are absorbed by barrier breach rather than by physiologic transport or diffusion.  
We strove to take an unbiased and uniform approach to classifying the EED markers. 
Our classification system was blinded to the assertions of study authors regarding marker 
category; however we did find that investigators’ categorizations were largely consistent with 
ours. Our classification system was based on the primary function/dysfunction that the test is 
likely to measure or the underlying pathophysiology and pathogenesis that the test may likely 
reflect. For example, the amount of D-xylose that is absorbed after an oral challenge is believed 
to reflect gut absorptive capacity, and D-xylose uptake from the challenge, measured either in 
the blood or urine, is therefore classified as a test of gut absorption. We also aimed to 
unambiguously place a marker in one group based on best fit when possible, though we 
recognize that markers might detect derangements of multiple functions. For example, the 
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 presence of lactose in the blood or urine likely indicates a loss of lactase enzyme in the 
intestinal brush border, and thus can be a marker of abnormal digestion or nonspecific intestinal 
injury. However, for lactose to traverse the mucosa and gain access to the systemic circulation, 
a porosity defect is needed. Hence, we chose to place this marker in the permeability category.  
Finally, we recognize that many tests reflect nonspecific injury and processes, which 
cannot be so easily binned into mechanistic or pathophysiologic categories. For example, while 
measures of surface area on a biopsy provide a general impression of absorptive capacity, we 
categorize histopathology as a measure of nonspecific injury, as the visualization of tissue 
portrays a general picture of derangements in architecture without specifying function.  
With these factors in mind, we formulated eight test categories, classified in Table 12, 
and constructed evidence tables based on these classifications. 
Table 12. Classification framework for biomarkers of intestinal function/dysfunction and 
inflammation. 
Evidence 
Table Type of Functional Measure 
1 Absorption 
2 Porosity/permeability (with or without assessment of absorption) 
3 Digestion 
4 Intestinal inflammation and/or intestinal immune activation 
5 Systemic inflammation and/or systemic immune activation 
6 Microbial drivers 
7 Nonspecific intestinal injury 
8 Non-small intestine organ function 
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Chapter 5. Systematic Review Results by 
Biomarker Classifications 
5.1 Markers of Absorption and Permeability: 
Overview 
Tests of gut permeability and of absorption often overlap in concept, and are frequently 
performed simultaneously. For this reason, it is appropriate to provide background in tandem. 
Proper functioning of the intestine depends on sufficient absorptive surface area and 
maintaining the barrier function and structural integrity of the lining of this organ. Absorptive 
surface is a function of individual villous surface area, as depicted in the photos below [3], and 
of gut length, which is probably not compromised in post-natally-acquired enteropathic 
syndromes. Absorption depends on the ability of various cellular mechanisms to assimilate 
nutrients from food that is ingested, using processes that rely on specialized pumps, pathways, 
and degradation. Integrity reflects 
sieve size, and presumably passive 
diffusion of large molecules across 
non-intact epithelia. To varying 
extents, these functionalities are 
hindered in EED, celiac disease, and 
small bowel Crohn’s disease, among 
other disorders.  
To perform its functions, the 
intestinal epithelium utilizes a layer of 
 
Microvilli of the small bowel, as seen with a magifying lens 
[3]. Normal finger-like projections are presented in the top 
panel. Enteropathy is characterized by flattened villi (bottom 
panel).  Reproduced from Gut, Booth, C.C., Vol. 5, p. 46, 
1964 with permission from BMJ Publishing Group Ltd. 
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 highly specialized columnar epithelial cells connected by the apical junctional complex of tight 
junctions and adherens junctions. Theoretically, specific molecules can be chosen strategically 
to interrogate these various attributes. For example, breaches in integrity that enable passive 
diffusion into the host could be measured by ingesting a substance that is not found in the diet, 
and measuring its concentration in the blood or urine. Another detection strategy would be to 
use a molecule that is easily absorbed in health and disease, but where absorption is limited 
only by mucosal surface availability, and, similarly, measure this tracer in urine and blood. The 
optimal challenge substances would resist digestion in the gut, be nontoxic, and be easily 
measured. Ideally, one attribute (surface area) can and should be measured in parallel with the 
other (specific uptake). Lastly, it might be difficult to separate one function (i.e., permeability) 
from the other (absorption); therefore these two processes are discussed in tandem in this 
section.  
5.1.1 Sugars as Tracers of Intestinal Function 
Historically, sugars have served well as tracers of intestinal function. These substances 
are nontoxic, easily detected in blood or urine, and, most importantly, neither made, nor 
degraded, by the host, so their presence in the body reflects gut uptake. Most of these sugars 
are assayed after ingestion of a load. Some of these sugars are “endomolecular,” i.e., 
consumed as part of a normal diet, but most are “xenomolecular,” i.e., foreign to natural diets, 
not metabolically necessary for the host, and absorbed without the benefit of specific 
transporters. Because they are foreign to the human diet, their use as a marker of intestinal 
function requires administration of a load to assay presence in body fluids. Moreover, depending 
on their size and the physiology of their assimilation, these sugars can be used to probe either 
amalgamated function, or specific processes or lesions (see Table 13).  
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assessed when found 
in blood and/or urine / 
Other comments 












synthesized by wood. 






Measure of small bowel 
permeability, although 













Measure of small bowel 
permeability. Usually 
normalized to mannitol. 
1 We use the term xenomolecular for probes that would not be ingested in a normal dietary environment, while endomolecular probes are common 
and/or necessary dietary constituents. Therefore, endomolecular probes or their breakdown products are typical constituents in body analytes. 
Table 13. Sugar probes.





assessed when found 
in blood and/or urine / 
Other comments 




Measure of total small 
bowel absorptive 
capacity. 








Has been used in lieu of 
mannitol as a measure of 









Measure of colonic 
permeability. Active 







Measure of gastric 
permeability. 
 
Table 13. Sugar probes.
 An early sugar that was employed as an indicator of intestinal function was D-xylose 
[181, 182], a pentose, which remains a standard for single sugar absorption testing worldwide. 
Humans do not synthesize D-xylose isomerase. Following an enteral challenge, the molecule is 
eliminated intact by renal clearance, after circulating in the blood. It is largely passively 
absorbed in the small bowel. The mechanism of clearance is glomerular filtration without 
demonstrated tubular reabsorption or renal tubular excretion. Hence, uptake of D-xylose can be 
assayed by seeking the peak in the serum or by collecting urine for assay. The assay for D-
xylose currently relies on isotopic or photometric assays [183]. Its main limitation is that a single 
sugar cannot differentiate loss of absorptive function from loss of absorptive area (e.g., due to 
shortened bowel length). Other single sugars that indicate absorptive function include mannitol 
and rhamnose. Sugars that are not absorbed by an intact healthy gastrointestinal tract better 
reflect porosity including lactose and lactulose in the small intestine, sucrose in the stomach, 
and sucralose in the large intestine. 
The second class of sugar absorption tests utilizes two sugars. One sugar reflects total 
small bowel absorptive capacity, and is most often mannitol or, occasionally, rhamnose. This 
"denominator" sugar requires no specific uptake mechanisms or host attributes except for 
available surface area. The “numerator” sugar in these dual tests is most often lactulose 
although lactose, sucrose, and sucralose have also been used. These large molecules enter the 
host by passive diffusion in the presence of alterations of the integrity of the small bowel 
(lactulose and lactose), stomach (sucrose), or colon (sucralose).  
Dual sugar tests have additional advantages. A single molecule might be affected by 
factors that are not related to the permeability process, e.g., rates of gastric emptying and 
intestinal transit, bacterial degradation, or the sufficiency of urine collection. In contrast, a ratio 
of excretion of two molecules is not susceptible to these factors, because such processes act on 
both molecules similarly, and the ratio is the key retained metric. However, absolute values 
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 might be low in these situations, and dynamic ranges for uptake are not well established. 
Finally, in adults, some data suggest that the use of hyperosmolar fluids (i.e., lactulose and 
mannitol) might affect absorption via solvent drag [184]. For purposes of comparison, the four 
grams of lactulose and one gram of mannitol dissolved in five milliliters of water, a commonly 
employed formulation [185] produces a solution that is 4,629 mOsm/kg as compared to normal 
plasma osmolality of 270-285 mOsm/kg.  
Variations on the challenge and recover motif used in the classic sugar absorption 
studies warrant discussion. Some studies use indirect assessments of uptake. For example, 
non-absorbed D-xylose can be metabolized by microbes in the bacteria-rich colon, and possibly 
also in small bowel bacterial overgrowth, and measured as exhaled carbon dioxide.  
We reviewed 36 studies that assessed small intestinal absorption or permeability using 
sugars as absorbed probes. Three studies measured lactose, an endomolecular sugar, either in 
the serum (n=1) or urine (n=2) among breastfeeding children. Of the 36 studies, 35 assessed 
malabsorption/permeability deficits by administering xenomolecular sugar challenges using 
lactulose, mannitol, rhamnose, or xylose (including one study each that also measured serum 
and urinary lactose). We reviewed five studies that reported xenomolecular probe results 
of single-only sugar tests, and 30 studies that reported results of dual sugar tests. The dual 
sugar tests included urinary L:M (n=25 studies), urinary or serum L:R (n=5), and urinary 
lactose:lactulose (n=1). The single sugar assay was used in six studies: urinary lactose (n=1) 
and D-xylose (two using serum measures, one using urine as a substrate, and two in which the 
body fluid from which the sugar was measured was not reported).  
5.1.2 Endomolecular Nutrients as Tracers of Intestinal Function  
Essential nutrients that are absorbed by healthy small intestine provide another 
opportunity to assess gut absorptive function. These types of marker assessments can provide 
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 especially valuable information regarding the role of derangement of gut function among 
children with nutrient deficiencies, i.e., how much of the deficiency is because of lack of intake 
rather than malabsorption. Since these molecules are naturally found in body analytes, load 
administration requires tagging such as with the use of radiolabeled molecules, quantification of 
which can then be assessed in breath, blood, urine, and/or stool as surrogate markers of 
absorptive capacity. We reviewed six studies that utilized such methodologies including 
assessments of zinc (n=3), lipid (n=2) and iron (n=1) absorption.  
We present in Evidence Tables 1 and 2 data from publications that utilized markers of 
absorption and permeability, respectively. Evidence Table 1 depicts data related to the 
systematic review from the articles that reported results of markers that were principally related 
to absorptive functions (such as D-xylose and fecal fat). Evidence Table 2 contains data on 
markers related to porosity or permeability. However, tests of gut permeability are often 
assessed simultaneously with markers of absorption. For example, the lactulose:mannitol ratio 
(L:M) and lactulose:rhamnose ratio (L:R) are often described as tests of permeability; however, 
by their nature they do include measures of absorption (via mannitol and rhamnose, 
respectively). For this reason, we present markers of permeability with or without concomitant 
assessment of absorption in Evidence Table 2. We identified 44 publications that assessed 
small intestinal absorption (13 studies) or permeability (primarily, sometimes also with some 
assessment of absorption based on dual sugar testing; 31 studies) in children in resource-poor 
settings. 
5.2 Markers of Absorption 
Data regarding markers of absorption are presented in Evidence Table 1. 
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Reference and 
Study Outcomes of  
Diagnostic Interest 
Location and  
Target Population 
Design and 
Sample Size Biomarker Results Conclusion Comments 
2002 
 
Dini E et al. 
 
Sudan III and 
steatocrit in the 




Fecal fat by four 
different testing 
methods as a 
marker of 
malabsorption 







6 mo-9 yr olds with 









• 30 with 
subclinical 
malnutrition 
• 34 with mild 
malnutrition  
• 30 with 
moderate 
malnutrition  





Fecal fat, by method: 
• Sudan III 
classic 








underwent testing for 
all four methods. 
 
Proportions testing positive for 
fecal fat ranged from 33%-41% 
overall, depending on test 
method used. 
 
The proportion testing positive 
varied by nutritional status 
across testing methods: 
• 80%-100% of severely 
malnourished subjects had a 
positive test 
• Similar proportions of subjects 
with subclinical, mild or 
moderate malnutrition tested 
positive, ranging from 30%-
47%  
• 13%-27% of controls tested 
positive 
These differences appeared to 
be significant, but statistical 
comparison results were not 
entirely clear. 
 
Fecal fat did not vary based on 
quantity of fat intake. 
  
By all four methods, a high 
percentage of children with 
parasites tested positive (~60%) 
compared to children without 
parasites (25%).  
 
Associations were observed 
between infection with Giardia 
lamblia or Blastocystis hominis 
and fecal fat (p<0.05); this held 
true across diagnostic methods.  
 
The presence of diarrhea at time 
of testing was positively 
associated with fecal fat by all 
test methods (p<0.02 for all 
except steatocrit classic, 
A majority of children 
studied tested negative 
for fecal fat.  
 
The highest percent 
testing positive was in 
those with severe 
malnutrition, followed by 
those with subclinical-
moderate malnutrition. 
Controls had the lowest 
percent testing positive.  
 
Subjects with enteric 
parasites or those 
experiencing diarrhea at 
time of testing excreted 
fat significantly more 
often than uninfected 
children without 
diarrhea, although the 
magnitude of difference 
was not reported.  
 
There was some 
variation between the 
different testing 
methods, for example 
their relationship with a 
history of diarrhea in the 









for fecal fat by 
history of diarrhea 
(current or 




between tests but 
did not report 
results of statistical 
testing of these 
estimates.  
 









Evidence Table 1. Markers of absorption. 
Biomarkers in bold are primarily markers of malabsorption.
Reference and 
Study Outcomes of  
Diagnostic Interest 
Location and  
Target Population 
Design and 
Sample Size Biomarker Results Conclusion Comments 
p=0.06).  
 
The relationship between fecal 
fat and history of diarrhea in the 
year prior to testing varied by 
test method:  
• Sudan III classic: p=0.134 
• Sudan III modified: p<0.001 
• Steatocrit classic: p=0.14 
• Steatocrit acid: p=0.015  
 
Agreement between all four 
methods was 72%. Agreement 















Small intestinal and 
rectal biopsy to 
assess morphology 





Sao Paulo, Brazil 
 
5 mo-12 yr old 
(median 24 mo) HIV-
infected subjects 
recruited from a 
hospital and clinic. 
 
All subjects had 







n=5 patients with 




n=6 patients with 











Biopsy of small 










100% had low D-xylose 
absorption: 
• Mean: 15.6 mg/dL 
• SD: 5 
• Range: 8.9-24.4 
• Median: 14.2  
 
Small intestinal biopsy:  
• 100% had some degree of 
villous atrophy based on a I-IV 
grading system: 
• Grade I: 3 
• Grade I/II: 2  
• Grade II: 1 
• Grade II/III: 1 
• Grade III/IV: 1 
• 2 samples were too 
superficial to assess 
• Intraepithelial lymphocytes 
were increased in half of the 
biopsies. 
• Lymphocytic and 
polymorphonuclear (PMN) 
infiltration of the lamina 
propria were present in 10/10 
and 7/10 biopsies, 
respectively. 
 
There was a high 




regardless of diarrhea 
status.  
 
All patients also had 
cellular infiltration of the 
lamina propria and 
varying degrees of 
villous atrophy. 
 
There was no correlation 
between D-xylose and 
degree of villous atrophy 




language article.  
 
D-xylose <25 mg/dL 
was defined as 
indicative of 
malabsorption. This 
value is higher than 
what some 
references have 




system of grading 
villous atrophy.  
 
Results were not 
presented by 
diarrhea status, 
perhaps due to 
small sample size. 
Evidence Table 1. Markers of absorption. 
Biomarkers in bold are primarily markers of malabsorption.
Reference and 
Study Outcomes of  
Diagnostic Interest 
Location and  
Target Population 
Design and 
Sample Size Biomarker Results Conclusion Comments 
Rectal biopsy: 
• 100% had normal architecture 
Lymphocytic and PMN infiltration 













with iron only or iron 






receiving zinc as 






3-4 yr olds residing 
in a poor community 
at the periphery of 
Lima with stunting 
and moderate 
anemia as a 
surrogate risk factor 






both initial and 
follow-up 
absorption assay 












wheat flour with 
iron and 3mg 





n=15 wheat flour 
with iron and 9mg 





Zinc excretion to 
measure fractional 
absorption of zinc 
(FAZ) and total 





Mean zinc parameters (SD) at 
initial assessment: 
• FAZ:  
• Group 1: 0.34 (0.11) 
• Group 2: 0.24 (0.05) 
• Group 3: 0.13 (0.04) 
• TAZ (mg/d):  
• Group 1: 0.71 (0.18) 
• Group 2: 1.11 (0.21) 
• Group 3: 1.34 (0.47) 
 
Neither mean FAZ nor TAZ 
changed significantly at 
subsequent assessments in any 
treatment group. 
 
In both the initial and 
subsequent assays, mean TAZ 
from zinc-fortified meals 
increased with increasing 
amounts of fortification (p< 
0.001). However mean FAZ was 
inversely related to zinc intake 
from these meals (p<0.001). 
 
Non-fortified dinner FAZ and 
TAZ were significantly lower in 
the group receiving the most 
zinc-supplementation at the 
initial assay (p=0.015 and 
p=0.012, respectively) despite 
no difference in zinc intakes 
from the unfortified dinner by 
treatment group. This 
relationship between groups was 
not observed at the second 
assay; however, a significant 
decrease of 16% in mean FAZ 
Despite a reduction in 
FAZ with increasing 
fortification, TAZ 
increased as more zinc 
was consumed and with 
increasing 
concentrations of zinc 
fortification. 
 
Authors speculate that 
reduction in FAZ with 
increasing fortification 
could be due to factors 
such as saturation 
kinetics.  
 
Authors described a 
unexpected finding:  
subjects consuming 
more zinc from the zinc-
fortified breakfast 
and lunch meals 
absorbed less zinc from 
the unfortified 
dinners during the initial 
absorption assay.  
 
Intestinal function 
could play a role in 
zinc (or other 
micronutrient) 
absorption; such 
factors were not 
explored in this 
study. 
 
The principal aim of 
this study was to 
determine 
appropriate extent 
of zinc fortification 
of a staple food in a 
specific community; 
we present only 
results relevant to 
this review. 
Evidence Table 1. Markers of absorption. 
Biomarkers in bold are primarily markers of malabsorption.
Reference and 
Study Outcomes of  
Diagnostic Interest 
Location and  
Target Population 
Design and 
Sample Size Biomarker Results Conclusion Comments 
and TAZ from the unfortified 
dinners was observed between 
initial and subsequent assays 
(p<0.001).  
 
Mean plasma zinc 
concentrations did not differ 
between treatment groups 
throughout the study period. The 
proportion with low fasting 
plasma zinc concentrations 
(<65μg/dL) was lower at the end 




Manary ML et al. 
 






Zinc absorption in a 






2–5 yr olds (mean 
age 43.6 mo, SD 
7.7) from rural area 
attending 
immunization clinic.  
 
There was a high 
prevalence of 
stunting and low 













Zinc excretion to 
measure fractional 
absorption (FAZ) 






• FAZ: 0.24 (0.04) 
• TAZ (mg/d): 1.30 (0.33)  
• EFZ (mg/d): 1.15 (0.33) 
 
Language in the discussion 
section strongly suggests, but 
does not explicitly state, that 
TAZ and EFZ were not 
correlated. Correlation analysis 
for these parameters was not 
reported. 
 
EFZ was higher than 
would be expected for a 
zinc deficient cohort, and 
EFZ was not correlated 
with TAZ as would have 
been expected. While 
high-phytate diets 
leading to poor zinc 
absorption might explain 
these findings, the 
authors note that in a 
previous study (among a 
somewhat older age 
group) there were no 
differences in EFZ 
among children 
consuming high- or low-
phytate diets [187]. They 
note that such 
perturbations in EFZ 
have also been reported 
in children with 
enteropathy due to 
cystic fibrosis [188] and 
suggest that a similar 
process could be going 
on in these Malawian 
children due to TE.  
 
Authors note that 
the lack of 
comparable 
data from children 
of the age range in 
this study limits 
data interpretation. 
They also provide 
results per body 
weight due to 
presumed 
relationship; validity 
of such measures 




that the methods 




accurate, but quite 
difficult to conduct, 
especially among 
children. 
Evidence Table 1. Markers of absorption. 
Biomarkers in bold are primarily markers of malabsorption.
Reference and 
Study Outcomes of  
Diagnostic Interest 
Location and  
Target Population 
Design and 
Sample Size Biomarker Results Conclusion Comments 
2001 
 
Mittal SK et al. 
 
Tropical sprue in 
north Indian children 
 
D-xylose and 
duodenal biopsy as 




0-15 yr old 
gastroenterology 
clinic patients with 
PD.  
 
Those with abnormal 
morphology on 
biopsy, abnormal D-
xylose test, and 
clinical response to 
antibiotics were 
diagnosed as having 
TS.  
 
Those with abnormal 
morphology and 
response to gluten-
free diet were 
diagnosed with CD. 
We include data on 








(38 with repeat 
biopsies) 
 
<5 yr old: n=44  
Duodenal biopsy, 






• D-xylose*  
 
 
* Not specified 
whether from urine or 




36 (38.3%) were diagnosed with 
TS including 14/44 (31.8%) who 
were under 5 years of age.  
 
18 (19.1%) were diagnosed with 
CD.  
 
Degree of villous atrophy among 
TS vs. CD patients:  
• Mild in 8/36 (22.2%) vs. 0 
• Moderate in 23/36 (63.9%) vs. 
4/18 (22.2%) 
• Severe in 5/36 (13.9%) vs. 
14/18 (77.8%)  
 
Mean hemoglobin concentration 
(range) among TS patients was 
8.3 g/dL (5.5-11) and did not 
differ from values of those with 
CD.  
 
Among the 22 TS patients, 
repeat biopsies showed: 
• 16 with normalization 
• 5 with improvement  
• 1 worsened despite marked 
clinical improvement  
 
The D-xylose test was abnormal 
in all TS patients by diagnostic 
definition. 
More than half of the GI 
clinic patients with PD 
had some degree of 
villous atrophy.  
 
More than one-third and 
almost one-fifth of 
subjects were diagnosed 
with TS and CD, 
respectively.  
 
By study diagnostic 
definition, all TS patients 
improved with treatment.  
Among those who had 
repeat biopsies, almost 
three-quarters showed 
normalization of 
histology, while 23% had 
partial improvement and 
1 patient had worsened 
pathology. 
 
Biopsy results were 
not provided for 
patients without TS 
or CD.  
 
It was unclear if 
there were patients 
with abnormal D-
xylose and 
histology who did 
not respond to 
antibiotic therapy 
and therefore were 
not diagnosed with 
TS. 
 
Cut-off points used 
to define abnormal 



















inclusion criteria of 
no GI symptoms, no 












• Lactose HBT  







* Reported as parts 
Mean lactose HBT (SE): 
• Cases pre-treatment: 3.6 
(0.75) ppm  
• Cases post-treatment:  -0.85 
(0.75) ppm (p<0.05 compared 
to pre-treatment) 
• Controls: 0.19 (0.81) ppm 





normal according to 
established cut-points 
among all subjects.  
 
However, lactose HBT 
was significantly higher 
among cases compared 
to controls and there 
Statistical methods 
might not have 




the same group of 
subjects (cases) 
before and after 
treatment.  
1 D-xylose results were expressed as % of dose administered. 
Evidence Table 1. Markers of absorption. 
Biomarkers in bold are primarily markers of malabsorption.
Reference and 
Study Outcomes of  
Diagnostic Interest 
Location and  
Target Population 
Design and 






breath test (HBT) as 
a marker of lactose 
absorption, and 
xylose breath test 
and urinary excretion 







preceding 3 wk, and 
no SBBO by 

















were verified for 
absence of 
parasites. 







positive HBT is 
considered to be a 
rise of >20ppm in 




** Investigators did 





us to assume that it 
was the dextrorotary 
(D) enantiomer. 
 
Mean xylose HBT (SE): 
• Cases pre-treatment: 2.2 
(0.69) ppm for infected group  
• Cases post-treatment:   -4.16 
(0.69) ppm (p<0.05 compared 
to pre-treatment) 
• Controls: 1.13 (0.74) ppm (NS 
compared to pre-treatment 
cases) 
 
Mean urinary excretion of xylose 
(SE) among cases pre-treatment 
and post- treatment was 34% (3) 
and 46% (11), respectively (NS), 





was also a significant 
decrease in lactose HBT 
among cases after 
treatment. The clinical 
relevance of such mildly 
elevated HBT results in 
asymptomatically 
infected children is 
unclear.  
 
Results did not 
demonstrate xylose 
malabsorption by either 
urinary or breath 
measures among any 
group. While urinary 
results did not differ 
before and after 
treatment, case xylose 
HBT was significantly 
lower after treatment; 
again the clinical 
significance of such 
results is not apparent. 
  
Investigators 
wished to exclude 
children with SBBO. 





production of H2 
following ingestion 
of lactulose and 
with minimal urinary 
indoxyl sulfate 
excretion. The 
number of children 
excluded due to 
failure to meet 












Stool recovery of 
radiolabeled 
products as markers 
of lipid digestion and 
absorption, and bile 
salt deconjugation 
as a marker of 
SBBO among 
children with severe 
Kingston, Jamaica 
 
5-23 mo olds 
admitted to the 
Tropical Metabolism 
Research Unit of the 
University of the 








divided into 3 
groups of 8 
children, each 





collected in three 
separate phases 
as described 
above in JL 
Murphy et al. 
2001 [149].   
Stool Tests: 
• Total and 
fractionated 13C 
following 
ingestion of one 





• 13C stool assay 
following 
administration of 




* To assess fat 
excretion as a % of 
Median total stool excretion of 
13C in phase 1 was 9% (range: 
1%-29%) and did not vary 
between TG groups.  
Median 13C excretion dropped 
33%-99% in phase 2 and 86%-
95% in phase 3 compared to 
phase 1 (p<0.05 each). 
 
Over the study period, there 
were significant associations 
between total lipid and the 
amount of 13C labeled TGs in 
stool for some groups, but not 
for others. 
 
Median 13C in TG and FA was 
similar across TG groups in all 
phases. 13C FA recovery was 
High concentrations of 
13C (compared to 
healthy UK children) 
[190] were observed in 
half of the subjects at 
admission, reflecting 
impaired digestion or 
absorption.  
 
The differences in stool 
13C were wide but not as 
extreme as in a previous 
study by same 
investigators (also 
examined in this review) 




Authors state that 
the study was not 
powered to 
compare the 
different TGs, but 
they contend that 
medium chain 
trilaurin did not 
appear to be 
processed 
differently than the 




Authors did not 
describe the 
method used to 
assign subjects to 
Evidence Table 1. Markers of absorption. 
Biomarkers in bold are primarily markers of malabsorption.
Reference and 
Study Outcomes of  
Diagnostic Interest 
Location and  
Target Population 
Design and 






proportion of 13C in 
triglyceride (TG) and 









** To assess bile salt 
deconjugation in the 
bowel caused by 
SBBO; conducted 
after the TG 
assessment and a 3 
day washout period. 
similar and reduced by ~2/3 
compared to Phase 1. 13C TG 
was not detectable in Phases 2 
or 3. Statistical comparisons 
between phases were not 
reported.  
 
13C after radiolabeled 
glycocholate administration was 
detected in stool at quantities 
considered to be in excess of 
the 7% recovery of dose 
administered upper limit of 
normal in U.S. adults in [189]: 
• Phase 1: 13/24 (54%) 
• Phase 2: 5/24 (20.8%)  
Phase 3: 3/24 (12.5%) 
13C excretion did not 
significantly differ 
between TG groups and 
declined with improving 
clinical course. 
 
Similar to their previous 
study, significantly more 
13C in stool was 
recovered as FA than 
TG, reflecting impaired 
absorption over poor 
lipid digestion/ 
hydrolysis. Unlike in their 
previous study, there 
was evidence of SBBO 
as measured post-
ingestion of 13C 
glycocholate. 
different TG groups.  
 
While it was noted 
that some subjects 
had positive stool 
cultures, details 
were not provided 















Fecal fat, stool 
recovery of 
radiolabeled 
products, and breath 
tests as markers of 
lipid digestion and 
absorption and bile 
salt deconjugation 




7-23 mo olds with 
malnutrition admitted 
to the University of 








collected in three 
separate phases 
(each lasting 9 
days): 
1. Within 48 hours 
of admission 
2. During early 
rehabilitation 
3. During late 
rehabilitation 
Stool Tests: 
• Fecal fat* 












• 13CO2 after 
administration of 
13C glycocholate 
(GCA)*** or 13C 
TP**** 
 
* In 72 hour stool 
collection (measured 
as total grams and as 
Mean fecal fat (SD): 
• Phase 1: 2.4 g/day (3.6) or 
5.9% (9.4) of dietary lipid 
intake 
• Phase 2: 1.7 (0.9) g/day, or 
3.3% (2.4) of intake  
• Phase 3: 0.9 (0.6) g/day, or 
1.4% (0.7) of intake 
• Differences between phases 
were not statistically 
significant. 
 
Total excretion of 13C in stool 
also varied widely across 
patients (0%-44%) and did not 
differ between study phases.  
 
Correlation between fecal fat 
and 13C (r=0.48; p<0.05) was 
observed.  
 
Lack of lipid digestion and 
absorption were assessed by 
Mean fecal fat was not 
elevated compared to 
published norms [191, 
192], during any study 
phase.  
 
There was wide variation 
in fecal fat at 
presentation, and wide 
variations in stool 13C 
across subjects. Authors 
indicate that this is the 
first such assessment in 
malnourished children; 
previous studies on 
healthy children from the 
UK demonstrated 
average excretion of 6% 
[190]. 
 
The majority of excreted 
13C was in the form of 
FA rather than TG. 
Statistical methods 
might be 
inappropriate for a 
small sample. 
 





this might have 
affected GCA 
testing. 
Evidence Table 1. Markers of absorption. 
Biomarkers in bold are primarily markers of malabsorption.
Reference and 
Study Outcomes of  
Diagnostic Interest 
Location and  
Target Population 
Design and 
Sample Size Biomarker Results Conclusion Comments 
children with severe 
malnutrition 
% of dietary fat 
intake). 
 
** To assess fat 
excretion as a % of 
dose administered. 
Also assessed 
proportion of 13C in 
triglyceride (TG) and 
fatty acid (FA) 
fractions to 
distinguish excretion 
caused by impaired  
digestion (presence 




*** To assess bile 
salt deconjugation in 
the bowel caused by 
SBBO; conducted 
after the TG 
assessment and a 3 
day washout period. 
 
**** Expressed as a 
percentage of 
absorbed label (dose 
administered - label 
recovered in stool) to 
assess oxidation for 
acute energy needs. 
measuring TG and FA fractions, 
respectively. Mean 13C TG 
recovery (SD) (% of 
administered dose), number of 
patients excreting TG: 
• Phase 1: 0.7% (1.6), n=3 
• Phase 2: 0.9% (2.8), n=1  
• Phase 3: no recovery from 
any subjects, differences 
between phases were NS 
 
13C FA fraction in stool declined 
during rehabilitation. 
Mean 13C FA recovery (SD): 
• Phase 1: 6.0% (7.3)  
• Phase 2: 4.8% (3.7)  
• Phase 3: 3.3% (3.8),  
differences between phases 
were NS 
  
Mean FA values were ~9x (NS), 
5x (p<0.001), and 3x (p<0.05) 
higher than mean TG values in 
Phases 1, 2, and 3, respectively. 
  
Following administration of 
labeled TP, absorbed 13C label 
by breath analysis was ~5% 
(range 0%-21.2%) and similar 
across study phases.  
 
Following the administration of 
labeled GCA, there was either 
no or minimal recovery of 13C in 
stool and 13CO2 on breath (as % 
of dose administered) in all 
phases. 
Authors interpreted this 
to reflect failure of lipid 
absorption in the face of 
adequate digestion/ 
hydrolysis. Each form 
(FA and TG) was found 
in decreasing values as 
the study phases 
progressed, suggesting 
improved digestion and 
absorption, although 
results did not differ 
significantly.  
 
Fecal fat was correlated 
with concentrations of 
13C in stool.  
There was no evidence 
of SBBO or bile acid 
malabsorption.  
 
13CO2 excretion following 
administration of 13C TP 
was minimal, suggesting 
a propensity for 
deposition in adipose 
tissues rather than 
oxidation for immediate 
energy needs. The 
authors report that this 
breath test has not been 
widely used, but that 
healthy UK children 
have breath excretion 
values from 15%-43% 
[190], compared to a 
mean of 5% and range 
0%-21% in this cohort; 
the latter findings were 
more similar to results 
from kwashiorkor 
patients where 13C-
labeled oleic acid was 
Evidence Table 1. Markers of absorption. 
Biomarkers in bold are primarily markers of malabsorption.
Reference and 
Study Outcomes of  
Diagnostic Interest 
Location and  
Target Population 
Design and 
Sample Size Biomarker Results Conclusion Comments 
used as substrate [193]. 
2000 
 
Nichols B et al. 
 
Contribution of 
villous atrophy to 
reduced intestinal 











maltase and villous 
atrophy and other 
mucosal intestinal 
markers indicative of 
loss of enterocytes 
and enterocytic 
function. 
Sao Paulo, Brazil 
 
Cases were children 
(mean age 9.9 mo, 
SD 8.1) hospitalized 
with malnutrition 




children (mean age 
3.6 mo, SD 1.0) with 
HAZ and WAZ 
scores >-2 and 
normal intestinal 
mucosa on biopsy, 
hospitalized for 






n=24 cases  
 











































* Mucosal atrophy 
was scored on a 
scale of 1 (absence 
of atrophy compared 
to an organ donor) to 
4 (similar to children 
with active CD). 
 
Mean villous atrophy score (SD): 
• Cases: 2.6 (0.8) 
• Controls: 1.2 (0.5), p=0.006) 
 
WAZ score was correlated with 
villous atrophy (r=0.65, p- value 
not reported).  
 
13/25 [sic] cases and 0/5 
controls had subnormal (defined 
as <94U/g protein) of maltase 
activity; mean maltase was 34% 
lower among cases (p=0.11). 
Maltase activity did not appear 
to decrease with WAZ score 
(further details not provided). 
 
However, in sub-analyses 
among those samples with an 
adequate β-actin, a 
housekeeping gene message, 
(n=10 cases, n=9 controls), 
cases’ findings expressed as a 
mean percent of controls' (SD) 
included: 
• Villous length (reciprocal of 
atrophy score): 38.9 (41.6), 
p=0.004 
• Maltase activity: 37.1 (23.2), 
p=0.001 
• MGA mRNA: 45.1 (36.4), 
p=0.016 
• Villin mRNA: 52.5 (22.6), 
p=0.003 
• SGLT mRNA: 66.6 (23.1), 
p=0.057 
• β-actin: 88.2 (15.8), p=0.189 
 
Both villous length and maltase 
activity in a subset of cases 
were less than 40% of control 
values.  
The malnourished 
children had significantly 
greater villous atrophy 
than the younger 
controls. 
 
Among the subset tested 
for mRNA messages, 
maltase activity as well 
as the mRNA 
abundances for MGA, 
villin and SGLT were 
significantly correlated 
with case status and 
were correlated with 
villous atrophy. 
 
While maltase deficiency 
has been reported in 
malnutrition in other 
studies, authors assert 
that these are the first 
results that directly 
support the hypothesis 
that reductions in 
maltase activity are due 
to villous atrophy. This 
study also nicely 
correlates mRNA 
relative abundance with 















they mocked up ex 
vivo mucosal 
biopsies in these 
controls, resections 




compared to cases’ 
samples derived 
from mucosal 
biopsies. While this 
probably doesn’t 







will bring in more 
diverse populations 
of cells; only some 
of them might have 
transcripts of 
interest. However, 
the bias is likely in a 
direction that would 
reduce effect size. 
 
Evidence Table 1. Markers of absorption. 
Biomarkers in bold are primarily markers of malabsorption.
Reference and 
Study Outcomes of  
Diagnostic Interest 
Location and  
Target Population 
Design and 
Sample Size Biomarker Results Conclusion Comments 
Histology among 




MGA, villin, and SGLT mRNA 
abundances were correlated 
with villous atrophy score 
(r=0.73), (r=0.76), and (r=0.54), 
respectively (p-values not 
reported)1.  
 
MGA mRNA abundance was 
correlated with maltase activity 
(r=0.32). 
It was unclear if 
control inclusion 
criteria included 
absence of atrophy 





might not have 
adequately taken 
into account the 




Subsets of subjects 
were investigated 
for various tests. 
For example, 10 
cases had mRNA 
analyses based on 
β-actin adequacy. 
Another instance of 
selected testing 
was the subset of 
22 and 15 cases 
that had WAZ score 




Rationale for subset 










18 mo-14 yr old HIV-
infected children with 









Prevalence of an abnormal D-
xylose result was 7.7%.  
 
Mean D-xylose (SD, range): 
42.8mg/dL (14.4mg/dL, 16-73 
D-xylose showed 
substantial variation 






D-xylose <25 mg/dL 
was defined as 
1 Villin and SGLT1 were assessed as a ratio with housekeeper gene β-actin. 
Evidence Table 1. Markers of absorption. 
Biomarkers in bold are primarily markers of malabsorption.
Reference and 
Study Outcomes of  
Diagnostic Interest 
Location and  
Target Population 
Design and 
Sample Size Biomarker Results Conclusion Comments 
of D-xylose in 





D-xylose as a 
marker of intestinal 
absorption among 
HIV-infected children 
with and without GI 
symptoms 
symptoms of HIV 
infection recruited 
from a pediatric 
AIDS center.  
mg/dL)  
 
D-xylose was not associated 
with age. 
 
Of the 8 children with abnormal 
results, 1 had diarrhea. Of 19 
with diarrhea, 1 had an 
abnormal result. 
 
Of those with abnormal results, 
50% had Cryptosporidium 
infection. Of the 33 subjects with 
Cryptosporidium infection, 4 had 








Poddar U et al. 
 
Celiac disease in 
India: Are they true 




xylose, and fecal fat 
in children with 





18 mo-14 yr olds 
with PD, FTT, or 




Subjects with normal 
crypt:villous ratio on 
biopsy were of 















* In 72-hour stool 
collection. 
 
** Not specified 
whether from urine or 
serum, and units of 
measurement not 
provided. 
38% had chronic inflammatory 
cell infiltrates in the lamina 
propria.  
 
55% had abnormal D-xylose 
concentrations. 
 
20% had abnormal fecal fat test. 
 
No results beyond proportion 
positive were reported for any of 
the above markers. 
 
Among controls with 
normal mucosal 
architecture by biopsy, 
more than one-third had 
PD. 
 
D-xylose and fecal fat 
might not correlate well 
with duodenal biopsy 
results. 
Relationships 
between fecal fat, 
D-xylose and 
biopsy results were 
not reported. 
 
While 38% of 
controls had PD, 
results for the 
markers studied 
were not stratified 
by PD for this 
group.  
 
Seven children with 
biopsies consistent 
with CD did not 
respond to gluten-
free diet and were 
excluded from the 
study.  
 
Cut-off points used 
to define abnormal 
D-xylose tests were 
not provided. 
Evidence Table 1. Markers of absorption. 
Biomarkers in bold are primarily markers of malabsorption.
Reference and 
Study Outcomes of  
Diagnostic Interest 
Location and  
Target Population 
Design and 
Sample Size Biomarker Results Conclusion Comments 
2004 
 










among children with 
iron deficiency 
anemia with and 




 2-5 yr old apparently 
healthy children from 
a periurban setting, 
screened for iron 











infected with H. 
pylori 
 
n=12 controls not 







Mean1 iron absorption from 
ferrous (Fe) sulfate and Fe 
fumarate:  
• Uninfected children: 15.6% 
and 5.4%, (p<0.001) 
• Infected children before 
treatment: 19.7% and 5.3%, 
(p<0.0001)  
• Infected children after 
treatment: 22.5% and 6.4%, 
(p<0.0001)  
• H. pylori treatment did not 
significantly affect absorption 
(Fe sulfate or fumarate), 
p=0.3 
 
Iron absorption from Fe 
fumarate was 
significantly lower than 
from Fe sulfate. 
  
Results do not support 
the hypothesis that H. 
pylori infection 
influences absorption of 
water-soluble (Fe 
sulfate) or non-water-
soluble (Fe fumarate) 
iron compounds.   
 
 
Data on iron 
absorption among 
2-5 yr olds are 
limited, making 
comparison of 





Sheng XY et al. 
 
Major variables of 
zinc homeostasis in 
Chinese toddlers 
 
Differences in zinc 
absorption in healthy 
toddlers with a high 
prevalence of zinc 
deficiency. 




19-25 mo olds 
recruited from a 
remote small town 
and 2 surrounding 
rural villages.  
 




Dietary zinc intake 
was low.  
 
There was a high 
prevalence of 














Zinc excretion to 
measure fractional 
absorption of zinc 
(FAZ) and total 







• FAZ: 0.35 (0.12) 
• AZ (mg/d): 0.63 (0.24) 
• EFZ (mg/d): 0.67 (0.23) 
 
The quantity of absorbed zinc 
was lower than physiologic 
requirements. 
 
There was no statistically 
significant difference in any 
laboratory value between the 
town and village groups. 
 
Zinc absorption was ~80% of 
estimated physiologic 
requirement and equivalent to 
the amount of endogenous zinc 
excreted via the intestine; it was 
expected that absorbed zinc 
would exceed excreted zinc 
[144, 187, 194, 195] 
Zinc absorption was 
lower than physiologic 
requirements and EFZ 
was higher than 
expected. 
 
The authors note that 
the results are difficult to 
explain and specifically 
state that they do not 
think (though without 
clear justification) that 
enteropathy is prevalent 
in the population and 
therefore could not be a 
contributing factor. 
 
Notes: Some studies included subjects ≥5 yr of age. Where these studies provided data separately for children <5 yr, we present results for only those subjects. 
Where these studies did not stratify results by age, but did report the number of children <5 yr included in the study, we provide a breakdown of under-5s. 
1 Geometric mean. 
Evidence Table 1. Markers of absorption. 
Biomarkers in bold are primarily markers of malabsorption.
Reference and 
Study Outcomes of  
Diagnostic Interest 
Location and  
Target Population 
Design and 
Sample Size Biomarker Results Conclusion Comments 
All studies reporting lactulose:rhamnose ratio results presented values multiplied by a factor of 100 for ease of reporting. 
 
Abbreviations: AD=acute diarrhea, ALT=alanine aminotransferase, AST=aspartate aminotransferase, CBC=complete blood count, CD=celiac disease, CI=95% confidence interval, 
Cr=creatinine, ∆=change in, EED=environmental enteric dysfunction, FTT=failure to thrive, GI=gastrointestinal, HAZ=height-for-age Z-(score), HDL=high density lipoproteins, 
HIV=human immunodeficiency virus, HLA=human leukocyte antigen, IEL=intraepithelial lymphocytes, IgA=immunoglobulin A, IgE=immunoglobulin E, IgG=immunoglobulin G, 
IgM=immunoglobulin M, IL=interleukin, IFN=interferon, LDL=low density lipoproteins, L:M=lactulose:mannitol ratio, mo=month(s), NS=not statistically significant, PD=persistent 
diarrhea, RCT=randomized controlled trial, SBBO=small bowel bacterial overgrowth, SD=standard deviation, SE=standard error, SES=socioeconomic status, Tc-99m=technetium 
99, T3=triiodothyronine, T4=thyroxine, TE=tropical enteropathy, TGF=transforming growth factor, TNF=tumor necrosis factor, TS=tropical sprue, WAZ=weight-for-age Z-(score), 
WBC=white blood cell count, WFA=weight-for-age, WHZ=weight-for-height Z-(score), wk=week(s), yr=year(s) 
 
 
Evidence Table 1. Markers of absorption. 
Biomarkers in bold are primarily markers of malabsorption.
Thirteen studies used markers of intestinal absorption among children in resource-
limited settings. The range of markers included urinary, breath and serum markers of sugar 
absorption, fecal fat as a marker of lipid absorption, measures of endomolecular absorption, and 
presence of messenger RNAs in intestinal tissue as markers of intestinal surface area, and, by 
inference, absorptive capacity.  
5.2.1 D-Xylose 
While single molecule tests have disadvantages compared with dual molecule tests, as 
discussed above, the D-xylose test has been commonly used to assess malabsorption in 
developing settings. There has been further criticism of this test, including its potential hepatic 
metabolism of the sugar [196] and jejunal absorption [197].  
D-Xylose was the most commonly reported measure of small bowel absorption in the 
literature that we reviewed and was employed in five studies. It was assessed either in serum 
(n=2) [136, 152] or urine (n=1) [147], although in two studies the substrate from which D-xylose 
was measured was not reported [146, 155]. Although one of these reports did not specify the 
xylose enantiomer [147], test functionality characteristics led us to assume it was the 
dextrorotary (D) enantiomer, as was used in the other studies. This study, in addition to 
assessment of urinary excretion of the sugar, also measured hydrogen excretion in breath 
before and after administration of the xylose. Three of the studies [136, 146, 147] provided 
demographic information stratified by age group and together included 58 children under five 
years of age. However, none of the studies presented D-xylose data by age group. Overall, the 
five studies included D-xylose results for 267 children up to the age of 14 years.  
Two of the studies investigated the association of D-xylose with degree of villous atrophy 
on biopsy. One of these studies performed D-xylose tests in children with symptoms of celiac 
disease and normal architecture on duodenal biopsy, although approximately one-third had 
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chronic inflammatory cell infiltrates in the lamina propria [155]. This publication reported 
abnormal D-xylose results in 55% of these subjects (but did not provide information on the 
range of normal and abnormal concentrations, sampling site, or units of measure of D-xylose). 
Their results suggested that the D-xylose test might not correlate well with intestinal 
histopathology, especially crypt:villous architecture. The other study was among HIV-infected 
children with protein-energy malnutrition in Brazil [136]. All subjects’ tissue had cellular 
infiltration of the lamina propria and varying degrees of villous atrophy on biopsy, and all 
subjects also had abnormally low D-xylose absorption (based on authors’ reported cutoff value 
of <25 mg/dL). However, there was no correlation between the proportion of serum D-xylose 
absorption and the degree of villous atrophy on biopsy. 
Another Brazilian study used the same definition of normal range for serum D-xylose 
among HIV-infected children with and without gastrointestinal symptoms. Eight percent of the 
children had D-xylose below the “normal” range in their blood following challenge [152]. The 
authors also examined the relationships between D-xylose absorption and history of diarrhea 
and Cryptosporidium infection. Of the eight children with abnormal D-xylose, one had diarrhea, 
and of 19 subjects with diarrhea, one had an abnormal result for D-xylose. Among subjects with 
abnormal results, 50% had Cryptosporidium infection, and of the 33 with Cryptosporidium 
infection (many of whom did not have diarrhea), four had an abnormal D-xylose test. They did 
not report statistical testing of association, but these clinical factors do not appear to be 
associated with D-xylose absorption in this cohort.  
Moya-Camarena et al. performed urinary D-xylose and xylose breath hydrogen tests in 
well-nourished children with asymptomatic Giardia intestinalis infection and healthy controls 
recruited from preschool centers [147]. Results did not demonstrate any disturbance in urinary 
xylose absorption among infected cases or healthy controls. Urinary results did not differ before 
and after treatment for Giardia. Breath hydrogen levels decreased significantly with treatment, 
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indicating improvement. The clinical and physiologic implications of this difference, in the face of 
hydrogen breath test results well within the range of normal, are not apparent. The investigators 
did not report on the relationship between breath and urinary D-xylose results. 
Finally, Mittal et al. used the D-xylose absorption test as part of their diagnostic criteria 
for tropical sprue among gastroenterology clinic patients presenting with persistent diarrhea. By 
definition, all of the children had abnormal xylose absorption results; however, information about 
the D-xylose dose, units of measure, cutoff point for normal, and even the identity of the 
sampled fluid (urine or serum) were not provided [146]. 
Methods of test performance and cutoff points were often not described adequately to 
enable comparing results across studies. For example, in two instances D-xylose abnormal cut 
points were specifically defined as <25 mg/dL [136, 152], This is higher than some references 
suggest as a cutoff point among infants and children [186]. Insufficient data were reported in 
these two studies for readers to assess how the proportion of those with D-xylose malabsorption 
might have shifted with differing cut points. In two other studies D-xylose results were only 
reported as normal or abnormal without defining a cutoff point [146, 155].  
5.2.2 Endomolecular Challenge Absorption Tests 
Six studies assessed absorption after administering labelled endomolecules (zinc (n=3), 
iron (n=1), and lipids (n=2)). These investigations rely on challenge with the molecule of interest, 
which is generally a stable isotope, and measure urinary excretion as an indicator of absorption, 
or fecal excretion, as an indicator of non-absorption. When examining stool, it is important to 
note that the fecal concentration could potentially represent uptake and subsequent excretion by 
the host. In one Peruvian study, there appeared to be saturation kinetics at high doses of zinc, 
and zinc dosing early in the day was related to diminished absorption of this divalent cation from 
unfortified foods later in the day [141]. Manary et al. identified an unexpectedly high fractional 
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excretion of the challenge zinc in children in Malawi [144]. In China, Sheng et al. demonstrated 
unexpectedly high fractional excretion of zinc in stool, and inferred diminished uptake of this 
nutrient, but also speculated that their population of children were not suffering from enteropathy 
[164]. Murphy et al. used 13C labeled triglycerides (TG) as trilaurin, triolein, or trilinolein, and 
determined that in a group of Jamaican children, many of whom had bacterial overgrowth, the 
uptake of challenge lipids was impaired, but that the defect was not related to impaired intestinal 
lipolysis [148] Earlier, Murphy et al. demonstrated that during acute malnutrition, there is 
impaired lipid uptake from the gut, and that this defect improved during rehabilitation [149]. 
Unlike in the cohort in their later study, small bowel bacterial overgrowth was not an issue in this 
cohort. Sarker et al. studied labeled iron uptake in children with and without Helicobacter pylori 
infection, and found no evidence for diminished uptake among the infected children [163]. 
Similarly, treatment of the H. pylori infection did not improve uptake. They inferred that this 
gastric infection did not play a role in diminished uptake of iron by children in Bangladesh, but 
did note that there are limited data on the physiology of normal iron uptake in children in the age 
group studied (2-5 year olds). 
5.2.3 Enterocyte-specific Proteins 
Nichols et al. assessed intestinal tissue markers of digestion (see Evidence Table 3) as 
well as two markers of absorption: intestinal messenger RNA (mRNA) abundances of villin and 
sodium-activated luminal glucose-galactose transporter 1 transcripts [53]. These are structural 
proteins expressed only in enterocytes. mRNAs for these proteins are found in reduced 
quantities if intestinal surface area is diminished and hence reflect absorptive capacity. Nichols 
et al. compared the mRNA abundances in intestinal biopsies of children with refractory 
malnutrition to values found in controls that were neither stunted nor wasted, and found a 
reduction of more than 50% in mRNA abundances for both proteins among cases. It is 
important to note that the controls were children with biliary atresia who, as part of their 
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management for the condition, underwent intestinal resection. Without having performed an ex 
vivo mucosal biopsy in the control subjects, it is not possible to rule out a lower ratio of villous to 
submucosa tissue present in resected tissue which might affect mRNA determinations, as 
transmural tissue can be expected to contain a more diverse population of cells, only some of 
which might contain the transcripts of interest. However, the bias, if any, is likely in the direction 
that would reduce effect size.  
5.2.4 Fecal Fat 
Data on fecal fat was reported in three studies as a marker of malabsorption, including 
one study that measured the fat by four different methods, with a high degree of consistency in 
results across techniques [116]. That study, conducted among children with varying nutritional 
status in Venezuela, and another study conducted in India among children with symptoms 
consistent with and being evaluated for celiac disease [155], reported results as percent of 
subjects that tested positive while another study of severely malnourished Jamaican children 
[149] presented results as mean fecal fat excretion in grams per day and as percent of intake; 
hence, the results of this third study could not be compared to the other two. Positive results 
among the Venezuelan children varied from 13-27% (depending on laboratory method) among 
well-nourished children to 80-100% (again, depending on method) among the most severely 
malnourished children [116], while the Indian study detected fat in the stools of 20% of the 
children [155].  
 The Jamaican study found the fecal fat results to correlate with recovery of radiolabeled 
lipids in the stool after administration of 13C tripalmitin. The Indian study found that 55% of 
subjects with symptoms of celiac disease but a negative serologic evaluation for that disorder 
had abnormal D-xylose absorption (although the authors did not report the units of measure, 
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cutoff point of normal-abnormal results, or whether or not they measured the sugar in the urine 
or serum) and 20% had abnormal fecal fat results; correlation testing was not reported. 
 5.2.5 Summary of Markers of Absorption 
The assessed markers demonstrated normal and abnormal enteric function, depending 
on the marker and the study. The proportion of abnormal urinary D-xylose excretion results 
ranged from none among well-nourished children with asymptomatic Giardia intestinalis 
infection and healthy controls [147] to 100% among HIV-infected children in Brazil with protein-
energy malnutrition [136]. Endomolecular markers also yielded varying results in different study 
populations. Apparent malabsorption was observed based on lipid uptake in a cohort of 
Jamaican children, some of whom had small bowel bacterial overgrowth [149]. In contrast, a 
study of iron uptake among children with and without Helicobacter pylori infection found no 
evidence of impaired absorption [163]. Malnourished children had reduced absorptive capacity 
relative to controls as inferred from reduced abundance of messenger RNA in biopsies for 
enterocyte-specific proteins [53]. Similarly malnourished children showed absorptive 
derangement by fecal fat test, with a notably higher proportion of positive tests than among well-
nourished children [116]. 
Two of the fecal fat studies were the only ones that assessed more than one marker that 
is primarily a measure of absorptive capacity. The Jamaican study was the only one that 
reported testing for correlation between these tests of absorption [149]. Several studies 
compared the relationship of markers of absorption to biopsy. D-xylose [136, 146, 155] and 
fecal fat [155] corresponded poorly with histopathology. The papers suggested that there was 
only a short interval between the performance of these tests and the biopsies, but the exact 
length of time was not provided. Abundance of messenger RNA for two enterocyte-specific 
proteins, villin and sodium-activated luminal glucose-galactose transporter 1, did correlate with 
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villous atrophy in a study examining biopsy-derived markers [53]. None of the studies compared 
markers of absorption to other types of markers of enteric dysfunction (i.e., other than to biopsy 
or other measures of absorptive function). 
Only one study reported data on an absorption marker in relation to the presence of 
diarrhea, finding no apparent association with D-xylose absorption, although this was not 
analyzed statistically [152]. None of the studies examined the association between absorption 
markers and growth outcomes. A Peruvian study was the only one to report an absorption 
marker as a clinical endpoint of an intervention trial, in this case a randomized, controlled trial of 
zinc supplementation [141]. It was also the only study to measure intra-individual longitudinal 
change outside of the context of intervention or convalescence. These investigators assessed 
zinc absorption longitudinally in controls without zinc supplementation and observed no change 
in absorption of this pentose sugar.  
 These absorption tests showed a range of logistical challenges for deployment in 
resource-limited settings. When methods were described, the D-xylose test was conducted by 
colorimetric or spectrophotometric means, whereas the tests of endomolecules involved more 
complex laboratory methods and the intestinal tissue markers, requiring biopsy, were most 
technically complicated and invasive. The D-xylose studies generally did not cite reference 
standards or compare their results to those from other studies. Two studies compared their fecal 
fat results to those in other published studies [116, 149]. One of these studies also conducted a 
lipid breath test and compared results to those previously published [149]. All of the zinc 
absorption studies discussed results in relation to expected values based on reference indices 
and other studies of zinc homeostasis [141, 144, 164]. In the iron absorption study, authors 
cited a lack of data available in the literature for subjects of similar age for comparison [163]. 
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5.3 Markers of Permeability 
Data regarding markers of permeability are presented in Evidence Table 2. As discussed 
above, many of the tests that assess permeability also entail a test component that assesses 
absorptive function.  
Thirty-one studies assessed markers of intestinal permeability. All but one of these 
included assessments of dual sugar tests as either lactulose:mannitol (L:M) (n=25) or 
lactulose:rhamnose (L:R) (n=5); the other reported measures of lactose in the urine as 
lactose:creatinine. Two studies reporting L:M test results also reported other markers of 




This category includes markers with dual assessment of absorption and permeability. Biomarkers in bold are primarily markers of permeability (with or without dual 
assessment of absorption). 
Reference and Study 
Outcomes of  
Diagnostic Interest 
Location and  
Target Population 
Design and 
Sample Size Biomarker Results Conclusion Comments 
2004 
 
Campbell DI et al. 
 
Intestinal inflammation 
measured by fecal 




growth failure, Giardia 
lamblia, and intestinal 
permeability 
 
Fecal neopterin and 
L:M as markers of 
intestinal inflammation 
and permeability, 
respectively, and their 
correlation with growth 
status and Giardia 
recovery in the stool  
Keneba, Gambia 
 
2 mo olds from 
rural area followed 



























Mean neopterin concentration was 
negatively correlated with long-term 
height (r=-0.29, p<0.009) and weight 
(r=-0.36, p<0.007) gain, but not with 
giardiasis. 
 
Mean2 L:M (CI): 0.31 (0.26, 0.34). 
 
Mean excretion of lactulose (CI): 
0.20 (0.18, 0.23).  
 
Mean excretion of mannitol (CI): 3.0 
(2.8, 3.2).  
 
Mean L:M was negatively correlated 
with long-term height gain (r value 
not provided, p<0.0001), but was not 
correlated with presence of Giardia. 
 
L:M and fecal neopterin were not 
correlated (p=0.11). 





Mean L:M in the 
Gambian children 
was substantially 
higher than normal 
values in children in 
the UK. These high 
L:M ratios appear to 
be driven by 
mannitol excretion. 
Study population 
might have some 
overlap with that of 
Campbell et al. also 




Campbell DI et al. 
 
Growth faltering in 
rural Gambian infants 
is associated with 
impaired small 
intestinal barrier 








All 2-11 mo olds 
were recruited 
from this rural 
village and 
followed up to 14 


















• C-reactive  
protein (CRP) 
At 8 wk of age:  
• Mean4 L:M: 0.169 (CI: 0.145, 
0.198; range: 0.058-0.657) 
• Mean lactulose recovery: 0.202 
(SD=0.159; range: 0.009-0.640) 
• Mean mannitol recovery: 3.80 
(SD=2.35; range: 0.52-8.58) 
 
L:M more than doubled between 12 
wk-1 yr of age (r=0.44, p<0.001) and 
was driven by both increasing 
lactulose (r=0.18, p<0.001) and 
decreasing mannitol (r=-0.14, 
p<0.01) excretion with age.  
Mean L:M ratios 
were elevated at 8 
weeks of age, and 
more than doubled 
in the first year of 
life. 
 




correlated with L:M 
and lactulose 
recovery.  
Presence of malaria 
parasites was 
assessed by blood 
smear at each 
study visit; the only 
parameter 
associated with 
malaria was CRP.  
 





                                                          
1 Lactulose and mannitol results were expressed as % of dose administered. 
2 Type of mean not specified. 
3 For lactulose and mannitol results, excretion measurement was not specified. 
4 Geometric mean. 
Evidence Table 2. Markers of permeability.
Reference and Study 
Outcomes of  
Diagnostic Interest 
Location and  
Target Population 
Design and 
Sample Size Biomarker Results Conclusion Comments 
intestinal permeability 
and its relationship 
with various 
inflammatory markers 
and endotoxin  
• IgA 
• IgM  
• IgG 
• Plasma endotoxin 




WAZ and HAZ scores were 
negatively correlated with L:M (r=-
0.41, p<0.001), and primarily driven 
by lactulose excretion (r=-0.39, 
p<0.001). 
 
Laboratory values were consistent 
with chronic, low level 
immunostimulation: 
• 50% of platelet and 39% of 
leukocyte counts were elevated, 
especially mean lymphocyte 
counts which were almost twice 
expected values [198]. 
• While the mean1 CRP was within 
the normal range, 25% of values 
were above the upper limit of 
normal (5 mg/L), and 17% were 
>10 mg/L [198]. 
• Mean IgG, IgA and IgM 
concentrations were near normal 
at 8 wk of age, but increased 
rapidly; all three were elevated 
above expected values in all other 
age groups [198, 199]  
• Mean2 free plasma endotoxin 
concentration was twice the upper 
limit of normal [200] and IgG 
endotoxin-core antibody 
concentrations were also elevated 
[198]  
• However, mean albumin 
concentrations (and 
concentrations within SD) were 
generally within normal range 
[198]. 
 
L:M was correlated with 
IgG and IgA (r=0.41 and 0.41, 
 
Poor growth was 
significantly 
correlated with L:M 
















ascribed to a gut 
source, endotoxin 
and its related core 
antibody are 
potentially a direct 
measure of 
intestinal 
inflammation due to 
gut gram negatives 






negative infection.  
 
Study population 
might have overlap 
with that of 
Campbell et al. 
2004 also included 
in this review [15]. 
                                                          
1 Geometric mean. 
2 Geometric mean. 
Evidence Table 2. Markers of permeability.
Reference and Study 
Outcomes of  
Diagnostic Interest 
Location and  
Target Population 
Design and 
Sample Size Biomarker Results Conclusion Comments 
respectively, p<0.001), and IgM 
(r=0.28, p<0.02). 
IgG and IgA were also correlated 
with lactulose recovery (r=0.26 and 
0.25, respectively, p<0.02). 
 
IgG endotoxin core antibody 
concentration was correlated with 
L:M and driven by lactulose 
recovery, (r=0.35, p<0.005 for both).  
 
Endotoxin concentrations were 
correlated with lactulose recovery 
(r=0.36, p<0.02) only. 
2003 
 




in rural west African 
children: relationship 
with nutritional status 




L:M as a marker of 
intestinal permeability, 






among rural Gambian 
children with differing 
degrees of malnutrition 
and compared to well-















nutritional status:  
1. WAZ score >-2, 
with GI 
complaints other 
than diarrhea  












• Group 1: n=4  
• Group 2: n=11 
(7 with diarrhea) 









reactivity tests:  
• Group 1: n=3 
• Group 2: n=8 




small bowel biopsy, 




computer analysis*  
• Intestinal tissue 
cytokines and 
immune markers:  
















Crypt-hyperplasia and villous 
atrophy were observed among all 
Gambian subjects, and the degree of 
histopathology did not differ among 
cases with differing nutritional status, 
nor was there a correlation with 
diarrhea. 
 
IEL1 means were ~3-fold higher in 
Gambian than UK children. 
 
Median CD3, CD4, CD8, CD19, and 
CD25 cell counts were significantly 
higher (2-5x higher) among each 
case group compared to the UK 
controls.  
 
IEL, γδ, syndecan-1, HLA-DR, and 
perforin were detected among the 
Gambian children in varying degrees 
but were not reported for UK 
controls. Syndecan, CD3, and CD8 
displayed a gradient proportional to 
malnutrition severity. 
 







and villous atrophy, 
and mean IELs >2 
SD above UK 
norms, independent 
of nutritional status 














L:M ratios were 






determine what was 
compared (e.g. type 
of central tendency 
measure and 
variance 
calculations for L:M 
not stated).  
 
Duration of diarrhea 
not specified, but 







and L:M results 
were not stratified 
by history of 
diarrhea. 
 
                                                          
1 These figures are presumed to represent IEL means; however, this was not explicitly stated. 
Evidence Table 2. Markers of permeability.
Reference and Study 
Outcomes of  
Diagnostic Interest 
Location and  
Target Population 
Design and 
Sample Size Biomarker Results Conclusion Comments 
with or without 
diarrhea 
3. Grade II PEM 
(WAZ score <-4) 
with or without 
diarrhea  
 
Controls from UK* 
who were well 
nourished children 
with GI complaints 
other than diarrhea 
and with normal 
endoscopy results 
were also studied. 
 
 
* UK subjects are 
presented in this 
table due to 
comparisons of 
interest made in 
the review. 
However we do 
not include these 
subjects in the 










* Biopsy involved 
morphometric 
assessment by 
computer analysis of 





density (per 100 
epithelial cells).  
 
immunoreactive mononuclear cell 
density (~200-450/mm2) than UK 
controls (30-80/mm2). 
 
Among subjects with elevated 
cytokines, similar densities were 
seen for both pro-inflammatory (IFN-
γ and TNF-α) and putative regulatory 
(IL-10 and TGF-β) cytokines. 
Epithelial expression of TGF-β was 
also enhanced compared to UK 
controls, but subjects with poorer 
nutritional status had lower densities 
of mucosal TGF-β+ cells, with 
median densities of 420 and 250 
cells/mm2 in the grade I and grade II 
PEM groups, respectively. 
 
L:M values1:  
• Group 1: 0.53 (0.4-1.3)  
• Group 2: 0.47 (0.02-2.20) 
• Group 3: 0.73 (0.14-2.2) 
• Not assessed among the UK 
controls 
 
Nutritional status was not associated 
with L:M, recoveries of lactulose or 
mannitol.  
 
L:M was correlated with mucosal B 
lymphocyte density (r=0.57, p<0.05), 
IEL (r=0.51, p<0.02), and perforin+ 
IEL (r=-0.64, p<0.03). 
without apparent 
correlation to host 




Campbell DI et al. 
 
Age-related 



















Mean3 L:M (SE) in 2-5 yr old group: 
0.353 (0.022).  
 
Mean lactulose and mannitol % 
recovery was ~0.45 and ~0.65, 
respectively. 
Mean L:M in 
asymptomatic 2 to 5 
yr olds was high and 
decreased 
significantly with 
increasing age, but 
Subjects were free 
from diarrhea 
symptoms for at 
least one week 
prior to urinary 
assessments. 
                                                          
1 Not clearly indicated if these figures represent mean (CI) or another measure of central tendency. 
2 Lactulose and mannitol results were expressed as % of dose administered. 
3 Type of mean not specified. 
Evidence Table 2. Markers of permeability.
Reference and Study 
Outcomes of  
Diagnostic Interest 
Location and  
Target Population 
Design and 
Sample Size Biomarker Results Conclusion Comments 
intestinal mucosal 
enteropathy with 
nutritional status in 
rural Gambian children 
 
L:M and urinary 
lactulose and mannitol 
recovery as a marker 
of intestinal 
permeability and its 
association with 
nutritional status at 
varying ages. Also 
assessed correlation 
of change in L:M with 






 (23 were re-
assessed) 
  
L:M was highest in 2-5 yr age group 
and decreased with increasing age 
(up to age 20) (p<0.001), but never 
fell within referenced UK normal 
ranges [201]. 
 
Most of the improvement in L:M was 
driven by a reduction in lactulose 
excretion (p<0.001), which fell within 
expected UK ranges by age 10 yr. 
 
In contrast, although mannitol 
excretion slightly decreased with 
age, this trend did not reach 
statistical significance. In fact, 
excretion proportions were at all 
times ½ - ⅓ of expected UK values 
[201]. 
 
L:M was inversely correlated with 
HAZ score1 (r=-0.31, p<0.001), but 
not with WAZ or body mass index 
(BMI) Z- scores. The correlation with 
HAZ score was mainly due to the 
higher lactulose excretion in subjects 
with poorer HAZ scores (r=-0.22, 
p=0.001) and held across all age 
groups.  
 
There was a small improvement in 
mean L:M (SE) between the two 
study time points from 0.198 (0.018) 
to 0.172 (0.010) (p=0.026 for change 
in L:M), driven by an improvement in 
mannitol recovery with no change in 
lactulose excretion.  
 
Indices of intestinal permeability 
within subjects showed a high  
 
never fell within 
expected range of 
values. 
 
Among all age 





months apart.  
 
Among all age 
groups, L:M was 
significantly 
inversely correlated 
with HAZ score, 
primarily driven by 
lactulose excretion.  
 
 
The authors sought 
correlation between 
the mean L:M of the 
two visits and 
∆BMIZ, ∆HAZ and 
∆WAZ scores, but 
statistical 
calculations were 
not provided.  
 
                                                          
1 Reported results were adjusted for age, sex, and visit. 
Evidence Table 2. Markers of permeability.
Reference and Study 
Outcomes of  
Diagnostic Interest 
Location and  
Target Population 
Design and 
Sample Size Biomarker Results Conclusion Comments 
degree of correlation between the 
two visits:  
• Lactulose: r=0.55, p<0.001 
• Mannitol: r=0.24, p<0.05 
• L:M: r=0.66, p<0.001 
 
Change in measures between visits 
(analysis not stratified by age): 
• Mean L:M (SD):  
• Visit 1: -1.62 (0.66) 
• Visit 2: -1.76 (0.55), 
(p=0.026) 
• Mean mannitol recovery (SD): 
• Visit 1: 5.25 (2.69) 
• Visit 2: 6.28 (3.03), 
(p=0.006) 
• Mean lactulose recovery (SD):  
• Visit 1: 0.28 (0.20)  
• Visit 2: 0.29 (0.18),  
NS (p-value not specified) 
2003 
 
Chen P et al. 
 
Association of vitamin 
A and zinc status with 
altered intestinal 
permeability: analyses 
of cohort data from 
northeastern Brazil 
 
L:M as a marker of 
intestinal permeability 
pre- and post-vitamin 
A and zinc 
supplementation 
among children with 
history of PD or low 
WAZ score  
Goncalves Dias 
favela in Fortaleza, 
Brazil  
 
2-97 mo olds 
recruited from an 




















history of PD or 








Baseline mean (SD): 
• L:M2: 0.29 (0.16) 
• Lactulose: 0.54 (0.29) 
• Mannitol: 2.07 (0.88) 
 
L:M was not correlated with age. L:M 
was inversely correlated with retinol 
(r=-0.55, p<0.0005), including after 
adjustment for zinc concentration 
and stratification on retinol 
concentrations.  
 
Retinol was correlated with mannitol 
(r=0.28, p=0.017) and lactulose (r=-
0.22, p<0.063) excretion.  
 
Lactulose, mannitol and their 
combined ratio were not correlated 
with zinc concentrations.  
  
Supplementation of 
vitamin A and zinc 
resulted in 
significant 
improvements in L:M 
among the cohort of 
children with a 
history of PD or low 










were not reported 
stratifying on 
underlying condition 
(i.e. PD history vs. 
WAZ score). 
 
Follow-up data on 
L:M were not 
provided for the 
children with normal 
WAZ score or no 
history of PD.  
 
Unclear how long 
after 
supplementation 
the L:M testing was 
done.  
 
                                                          
1 For lactulose and mannitol results, excretion measurement was not specified. 
2 Type of mean not specified. 
Evidence Table 2. Markers of permeability.
Reference and Study 
Outcomes of  
Diagnostic Interest 
Location and  
Target Population 
Design and 
Sample Size Biomarker Results Conclusion Comments 
 
* These subjects 
received a single 
oral dose of 
vitamin A and a 2-
wk course of daily 
zinc supplements. 
 
L:M improved after supplementation 
for the cohort of 20 children followed 
longitudinally with PD or low WAZ 
score: 
L:M mean (SD):  
• Pre-treatment: 0.28 (0.12) 
• Post-treatment: 0.19 (0.07) 
However, lactulose and mannitol 




L:M results in the 
text of the 
publication differed 
somewhat from 
what was reported 




Darboe MK et al. 
 
Effectiveness of an 
early supplementation 
scheme of high-dose 
vitamin A versus 
standard WHO 
protocol in Gambian 




L:M as a marker of 
intestinal epithelial 
integrity among infants 
receiving high-dose 
vitamin A or standard 





at birth from rural 
community. Age 
range during study 



















Mean1 L:M and proportion with 
values >0.30 among those receiving 
standard doses of vitamin A, by age: 
• 2 mo: 0.195, 12% 
• 5 mo: 0.197, 13% 
• 7 mo: 0.212, 22% 
• 9 mo: 0.286, 30% 
• 12 mo: 0.322, 34% 
 
Mean L:M differed between the two 
groups only at 7 mo (0.276 in high-
dose vitamin A group, p=0.014), 
although there was no difference in 
percentages with L:M >0.30.  
 
 
L:M values rose by 
~50% from age 2 
mo to 1 yr and were 
not affected by 
dosing of vitamin A.  
The L:M normal 
cutoff was defined 
higher than for most 
other L:M studies, 
as 0.30. This was 
derived from the 
mean plus 2 SD 




Filteau SM et al. 
 
The effect of antenatal 
vitamin A and (beta)-
carotene 
supplementation on 






between 28-32 wk 
gestation recruited 
from antenatal 








(26 with HIV 
infection) 
Urine Tests: 
• Lactulose2  





• 1 wk: 
• Treatment: 
Mean L:M3 (CI) at 1 wk among 
infants without reports of illness was 
0.12 (0.08, 0.17). L:M did not change 
with increasing age and did not 
significantly increase with reported 
morbidity. 
 
While a history of ever having been 
breastfed was an important 
Mean L:M overall 
was within normal 
range. However, 
mean L:M for 
placebo-treated, 
HIV-infected infants 
by 14 weeks was 
significantly elevated 




urinary creatinine to 
control for variation 
in renal function.  
                                                          
1 Geometric mean. 
2 For lactulose and mannitol results, excretion measurement was not specified. 
3 Geometric mean. 
Evidence Table 2. Markers of permeability.
Reference and Study 
Outcomes of  
Diagnostic Interest 
Location and  
Target Population 
Design and 
Sample Size Biomarker Results Conclusion Comments 
of HIV-infected South 
African women 
 
L:M as a marker of 
intestinal permeability 
among infants of HIV-
infected mothers 





followed until 14 













and at delivery.   
n=104 
• Placebo: n=104 
• 6 wk: 
• Treatment: 
n=100 
• Placebo: n=105 
• 14 wk: 
• Treatment: n=99 
• Placebo: n=95 
 
contributor to L:M at 1 wk (ΔR2=0.22, 
p=0.008), a significant effect was not 
seen at 6 and 14 weeks1. Current 
feeding status had a modest effect 
on L:M only at 14 wk (ΔR2=0.06, 
p=0.04).  
 
Birth weight contributed significantly 
at 1 wk (ΔR2=0.07, p=0.02), but 
current weight did not contribute 
significantly to L:M at any time point.  
 
HIV infection status by 14 wk was 
the major factor contributing to L:M 
at 6 wk (ΔR2=0.22, p=0.008) and 14 
wk (ΔR2=0.21, p=0.01). 
 
Maternal HIV viral load during 
pregnancy was not consistently 
significantly correlated with infant 
L:M. Maternal lymphocyte counts 
and plasma retinol concentrations 
were not associated with infant L:M. 
 
While maternal vitamin A 
supplementation had no effect on 
L:M of uninfected infants, it 
appeared to prevent the increase in 
L:M of HIV-infected infants2: 
Mean L:M (CI):  
• Uninfected: 
• Vitamin A group: 0.11 (0.08, 
0.15)  
• Placebo group: 0.09 (0.06, 
0.12)  
• HIV-infected: 
• Vitamin A group: 0.17 (0.13, 
0.23) 
• Placebo group: 0.50 (0.37, 
0.68)  
 
While HIV infection 
did not affect 
mannitol excretion, it 




                                                          
1 Reported results were adjusted for confounding variables, unless otherwise noted. 
2 Reported results were adjusted for confounding variables included an interaction with HIV infection. 
Evidence Table 2. Markers of permeability.
Reference and Study 
Outcomes of  
Diagnostic Interest 
Location and  
Target Population 
Design and 
Sample Size Biomarker Results Conclusion Comments 
Mannitol was not affected by vitamin 
A. HIV infection was not consistently 
significantly associated with mannitol 
across age groups. 
 
Lactulose also did not consistently 
differ between treatment groups or 
by HIV-status, although vitamin A 
prevention of increase in lactulose 
among HIV-infected infants neared 
significance at 14 wk (p=0.058)1.   
2005 
 
Galpin L et al. 
 
Effect of Lactobacillus 
GG on intestinal 
integrity in Malawian 
children at risk of 
tropical enteropathy 
 
L:M and sucrose: 
lactulose ratio (SUC:L) 
as markers of 




presumed at risk of 
EED 
Mwenye, Malawi  
 
36-60 mo olds 
recruited from a 
rural community, 
excluding children 






considered at risk 
for EED due to 
residence in a 




Presumed that if 
SBBO is etiology 
for EED, treatment 
with Lactobacillus 





















or placebo. Only 
the 161 subjects 
who completed 





• Sucrose (SUC) 





• 73% had L:M >0.10  
• 40% had L:M >0.20 
• Mean3 L:M (SD): 
• Treatment: 0.18 (0.16) 
• Placebo: 0.22 (0.20)  
• Mean lactulose (SD) in treatment 
group: 0.25 (0.17) 
• Mean mannitol (SD) in treatment 
group: 8.0 (4.5)  
• Mean SUC:L (SD):  
• Treatment: 0.58 (0.64)  
• Placebo: 0.60 (0.64) 
 
Mean excretion of sucrose (SD) 
increased from 0.057 (0.042) to 
0.078 (0.058) in the treatment group 
(p=0.01), but similar results were 
observed in the placebo group. 
Otherwise there were no changes in 
lactulose, mannitol, L:M, or SUC:L 
after treatment or placebo. 
A high baseline 
prevalence of 
abnormal L:M was 





excretion (relative to 
UK norms) drove the 
abnormal L:M. 
 
There was little 
effect on SUC:L with 
intervention; sucrose 
excretion increased 
in both treatment 
and control groups.  
Difficult to interpret 
sucrose tests 
because there are 
limited data on 
laboratory values 








Urine Test: Mean L:M1 (SD) at baseline was 
0.18 (0.24) in treatment groups, with 
High L:M ratios 
overall with 
High L:M ratios 
were defined as 
                                                          
1 P-values are from reported results that were adjusted for confounding variables. 
2 Lactulose, mannitol, and sucrose results were expressed as % of dose administered. 
3 Arithmetic mean.  
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Location and  
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Design and 
Sample Size Biomarker Results Conclusion Comments 
Goto R et al. 
 
Impact of anti-Giardia 
and anthelminthic 
treatment on infant 
growth and intestinal 
permeability in rural 
Bangladesh: a 
randomised double-
blind controlled study 
 
L:M as a marker of 
intestinal permeability, 
IgG as a marker of 
chronic immune 
stimulation, and α-1-
acid glycoprotein as an 










3-15 mo olds from 
a rural area were 
enrolled and 
followed in a 9-mo 
trial.  
 
There was a high 
prevalence of 

















* Those who fully 
participated and 
for whom data 
were analyzed 
are included in 
this review. 
• L:M  
 
 






no significant difference in placebo 
group or in testing post-intervention. 
 
Proportion with elevated L:M at any 
study time point varied between 
58%-74%. >57% consistently 
elevated L:M ratios. 
 
Seasonal variation in L:M was 
observed (p <0.001), with highest 
mean values in the monsoon 
season.  
 
L:M was associated with ∆WAZ and 
∆WHZ scores at 24 weeks (p=0.001 
and p<0.001, respectively, point 
estimates not provided.) 
 
Serum immune marker values were 
similar in all groups and did not 
change substantially with 
interventions. 
 
AGP concentrations were negatively 
associated with ∆WAZ score at 24 
weeks (p=0.004, point estimate not 
provided), and were associated with 






Interventions did not 





weight with better 
L:M values, the 
degree to which this 
occurred was not 
reported.   
 
 
greater than the 





reported by this 
group in another 
study also included 
in this review [123]. 
2008 
 
Goto R et al. 
 
Impact of intestinal 
permeability, 
inflammation status 
and parasitic infections 
on infant growth 





3-15 mo olds from 
a rural area were 
enrolled and 
followed in a 9-mo 
trial.  
 
There was a high 
prevalence of 
Longitudinal data 
extracted from an 





Urine and blood 
samples were 













Mean2 L:M: 0.15 
 
L:M showed a decreasing trend with 
age (p=0.003), and was associated 
with female gender (p=0.004), HAZ 
score (p=0.039), and WAZ score 
(p=0.019), but not with giardiasis or 
any of the serum immune markers. 
 
IgG, AGP, and albumin were 
associated with giardiasis, but 
Mean L:M was 
elevated. L:M was 
not associated with 
any of the tested 
serum markers of 
inflammation or with 
giardiasis. 
 
IgG rose with 




very low; testing for 
association with 





presence of a 
Giardia-specific IgM 
                                                                                                                                                                                                                                                                                               
1 Geometric mean. 
2 Geometric mean. 
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L:M as a marker of 
intestinal permeability, 
IgG as a marker of 
chronic immune 
stimulation, and α-1-
acid glycoprotein as an 




giardiasis and growth 
parameters.   










hemoglobin was not. 
 
Mean circulating albumin 
concentration was normal for age 
[203]. Compared to UK age-matched 
reference [199], rate of rise in IgG 
with increasing age was similar, but 
concentrations were consistently 
~3g/L higher.  
 
IgG was not associated with growth 
parameters. Albumin was associated 
with HAZ score only (p=0.016). AGP 
was inversely associated with HAZ 
(p=0.011) and WAZ (p=0.005) 
scores. 
(compared to UK 
norms) [199] but at 
higher 
concentrations 










reported by this 
group in another 
study also included 






have not been 
determined for 
AGP. UK norms for 
10 mo olds-adults 
are 0.88 g/L mean 
(0.21 SD) [204]. 
2002  
 
Goto R et al. 
 
Poor intestinal 
permeability in mildly 
stunted Nepali 
children: Associations 
with weaning practices 
and Giardia lamblia 
infection 
 
L:M as a marker of 
intestinal permeability, 





and growth status. 
Kathmandu, Nepal 
 
0-5 yr olds (mean 
age 3.8 yr) from 
two urban squatter 
settlements.  
 




















• 92% had values >UK norms 
• Mean3 L:M (SD, range): 0.26 (0.21, 
0.04-1.71).  
• Giardia-infected versus uninfected 
means: 0.43 vs. 0.25, p=0.014 
 
The duration of ingestion of solid 
foods (with or without concurrent 
breastfeeding) was not associated 
with L:M in multivariate analysis.  
 
L:M was correlated with longer 
duration of breastfeeding (r=0.27, 
p<0.019). Specifically, children who 
breastfed for >2 yr had higher L:M 
ratios than children who breastfed 
for shorter times (data not provided).  
 
L:M was not associated with:  





observed in L:M 
ratios. 
 
L:M was associated 
with giardiasis but 






significantly higher in 
breastfed subjects 
than in those that 
were not breastfed, 
Low lactase activity 
was defined as 
lactose:lactulose 
ratio >0.4.  
 
Specific L:M data 
by WAZ and HAZ 
scores were not 
reported, although 
authors state that 





                                                          
1 Lactulose and mannitol results were expressed as % of dose administered. 
2 Lactose results were expressed in mg/L. 
3 Geometric mean. 
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• WAZ or HAZ scores 
 
Lactulose excretion ranged from 
0.02–15.00. Mannitol excretion 
ranged from 0.5–15.00. 
 
47% showed low lactase activity. 
Lactose values and lactose:lactulose 
ratios decreased with age (R2=28%, 
p<0.0001), but were not associated 
with sex, ethnicity, and location nor 
were they associated with L:M.  
 
Mean1 urinary lactose 
concentrations (mg/L) by feeding 
mode: 
• Breastfed: 172.5  
• Non-breastfed: 44.5, p<0.0001 
corrected for infant age  
 
Mean2 lactose:lactulose ratio by 
feeding mode:  
• Breastfed: 2.76 
• Non-breastfed: 0.31,  
p<0.0001 corrected for infant age 
 
Mean L:M by feeding mode: 
• Breastfed: 0.23 
Non-breastfed: 0.28, non-significant, 
p-value not specified 
despite similar 
intestinal 
permeability values.  
 
There were some 
unexpected findings: 
the duration of 
breastfeeding, and 
not the timing of 
introduction of solid 
foods, was 
correlated with L:M, 
and the correlation 
was direct, not 
inverse. Authors 
speculate that this 
could be due to 
higher mean age of 
their cohort 
compared to another 
study that 
demonstrated 
beneficial effect of 
duration of 
breastfeeding on 









Cases were >4 mo 












Among the subset with both blood 
and urine specimens: 
• Urine L:R: 
• Mean3 (CI): 




L:R ratios by both 
blood and urine 
Authors used data 
from non-diarrheal 
controls from their 
clinical practice to 
derive cut-points for 
                                                          
1 Geometric mean. 
2 Geometric mean. 
3 Geometric mean. 
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ratio (L:R) as a marker 
of intestinal 
permeability in children 
with or without 
diarrhea. Also directly 
compared blood and 
urine methods of L:R 








GI illness.  
 
More than 75% of 

















• 24 had both blood 
and urine L:R 
• 98 had blood L:R 
only 




• 25 had both blood 
and urine L:R 
• 36 had blood L:R 
only 
• 53 had urine L:R 
only 
 
A total of 49 subjects 
were tested with both 
blood and urine L:R 
methods to allow 
direct comparison of 
values. 
• Controls: 6.7 (5.0, 8.8), 
p=0.004 
• Distribution across ratios:  
• Low: n=31 
• Intermediate: n=9 
• High: n=9 
• Blood L:R: 
• Mean1 (CI): 
• Cases: 9.4 (6.7, 13.1) 
• Controls: 5.9 (4.4, 7.8), 
p=0.04  
• Distribution across ratios: 
• Low: n=27 
• Intermediate: n=11 
• High: n=11 
 
Among subjects with only urine 
tested: 
Mean2 urine L:R (CI):  
• Cases: 15.7 (12.6, 19.6)  
• Controls: 6.7 (5.7, 8.0), p<0.0001  
 
Among subjects with only blood 
tested: 
Mean3 blood L:R (CI):  
• Cases: 12.8 (10.3, 16.0) 
• Controls: 3.7 (2.8, 4.9), p<0.0001   
 
Even though blood L:R was 
consistently lower than urine L:R by 
a geometric mean (CI) of 1.09 (1.02, 
1.16), there was strong correlation 
between L:R ratios in blood and 
urine as measured by:  
• Concordance correlation coefficient 
for agreement (CI) of 0.76 (0.64, 
0.88) 
• Kappa statistic (CI) of 0.71 (0.51, 
testing compared 






urine and blood L:R 
tests in the same 
subjects. 
 
Urine has been an 
established 
substrate for sugar 
excretion 





collection of urine is 
not a trivial task, 
especially among 
female children, and 
contamination with 
stool is problematic, 
especially in children 
with diarrhea. 
However, the much 
lower concentrations 
of probe sugars in 
blood compared to 
urine had posed a 
challenge to 




(HPLC) methods, as 
L:R ratios used in 
this study:  
• Blood L:R: 
• Low= <7 
• Intermediate= 
7-12.5 
• High= >12.5 
• Urinary L:R: 
• Low= <10 
• Intermediate= 
10-18 




than the cases, but 
authors suggest 
that age differences 




subjects do not 
always match up 
(e.g. numerator in 
test failure rate 
calculations does 




Analyses of those 
subjects who had 
both blood and 




Analyses of those 
                                                          
1 Geometric mean. 
2 Geometric mean. 
3 Geometric mean. 
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Design and 
Sample Size Biomarker Results Conclusion Comments 
0.92) (when L:R ratios are divided 
into 3 ordered categories) 
• Sensitivity and specificity of blood 
tests of 81% (25/31) and 89% 
(16/18), respectively, when using 
the urine testing as the standard. 
 
The failure rate* for serum L:R 
testing (20/197, 10%) was lower 




* Defined as emesis with 
rhamnose/lactulose oral challenge 
(same dose for urine and serum 
testing), urine leakage or 
contamination with stool, or plasma 
quantity from blood draw of 
insufficient quantity for analysis. 
used in this study, 
now provide a more 




The failure rate of 
L:R blood testing 
was significantly 
lower than that of 
urine testing.   
 
 
with and without 
diarrhea would 
have been of 
interest. One would 
expect children with 
diarrhea to have 
higher rates of urine 
test failure due to 
contamination with 
stool and to have 
higher failure rates 
using either 
analytes due to 
higher rates of 
emesis.  
 
Spot blood testing 
might be more 
feasible than timed 
urine collections, 
but HPLC might not 




This study appears 
to report on the 
same population as 
two other studies in 
this review which 
also assessed 
serum L:R as a 





Kukuruzovic R et al. 
 
Increased nitric oxide 
production in acute 
diarrhea is associated 




1-6 yr old 
Aboriginal and 
non-Aboriginal 
















• Mean corpuscular 
volume (MCV) 
NO among Aboriginal children with 
diarrhea was >3x higher than any 
other group and >5x higher than in 
non-Aboriginal controls. 
• NO was >3x and >2x higher 
among Aboriginal than non-
Aboriginal children in the diarrhea 
(p<0.001) and no infections groups 
NO2 + NO3:Cr ratio, 
as a measure of 
endogenous nitric 
oxide production, 
was used as a 
marker of gut 
permeability and 
inflammation, with 
Positive stool RS 
was defined as 
>0.5%.  
 
Abnormal L:R was 
defined as >7.6; no 
reference or 
derivation was 
Evidence Table 2. Markers of permeability.
Reference and Study 
Outcomes of  
Diagnostic Interest 
Location and  
Target Population 
Design and 
Sample Size Biomarker Results Conclusion Comments 
permeability, 
hypokalemia and 




Nitric oxide (NO) as a 




ratio (L:R) as a marker 
of intestinal 
permeability and the 
relationship between 
NO and L:R, growth 
parameters, mean 
corpuscular volume 
(as a surrogate of iron 
deficiency), and stool 
reducing substances 
among children with 




1. Children with 
AD 
2. Children with no 




3. Children without 





• 73 with non-GI 
infections (49 
Aboriginal) 








(169 cases tested)  
 
 
* NO is an unstable 
free radical and is 
converted to nitrite 
and nitrate. Urine 
nitrate (NO3)+ nitrite 
(NO2) was expressed 
as a ratio with urine 
creatinine (NO2 + 
NO3:Cr) in order to 
account for 
differences in urine 
concentration. 
 
** Measured only 




(p<0.001), respectively, but there 
was no difference between them in 
the non-GI infections group.  
• NO was >3x and ~2x higher in the 
diarrhea compared to the no 
infections group among 
Aboriginals (p<0.001) and non-
Aboriginals (p<0.03), respectively.  
• NO was virtually the same among 
the Aboriginal non-GI infections 
and no infections groups, as well 
as among the non-Aboriginal 
diarrhea and non-GI infections 
groups.  
 
112/152 (74%) and 31/169 (18%) of 
children with AD had abnormal L:R 
ratios1 and positive stool RS, 
respectively. 
 
NO and L:R were measured at 
“convalescence” on Day 5 among 
those with diarrhea: the mean 
improvement in NO was 21.7% 
compared with 54.6% for L:R 
(p=0.01). 
 
NO and L:R were correlated (n=193, 
r=0.37, p<0.001)1; the correlation 
was stronger for lactulose (effect 
ratio=1.47, p<0.001) than for 
rhamnose (effect ratio=0.80, 
p=0.022).  
 
NO was not correlated with stool 
RS3 or MCV, but was correlated with 
lower WAZ score (effect ratio=0.88, 
p=0.05). 
an attempt to identify 
how much more it 
reflects as response 
to inflammation from 





NO production was 
the same among 
those with diarrhea 
and non-GI 
infections (and 
higher compared to 
controls). NO was 




to any other group. 





due to (clinically 
silent) enteropathy 
could explain the 
concentrations seen 
among Aboriginal 
controls in this 
study. 
 
NO appeared to 
decrease 
significantly more 
slowly than L:R 
among children 




appears to be the 
same as in another 
Kukuruzovic, et al. 
study also included 
in this review which 
assessed serum 
lactulose:rhamnose 
as a marker of 
intestinal 
permeability [58]. 
                                                          
 
1 Reported results appear to have been adjusted for age and race. 
2 Reported results were adjusted for age and race. 
3 Reported results among children with diarrhea were adjusted for age and race. 
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recovering from 
diarrhea. 
NO was found to 
correlate with L:R. 
NO was more 
strongly correlated 




Kukuruzovic RH et al. 
 






ratio (L:R) as a marker 
of intestinal 
permeability among 
children with diarrhea 
and/or malnutrition 
treated with milk 







<3 yr old with AD 
and/or WAZ score 
<-2. 
 
60% of subjects 
had low WAZ 




































L:R testing was 
repeated in 150 
subjects at day 5: 
• De-Lact: n=48  
• O-Lac: n=52 
• Alfaré: n=50 
Baseline mean1 L:R (CI) in De-Lact 
group was 14.9 (10.4, 21.5), with no 
difference between groups. 
 
The mean improvement* in L:R (CI) 
was 13.0 (9.3, 16.6) with some 
significant differences between the 
various formulas: 
• De-Lact: 18.6 (10.6, 26.6)  
• O-Lac: 12.0 (7.5, 16.6), p=0.15 
compared to De-Lact  
• Alfaré: 8.5 (2.1, 14.9), p=0.049 
compared to De-Lact  
 
 
* Improvement in L:R was calculated 




Authors noted that 
treatment with all of 
the low-lactose 
formulas studied 
resulted in improved 
L:R among this 




most marked with 

















The study did not 
include a control 
arm (of standard 
care) to which 




the advantages of 
serum over timed 
urine collection for 
assessment of L:R 
as discussed in 
another publication 
in this review [125]. 
2002 
 














27/75 (36%) of Aboriginal controls 
and 0 non-Aboriginal controls had 
abnormal L:R ratios. 
 
Mean L:R ratios of 
Aboriginal children 
were approximately 
double those of non-
Positive stool RS 
was defined as 
>0.5%.  
 
                                                          
1 Geometric mean. 
2 Lactulose and rhamnose results were expressed as % of dose administered. 
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rhamnose ratio (L:R), 
serum lactose, and 
stool reducing 
substances as 





























• L:R  
• Hemoglobin  









L:R testing was 
repeated on day 5 for 
a subset of Aboriginal 
subjects: 
• 174/264 admissions 
for acute diarrhea  




* Measured only 








Mean1 L:R at baseline: 
Cases: 
• Aboriginal: 16.4  
• Non-Aboriginal: 7.9, p=0.002 
compared to Aboriginal cases 
Controls: 
• Aboriginal: 4.6 
• Non-Aboriginal: 2.5, p=0.02 
compared to Aboriginal controls  
 
Mean improvement2 in L:R (CI) at 
day 5 among those with repeat 
testing: 
• Aboriginal cases: 14.6 (11.2, 18.0)  
• Aboriginal controls: -0.63 (-4.0, 
2.7)  
 
Mean lactulose recovery3: 
• Cases day 1: 0.085 (0.070–0.103)  
• Cases day 5: 0.039 (0.033–0.046) 
• Controls: 0.024 (0.019–0.029) 
All 3 values significantly differed 
from one another. 
 
Mean rhamnose recovery: 
• Cases day 1: 0.479 (0.424–0.542) 
• Cases day 5: 0.555 (0.498–0.616) 
• Controls: 0.585 (0.500–0.685) 
These values did not significantly 
differ from one another. 
 
Confidence intervals (CIs) in the 
authors' graphical representation of 
mean L:R at admission did not 
overlap, and the difference in means 
was particularly evident between 




both among those 











improved over 5 
days among 
Aboriginal cases. 
Children with severe 
diarrhea had higher 
mean L:R. 
 
Higher case L:R was 
driven more by high 
lactulose than by low 
rhamnose.  
Similarly, 
improvement in L:R 
among cases was 
primarily due to 
decreased lactulose.  
 
Stool RS and serum 






latter was weakly 
associated with 
Abnormal L:R was 
defined as >5.6, 
derived from 2 SD 
above the 
arithmetic mean for 
non-Aboriginal 
controls in this 
study. The rationale 
for the choice of 2 
SD above the 
arithmetic, instead 
of the geometric, 





were not reported. 
 
Analysis included 







analysis methods.  
Repeat L:R testing 
was conducted on 
controls of both 
racial groups, but 
among cases it was 
only conducted on 
Aboriginal cases. 
 
This study appears 
to report on the 
                                                          
1 Geometric mean. 
2 Improvement in L:R appears to have been calculated as baseline L:R minus repeat L:R, as described in another publication in this review; however, this was not expressly stated. 
Reference 134. Kukuruzovic RH, Brewster DR. Milk formulas in acute gastroenteritis and malnutrition: a randomized trial. J Paediatr Child Health, 2002. 38(6):571-577.  
3 Figures reported parenthetically after the mean percent recoveries of lactulose and rhamnose were not specified as ranges or CIs. 
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Factors associated with L:R among 
cases were1:  
• Acidosis (p=0.007) 
• Hypokalemia (p=0.035) 
• Diarrhea severity (p=0.001)  
 
Age and malnutrition were not 
associated with L:R. 
 
38% and 27% of Aboriginal cases 
had positive serum lactose and stool 
RS, respectively. 12% of Aboriginal 
and non-Aboriginal controls 
combined had lactosemia.  
 
Presence of lactosemia was 
associated with L:R, adjusted 
relative risk (CI)=1.06 (1.03, 1.10)2. 
Stool RS, anemia, and MCV were 
not associated with L:R. 
increased lactulose. same population as 
in the Kukuruzovic, 
et al. 2003 
reference also 







the advantages of 
serum over timed 
urine collection for 
assessment of L:R, 
as discussed in 
another publication 
in this review [125]. 
2010 
 
Lima AA et al.  
 
Effects of vitamin A 
supplementation on 
intestinal barrier 
function, growth, total 
parasitic, and specific 
Giardia spp infections 






L:M as a marker of 
intestinal barrier 
function, and stool 
Fortaleza, Brazil 
 
2 mo-9 yr olds 
(mean 43 mo) from 
an impoverished 
urban community, 
eligible if HAZ 
score was 






































Median L:M at baseline was 0.089. 
There was no significant change in 
L:M at 4 mo follow-up within either 
treatment group.  
 
No significant difference in L:M was 
observed between treatment groups. 
 
Both median lactulose and mannitol 
excretions decreased at 4 mo follow-
up among the vitamin A compared to 
the placebo group: 
• Lactulose: 0.21 to 0.74, p=0.042  
• Mannitol: 3.06 to 8.25, p=0.008  
 
Overall proportion of lactoferrin was 
23% initially. At 1 mo follow-up, there 
was no difference in prevalence 
between vitamin A (33%) and 




While vitamin A 
supplementation 
was associated with 
reduced lactulose 
excretion, it was also 
associated with 
reduced mannitol 
excretion, with no 




was not associated 
with presence of 
lactoferrin or 
Authors did not 







fecal cytokines, or 
between these 




Cut-point values for 
lactoferrin positivity 
and abnormal L:M 
were not described.  
 
                                                          
1 Reported results were adjusted for confounding variables, unless otherwise noted. 
2 Reported results were adjusted for severity of diarrhea, acidosis, hypokalemia, and age. 
3 For lactulose and mannitol results, excretion measurement was not specified. 
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lactoferrin and specific 
intestinal 
immunological 




children who received 
either vitamin A or 
placebo  
placebo (31%) groups. 
 
Cytokine concentrations did not 
significantly differ between placebo 





were excluded from 
study participation 
due to assessment 




Lima AA et al. 
 
Intestinal barrier 
function and weight 






L:M as a marker of 
intestinal permeability 
and various stool tests 
among children with 
malnutrition or PD who 






2-60 mo olds 
hospitalized with 
WAZ score <-2, 
~70% of whom 
had PD.  
RCT 
 





• 27 with glycine 















• Lactoferrin  
• Leukocytes  





* n=80 tested at 
enrollment, n=65 
tested at day 10. 
 
** n=60 tested. 
Mean2 L:M (SE):  
• Glutamine group: 
• Baseline: 0.31 (0.10) (similar in 
all three groups) 
• Day 10: 0.10 (0.02); significant 
decrease, (p=0.01) 
• No significant decrease in L:M in 
glycine and nonsupplemented 
formula groups at day 10 
 
Mean lactulose (SE):  
• Glutamine group: 
• Baseline: 0.97 (0.46) (similar in 
all three groups) 
• Day 10: NS decrease in all 3 
groups 
 
Mean mannitol (SE):  
• Glutamine group: 
• Baseline: 3.42 (0.64) (similar in 
all three groups) 
• Day 10: NS decrease in all 3 
groups 
 
Proportion of stool markers at 
baseline among all subjects:  
• Lactoferrin: 53.3% 
• Leukocytes: 11.7% 
• RS: 3.3% 
• Occult blood: 5.0%  
L:M significantly 









RS, and occult blood 
were detected in 




markers and L:M 
was not reported.  
 
Data were not 
stratified by history 
of PD. 
 
Fecal fat was 
assessed, but 
results were not 
reported. 
 
Cut-off values for 
lactoferrin positivity 




were excluded from 
study participation 
due to assessment 
of stool lactoferrin. 
 
 
                                                          
1 Lactulose and mannitol results were expressed as % of dose administered. 
2 Type of mean not specified. 
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2007 
 
Lima NL et al. 
 
Wasting and intestinal 










to improve intestinal 









6 mo-8 yr olds 
(mean age 3.5 yr) 
from an urban 
setting with HAZ, 




















L:M median (range) at baseline: 
• Treatment: 0.0385 (0.8922 [sic])  
• Placebo: 0.0302 (5.5812 [sic]) 
 
Lactulose and mannitol excretion 
both significantly decreased in the 
treatment group only (p=0.05 for 
both sugars)2. L:M did not change 
significantly within or across groups 
days after treatment. 
 
Lactulose excretion was not 
associated with WHZ, WAZ or HAZ 
scores in either group3. Mannitol 
was not associated with growth 
parameters in the control group, but 
was associated with WHZ (r2=-
0.386, p=0.027) and WAZ (r2=-
0.385, p=0.027) scores in the 
supplemented group. Data for L:M 
and growth parameter association 
was not provided. 
Even though 
lactulose excretion 








and L:M did not 
change significantly 
in the placebo 
group. 
Authors state that 
L:M median and 
range values were 
within the 
confidence interval 
for values of 









chronic diarrhea in 
their methods, they 
did not report data 
stratified according 
to these conditions. 
 
Authors provide 




results; these likely 








of rural Bangladeshi 
children: effect on host 
physiology, growth, 





2-5 yr olds from 
poor rural villages, 
sampled randomly 






















Mean L:M4 at baseline: 
• Treatment: 0.22 
• Placebo: 0.25 
 
Seasonal variation in L:M was 
observed, with highest values 
following the monsoon season.  
 
Within-subject L:M analysis showed 
L:M ratios were high 
overall and 
demonstrated 
seasonal variation.  
 
Intra-individual L:M 
values did not 
change significantly 
over time, nor were 
they associated with 
Baseline study data 
were lost, so 
analysis began with 




between the serum 
markers and 
intestinal 
                                                          
1 Lactulose and mannitol results were expressed as % of dose administered. 
2 Reported results were adjusted for age and season. 
3 Reported results were adjusted for age and season. 
4 Geometric mean. 
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L:M as a marker of 
intestinal permeability, 
and α 1-
antichymotrypsin as a 
marker of inflammation 
and immune activation 
to treatment among 













* Randomized at 




Among 93 subjects 
with L:M at baseline:  
• 46 received 
treatment 
• 47 received 
placebo 
 
Among 66 subjects 
with repeated L:M 
testing: 
• 34 received 
treatment 
• 32 received 
placebo 
no significant association with 
intestinal helminthiasis and no 
significant improvement in treatment 
or placebo groups over 1 yr. L:M 
was generally not associated with 
giardiasis (with the exception of one 
group at one study interval). 
 
L:M was inversely correlated with 
∆HAZ and ∆WAZ scores at some of 
the follow-up intervals (r=-0.22, 
p<0.02 and r=-0.21, p<0.05, 
respectively, at 12 mo follow-up 
visit). 
 
Mean serum ACT, albumin and total 
protein were within normal ranges 
and were not associated with growth 
parameters. ACT and albumin 
concentrations did not significantly 
change with treatment, whereas total 







were seen between 
L:M and growth 
parameters. 
 
Serum markers were 
within normal range. 
The only significant 
change in these 
markers was a 
decrease in total 
protein in the 
treatment group 
without concomitant 
change in albumin; 











Panter-Brick C et al. 
 
Pathways leading to 
early growth faltering: 
An investigation into 
the importance of 
mucosal damage and 
immunostimulation in 
different socio-





3-18 mo olds in 
two cohorts: 
1. All children in 













n=48 in squatter 
cohort  
 










Mean1 Lactose:Cr (CI): 
• Squatter: 0.14 (0.12, 0.16) 
• Middle Class: 0.08 (0.07, 0.10) 
• Statistically significant difference 
between the 2 groups among the 
6-12 mo olds (p=0.007) and 18-24 
mo olds (p=0.002), but not among 
12-18 mo olds.  
• For both SES groups, Lactose:Cr 
values decreased with increasing 
age (p<0.001). 
 
HAZ, WAZ, WHZ, and ∆WAZ scores 
were strongly associated with mean 
Authors speculate 
that Lactose:Cr 
accounted for less of 
the deterioration in 
nutritional status 
among the squatter 




that impact the 
nutritional status of 





urinary creatinine to 
control for variation 





not be as accurate 
as L:M, it might be 
a more field-friendly 
assessment of 
                                                          
1 Geometric mean. 
Evidence Table 2. Markers of permeability.
Reference and Study 
Outcomes of  
Diagnostic Interest 
Location and  
Target Population 
Design and 
Sample Size Biomarker Results Conclusion Comments 
Lactose:creatinine 
ratio (Lactose:Cr) as a 




and IgG as markers of 
immunostimulation. 
The latter were also 
assessed for their 
relationship to 
nutritional status. 
households Lactose:Cr (p<0.001 each) as was 
∆HAZ score (p=0.004); ∆WHZ score 
was not. The strength and 
magnitude of association between 
∆WAZ score and Lactose:Cr was 
most pronounced among the 
wealthier cohort and there was no 
association between ∆HAZ score 
and Lactose:Cr among the squatter 
children.  
 
Hemoglobin concentrations were 





status. mucosal damage 
compared to L:M, 
requiring only spot 
urine collection and 
no substrate 
dosing. However, 
L:M was not 
assessed in this 
study; direct 
comparison of the 





inversely related to 
Lactose:Cr, testing 
for associations of 
other measured 
blood markers (IgG, 
AGP and albumin) 
with Lactose:Cr 
was not reported. 
2000 
 
Quadro L et al. 
 
Retinol and retinol-
binding protein: gut 
integrity and circulating 
immunoglobulins 
 
L:M as a marker of 
small intestinal 
permeability, and its 
correlation with serum 
retinol among mildly 
malnourished children 
Goncalves Dias 
favela in Fortaleza, 
Brazil 
  
1-9 yr olds with 
mild malnutrition 
selected from a 
large cohort of 
children from an 
urban slum. They 
were recruited at 
birth and followed 
longitudinally. 
 
19 (63%) had 





 n =30 
 
  
 Urine Tests: 
• Lactulose1 
• Mannitol 







80% of subjects had abnormal L:M, 
defined as >=0.030.  
 
Serum retinol was:  
• Inversely correlated with L:M 
(r=0.46, p=0.012) 
• Directly correlated with mannitol 
(r=0.66, p<0.01)  
Not correlated with lactulose (data 
not reported) 
Children with low 





The L:M normal 
cutoff was defined 
lower than for most 
other L:M studies, 
as 0.030. The 
authors reference 
several studies 
regarding use of 
this cut point. 
                                                          
1 Lactulose and mannitol results were expressed as % of dose administered. 
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these had mild 
deficiency, except 





Rabbani GH et al. 
 
Green banana and 
pectin improve small 
intestinal permeability 





L:M as a marker of 
intestinal permeability 
among infants with PD 
who are treated with 
green banana, pectin, 






5-12 mo old males 
admitted to the 
hospital of the 
International  
Centre for  
Diarrhoeal Disease 
Research with PD 





























Mean L:M (SD) by treatment group, 
pre- and post-treatment:  
• Banana: pre=0.50 (0.14), 
post=0.21 (0.12), p<0.01 
• Pectin: pre=0.54 (0.17), post=0.23 
(0.09), p<0.01 
• Placebo: pre=0.41 (0.11), 
post=0.45 (0.13), p>0.6 
 
Lactulose and mannitol excretion did 
not differ between groups at 
baseline.  
 
Lactulose excretion was not 
significantly reduced after 
intervention in the placebo group. 
Mean (SD): 
• Pre-treatment: 1.45 (0.12) 
• Post-treatment: 1.35 (0.15) 
 
Both treatment groups had 70-80% 
reduced lactulose excretion following 
treatment (p<0.01). 
 
Mannitol excretion increased in all 
groups compared to their pre-
treatment values, but only 
significantly so in the banana and 
pectin groups (p<0.05).  
 
Mean mannitol % excretion (SD), 
pre- vs. post-treatment:  
• Banana: 1.82 (0.13) vs. 3.21 
(0.16) 
• Pectin: 1.91 (0.12) vs. 3.2 (0.18) 
• Placebo: 2.10 (0.11) vs. 2.33 
L:M values were 
high at baseline 
among the study 
population of 
inpatient young 
children with PD. 
Mean L:M 
significantly 
improved with the 
green banana or 
pectin intervention 
but were still above 
normal range 
following 7 days of 
treatment. The 
improvements in L:M 
were driven by both 
mannitol and 
lactulose, with the 
latter having an 
impact of greater 
magnitude.  
 
Authors cite studies 
postulating that the 
effectiveness of 
green banana in 
reducing diarrheal 
fluid loss is due to its 








                                                          
1 Lactulose and mannitol results were expressed as % of dose administered. 
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(0.18) 
 
The banana and pectin groups 
stopped having diarrhea more often 
compared to controls (e.g. p<0.01 by 
day 4). Among the banana and 
pectin groups, stool reductions were 
associated with percent change in 
L:M before and after treatment 
(R2=0.84 for pectin and R2=0.86 for 
banana; p<0.05 for each). 
acids in the colon, 
stimulating colonic 
salt and water 
absorption. Pectin is 
thought to work by a 
similar mechanism. 
Authors also 
suggest that short 




resulting in the 
observed changes in 
intestinal 
permeability [206].  
2009 
 
Ritchie BK et al. 
 
13C-sucrose breath 
test: novel use of a 
noninvasive biomarker 
of environmental gut 
health 
 
Sucrose breath test 
(SBT) as a marker of 
small bowel mucosal 
damage vis a vis 
sucrase activity among 
an Australian 
Aboriginal population. 
































cases with AD 
 
n=25 controls: 







(32 Aboriginal cases 
and controls tested) 
• C-reactive protein 
(CRP) 










20/32 (63%) of Aboriginal children 
had abnormal L:R ratios. 
 
Mean1 L:R (CI): 
• Diarrhea cases: 31.8 (24.9, 40.7)  
• Aboriginal controls without 
diarrhea: 11.4 (8.5, 15.5),  
significant difference (p<0.0001) 
 
SBT Mean (CI): 
• Diarrhea cases: 1.9% (0.9, 3.0), 
p<0.0001 compared to non-
Aboriginal controls and p=0.004 
compared to Aboriginal controls 
• Aboriginal controls: 4.1% (3.0, 
5.2), p=0.032 compared to non-
Aboriginal controls 
• Non-Aboriginal controls: 6.1% 
(4.8, 7.3) 
Significant differences were 
observed between all three groups.  
 
SBT results were not associated with 
wasting or with patient age or 
breastfeeding status. 
SBT values were 
significantly lower 




diarrhea than among 
those without GI 







This is consistent 
with previous reports 
of high prevalence of 
clinically silent TE in 





with L:R.  
Abnormal L:R ratios 
were defined as 
>16; no reference 
or derivation was 
provided for this 
cut-point.  
 






analysis was based 




analysis was not 
reported and could 
be of interest 
considering the 
large difference in 
L:R observed 
between these 
                                                          
1 Geometric mean. 
Evidence Table 2. Markers of permeability.
Reference and Study 
Outcomes of  
Diagnostic Interest 
Location and  
Target Population 
Design and 
Sample Size Biomarker Results Conclusion Comments 
 
SBT and L:R were inversely 
correlated (r=0.67; CI: 0.42, 0.62; 
p<0.0001). L:R explained 45% of the 
variance in SBT; diarrhea explained 
28% of variance. 
 
SBT was associated with increased 
MCV, relative risk (CI)=3.9 (2.8, 5.0). 
SBT was not associated with 




MCV, CRP, and 
hemoglobin with 
SBT after adjusting 
for potentially 
confounding 










longitudinal study in 
infants of HIV-infected 
South African women 
 
L:M as a marker of gut 
mucosal integrity and 
urinary neopterin 
excretion as a marker 
of cell-mediated 
immunity in infants 






1, 6, and 14 wk old 









• L:M  
• Neopterin  
Mean2 L:M (CI): 
• HIV-infected subjects: 
• 1 wk: 0.12 (0.06, 0.27)  
• 6 wk: 0.24 (0.15, 0.38) 
• 14 wk: 0.24 (0.14, 0.44) 
• Uninfected subjects:  
• 1 wk: 0.13 (0.09, 0.19) 
• 6 wk: 0.08 (0.06, 0.11) 
• 14 wk: 0.09 ( 0.07, 0.13) 
 
HIV-infection by 14 wk of age was 
significantly associated with 
increased L:M. 
 
A non-significant, positive trend in 
neopterin excretion was observed 
among HIV-infected infants.  
L:M was generally 
normal (compared to 






after 6 weeks. 
 
The increased L:M 
in HIV-infected 
infants was primarily 
driven by lactulose 




infected infants was 
observed but this 




between L:M and 




















• L:M  
• Neopterin  
Mean4 L:M: 
• Group 1:  
• Day 0: ~1.8 
• Day 3: ~2.4  
• Group 2:  
Mean L:M ratios 
were very high 
(~10x) (at baseline 
and at day 3 in both 
groups) compared to 
Urine testing could 
only be conducted 
in the laboratory on 
certain days; hence 
only a subset of 
                                                          
1 Lactulose and mannitol results were expressed in mg. 
2 Geometric mean. 
3 For lactulose, mannitol, and neopterin results, excretion measurement was not specified. 
4 Geometric mean. 
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supplementation of 
South African children 
with diarrhea: optimum 
timing for improving 
biochemical and 
clinical recovery and 
subsequent vitamin A 
status 
 
L:M as a marker of 
intestinal permeability 
and urinary neopterin, 
serum α-1 acid 
glycoprotein, and C-
reactive protein as 
markers of 
inflammation among 




















involved vitamin A 
supplementation 
either on the day 
of 







• C-reactive protein 
(CRP) 
• α-1 acid 
glycoprotein (AGP) 
 
49 subjects received 
urine testing: 
• Group 1: n=25 
• Group 2: n=24  
 
 
Blood and urine were 
tested on days 0 and 
3. 
 
• Day 0: ~1.2 
• Day 3: ~0.7 
 
There were no differences in mean 
L:M between groups or within groups 
between days 0 and 3, although 
there was a significant difference in 
paired analysis within individuals at 
the two time points (data not 
presented, and direction, magnitude 
and degree of significance not 
reported). 
  
Lactulose and mannitol excretion 
were assessed only in the paired 
analysis. Lactulose excretion 
decreased between days 0 and 3 
(magnitude of effect and degree of 
significance not reported), while 
mannitol excretion showed no 
change.  
 
Mean1 neopterin and AGP 
concentrations did not differ between 
groups or within groups on the 
different study days or in the paired 
analysis. When initial CRP (~2x 
higher in Group 2 compared to 
Group 1, p<0.004) was taken into 
account, mean CRP on day 3 did not 
differ between the 2 groups. 
However in the paired analysis, CRP 
concentrations were significantly 
different between days 0 and 3.  





that this could have 
been due to the 








not result in 
significant 
improvement in L:M, 
neopterin, or AGP 
regardless of timing 






those tests.  
 




WBCs and AGP, 




compared to group 
1 at baseline. 
Authors note that 
these parameters 
suggest that Group 
2 patients might 
have been more ill 
at baseline. For the 
subset of 49 
patients undergoing 
urine testing, the 
mean L:M and 
neopterin 
concentrations 
were lower among 
Group 2 than Group 
1 subjects (NS). 
However, baseline 
differences in acute 
phase and vitamin 
A markers at 
baseline were not 
reported separately 
for these 49 
subjects. 
 
Data for lactulose 
and mannitol 
excretion were not 
                                                          
1 Geometric mean. 
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of these molecules 
expressed as ratios 
with creatinine was 
not explained.  
 
Authors suggest 
that their 3-day 
testing period 
(based on their 
previous work in a 
different setting 
[207] might have 
been too short to 
identify effect as 
demonstrated by 
McCullough et al. at 




Thurnham DI et al. 
 
Innate immunity, gut 
integrity, and vitamin A 
in Gambian and Indian 
infants 
 
L:M as a marker of 
intestinal integrity 
among children 
receiving vitamin A 
supplementation 
 
Orissa State, India 
 
Subjects were 




for “diarrheal or 
respiratory 
disease,” mean 













• 31 received 
vitamin A at day 
1 
• 32 received 
vitamin A at 
discharge (up to 
day 5) 














subjects, L:M was 
assessed at baseline, 
discharge from 
hospital, and 10 or 30 
days after discharge. 
 
For clinic-based 
subjects, L:M was 
assessed at baseline, 
4, and 8 wk. 
Mean L:M was ~3-fold higher among 
hospitalized compared to clinic 
patients at baseline. Within the 
allocation groups, mean baseline 
L:M did not differ for either the 
hospitalized or clinic subjects. 
 
Among the hospital cohort, mean 
L:M declined significantly in the two 
vitamin A groups compared to the 
placebo group, and remained lower 
at day 30 among the treatment 
groups, but the difference was no 
longer significant compared to the 
placebo group. 
 
Among the clinic cohort, mean L:M 
reduction was accelerated in vitamin 
A-supplemented children. However, 
mean L:M did not significantly differ 
between treatment groups at any 
time point.  
Mean L:M values, 
including post-
intervention values, 
were 2-5 times 
higher than those 
observed in the UK 
[209]. 
 





study mean values 
did not differ 
statistically between 
allocation groups in 
either the clinic or 




values were not 
reported, rather L:M 
results were 
portrayed in figures 
with units 
expressed in mg, 
making it difficult to 
compare these 
results to those of 
other studies.  
 
Information on 





The article also 
reported re-
analyzed data from 
a 1991 report from 
Evidence Table 2. Markers of permeability.
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randomized to 
receive vitamin A 




* Number of 
subjects in each 
treatment group 




The rate of decline in L:M was most 
steep among the vitamin A-treated 
hospitalized patients, in whom the 
mean L:M value decreased by 63% 
over 30 days, followed by placebo-
treated hospitalized patients, with a 
decrease of 38% over 30 days. 
Mean L:M decreased by 57% in the 
vitamin A-treated clinic patients, 
while there was no change in L:M 
among the clinic placebo group. 
The Gambia [209]. 
2009  
 




controlled trial of 
rifaximin, a 
nonabsorbable 
antibiotic, in the 




sucrose:lactulose, and  
sucralose:lactulose as 
markers of small 




rifaximin or placebo  
Limela, Malawi 
 
All 3-5 yr olds from 















It was presumed 
that if SBBO is 









• Sucrose (SUC) 
• Sucralose (SCL) 




ratio (SCL:L)  
 
 
Subjects were tested 
before and after 
treatment. 
At enrollment: 
• Mean mannitol (SD):  
• Treatment: 9.57 (5.24)  
• Placebo: 10.29 (6.62) 
• Mean lactulose (SD): 
• Treatment: 0.30 (0.18) 
• Placebo: 0.34 (0.25) 
• Mean SUC (SD):  
• Treatment: 0.062 (0.04)  
• Placebo: 0.074 (0.058) 
• Mean SCL (SD):  
• Treatment: 0.51 (0.29)  
• Placebo: 0.58 (0.53) 
• Mean L:M (SD): 
• Treatment: 0.18 (0.12) 
• Placebo: 0.17 (0.09) 
• Mean SUC:L (SD): 
• Treatment: 0.50 (0.34) 
• Placebo: 0.64 (0.90) 
• Mean SCL:L (SD): 
• Treatment: 0.42 (0.32) 
• Placebo: 0.39 (0.23) 
• For both groups combined:  
• 76% had L:M >0.10 
• 34% had L:M >0.20 
 
No significant post- intervention 
There was a high 
proportion with 
elevated L:M which 





this study resembled 






SCL excretion in this 
population was 
similar to that found 
in healthy American 
children (0.4%), 
while SCL:L was 
comparatively lower 
(0.8) and driven by 
lactulose [210]. 
SCL:L might be a 






and testing, in 
particular for SCL 
excretion, might 
account for some 
differences in 
values compared to 
other studies.  
 
This was the first 
use of SCL for site-
specific absorption 
testing in a 
developing country 
setting.  
                                                          
1 Lactulose, mannitol, SUC, and SCL results were expressed as % of dose administered. 
2 Type of mean for sugar ratios not specified. 
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differences were observed in any 
fractional sugar excretion or dual 
sugar test, including among children 
with elevated pre-intervention L:M. 
 






Few data exist on 
SUC excretion. 
Results in this trial 
are similar to those 




and high compared 




0.03%) [210, 212]. 
2008 
 
Vieira MM et al. 
 
Carotenoids, retinol, 
and intestinal barrier 








leukocytes as markers 
of intestinal 
inflammation, and 
CRP and AGP as 
acute phase reactants 
among children with 
varying vitamin A 
Fortaleza, Brazil 
 
2 mo-9 yr olds 




eligible if HAZ 



























48.5% had abnormal L:M.  
 
L:M and excretion of each sugar 
separately did not vary with retinol 
concentration. 
 
L:M was associated with levels of 
common dietary carotenoids, 
primarily driven by lactulose. 
However, the association was not 
always statistically significant, and 
the direction of association varied 
depending on precursor.  
 
40% of stool samples were positive 
for lactoferrin. 
 
1% of stool samples were positive 
for fecal leukocytes. 
 
30% of stool samples were positive 
Almost half of 
subjects had 
increased L:M, and 




While serum retinol 
concentrations were 
not associated with 
L:M, serum 
carotenoids were; 
authors suggest that 
these retinol 







L:M threshold for 
abnormal values 
was defined as 
>0.0864 [214]. Cut-
off values for 
lactoferrin positivity 











between L:M and 
lactoferrin or fecal 
leukocytes as well 
as those between 
                                                          
1 Lactulose and mannitol results were expressed as % of dose administered. 
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status  for parasites but this had no impact 
on L:M results, lactoferrin, or acute 








lactoferrin or fecal 





were excluded from 
study participation 
due to assessment 
of stool lactoferrin. 
2007 
 









L:M and plasma 
immunoglobulins and 
acute phase reactant 
proteins (albumin, C-









West Kiang region, 
Gambia 
 
4-10 mo olds from 
a rural area 
followed during the 
5-month rainy 









amino acids was 
orally 
administered 
twice daily during 











• L:M  
 
Blood markers 










Mean2 L:M (CI):  
• Baseline:  
• Glutamine group: 0.33 (0.25, 
0.43) 
• Placebo group: 0.33 (0.26, 
0.41) 
• Post-intervention: 
• Glutamine group: 0.29 (0.23, 
0.35) 
• Placebo group: 0.26 (0.21, 
0.32) 
 
Mean excretion of lactulose (CI):  
• Baseline:  
• Glutamine group: 0.21 (0.16, 
0.28) 
• Placebo group: 0.20 (0.15, 
0.26) 
• Post-intervention: 
• Glutamine group: 0.17 (0.13, 
0.21) 
• Placebo group: 0.14 (0.11, 
0.18) 
 
Mean excretion of mannitol (CI):  
• Baseline:  
• Glutamine group: 2.65 (2.02, 
L:M values were 
elevated in this 









either at baseline or 
at the end of 
supplementation. 
Growth outcomes 





between L:M and 
growth parameters, 
immuno-globulins, 
and acute phase 
proteins were not 
reported. 
                                                          
1 Lactulose and mannitol results were expressed as % of dose administered. 
2 Geometric mean. 
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3.48) 
• Placebo group: 2.50 (1.87, 
3.36) 
• Post-intervention: 
• Glutamine group: 2.48 (1.99, 
3.11) 
• Placebo group: 2.14 (1.62, 
2.82) 
 
L:M values did not differ significantly 
between treatment groups before or 
following intervention. However, a 
repeated measures ANOVA showed 
that during supplementation, L:M 
values were borderline elevated 
among the glutamine-supplemented 
group relative to the placebo group 
(p=0.05), counter to expectation. 
 
Neither ACT, CRP, albumin, nor 
immunoglobulins IgA, IgG, or IgM 
differed significantly between 
treatment and placebo groups, either 
at baseline or at the end of 
supplementation. 
 
Mean levels of IgA and IgG 
increased during the study (p 
<0.001), while IgM levels did not. 
Concentrations of each of these 
immunoglobulins did not differ 
between treatment and placebo 
groups. 
 
Plasma albumin, ACT, and CRP 
values showed no change over the 
course of the study. 
 
Proportions of children with elevated 
CRP ranged from 30-41% at 
different collection time points. The 
glutamine intervention had no effect 
on proportion of children with 
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elevated CRP. 
 
Treatment and placebo groups 
experienced decreases in WAZ, 
HAZ, and MUAC coinciding with the 
rainy season; however, there was no 
significant difference observed 
between the groups for any of these 
parameters. 
  
Treatment and placebo groups did 
not differ in morbidity indices (i.e. 
percentage of time reported with a 
particular illness or illness overall). 
2000 
 
Willumsen JF et al. 
 
Subclinical mastitis as 




L:M as a marker of 
infant intestinal 









mothers and their 
infants followed up 




clinic via a vitamin 
A supplementation 








an RCT  
 
n=104 mothers  
 
n=108 infants (4 
pairs of twins), 
(26 were HIV-






There was no significant association 
between L:M and subclinical mastitis 




was not associated 
with magnitude of 
L:M. 
 
Actual L:M values 
were not reported 
but are found in a 
companion study, 
also included in this 
review [119].The 
study group in 
Willumsen, et al. 
represents a 
subsample of the 
study population 








test in children with 






0-36 mo olds with 
watery diarrhea 
admitted to oral 







• 15 with C. 
parvum alone 
• 7 with rotavirus 
alone 
• 7 with bacteria 






convalescent (at day 
20) L:M ratios were 
assessed. 
Mean1 L:M (SE) at day 1, day 20: 
• Rotavirus only: 0.67 (0.38), 0.19 
(0.09) 
• Cryptosporidium only: 0.76 (0.43), 
0.28 (0.14) 
• Bacterial infection: ranged from 
0.2-0.87, 0.11-0.99 
• Unknown etiology: 0.26 (0.12), 
0.29 (0.18) 
 
Mean L:M ratios significantly 
L:M ratios were 
significantly 
elevated in children 
with rotavirus or 
Cryptosporidium 
infection compared 
to those with 
diarrhea not caused 
by rotavirus, 
Cryptosporidium, or 
identifiable bacteria.  
 
                                                          
1 Arithmetic mean. 
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L:M as a marker of 
intestinal permeability 









n=7 controls with 
unknown etiology 
 
differed between the unknown 
etiology and both the rotavirus (p< 
0.01) and Cryptosporidium groups 
(p<0.05) at baseline, but not at day 
20.  
 
Mean L:M ratios decreased between 
baseline and day 20 for both the 
rotavirus (p<0.001) and 
Cryptosporidium (p<0.05) groups. 
 
Among the group of subjects with 
enteric bacterial infections, the 
causative agents identified and 
mean L:M ratios (baseline, day 20) 
were: Campylobacter jejuni and 
rotavirus infection (0.86, 0.18), C. 
jejuni and 
Cryptosporidium infection (0.87, 
0.53), Salmonella sp. (0.2, 0.11), C. 
jejuni (0.69, 
0.99), and Aeromonas sp. (0.38, 
0.11). The L:M ratios of this group of 
seven infants were not included in 
the statistical analyses. 
 
Mean L:M did not 
change significantly 
among those with 
diarrhea of unknown 
etiology, but did 
significantly 
decrease among 




similar to those with 





Notes: Some studies included subjects ≥5 yr of age. Where these studies provided data separately for children <5 yr, we present results for only those subjects. Where these studies 
did not stratify results by age, but did report the number of children <5 yr included in the study, we provide a breakdown of under-5s. 
All studies reporting lactulose:rhamnose ratio results presented values multiplied by a factor of 100 for ease of reporting. 
Further details on L:M studies can be found in Table 19.  
 
Abbreviations: AD=acute diarrhea, ALT=alanine aminotransferase, AST=aspartate aminotransferase, CBC=complete blood count, CD=celiac disease, CI=95% confidence interval, 
Cr=creatinine, ∆=change in, EED=environmental enteric dysfunction, FTT=failure to thrive, GI=gastrointestinal, HAZ=height-for-age Z-(score), HDL=high density lipoproteins, 
HIV=human immunodeficiency virus, HLA=human leukocyte antigen, IEL=intraepithelial lymphocytes, IgA=immunoglobulin A, IgE=immunoglobulin E, IgG=immunoglobulin G, 
IgM=immunoglobulin M, IL=interleukin, IFN=interferon, LDL=low density lipoproteins, L:M=lactulose:mannitol ratio, mo=month(s), NS=not statistically significant, PD=persistent 
diarrhea, RCT=randomized controlled trial, SBBO=small bowel bacterial overgrowth, SD=standard deviation, SE=standard error, SES=socioeconomic status, Tc-99m=technetium 
99, T3=triiodothyronine, T4=thyroxine, TE=tropical enteropathy, TGF=transforming growth factor, TNF=tumor necrosis factor, TS=tropical sprue, WAZ=weight-for-age Z-(score), 
WBC=white blood cell count, WFA=weight-for-age, WHZ=weight-for-height Z-(score), wk=week(s), yr=year(s) 
 
 
Evidence Table 2. Markers of permeability.
5.3.1 The Urinary Lactulose:Mannitol Ratio (L:M) 
The urine L:M test is the permeability test that has been most extensively used to 
measure gut function in children in the literature identified for this review. This noninvasive test 
involves oral administration of a dose of both sugars (i.e., lactulose and mannitol), followed by a 
timed urine collection. As reviewed above, lactulose is a large sugar (a disaccharide) that is 
minimally absorbed from an intact small intestine. However, if permeability is altered, this 
disaccharide traverses intracellular spaces of the gut, is then cleared by glomerular filtration 
without renal tubular reabsorption, and becomes measurable in the urine. Mannitol is a sugar 
alcohol that is absorbed (via transcellular pathways) proportional to the small bowel absorptive 
capacity (i.e. surface area). Shortened microvilli diminish uptake and subsequent urinary 
excretion of mannitol, which, like lactulose, is filtered and not reabsorbed.  
5.3.1.1 Technical Issues with the L:M Test 
Prior to delving into the results of the L:M tests, it is important to note that all of the 
biomarkers examined in this review have particular and general performance considerations, 
perhaps none more so than the L:M test. These considerations for the L:M test are summarized 
in Table 14, which demonstrates the tremendous variability in methods, citation of methods, 
ranges of purported normal values of abnormal cutoff points, and the way that results were 


































Campbell DI et al. 
Intestinal inflammation 
measured by fecal neopterin in 
Gambian children with 
enteropathy 
2 mo olds from a 
rural area followed 




1 hr after 
loading dose  
A 5 hr Enzymatic assay 
per Northrop CA et 
al. [215] and Lunn 





Normal value cut points
6
: <0.10 based on UK norm. Campbell DI et al. cited Travis & Menzies et al. [201] but it was unclear if the citation was related to normal values 
for lactulose and mannitol individually or also for L:M. Travis & Menzies did not report primary L:M data, but cited a mean (type not specified) of 0.016 (SEM 0.002), per 
Juby et al. [217], as normal. 
 
2003  
Campbell DI et al. 
Growth faltering in rural 
Gambian infants is associated 
with impaired small intestinal 
barrier function 
2-11 mo olds from 
a rural village 
followed up to 14 
mo of age. 
Not specified 2 hr after 
loading dose  
A  5 hr Enzymatic assay  
per Northrop CA et 








Normal value cut points: Based on UK norms, value was not specified, per Freeman JV et al. [219], Weaver [220], Lunn PG et al. [202], and Lunn [52]. Freeman JV et 
al. [219] reported no data relevant to L:M. Weaver reported data for breastfed English infants and a derived median L:M from this data of ~0.2. Lunn PG et al. [202] 
reported a mean (SEM) L:M for UK 3-15 mo olds of 0.12 (0.02) based on “data from [their] laboratory”, but did not portray the data or cite another reference. Text suggests 
this was a geometric mean, but this was not clearly stated. Lunn [52] described L:M patterns, but not specific values. 
                                                             
1
 Some titles are abbreviated. 
2
 A = 400 mg/kg of lactulose, 100 mg/kg of mannitol, B = not reported, C = 4 g lactulose, 1 g mannitol, D = 5 g lactulose, 1 g mannitol, E = 200 mg/kg of lactulose, 
50 mg/kg of mannitol, F = 400 mg/kg of lactulose, 100 mg/kg of mannitol, G = 400 mg/kg of lactulose (maximum 4 g), 100 mg/kg of mannitol (maximum 1 g), H = 
500 mg/kg of lactulose (maximum 5 g), 100 mg/kg of mannitol (maximum 1 g). 
3
 Where authors cited references for these parameters, they are provided. 
4
 Where authors cited references for these parameters, they are provided. 
5
 Other than studies presented within the “Normal value cut points” row. 
6
 Where authors cited references for normal value cut-points, they are provided along with the relevant information from those citations. 
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Campbell DI et al. 
Chronic T cell-mediated 
enteropathy in rural west African 
children: relationship with 
nutritional status and small 
bowel function 
6 mo-3 yr old 
malnourished in- 
and out-patients 
from rural areas. 
Compared to well-
nourished UK 
children with GI 
complaints other 
than diarrhea. 
Not specified Not reported B 5 hr Enzymatic assay  
per Sullivan PB et 
al. [221] and Lunn 







Normal value cut points: <0.10 based on UK norms, per Fagundes-Neto U et al. [17] and Beattie RM et al. [222]. We were unable to obtain the article by Fagundes-Neto 




Campbell DI et al. 
Age-related association of small 
intestinal mucosal enteropathy 
with nutritional status in rural 
Gambian children 
2-60 yr olds from 
rural communities.  
Not specified Not reported C 5 hr Enzymatic assay 
per Northrop CA et 






Adults in UK & 
tropics [57] and 
previous results in 
Gambian & UK 
subjects [202]  
Normal value cut points: <0.10 based on UK norm per Freeman JV et al. [219] and Travis & Menzies [201]. Freeman JV et al. reported no relevant data. Travis & 
Menzies cited a mean (type not specified) L:M ratio of 0.016 (SEM 0.002), per Juby LD et al. [217], as normal.  
 
2003 
Chen P et al. 
Association of vitamin A and 
zinc status with altered intestinal 
permeability 




Not specified Not reported D 5 hr HPLC 






Normal value cut points: Not reported. 
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Darboe MK et al. 
Effectiveness of an early 
supplementation scheme of 
high-dose vitamin A versus 
standard WHO protocol in 
Gambian mothers and infants 
0-12 mo olds from 





blood sample  
Exclusion: birth 
weight <2.2 kg, 





Not reported E 5 hr Enzymatic assay 






Normal value cut points: <0.30, authors derived this from Lunn PG et al. [202] UK infants’ mean plus 2 SD. Lunn PG et al. stated a mean (type not specified) (SE) of 




Filteau SM et al. 
The effect of antenatal vitamin A 
and (beta)-carotene 
supplementation on gut integrity 





antenatal clinic and 
followed until 14 wk 
of age.  
Not specified Not reported A 5 hr Enzymatic assay 
per Lunn PG et al. 
[209] and 





Normal value cut points: Based on norms, values not specified, per Catassi C et al. [223] and Lunn PG et al. [209]. Catassi C et al. reported data from 72 Italian infants. 
Their L:M values were calculated in two ways: 1) absolute ratio of lactulose and mannitol in mg/dl with L:M mean (type not specified) (SD) ranging from 1.27 (0.73)-0.22 
(0.21) and 2) ratio of lactulose and mannitol as percent dose ingested with L:M mean (type not specified) (SD) of 0.09 (0.08). Lunn PG et al. stated that UK infants’ norm 
as a mean (type not specified) (SD) of 0.12 (0.09), but did not portray the related data or cite another reference for this UK norm.  
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Galpin L et al. 
Effect of Lactobacillus GG on 
intestinal integrity in Malawian 
children at risk of tropical 
enteropathy 
 
36-60 mo olds from 








Overnight D 3 hr Cation-exchange 
column and 
refractometer by 
modified method of 
Catassi C et al. 
[224] and Shulman 




Normal value cut points: <0.10 based on developed world norms between 0.03-0.12, per Goto R et al. [205], van Elburg RM et al. [226], Campbell DI et al. [112]. Goto R 
et al. reported data based on 158 Guatemalan infants aged 0-11 mo without diarrhea in preceding week; the L:M median ranged from 0.41-0.54. They also used 0.07 as a 
cut point for normal L:M based on another reference by Ford RP et al. [227] which did not report data relevant to L:M. van Elburg RM et al. reported L:M based on 30 
Dutch 0-16 yr olds. L:M was calculated in two ways: 1) absolute ratio of lactulose and mannitol in mmol/mol creatinine with L:M mean (type not specified) (SD) 0.043 
(0.045) and 2) ratio of lactulose and mannitol as percent dose ingested with L:M mean (type not specified) (SD) 0.034 (0.033). Campbell DI et al. reported mean (type not 




Goto R et al. 
Impact of anti-Giardia and 
anthelminthic treatment on infant 
growth and intestinal 
permeability in rural Bangladesh 
3-15 mo olds from 
a rural community 
followed over 9 
mos. Malnutrition 
was prevalent. 
Not specified Not reported  A 
  
Usually 3 
hr, but up 
to 5-6 hr if 
no urine 
output 
within 3 hr 
per Akram 
S et al. 
[228] 
Enzymatic assay 
per Lunn PG et al. 
[216] and Northrop 





subjects per Lunn 
PG et al. [209] and 
Rousham EK et al. 
[229] 
Normal value cut points: < upper CI for UK infants, value not specified, per Lunn PG et al. [209]. Lunn PG et al. stated that UK infants’ norm as a mean (type not 
specified) (SD) of 0.12 (0.09), but did not portray the related data or cite another reference for this UK norm.  
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Goto R et al. 
Impact of intestinal permeability, 
inflammation status and 
parasitic infections on infant 
growth faltering in rural 
Bangladesh 
 
3-15 mo olds from 
a rural community 
followed over 9 
mos. Malnutrition 
was prevalent. 
Not specified 1 hr before 
load 
A  5 hr for 
first exam. 
Reduced 









S et al. 
[228] 
Enzymatic assay 
per Lunn PG et al. 
[216] and Northrop 










subjects per Lunn 
PG et al. [209] and 
Rousham EK et al. 
[229] 
Normal value cut points: Geometric mean 0.12 for UK infants per Lunn PG et al. [209]. Lunn PG et al. stated that UK infants’ norm as a mean (type not specified) (SD) 
of 0.12 (0.09), but did not portray the related data or cite another reference for this UK norm.  
2002  
Goto R et al. 
Poor intestinal permeability in 
mildly stunted Nepali children: 
Associations with weaning 
practices and Giardia lamblia 
infection 
 














5 hr Enzymatic assay 
per Lunn PG et al. 
[216]; 
Northrop CA et al. 
[215]; Blood et al. 










subjects per  
Northrop-Clewes 
CA et al. [150] and 
Rousham EK et al. 
[229]. Gambian 
subjects per  
Lunn PG et al. [202] 






Goto R et al. [205] 
 
Normal value cut points: <0.12 based on UK geometric mean per Lunn PG et al. [202]. Lunn et al. stated that UK infants’ norm as a mean (type not specified) (SD) of 
0.12 (0.09), but did not portray the related data or cite another reference for this UK norm.  
                                                             
7
 Authors present positive log L:M values, however, logged values would be expected to be negative for ratios between 0-1 as is the case for L:M ratios. 
8
 Authors calculated the geometric standard error using the formula: antilog (mean + standard error of logged values) - geometric mean. 
9
 For this study, medians were reported rather than means. 
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Lima AA et al. 
Effects of vitamin A 
supplementation on intestinal 
barrier function, growth, total 
parasitic, and specific Giardia 
spp infections in Brazilian 
children 













another study in 
past 2 yr, or 
febrile illness at 
enrollment 
Not reported F Per 
Barboza 
MS et al. 
[214] 
Per Lunn PG et al. 
[216] and Northrop 






Normal value cut points: Not reported. 
2005 
Lima AA et al. 
Intestinal barrier function and 
weight gain in malnourished 
children taking glutamine-
supplemented enteral formula 
 
2-60 mo olds 
hospitalized with 
malnutrition, ~70% 
of whom had PD. 
Inclusion: history 
of PD or WAZ 
score <-2 and 








another study in 
past 2 yr, illness 
at enrollment 
3 hr before 
load 
G 5 hr HPLC per Barboza 





Normal value cut points: Not reported. 
 
 
                                                             
10
 Authors used the term "range," but for some of the L:M medians, only one value was reported, apparently the maximum L:M value observed. 
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Lima NL et al. 
Wasting and intestinal barrier 
function in children taking alanyl-
glutamine-supplemented enteral 
formula 
6 mo-8 yr olds from 
an urban setting 
with HAZ, WAZ, or 






another study in 
the past 2 yr, 
sibling enrolled in 
this study, 
chronic or severe 
or febrile illness 
at enrollment 
3 hr before 
load 
D 5 hr HPLC per Barboza 







Normal value cut points: Within the CI for values of healthy children in the community, values were not reported and no reference was provided. 
2001 
Northrop-Clewes CA et al. 
Anthelmintic treatment of rural 
Bangladeshi children: effect on 
host physiology, growth, and 
biochemical status 
2-5 yr olds from 
poor rural villages. 
 
 





5 hr Enzymatic assay  
per Northrop CA et 











Northrop CA et al. 
[232] 
Normal value cut points: <~0.15 based on UK norm per Lunn PG et al. [209]. Lunn PG et al. stated that UK infants’ norm as a mean (type not specified) (SD) of 0.12 
(0.09), but did not portray the related data or cite another reference for this UK norm. 
2000  
Quadro L et al. 
Retinol and retinol-binding 
protein: gut integrity and 
circulating immunoglobulins 
1-9 yr olds with mild 
malnutrition from an 
urban slum. Vitamin 
A deficiency was 
prevalent. 
Inclusion: no sign 















Normal value cut points: <0.030 based on norms per Lima AA et al. [234], Deitch [235], Ukabam & Cooper [236],Wyatt J et al. [237], Pearson AD et al. [238], and Ford 
RP et al. [227] Lima AA et al. reported mean L:M (type not specified) (SE) of 0.017 (0.002) based on data from 13 Brazilian adults without HIV infection. Deitch reported 
mean L:M from 8 healthy American adult controls. Mean L:M was 1.7; SE was only presented graphically. L:M was expressed as lactulose/mannitol x 100 and the ratio 
was calculated as units rather than % dose administered; type of mean was not otherwise specified. Baseline values of mannitol (from pre-test samples) were subtracted 
from test samples. Ukabam & Cooper reported separate lactulose and mannitol excretion means for 25 healthy adult controls, presumably from the UK based on address 
of corresponding author. They did not report data on the L:M ratio. Wyatt J et al. reported mean (type not specified) L:M (SE) of 0.018 (0.002) based on data from 30 
healthy adults (presumably in Austria based on corresponding author’s address.) They defined a normal cutoff of 0.030 based on mean L:M + 2 SD. Pearson AD et al. 
reported mean L:M (type not specified) (range) of 0.018 (0.005-0.028) based on data from 31 healthy 2-13 yr olds (presumably in UK based on corresponding author’s 
address.) Ford RP et al. reported no data relevant to L:M.  
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Rabbani GH et al. 
Green banana and pectin 
improve small intestinal 
permeability and reduce fluid 
loss in Bangladeshi children with 
persistent diarrhea 
5-12 mo old males 
admitted to hospital 












5 hr Enzymatic assay  







Normal value cut points: Based on norms, value not specified, per Lunn PG et al. [209], Barboza MS et al. [214], Behrens RH et al. [231], Roy SK et al. [241], Ford RP 
et al. [227]. Lunn PG et al. stated that UK infants’ normal values are: mean (type not specified) (SD) 0.12 (0.09), but did not portray the related data or cite another 
reference for this UK value. Barboza MS et al. reported mean L:M (type not specified) (SD) of 0.0394 (0.0235) based on 15 Brazilian under-5s from a low SES area 
without diarrhea in the preceding 2 weeks. Behrens RH et al. reported mean L:M (type not specified) (+/-2SD) of 0.42 (0.2, 1.4) and 0.52 (0.2, 2.2) based on 255 tests on 
60 healthy Gambian 0-18 mo olds with HFA >80% of NCHS median and 45 tests on 15 Gambian 0-18 mo olds with HFA between 60-80% of NCHS median. Roy SK et al. 
reported geometric mean L:M (CI) of 0.13 (0.1, 0.16) based on 53 asymptomatic Bangladeshi controls. Ages of controls were not described but diarrheal cases were aged 
3-24 mo. Ford RP et al. reported no data relevant to L:M. 
2001 
Rollins NC et al. 
Feeding mode, intestinal 
permeability, and neopterin 
excretion: A longitudinal study in 
infants of HIV-infected South 
African women 
1, 6, and 14 wk old 
infants born to HIV-
infected mothers. 
Not specified  Not reported A 5 hr 
 
  
Enzymatic assay  





Normal value cut points: Based on norms, value not specified, per Catassi C et al. [223] and Behrens RH et al. [231]. Catassi C et al. reported mean L:M based on data 
from 72 Italian infants. Their L:M values were calculated in two ways: 1) absolute ratio of lactulose and mannitol in mg/dl with L:M mean (type not specified) (SD) ranging 
from 1.27 (0.73)-0.22 (0.21) and 2) ratio of lactulose and mannitol as percent dose ingested with L:M mean (type not specified) (SD) of 0.09 (0.08). Behrens RH et al. 
reported mean L:M (type not specified) (+/-2SD) of 0.42 (0.2, 1.4) and 0.52 (0.2, 2.2) based on 255 tests on 60 healthy Gambian 0-18 mo olds with HFA >80% of NCHS 
median and 45 tests on 15 Gambian 0-18 mo olds with HFA between 60-80% of NCHS median.  
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Rollins NC et al. 
Vitamin A supplementation of 
South African children with 
diarrhea: optimum timing for 
improving biochemical and 
clinical recovery and subsequent 
vitamin A status 





could be performed 












inability to take 
oral fluids 




Enzymatic assay  







Normal value cut points: Not reported. 
2000 
Thurnham DI et al. 
Innate immunity, gut integrity, 





mean age 9 mos. 
And out-patients 
with “minor 
ailments”, age not 
specified.  
Not specified Not reported B 5 hr Not specified per 






Normal value cut points: <0.12 based on UK norm per Lunn PG et al. [209]. Lunn PG et al. stated that UK infants’ norm as a mean (type not specified) (SD) of 0.12 
(0.09), but did not portray the related data or cite another reference for this UK norm. 
2009 
Trehan I et al. 
A randomized, double-blind, 
placebo-controlled trial of 
rifaximin, a nonabsorbable 
antibiotic, in the treatment of 
tropical enteropathy 












4 hr HPLC per Shulman 
RJ et al. [212] and 






Normal value cut points: <0.10 based on norms of 0.03-0.12 per Campbell DI et al. [112], Goto R et al. [205], and Galpin L et al. [120]. Campbell DI et al. reported mean 
(type not specified) (SE) L:M of 0.353 (0.022) based on 26 Gambian 2-5 yr olds without diarrhea. They also reference UK norms but do not report specific values (see 
above). Goto R et al. reported L:M values based on 158 Guatemalan infants aged 0-11 mo without diarrhea in preceding week. L:M median ranged from 0.41-0.54. They 
also used 0.07 as a cut point for normal L:M based on another reference by Ford RP et al. [227] which did not report data relevant to L:M. Galpin L et al. reported 
arithmetic mean (SD) L:M of 0.18 (0.16) and 0.22 (0.20) based on 2 groups of 80 and 81 healthy Malawian 3-5 yr old children, respectively.  
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Vieira MM et al. 
Carotenoids, retinol, and 
intestinal barrier function in 
children from northeastern Brazil 











another study in 
past 2 yr or 
febrile illness at 
enrollment 
1 hr after 
load, fasted 






5 hr HPLC per Bao Y et 
al. 
 [233], Lima, et al. 
[234], and Barboza 












Normal value cut points: <0.0864, calculated as mean + 2SD based on data from Barboza MS et al. [214]: mean L:M (type not specified) (SD) of 0.0394 (0.0235) based 
on 15 Brazilian under-5s from low SES area without diarrhea in preceding 2 weeks. 
2007 




in growth-faltering Gambian 
infants 
 
4-10 mo olds from 
a rural area 
followed during the 
5-month rainy 
season and for 6 
months afterward 
All age-eligible 















F 5 hr Not specified. 
Williams et al. cited 





permeability; it was 
unclear which 







Normal value cut points: Not reported. 
Normal value cut points: Not reported. 
2000  
Willumsen JF et al. 
Subclinical mastitis as a risk 













Enzymatic assay  
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Zhang Y et al. 
Lactulose-mannitol intestinal 
permeability test in children with 
diarrhea caused by rotavirus 
and Cryptosporidium  
0-36 mo olds with 
watery diarrhea 










of renal disease, 
or current 
antibiotic use 
Not reported A  
 













Normal value cut points: Not reported. 
 
Abbreviations: AIDS=Acquired immune deficiency syndrome, CI=95% confidence interval, GI=Gastrointestinal, HAZ=Height-for-age Z (score), HFA=Height-for-age, 
HIV=Human immunodeficiency virus, HPLC=High performance liquid chromatography, hr=Hour(s), L=Lactulose, L:M=lactulose:mannitol, M=Mannitol, mo=Month(s), 
PD=Persistent diarrhea, SD=Standard deviation, SE=Standard error, TB=Tuberculosis, UK=United Kingdom, WAZ=Weight-for-age Z (score), WFA=Weight-for-age, 




Table 14. Comparisons of L:M test study methods and reporting frameworks.
An important initial methodological consideration is that administration of a loading dose 
is required; dosing among the studies we reviewed varied. Ideally, the dosing should be related 
to body mass, or at least to body weight, in view of the large range in body size and composition 
of the subjects to whom it is administered. Such dosing was reported to have been performed in 
only 13 of the 25 L:M studies we reviewed. It should be noted that either or both of these 
molecules can cause diarrhea via their hyperosmolar properties, and that sometimes the load 
causes vomiting. These side effects, although not serious, might be more prominent among 
children with certain characteristics thus skewing results. Indeed, the hyperosmolar effect is 
proposed to potentially interfere with absorption by causing solvent drag (retention of the 
measured solute in the gut), and has prompted consideration of a liquid meal with which to 
administer these exomolecular probes of intestinal absorption and permeability [184].  
Because gastric emptying could delay kinetics of absorption, a standard and perhaps 
prolonged fasting interval should be employed. This presents a challenge when testing infants 
who cannot tolerate fasts of greater than 3-6 hours depending on age, especially if exclusively 
breastfed since breastmilk is easily and relatively quickly digested. Furthermore, even a three-
hour fasting interval may not be tolerated among acutely malnourished children. However, 
fasting is most important for assessment of individual component measurements. Twelve of the 
25 reviewed studies reported that the children were fasted prior to challenge, but the duration of 
fasting differed across studies.  
There are additional theoretical concerns with hyperosmolar sugar absorption tests. 
First, there is evidence in humans that intestinal permeability can be altered by the 
administration of such solutes [243, 244]. Second, there is a small degree of endogenous 
mannitol production and excretion [243]. Third, the use of lactulose can accelerate orocecal 
transit time [245]. None of these factors were mentioned by any of these studies. These 
potential technical limitations have also not received much attention outside of the field of 
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environmental enteric dysfunction in the last two decades. Both the individual mannitol and 
lactulose component measures provide unique information as mentioned above, and thus 
should be reported separately; nearly three-quarters of the studies we reviewed did so. Ideally, 
the individual components should be presented as percent of dose administered, and also as an 
(ideally standardized) osmolarity of the ingested probe. Of the 18 studies reporting that 
components were measured separately, 11 presented results as such. Indeed, the report of 
Lima et al. exemplifies the merit of reporting such metadata, as a paradoxically inverse 
relationship between mannitol uptake and poor growth was identified [139]. 
Five-hour timed urine collections are considered standard. Timed urine collection among 
infants and young children presents a challenge in the best of circumstances and it can be even 
more challenging when subjects have loose stools, as is often the case among the very cohort 
of children for whom assessment of intestinal permeability is desired. Urine collection times 
varied across the studies in this review, and two did not report the information. Additionally, 
urinary bacteria, either representing clinical bacteriuria or contamination and replication prior to 
freezing, could alter sugar concentrations [246].  
Laboratory detection method varied as described in Table 14. Limits of normal results 
have not been determined for populations in resource-limited settings. Comparisons are made 
to those derived from developed-country settings. Table 14 demonstrates the various norms, 
primarily from the United Kingdom (UK), that were cited and referenced within the studies that 
we reviewed. Furthermore, the results were reported in varying ways. For example, L:M values 
can change with age of the subject, and in the setting of low urinary flow, as in dehydration, the 
impermeability of the proximal tubule has not been adequately assessed in children. 
Stratification of results based on age was often non-existent or suboptimal for determining its 
contribution to high L:M values. Also, it was difficult to compare the same age groups between 
studies. Perhaps the most striking deficiency was the lack of standard reporting of central 
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tendency measures, which were variably provided as medians or means. The latter were 
calculated as arithmetic or geometric means; the geometric method is more appropriate for ratio 
measures such as L:M. Some studies did not report central tendency measures but only the 
proportion with abnormal results. Among the 25 L:M studies we reviewed, three reported no 
central tendency values, two reported medians, and 20 reported means. Of the studies reporting 
means, 10 reported the geometric mean, which is a mathematically preferred expression of a 
mean for ratios, while two reported arithmetic means, and eight reported means without 
specifying their type. Clearly, despite the relative abundance of recent L:M data, the wide 
variation in study and reporting methods hamper our ability to make inter-study comparisons.  
5.3.1.2 Range of L:M Values Reported 
The majority of studies that we reviewed found elevated L:M values in their subjects, 
consistent with reports from before the interval of publication of papers that we assessed for this 
systematic review (i.e., studies published prior to 2000). These elevated L:M values were largely 
compared to norms reported for Western (primarily from the UK) childhood values [201, 217, 
220, 223, 226, 235, 237, 238] and less often related to presumed norms of children in 
developing-country settings [112, 120, 205, 214, 231, 234, 241].  
Delineation of normal values is a challenge for several reasons. Normative curves are 
often established based on assessments among a small sample of children in a developed 
country. Two standard deviations are frequently used as cutoff point to define normal/abnormal 
levels. However, this may not always be an appropriate method for a variety of reasons. Genetic 
factors might or might not influence test results. Marker response to environmental exposures 
might, at least initially, reflect adaptive rather than pathologic responses.  
As noted above, comparison of L:M values across the 25 studies that we reviewed was 
also challenged by differences in the way the values were reported (see Table 14). Among 
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studies reporting the ratio results as geometric means, the values (ratios) ranged from 0.08 to 
2.4 and both extremes were published by the same author group in two different studies, 
although among different populations. The lowest (i.e. least abnormal) values were reported 
among HIV-negative South African infants under four months of age born to HIV-infected 
mothers [160, 161], while the highest values were found in children aged six to 60 months 
hospitalized with severe diarrhea, also in South Africa [161]. The fact that the highest values 
were an order of magnitude higher than in other studies reviewed led us to speculate that L:M 
values might have been expressed as a multiple for portrayal on the same graph with urinary 
neopterin and serum retinol-binding data. 
Among children in rural Bangladesh, one study found a geometric mean L:M value of 
0.15 [123]. In two different rural Bangladesh intervention trials, baseline L:M values were 0.18 in 
each of the anti-helminthic treatment groups and 0.16 in the placebo group in the same setting 
[122], but were 0.22 and 0.25 in a different rural setting also among anti-helminthic treatment 
and placebo groups, respectively [150].  
In Nepal, the mean L:M value among mildly stunted children aged 0-60 months was 
0.26, but did significantly differ between those infected with Giardia (0.43) vs. those without 
evidence of giardiasis (0.25) [124]. A series of studies conducted in The Gambia reported L:M 
geometric mean values of 0.169 [110], 0.353 [112], and 0.31 [15]. Another study demonstrated 
similar results, ranging from 0.26 to 0.37 in placebo-treated children, depending on month of the 
study [170]. These studies support the concept of widespread intestinal permeability issues 
among children in developing settings with considerable variation between studies, generally 
finding a greater degree of permeability in central African settings.  
However, in contrast to the Asian and central African studies, some South African [119, 
160] studies found L:M values that were similar to established norms (i.e., mean values from 
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healthy children in developed settings). These apparent contradictions could reflect the 
emergence of the economies in which these children reside, with concomitant improvement in 
gut health. Three [119, 160, 161] of the four L:M studies from South Africa presented geometric 
means (notably, each of these four studies were performed by the same investigator group). 
The fourth study [171] presented a subset of data published by Filteau et al. [119]. Filteau et al. 
[119] and Rollins et al. [160] assessed L:M among infants born to HIV-infected mothers and 
generally found normal values that did not increase with age. Filteau et al. also noted no change 
in L:M measures with increasing morbidity. However, in both studies the mean value of L:M for 
the infants who became infected with HIV was increased; the Rollins et al. observational study 
reported a mean of 0.24 and the Filteau et al. intervention trial reported a mean of almost 0.5 
among those whose mothers had not received vitamin A supplementation.  
Similarly, some South American [137, 139] studies found L:M values that were similar to 
mean values for healthy children. Six L:M studies from Brazil were conducted by one team of 
investigators [113, 137-139, 156, 169]. Three of the studies reported baseline L:M values but 
did not classify them as normal or abnormal [113, 137, 138]. Two studies assessing similar 
populations of mildly malnourished children from an impoverished urban community in Brazil 
[156, 169] reported that a high proportion of their subjects had abnormal L:M values. L:M 
median and range data collected a few years later in the same setting and with the same 
inclusion criteria were noted by the authors to be within the confidence interval for values of 
healthy children in the study community [139] (the reference for this confidence interval was not 
cited).  
Several studies measured the variability of L:M values between and within individuals. 
Some of these identified wide ranges [122, 124], and Campbell et al. [112] found that L:M 
showed significant intra-subject correlation between tests conducted 3.5 months apart. In 
contrast, Northrop-Clewes et al. [150] observed that intra-individual L:M values in the placebo 
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group of an anti-helminthic trial did not change significantly over 12 months. Of note, L:M values 
might change with increasing age because of normal changes of physiologic maturation. 
However, the studies that we reviewed rarely reported data stratified by age, thereby prohibiting 
rigorous comparisons from one study to the next. 
Very few studies investigated longitudinal change in a measure of central tendency of 
L:M values for their study sample. Campbell et al. found a small but significant improvement in 
mean L:M value between the two study time points (from 0.198 to 0.172, type of mean not 
mentioned), driven by an improvement in mannitol recovery with no change in lactulose 
excretion [112]. The interval between sampling was 3.5 months.  
Three studies observed seasonal variation in L:M values. Two of these studies were 
conducted in rural Bangladesh; the timing of peak L:M values differed slightly between them. In 
one study [122], the highest values were observed during the monsoon season while in the 
other [150], the peak followed the monsoon season. A study in The Gambia reported monthly 
variation in geometric mean L:M values, ranging from 0.37 in July to 0.26 in October in placebo-
treated children [170]. 
5.3.1.3 Associations between L:M and Growth Outcomes 
The L:M test has been used extensively to assess small intestinal function in relation to 
nutritional status in children in resource-limited settings. Several studies have found inverse 
relationships between L:M and growth parameters, while others have not (Table 15). Goto et al. 
[123] and Campbell et al. [110] found that L:M was inversely associated with height-for-age Z-
scores (HAZ) and weight-for-age Z-scores (WAZ). A longitudinal study by Goto et al. [122] 
found associations between change in L:M and changes in weight-for-age Z-scores (∆WAZ) and 
weight-for-height Z-scores (∆WHZ),showing improvement in growth parameters with decreased 
L:M values. A later study by Campbell et al. [15] found that long-term height gain was negatively 
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associated with mean L:M value. Northrop-Clewes et al. [150] observed that L:M was inversely 
correlated with change in height-for-age Z- (∆HAZ) and ∆WAZ scores at 12 months of follow-up. 
However, several studies did not find an association between L:M and growth 
parameters. Goto et al. [124] reported no association between L:M values and growth status, 
although they did not specify which of the assessed growth measures (HAZ and WAZ) were 
used to evaluate this. A 2003 study by Campbell et al. similarly found no association between 
L:M and grade of protein energy malnutrition [111]. The same group earlier demonstrated that 
L:M was inversely associated with HAZ after correcting for age, gender, and study visit, but not 
with WAZ or body mass index z-scores [112]. In these studies, the association with HAZ was 
mainly attributed to the greater lactulose excretion in subjects with poorer HAZ scores and was 
constant across all age groups. There was no significant association between L:M calculated as 
the mean of the two data collection points and change in nutritional status parameters.  
Several factors complicate comparison of the relationship between L:M and growth 
parameters across studies. Anthropometric indices used in these assessments varied. Markers 
were sometimes associated with different anthropometric measures within the same study. In 
one instance [112], a relationship was identified between L:M and HAZ score but not WAZ 
score. When the relationship between L:M values and growth parameters is not reported, it is 
not clear if the anthropometric indicator was either not evaluated or whether a significant 
relationship was not identified (i.e., only positive results were presented). One study assessed 
association with single sugar excretion only, reporting no significant associations between HAZ, 
WAZ, or weight-for-height Z- (WHZ) scores and lactulose, but significant associations with both 
WAZ and WHZ scores and mannitol [139]. The article did not mention HAZ score when 
reporting the results of mannitol analyses, leaving unspecified whether the relationship was 
assessed and found to be nonsignificant, or not assessed at all.
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Table 15. Associations between anthropometric indicators and biomarkers of EED. 
Data presented are from one study unless otherwise indicated in parentheses. 
 
Anthropometric 















HAZ Y (3) 
N (1) 
N  Y     Y By 2 of 3 digital 
morphometric 
measures1: Y 
∆HAZ Y (2)   Y N Y     
WAZ Y (2) 
N (3) 







∆WAZ Y (2)   Y  Y     
WHZ Y N Y Y      By 2 of 3 digital 
morphometric 
measures1: Y 
∆WHZ    Y       
BMI N          
Y=yes, a statistically significant relationship was found. 
N=no, a statistically significant relationship was not found. 
                                                             
1 The three digital morphometry measures included enterocyte height, enterocyte brush border, and enterocyte nucleus height. The two measures 
that were significantly associated with anthropometric indicators differed for each type of anthropometric indicator assessed.  
5.3.1.4 Associations between L:M and Other Outcomes 
Four studies assessed the potential association between L:M values and Giardia 
infection. Two found no association [15, 123]. A Bangladeshi antihelmintic trial [150] found that 
L:M and giardiasis were not associated overall; they only identified an association among the 
treatment group in their intervention trial at a single time point over the course of the 12-month 
study period. In the fourth study, the geometric mean L:M among mildly stunted Nepalese 
children from urban squatter settlements aged five years and under was 0.26, but statistically 
significantly differed between Giardia-infected and non-infected children (0.43 vs. 0.25, 
respectively) [124].  
Several studies investigated the relationship between subject age and L:M values; three 
found no association [113, 119, 124]. Goto et al. demonstrated a decreasing L:M trend with age 
among a cohort of Bangladeshi 3-15 month olds [123]. Campbell et al. [112] compared 
Gambian 2-5 year olds with older children and found a significant association between age and 
L:M values as well as a small but statistically significant improvement in mean L:M over 3.5 
months driven by improved mannitol excretion without change in lactulose excretion. They later 
[110] reported study results among another cohort of Gambian children that showed that L:M 
values showed a large and statistically significant increase between 12 weeks and one year of 
age, a change driven by both increasing lactulose and decreasing mannitol excretion. Darboe et 
al. [115] observed that L:M values rose by about 50% from age two months to one year, but did 
not analyze the trend statistically.  
Various studies examined the L:M marker in the context of other conditions. No 
association was found between L:M and diarrhea history [124] or helminthiasis [150, 205]. 
Associations were found between L:M and infection with HIV [119, 160] and Cryptosporidium 
and rotavirus [172]. Two studies reported seasonal L:M variation in rural Bangladesh, with 
peaks during [122] or following [150] monsoon season. 
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5.3.1.5 Use of the L:M Test as an Endpoint for Intervention Trials 
Multiple studies have used the L:M marker as an endpoint to assess intestinal 
permeability in randomized, controlled trials. The specific interventions varied widely, including 
micronutrient supplementation, probiotics, therapeutic diets, and antibiotic and anti-helminthic 
drug administration. 
Four studies utilized L:M as an outcome in vitamin A supplementation intervention trials 
and found no association with L:M overall [115, 119, 137, 168] although Filteau et al. did identify 
a significant reduction in L:M values among HIV-infected children treated with vitamin A [119]. 
While Darboe et al. noted that a vitamin A-supplemented group experienced a reduction in 
lactulose uptake, they also observed an accompanying decrease in mannitol absorption; 
therefore the ratio of the two sugars did not change [115]. This finding demonstrates the value 
of reporting the absorption of the two sugars separately, in addition to reporting the ratio. In 
contrast, Chen et al. observed improved L:M values after treating a cohort with persistent 
diarrhea or low WAZ with a single dose of vitamin A and a two-week course of daily zinc [113]. 
Lima et al. conducted two studies using L:M as an outcome to assess the beneficial 
effects of formulas of different compositions used in therapeutic rehabilitation of children with 
persistent diarrhea and/or malnutrition. In the study assessing glycine-supplemented formula, 
L:M values improved in the treatment group [138]. However in a trial in which this group 
examined alanyl-glutamine-supplemented formula, even though lactulose excretion improved, 
mannitol excretion worsened and therefore L:M values did not change after the intervention 
[139]. In another trial of glutamine supplementation, conducted by Williams et al. in The 
Gambia, the intervention did not improve L:M values; in fact, analysis by repeated measures 
analysis of variance (ANOVA) indicated that L:M values were borderline elevated in the 
glutamine-supplemented group (p=0.05), contrary to what was expected [170].  
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Another dietary intervention trial examined the efficacy of green banana and pectin 
among children with persistent diarrhea [157]. While post-intervention L:M values were still 
elevated, both lactulose and mannitol excretion improved after treatment, with lactulose being 
the primary driver of the improvements seen in the ratio of these two sugars.  
Four other trials examined the degree to which L:M values improved as a result of 
various interventions, with no effect observed: probiotics [120] and antibiotics (rifaximin) [13] to 
target small bowel bacterial overgrowth as a potential cause of impaired intestinal integrity in 
Malawi, and various anti-helminthic and anti-Giardia treatments in Bangladesh [122, 150]. 
Interestingly, a Brazilian vitamin A trial demonstrated reduced lactulose as well as mannitol 
excretion, but an unchanged overall ratio [137], thereby highlighting the value of reporting 
absorption of the sugars separately. 
In many of these studies, power considerations were not addressed at all, or 
incompletely addressed, and were often subordinated to study realities. Several examples 
illustrate the issue. Goto et al. recruited 222 children, into two treatment groups and one 
placebo group [122]. They estimated their sample size based on baseline recent Bangladeshi 
infant data [247]. They calculated that to improve HAZ by 33%, a sample size of 68 was needed 
(using an α of 0.05, and 80% power). For WAZ, the sample size needed was 73. So, after 
allowing for attrition, they aimed to recruit approximately 100 infants in each group. The anti-
Giardia treatment used in this study, secnidazole, is unpalatable, so there was concern that 
there might be more attrition in those receiving this treatment. Therefore the treatment groups 
were increased by about 10% relative to the control group (n = 142, 141 and 127, respectively). 
However, because of large loss of subjects to follow-up as well as other methodological issues, 
including inaccurate dosing by many subjects and switching to analysis on actual treatment 
received rather than on an "intent-to-treat" basis, the final group sizes were 75 (secnidazole & 
albendazole), 59 (secnidazole only), and 88 (control). Hence, the size of the second group fell 
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below sample size targets for adequate power, while the other groups were still of sufficient size 
for projected HAZ and WAZ outcomes. 
Northrop-Clewes et al. [150] did not report sample size calculations, indicating that their 
target sample size of 120 was based on logistical reasons. They went on to state “the null effect 
of deworming in this study could perhaps have stemmed from an inadequate sample size or 
duration of follow-up. However, significant improvements were observed in studies with smaller 
samples (e.g., n = 23, n = 55, and n = 72; 42, 10, 11) and of much shorter duration (seven and 
nine weeks) [248-250]". This comparison draws attention to the potential role of publication bias 
in any review of the literature. 
5.3.1.6 Associations between L:M and Other Markers 
Five of the 25 publications examined L:M results in relation to other potential markers of 
intestinal dysfunction, including one study that found that it was not correlated with urinary 
lactose or lactose:lactulose [124]. Two studies assessed L:M and markers of systemic 
inflammation and found differing results [110, 123]. A fourth study found no correlation with stool 
neopterin [15]. The only study that we reviewed that examined L:M in relation to intestinal tissue 
reported a variety of intestinal tissue measurements by morphometry and reported positive 
correlation with mucosal B-lymphocyte density, intraepithelial lymphocytes (IEL), and IELs 
staining positive for perforin [111]. It is not clear if the other intestinal markers were not 
correlated or merely not assessed for correlation. 
5.3.2 The Lactulose:Rhamnose Ratio (L:R) 
Similar to the L:M, the lactulose:rhamnose ratio (L:R) has been used as an index of gut 
mucosal function. As in the L:M test, lactulose is used as the measure of barrier function, but 
rhamnose replaces mannitol as the marker of absorptive capacity. L:M is performed on urine 
samples and, as mentioned above, in timed collections, ranging from three to six hours. The L:R 
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test had been performed on similarly timed urine specimens as well. To our knowledge, there 
are no published data comparing rhamnose directly to mannitol in children with enteric 
dysfunction, but in adults with inflammatory bowel disease the two sugars are absorbed 
comparably [251].  
5.3.2.1 The L:R Test as a Reflection of Issues in Serum or Urine Sugar 
Testing in Children 
Recent advances in high-performance liquid chromatography (HPLC) now permit 
sensitive detection of lactulose, mannitol and rhamnose in the blood. While timed blood 
specimens have been evaluated in animals and human adults [252-256], the invasiveness of 
repeated phlebotomies presents practical and ethical challenges in pediatric research. However, 
collection of urine over a period of time in young children, while less invasive, is not a trivial task 
either. While application of urine “bag” collectors permits noninvasive capture of urine, loss of 
urine because of leakage around the bag is common, as is contamination by stool, especially 
among children with diarrhea. Indeed, it should be noted that the children in most need of 
intestinal function testing often have diarrhea, and the ingestion of the sugar loads themselves 
can lead to osmotic diarrhea.  
Haase et al. compared the validity of L:R testing on one-time collections of blood to 5-
hour urine collections [125] in children. They found that blood L:R values were consistently 
lower than urine L:R values by a geometric mean (95% confidence interval (CI)) of 1.09 (1.02, 
1.16). There was substantial agreement between the two tests as measured by a kappa statistic 
of concordance (95% CIs) of 0.71 (0.51, 0.92). Assuming urine L:R as a gold standard, Haase 
et al. calculated sensitivity and specificity of blood L:R as 81% and 89% respectively. 
As discussed above, test failure can occur for various reasons when tests rely on urine 
samples, particularly timed samples. However, test failure can also occur with blood specimens 
because of insufficient volumes collected to run the assay, and potentially from edema if blood 
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is obtained by finger stick [257]. In addition, the assay cannot be performed using either analyte 
if children vomit, or refuse to ingest, the sugars. Haase et al. defined test “failure” as emesis of 
the sugar load, urine leakage or contamination with stool, or blood collection insufficient for 
analysis (<0.25 mL of plasma). While they did not delineate the reasons for failure among the 
blood vs. the urine collections, they did observe a significantly higher failure rate for the urine 
(37%) compared to the blood assays (10%) (p<0.0001). Interestingly, a study published in 1999 
(and therefore not included in the analysis of this systematic review) by the same authors also 
reported a 37% failure rate for urine L:R testing and in this earlier study they specified the 
proportions by cause of failure. They noted that the failure rate for a five-hour urine collection 
varied between 47% (32 of 68) in girls with acute diarrhea to 17% (14 of 82) in non-diarrheal 
controls. They also noted that causes of test failure consisted of vomiting or refusal to drink the 
probe sugar solution in 21 (9%) of the tests [258]. 
The remaining four studies that used L:R as a marker of gut permeability measured 
these ratios in blood specimens. We found that rates of technical failure of testing were not 
often reported in the sugar absorption/permeability studies that we reviewed. Of the four studies 
using serum L:R, two discussed failure to complete testing. One study specifically reported 
difficulty with venipuncture in two of 34 subjects [159]. In the other study, L:R was measured at 
baseline as well as following an intervention with specific milk formulas [134]. It was not entirely 
clear, but it did seem that baseline L:R testing was successfully completed on all subjects while 
there was a reported “failure” of post-intervention testing among 10 of 150 children. Reasons for 
test failure in the second determination were not reported. Among the five studies that used D-
xylose (either urine or serum) [136, 146, 147, 152, 155] no mention was made of lack of 
completion of testing among the subjects enrolled. Only seven [124, 138, 139, 150, 161, 169, 
172] of the 25 urinary L:M studies included in this review specifically mentioned the number of 
children who completed L:M testing compared to the number recruited into the study. It was not 
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always clear why incomplete L:M testing occurred, but it appears that in five of these studies 
there was a failure in testing because of improper compounding of the sugar solution, inability to 
collect urine during the testing period, urine leakage or stool contamination, or refusal to ingest 
the sugar solution. Similar to the study that expressly measured and reported failure rates in L:R 
testing [125], Goto et al. reported in 1999 (and therefore not included in this review) that the L:M 
test failure rates were 32% [205]. 
It should be noted that each of the five L:R studies in this review was conducted by the 
same researchers in Darwin, Northern Territories, Australia (one of their studies also included 
subjects from Adelaide, South Australia, Australia). It appears that some of the studies might 
represent data from overlapping cohorts of children. It should also be noted that while Australia 
clearly falls within the classification of a high income country, our inclusion definition of children 
in “developing-country setting” included marginalized or indigenous populations in a developed 
country who are plausibly exposed to the same environmental and/or infectious risks for EED as 
children in developed-country settings. In fact, research among Aboriginal populations in 
Australia has contributed a great deal to the EED field [58, 258].  
5.3.2.2 Range of L:R Values Reported and Associations with Growth 
Outcomes 
Many investigators report the L:R value multiplied by 100 for ease of reporting; this 
convention was followed within the articles examined for this review. The geometric mean was 
the measure of central tendency consistently used in these studies, facilitating comparison of 
results. However, while the L:M studies referenced various ranges of normal standards, none of 
the L:R studies cited such reference standards. Furthermore, the three studies that reported the 
proportion of children with abnormal L:R results used different cutoff points and did not cite 
references for these demarcations of normal and abnormal values that they employed. One 
study defined an abnormal L:R value as >16, with 20 of 32 children (63%) exhibiting values 
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above this threshold [159], another used 7.2 as their defined cutoff point with 112 of 152 
subjects (74%) above that threshold [43], and a third explained the derivation of its cutoff point 
of >5.6 as two standard deviations above the arithmetic mean for non-Aboriginal children 
without diarrhea [58]. No citation was given for this standard value, implying that it might have 
been derived from the data collected in this study. However, the authors reported that none of 
the study’s non-Aboriginal children without diarrhea had abnormal permeability values, 
suggesting that perhaps the cutoff point was derived from a different study. While their study 
included Aboriginal children with diarrhea, they did not report proportions of children with L:R 
values >5.6 for this group. 
Three studies compared serum L:R values among primarily Aboriginal cases with 
diarrhea and controls without this disorder. Baseline geometric means for L:R (95% CIs) in the 
two studies ranged from 3.7 (2.8, 4.9) [134] to 5.9 (4.4, 7.8) [125] to 11.4 (8.5, 15.5) [159] 
among controls and 9.4 (6.7, 13.1) [125] to 12.8 (10.3, 16.0) [134] to 31.8 (24.9, 40.7) [159] 
among cases.  
In a randomized trial of three different milk formulas in Aboriginal children with 
malnutrition and/or diarrhea, baseline geometric mean L:R values (95% CIs) were 14.9 (10.4, 
21.5) in one treatment group; baseline values were similar in the other groups [134]. Although 
subjects were randomized to treatment groups, the study did not include a control arm of 
standard care to which change in L:R could be compared. Mean improvement in L:R (95% CIs) 
was 13.0 (9.3, 16.6) with some significant differences across treatment groups. This was the 
only study in this review using L:R as an outcome measure in an intervention trial.  
A similar study reported that mean L:R values among Aboriginal children were 
approximately double those of non-Aboriginal children, whether examining across groups of 
subjects either with or without diarrhea, consistent with the authors’ suggestion that clinically 
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silent enteric dysfunction is prevalent among Aboriginal children [58]. Geometric mean L:R 
among the children without diarrhea was 2.5 and 4.6 among non-Aboriginal and Aboriginals, 
respectively (p=0.02). Geometric mean L:R among those with diarrhea was 7.9 and 16.4 among 
non-Aboriginals and Aboriginals, respectively (p=0.002).  
One study examined the relationship between L:R and growth and found no association 
with nutritional status or age. Associations were, however, found between high L:R and acidosis 
(p=0.007), hypokalemia (p=0.035) and diarrhea severity (p=0.001) among children with diarrhea 
[58]. 
5.3.2.3 Associations between L:R and Other Markers 
Serum L:R was compared to other biomarkers for EED in three of the other four studies. 
Ritchie et al. found L:R to be significantly inversely correlated with the 13C sucrose breath test 
(r=0.67; CI: 0.42, 0.62; p<0.0001) [159]. Kukuruzovic et al. studied urinary nitric oxide excretion 
in relation to L:R in Aboriginal and non-Aboriginal in-patients with acute diarrhea, non-
gastrointestinal infections, or without infections or diarrhea [43]. They found that 
NO2/NO3:creatinine and L:R were correlated (r=0.37, p<0.001), after adjusting for age and race. 
The association was stronger for lactulose permeability, with an effect ratio (95% CIs) of 1.47 
(1.29, 1.66), than it was for rhamnose malabsorption, with an effect ratio (95% CIs) of 0.80, 
(0.67, 0.97). NO2/NO3 concentrations decreased significantly less rapidly than L:R values 
among children recovering from diarrhea. Another study by Kukuruzovic et al. assessed the 
association between L:R and red cell indices, stool reducing substances, and lactosemia and 
identified an association only with the latter, but the degree of correlation was minimal [58]. 
5.3.2.4 Methodological Issues with the L:R Test 
Overall, there were fewer issues with consistency in reporting of L:R results across 
studies, perhaps because all of the L:R studies in our review were performed by the same group 
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of investigators. Four of the five studies reported a measure of central tendency for L:R and it 
was consistently in the form of a geometric mean multiplied by 100. Dosing of the sugars was 
the same across the studies. The timing for serum sampling was similar, with most using a 
collection time of 90 minutes following administration of the dose; only one study differed 
slightly, with testing occurring in a range between 90 to 120 minutes. HPLC was the test method 
for the serum L:R throughout. However, in striking contrast to the L:M studies, reference 
standards for L:R values were not cited. The three studies that reported proportions with 
abnormal L:R values used markedly different cutoff values that were either not defined or given 
insufficient explanation. 
The urinary L:R test has disadvantages typical of any urinary method for dual-sugar 
permeability testing; the serum method avoids these issues, and, indeed, Haase et al. found a 
lower test failure rate with this method. 
5.3.3 Serum and Urinary Lactose 
As mentioned above, we assigned markers to categories based on their best fit, 
recognizing that biomarkers could indicate derangement of more than one function. For 
example, lactose is not normally absorbed across the intestine, but rather requires breakdown 
to products that are absorbed, namely galactose and glucose. This digestion is catalyzed by 
lactase, an intestinal brush border enzyme. While the presence of lactose in the serum or urine 
would in most instances indicate a lack of lactase (as opposed to presence of lactose excessive 
to lactase saturation), it also, and primarily, reflects a permeability defect, because even if 
lactose is not broken down, its size should preclude traversing the mucosa unless a porosity 
defect also exists.  
We identified three studies that measured lactose in the blood (n=1) or urine (n=2) in the 
context of putative intestinal injury. Kukuruzovic et al. tested markers of intestinal permeability, 
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including serum lactose, among hospitalized Aboriginal and non-Aboriginal children with and 
without diarrhea [58]. Circulating lactose was detected in 38% of Aboriginal cases and 12% of 
controls (Aboriginal and non-Aboriginal combined). Lactosemia was weakly associated with an 
abnormal L:R. Another study of children from two urban squatter settlements with high rates of 
malnutrition primarily focused on identifying lactase deficiency via urinary lactose:lactulose, 
finding that nearly half of subjects had low lactase activity [124]. Urinary lactose concentration, 
as well as lactose:lactulose ratio, decreased with increasing age, but neither was associated 
with the L:M. The authors noted that lactose concentrations and lactose:lactulose ratios were 
significantly higher in breastfed subjects than those not breastfed, despite similar L:M values. 
However, the paper did not specify the nature of the dietary lactose sources in the non-
breastfed babies. That is to say, if the bioavailability of the lactose or the quantity ingested is 
low, mucosal function could appear to be inappropriately normal. The final study measured the 
lactose:creatinine (L:Cr) ratio in Nepali children living either in squatter settlements or lower 
middle-class periurban households [151]. Mean L:Cr was significantly higher among the 
squatter compared to the lower-middle class group. For both SES groups, L:Cr values 
decreased with increasing age (p<0.001). HAZ, WAZ, WHZ, and ∆WAZ scores were strongly 
associated with mean L:Cr (p<0.001 for each parameter) as was ∆HAZ score (p=0.004); ∆WHZ 
score was not. Interestingly, the strength and magnitude of association between ∆WAZ score 
and L:Cr was most pronounced among the wealthier cohort and there was no association 
between ∆HAZ score and L:Cr among the squatter children, perhaps because of poor diets 
accounting for more of an effect among the squatter children.  
5.3.4 Summary of Markers of Permeability 
Despite logistical challenges, the L:M and L:R tests and other tests of permeability have 
been utilized extensively to assess intestinal function in children in resource-limited settings. 
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L:M values were often, but not always, elevated above published developed country 
norms in community-based studies of asymptomatic children in resource-limited settings. The 
other tests of permeability generally were not compared to a reference standard, limiting 
comparison of results across studies and different settings. 
The L:M test was more extensively studied than the other permeability markers and was 
used more widely as an endpoint for intervention trials, including evaluation of micronutrient 
supplementation, dietary interventions and probiotics, and anti-bacterial and anti-parasitic drug 
treatments. L:R was used as an outcome measure for one intervention study. With new HPLC 
laboratory methods that are sufficiently sensitive to detect lactulose, rhamnose and other 
sugars, dual sugar tests might become more widely used.  
While we identified two studies that compared serum L:R to serum lactose [58] and L:M 
to urinary lactose and lactose:lactulose [124], we did not find comparisons of L:M and L:R test 
results; a head-to-head comparison of the two most extensively used permeability tests would 
be informative.  
The relationship between L:M and age varied across studies; some observed an 
association [110, 112, 115, 123], while others did not [113, 119, 124]. The single study that 
investigated the relationship between L:R and age did not find an association [58]. Furthermore, 
while most studies found an inverse association between L:M and anthropometric status, results 
were mixed. One study investigated the relationship between L:R and growth, and did not 
observe an association [58].  
As with the D-xylose and endomolecular tests of absorption, lack of consistency in what 
was used as a cutoff point for normal (or what was reported to have been used) in the dual 
sugar permeability tests made it very difficult to compare results from one study to the next. 
Across permeability tests, we found a wide spectrum of depth of reporting and insufficient 
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details were often provided. The L:M studies best portrayed issues with methodology, reporting, 
and poor comparability caused by wide differences in how the test was performed across 
studies, differences in subject preparation and feeding mode, dosage of test sugars, and timing 
of urine collection, all of which can influence test results. Further complicating comparability, the 
measures of central tendency for reporting L:M varied. 
While L:R tests have been conducted by evaluating the different biological sampling 
media of urine or serum, the serum test was used much more widely in the last decade and 
serum tests have been conducted in a much more standard manner than the urinary L:M test. 
Urinary L:R has disadvantages typical of any urinary method for dual-sugar permeability testing; 
the serum method avoids these, and Haase et al. [125] found fewer test failures with this 
method.  
We found only one example of the urinary lactose:creatinine test having been employed 
in a pediatric population in a resource-limited setting [151]. The lactose in the urine is waste 
from endogenous metabolism of ingested material, and the creatinine is also a waste product 
naturally present in the urine. Testing endogenous metabolites eliminates the need for a loading 
dose as well as a post-dose delay of multiple hours for sample collection, which are inherent 
parameters of dual-sugar tests. These aspects of the L:Cr test could provide advantages 
compared to dual-sugar tests in resource-limited settings. However, in comparing the tests, it 
will be important to consider other parameters such as sample processing, as well as the 
comparative accuracy and reproducibility of the different tests. Recent data on the use of the 
L:Cr ratio to assess intestinal permeability in pediatric populations in resource-limited settings is 
scarce. None of the studies from our review assessed both L:M and L:Cr ratios in the same 
individuals, so it is not possible to compare the tests directly from the available data. 
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It should be noted that many elements of this chapter, especially pertaining to the L:M 
test, were published in 2014 [185]. 
5.4 Markers of Digestion 
Twelve studies [43, 53, 58, 102, 109, 124, 132, 138, 147-149, 159] utilized a variety of 
markers that reflect intestinal digestive function. The particular data relevant to this review are 
listed for each of these studies in Evidence Table 3. Thirteen markers were assessed across the 
studies: eleven and two were markers of carbohydrate and lipid digestion, respectively. Testing 
for reducing substances in the stool was used in four studies as a marker of nonspecific poor 
digestion of sugars [43, 58, 132, 138]. Two other studies used biopsied intestinal tissue to 
measure specific disaccharidase activity or mRNA abundances [53, 109]. Three studies tested 
exhaled breath to assess maldigestion of lactose or sucrose [102, 147, 159]. 
One study employed urine lactose:lactulose ratio as a marker of lactase function [124]. 
Lastly, two studies, both by the same investigators, assessed intestinal lipid digestive capacity 
by measuring total triglyceride compared to fatty acids in the stool [148, 149].
157
Reference and 
Study Outcomes of  
Diagnostic Interest 
Location and  
Target Population 
Design and 
Sample Size Biomarker Results Conclusion Comments 
2002 
 
Alves GM et al. 
 
Nutritional status 
and breath hydrogen 
test with lactose and 
lactulose in Terena 
Indian children 
Lactose hydrogen 
breath test (HBT) as 
a marker of lactase 
activity, and 
lactulose HBT as a 
marker of SBBO 
Limão Verde and 
Córrego Seco, Mato 
Grosso du Sul, Brazil 
 
All children <10 yr 
old were recruited 






<5 yr old: n=145  
 
(However results 
were provided by 
<4 and >4 yr old 
age groups.) 
Breath Tests: 
• Lactose HBT 
(251 tested) 




• Elevated: 27.1% among all 
subjects 
• Borderline: 43.0% among all 
subjects 
• 0% of subjects <4 yr had 
elevated or borderline results 
 
Lactulose HBT positive: 
• 11.5% of all subjects 
8.6% of subjects <4 yr 
The prevalence of 
lactase deficiency as 
measured by lactose 
HBT was >25%, but 
non-existent among 
those <4 yr of age. 
 
Prevalence of SBBO as 
assessed by lactulose 









Bustos M et al. 
 
Disaccharidase 




Jejunal biopsy and 
disaccharidase 
activities in children 
with PD and different 




3-34 mo old 
Amerindians 
hospitalized with PD 
and moderate or 
severe malnutrition 
in an urban setting. 
Cohort 
 
n=42 cases with 
PD and 
malnutrition: 
• 2 with 
kwashiorkor 
• 20 with 
marasmus 







admission and at 

















Histology was scored 
on a scale of 1 
(normal) to 4 (severe 
morphological 
damage or flat 
mucosa). 
 
Most subjects had mild to 
moderate (score of 2-3) 
histological abnormalities, with 
one kwashiorkor patient having 
completely flat villi.  
 
Second biopsy showed a trend 
of improved mucosa, but 
difference was not significant 
based on histology score, 
intraepithelial lymphocyte 
density, or degree of infiltration 
of lamina propria. 
 
Percentages with enzymatic 
activity below normal at 
baseline, discharge:  
• Lactase: 64%, 59% 
• Sucrase-isomaltase: 97%, 
90% 
• Maltase: 45%, 52% 
All changes were statistically 
significant.  
 
Lactase recovery was 
associated with admission HAZ 
(p=0.05) and WAZ (p=0.03) 
scores.  
Patients had diminished 
intestinal disaccharidase 
activity and substantial 
pathology on biopsy at 
admission and at three 













activity were not 
provided. 
 




was not reported. 
Authors did not 
report whether they 
had tested for 
associations 




Evidence Table 3. Markers of digestion.  
Biomarkers in bold are categorized as primarily markers of digestion.
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Study Outcomes of  
Diagnostic Interest 
Location and  
Target Population 
Design and 
Sample Size Biomarker Results Conclusion Comments 
 
Despite continued high 
disaccharidase deficiency 
prevalence at discharge, all 
children tolerated the lactose-
containing formula challenge. 
2002  
 
Goto R et al. 
 
Poor intestinal 





and Giardia lamblia 
infection 
 












0-5 yr olds (mean 


























• 92% had values >UK norms 
• Mean3 L:M (SD, range): 0.26 
(0.21, 0.04-1.71).  
• Giardia-infected versus 
uninfected means: 0.43 vs. 
0.25, p=0.014 
 
The duration of ingestion of solid 
foods (with or without concurrent 
breastfeeding) was not 
associated with L:M in 
multivariate analysis.  
 
L:M was correlated with longer 
duration of breastfeeding 
(r=0.27, p<0.019). Specifically, 
children who breastfed for >2 yr 
had higher L:M ratios than 
children who breastfed for 
shorter times (data not 
provided).  
 
L:M was not associated with:  




• WAZ or HAZ scores 
 
Lactulose excretion ranged from 
0.02–15.00. Mannitol excretion 
ranged from 0.5–15.00. 
L:M ratios were high 
overall. 
 
Wide individual variation 
was observed in L:M 
ratios. 
 
L:M was associated with 






were significantly higher 
in breastfed subjects 
than in those that were 
not breastfed, despite 
similar intestinal 
permeability values.  
 
There were some 
unexpected findings: the 
duration of 
breastfeeding, and not 
the timing of introduction 
of solid foods, was 
correlated with L:M, and 
the correlation was 
direct, not inverse. 
Authors speculate that 
this could be due to 
higher mean age of their 
Low lactase activity 
was defined as 
lactose:lactulose 
ratio >0.4.  
 
Specific L:M data 
by WAZ and HAZ 
scores were not 
reported, although 
authors state that 
L:M was not 
associated with 
“growth status.” 
                                                          
1 Lactulose and mannitol results were expressed as % of dose administered. 
2 Lactose results were expressed in mg/L. 
3 Geometric mean. 
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47% showed low lactase activity. 
Lactose values and 
lactose:lactulose ratios 
decreased with age (R2=28%, 
p<0.0001), but were not 
associated with sex, ethnicity, 
and location nor were they 
associated with L:M.  
 
Mean1 urinary lactose 
concentrations (mg/L) by feeding 
mode: 
• Breastfed: 172.5  
• Non-breastfed: 44.5, p<0.0001 
corrected for infant age  
 
Mean2 lactose:lactulose ratio by 
feeding mode:  
• Breastfed: 2.76 
• Non-breastfed: 0.31,  
p<0.0001 corrected for infant 
age 
 
Mean L:M by feeding mode: 
• Breastfed: 0.23 
Non-breastfed: 0.28, non-
significant, p-value not specified 
cohort compared to 
another study that 
demonstrated beneficial 
effect of duration of 
breastfeeding on 
reduced L:M in 















<18 mo olds from a 
low SES setting 
recruited from the 










n=17 cases with 
Cryptosporidium 
and diarrhea (5 















Proportion RS-positive:  
• 33.3% cases 
• 64.7% diarrhea controls 
• 46.7% healthy controls, (p=0.2) 
 
Proportion lactoferrin-positive:  
• 83.3% cases  
• 60.0% diarrhea controls 
• 28.6% healthy controls, 
(p=0.01) 
 
Fecal lactoferrin was 
identified most often in 
children with diarrhea, 
especially in those with 
Cryptosporidium. While 
some fecal cytokines 
were detected in as 
many as 40% of healthy 
controls and 70% of 
controls with diarrhea, 
they were generally 
Reported results 
were not stratified 




Cut-off values for 
lactoferrin positivity 
were not described.  
 
Stools from children 
                                                          
1 Geometric mean. 
2 Geometric mean. 
3 The Haitian Group for the Study of Kaposi's Sarcoma and Opportunistic Infections. 
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markers of intestinal 
inflammation of 









those with and 
without diarrhea. 
Cryptosporidium; 
• 17 with diarrhea 
(5 with PD)  
• 15 healthy 





IFN-γ was not recovered in any 
stools. 
 
All other fecal cytokines were 
significantly associated with 
Cryptosporidium cases 
compared to diarrhea and 
healthy controls.  
 
Additionally, TNF-α receptor I, 
IL-8, IL-13 were found in 
diarrhea and healthy controls, 
while IL-4 and IL-10 were not.  
 
Fecal lactoferrin was associated 
with the presence of TNF-α 
receptor I (point estimate not 
provided, p=0.03). 
 
Mean WBC counts were within 
normal range in all 3 groups. 
associated with 
Cryptosporidium 
infection. The other stool 
tests did not discriminate 








Kukuruzovic R et al. 
 
Increased nitric 
oxide production in 









Nitric oxide (NO) as 




ratio (L:R) as a 




1-6 yr old Aboriginal 
and non-Aboriginal 
hospital inpatients.  
 
Subjects were 
grouped as follows: 
1. Children with AD 
2. Children with no 
diarrhea but with 
non-GI infectious 
conditions 
3. Children without 











• 73 with non-GI 
infections (49 
Aboriginal)  








• L:R  
• Mean corpuscular 





substances (RS)**  
(169 cases tested)  
 
 
* NO is an unstable 
free radical and is 
converted to nitrite 
and nitrate. Urine 
nitrate (NO3)+ nitrite 
(NO2) was expressed 
NO among Aboriginal children 
with diarrhea was >3x higher 
than any other group and >5x 
higher than in non-Aboriginal 
controls. 
• NO was >3x and >2x higher 
among Aboriginal than non-
Aboriginal children in the 
diarrhea (p<0.001) and no 
infections groups (p<0.001), 
respectively, but there was 
no difference between them 
in the non-GI infections 
group.  
• NO was >3x and ~2x higher 
in the diarrhea compared to 





• NO was virtually the same 
NO2 + NO3:Cr ratio, as a 
measure of endogenous 
nitric oxide production, 
was used as a marker of 
gut permeability and 
inflammation, with an 
attempt to identify how 
much more it reflects as 
response to 




controls, NO production 
was the same among 
those with diarrhea and 
non-GI infections (and 
higher compared to 
controls). NO was 
highest by far among 
Aboriginal children with 
diarrhea compared to 
Positive stool RS 
was defined as 
>0.5%.  
 
Abnormal L:R was 
defined as >7.6; no 
reference or 
derivation was 




appears to be the 
same as in another 
Kukuruzovic, et al. 
study also included 
in this review which 
assessed serum 
lactulose:rhamnose 
as a marker of 
intestinal 
permeability [58]. 
Evidence Table 3. Markers of digestion.  
Biomarkers in bold are categorized as primarily markers of digestion.
Reference and 
Study Outcomes of  
Diagnostic Interest 
Location and  
Target Population 
Design and 
Sample Size Biomarker Results Conclusion Comments 
permeability and the 
relationship between 
NO and L:R, growth 
parameters, mean 
corpuscular volume 
(as a surrogate of 
iron deficiency), and 
stool reducing 
substances among 
children with and 
without diarrhea 
as a ratio with urine 
creatinine (NO2 + 
NO3:Cr) in order to 
account for 
differences in urine 
concentration. 
 
** Measured only 
among children with 
profuse diarrhea. 
among the Aboriginal non-GI 
infections and no infections 
groups, as well as among 
the non-Aboriginal diarrhea 
and non-GI infections 
groups.  
 
112/152 (74%) and 31/169 
(18%) of children with AD had 
abnormal L:R ratios and positive 
stool RS, respectively. 
 
NO and L:R were measured at 
“convalescence” on Day 5 
among those with diarrhea: the 
mean improvement in NO was 
21.7% compared with 54.6% for 
L:R (p=0.01). 
 
NO and L:R were correlated 
(n=193, r=0.37, p<0.001)1; the 
correlation was stronger for 
lactulose (effect ratio=1.47, 
p<0.001) than for rhamnose 
(effect ratio=0.80, p=0.022).  
 
NO was not correlated with stool 
RS3 or MCV, but was correlated 
with lower WAZ score (effect 
ratio=0.88, p=0.05). 
any other group. Authors 
suggest that high basal 
concentrations of NO 
among Aboriginal 
children due to (clinically 




controls in this study. 
 
NO appeared to 
decrease significantly 




NO was found to 
correlate with L:R. NO 
was more strongly 































• L:R  
• Hemoglobin  
• Mean corpuscular 
27/75 (36%) of Aboriginal 
controls and 0 non-Aboriginal 
controls had abnormal L:R 
ratios. 
 
Mean5 L:R at baseline: 
Cases: 
• Aboriginal: 16.4  
Mean L:R ratios of 
Aboriginal children were 
approximately double 
those of non-Aboriginal 
children both among 
those with and without 
diarrhea, consistent with 
authors’ suggestion that 
Positive stool RS 
was defined as 
>0.5%.  
 
Abnormal L:R was 
defined as >5.6, 
derived from 2 SD 
above the 
                                                          
1 Reported results appear to have been adjusted for age and race. 
2 Reported results were adjusted for age and race. 
3 Reported results among children with diarrhea were adjusted for age and race. 
4 Lactulose and rhamnose results were expressed as % of dose administered. 
5 Geometric mean. 
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(L:R), serum lactose, 
and stool reducing 
substances as 























substances (RS)*  
 
 
L:R testing was 
repeated on day 5 for 
a subset of Aboriginal 
subjects: 
• 174/264 admissions 
for acute diarrhea  




* Measured only 




tested not provided. 
• Non-Aboriginal: 7.9, p=0.002 
compared to Aboriginal cases 
Controls: 
• Aboriginal: 4.6 
• Non-Aboriginal: 2.5, p=0.02 
compared to Aboriginal 
controls  
 
Mean improvement1 in L:R (CI) 
at day 5 among those with 
repeat testing: 
• Aboriginal cases: 14.6 (11.2, 
18.0)  
• Aboriginal controls: -0.63 (-
4.0, 2.7)  
 
Mean lactulose recovery2: 
• Cases day 1: 0.085 (0.070–
0.103)  
• Cases day 5: 0.039 (0.033–
0.046) 
• Controls: 0.024 (0.019–0.029) 
All 3 values significantly differed 
from one another. 
 
Mean rhamnose recovery: 
• Cases day 1: 0.479 (0.424–
0.542) 
• Cases day 5: 0.555 (0.498–
0.616) 
• Controls: 0.585 (0.500–0.685) 
These values did not 
significantly differ from one 
another. 
 
Confidence intervals (CIs) in the 
authors' graphical representation 
of mean L:R at admission did 
not overlap, and the difference in 
clinically silent 




Mean L:R significantly 
improved over 5 days 
among Aboriginal cases. 
Children with severe 
diarrhea had higher 
mean L:R. 
 
Higher case L:R was 
driven more by high 
lactulose than by low 
rhamnose.  
Similarly, improvement 
in L:R among cases was 
primarily due to 
decreased lactulose.  
 
Stool RS and serum 
lactose were found in 
approximately one-
quarter and one-third of 
Aboriginal cases, 
respectively. The latter 
was weakly associated 
with increased lactulose. 
arithmetic mean for 
non-Aboriginal 
controls in this 
study. The rationale 
for the choice of 2 
SD above the 
arithmetic, instead 
of the geometric, 





were not reported. 
 
Analysis included 







analysis methods.  
 
Repeat L:R testing 
was conducted on 
controls of both 
racial groups, but 
among cases it was 
only conducted on 
Aboriginal cases. 
 
This study appears 
to report on the 
same population as 
in the Kukuruzovic, 
et al. 2003 
reference also 
                                                          
1 Improvement in L:R appears to have been calculated as baseline L:R minus repeat L:R, as described in another publication in this review; however, this was not expressly stated. 
Reference 134. Kukuruzovic RH, Brewster DR. Milk formulas in acute gastroenteritis and malnutrition: a randomized trial. J Paediatr Child Health, 2002. 38(6):571-577. 
2 Figures reported parenthetically after the mean percent recoveries of lactulose and rhamnose were not specified as ranges or CIs. 
Evidence Table 3. Markers of digestion.  
Biomarkers in bold are categorized as primarily markers of digestion.
Reference and 
Study Outcomes of  
Diagnostic Interest 
Location and  
Target Population 
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means was particularly evident 
between Aboriginal and non-
Aboriginal subjects. 
 
Factors associated with L:R 
among cases were1:  
• Acidosis (p=0.007) 
• Hypokalemia (p=0.035) 
• Diarrhea severity (p=0.001)  
 
Age and malnutrition were not 
associated with L:R. 
 
38% and 27% of Aboriginal 
cases had positive serum 
lactose and stool RS, 
respectively. 12% of Aboriginal 
and non-Aboriginal controls 
combined had lactosemia.  
 
Presence of lactosemia was 
associated with L:R, adjusted 
relative risk (CI)=1.06 (1.03, 
1.10)2. Stool RS, anemia, and 
MCV were not associated with 
L:R. 






the advantages of 
serum over timed 
urine collection for 
assessment of L:R, 
as discussed in 
another publication 
in this review [125] 
2005 
 
Lima AA et al. 
 
Intestinal barrier 
function and weight 






L:M as a marker of 
Fortaleza, Brazil 
 
2-60 mo olds 
hospitalized with 
WAZ score <-2, 









• 27 with glycine 













• Occult blood 
• Reducing 
substances (RS) 
Mean4 L:M (SE):  
• Glutamine group: 
• Baseline: 0.31 (0.10) 
(similar in all three groups) 
• Day 10: 0.10 (0.02); 
significant decrease, 
(p=0.01) 
• No significant decrease in L:M 
in glycine and 
nonsupplemented formula 
groups at day 10 
 
L:M significantly 
improved in the 
glutamine group only. 
 
>50% of subjects had 
intestinal inflammation 
by stool lactoferrin. 
Fecal leukocytes, RS, 
and occult blood were 
detected in fewer 
subjects than lactoferrin. 
The relationship 
between stool 
markers and L:M 
was not reported.  
 
Data were not 
stratified by history 
of PD. 
 
Fecal fat was 
assessed, but 
results were not 
reported. 
                                                          
1 Reported results were adjusted for confounding variables, unless otherwise noted. 
2 Reported results were adjusted for severity of diarrhea, acidosis, hypokalemia, and age. 
3 Lactulose and mannitol results were expressed as % of dose administered. 
4 Type of mean not specified. 
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intestinal 
permeability and 
various stool tests 
among children with 
malnutrition or PD 
who received either 
glycine or glutamine 
supplemented 





* n=80 tested at 
enrollment, n=65 
tested at day 10. 
 
** n=60 tested. 
Mean lactulose (SE):  
• Glutamine group: 
• Baseline: 0.97 (0.46) 
(similar in all three groups) 
• Day 10: NS decrease in all 
3 groups 
 
Mean mannitol (SE):  
• Glutamine group: 
• Baseline: 3.42 (0.64) 
(similar in all three groups) 
• Day 10: NS decrease in all 
3 groups 
 
Proportion of stool markers at 
baseline among all subjects:  
• Lactoferrin: 53.3% 
• Leukocytes: 11.7% 
• RS: 3.3% 
Occult blood: 5.0% 
 
Cut-off values for 
lactoferrin positivity 




were excluded from 
study participation 
due to assessment 

















breath test (HBT) as 
a marker of lactose 
absorption, and 
xylose breath test 
and urinary excretion 








inclusion criteria of 
no GI symptoms, no 
antibiotics in the 
preceding 3 wk, and 
no SBBO by 






















and 3 wk after 
treatment with 
Breath Tests*: 
• Lactose HBT  







* Reported as parts 







positive HBT is 
considered to be a 
rise of >20ppm in 
breath H2 above 
Mean lactose HBT (SE): 
• Cases pre-treatment: 3.6 
(0.75) ppm  
• Cases post-treatment:  -0.85 
(0.75) ppm (p<0.05 compared 
to pre-treatment) 
• Controls: 0.19 (0.81) ppm 
(p<0.05 compared to pre-
treatment cases) 
 
Mean xylose HBT (SE): 
• Cases pre-treatment: 2.2 
(0.69) ppm for infected group  
• Cases post-treatment:   -4.16 
(0.69) ppm (p<0.05 compared 
to pre-treatment) 
• Controls: 1.13 (0.74) ppm (NS 
compared to pre-treatment 
cases) 
 
Mean urinary excretion of xylose 
Lactose HBT 
concentrations were 
normal according to 
established cut-points 
among all subjects.  
 
However, lactose HBT 
was significantly higher 
among cases compared 
to controls and there 
was also a significant 
decrease in lactose HBT 
among cases after 
treatment. The clinical 
relevance of such mildly 
elevated HBT results in 
asymptomatically 
infected children is 
unclear.  
 
Results did not 
Statistical methods 
might not have 




the same group of 
subjects (cases) 




wished to exclude 
children with SBBO. 





production of H2 
following ingestion 
                                                          
1 D-xylose results were expressed as % of dose administered. 
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** Investigators did 





us to assume that it 
was the dextrorotary 
(D) enantiomer. 
(SE) among cases pre-treatment 
and post- treatment was 34% (3) 
and 46% (11), respectively (NS), 
well above cut-offs indicative of 
malabsorption. 
demonstrate xylose 
malabsorption by either 
urinary or breath 
measures among any 
group. While urinary 
results did not differ 
before and after 
treatment, case xylose 
HBT was significantly 
lower after treatment; 
again the clinical 
significance of such 
results is not apparent. 
of lactulose and 
with minimal urinary 
indoxyl sulfate 
excretion. The 
number of children 
excluded due to 
failure to meet 












Stool recovery of 
radiolabeled 
products as markers 
of lipid digestion and 
absorption, and bile 
salt deconjugation 
as a marker of 
SBBO among 




5-23 mo olds 
admitted to the 
Tropical Metabolism 
Research Unit of the 
University of the 








divided into 3 
groups of 8 
children, each 





collected in three 
separate phases 
as described 
above in JL 
Murphy et al. 
2001 [149]. 
Stool Tests: 
• Total and 
fractionated 13C 
following 
ingestion of one 




or trilinolein*  
• 13C stool assay 
following 
administration of 




* To assess fat 
excretion as a % of 
dose administered. 
Also assessed 
proportion of 13C in 
triglyceride (TG) and 





of TG) vs. poor 
absorption (presence 
Median total stool excretion of 
13C in phase 1 was 9% (range: 
1%-29%) and did not vary 
between TG groups.  
Median 13C excretion dropped 
33%-99% in phase 2 and 86%-
95% in phase 3 compared to 
phase 1 (p<0.05 each). 
 
Over the study period, there 
were significant associations 
between total lipid and the 
amount of 13C labeled TGs in 
stool for some groups, but not 
for others. 
 
Median 13C in TG and FA was 
similar across TG groups in all 
phases. 13C FA recovery was 
similar and reduced by ~2/3 
compared to Phase 1. 13C TG 
was not detectable in Phases 2 
or 3. Statistical comparisons 
between phases were not 
reported.  
 
13C after radiolabeled 
glycocholate administration was 
detected in stool at quantities 
considered to be in excess of 
High concentrations of 
13C (compared to 
healthy UK children) 
[190] were observed in 
half of the subjects at 
admission, reflecting 
impaired digestion or 
absorption.  
 
The differences in stool 
13C were wide but not as 
extreme as in a previous 
study by same 
investigators (also 
examined in this review) 




13C excretion did not 
significantly differ 
between TG groups and 
declined with improving 
clinical course. 
 
Similar to their previous 
study, significantly more 
13C in stool was 
recovered as FA than 
TG, reflecting impaired 
Authors state that 
the study was not 
powered to 
compare the 
different TGs, but 
they contend that 
medium chain 
trilaurin did not 
appear to be 
processed 
differently than the 




Authors did not 
describe the 
method used to 
assign subjects to 
different TG groups.  
 
While it was noted 
that some subjects 
had positive stool 
cultures, details 
were not provided 
on the nature of the 
enteric infections. 
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of FA). 
 
** To assess bile salt 
deconjugation in the 
bowel caused by 
SBBO; conducted 
after the TG 
assessment and a 3 
day washout period. 
the 7% recovery of dose 
administered upper limit of 
normal in U.S. adults in [189]: 
• Phase 1: 13/24 (54%) 
• Phase 2: 5/24 (20.8%)  
• Phase 3: 3/24 (12.5%) 
 
absorption over poor 
lipid digestion/ 
hydrolysis. Unlike in their 
previous study, there 
was evidence of SBBO 
as measured post-















Fecal fat, stool 
recovery of 
radiolabeled 
products, and breath 
tests as markers of 
lipid digestion and 
absorption and bile 
salt deconjugation 
as a marker of 
SBBO among 




7-23 mo olds with 
malnutrition admitted 
to the University of 







collected in three 
separate phases 
(each lasting 9 
days): 
1. Within 48 hours 
of admission 
2. During early 
rehabilitation 
3. During late 
rehabilitation 
Stool Tests: 
• Fecal fat* 






















* In 72 hour stool 
collection (measured 
as total grams and as 
% of dietary fat 
intake). 
 
** To assess fat 
excretion as a % of 
dose administered. 
Also assessed 
Mean fecal fat (SD): 
• Phase 1: 2.4 g/day (3.6) or 
5.9% (9.4) of dietary lipid 
intake 
• Phase 2: 1.7 (0.9) g/day, or 
3.3% (2.4) of intake  
• Phase 3: 0.9 (0.6) g/day, or 
1.4% (0.7) of intake 
• Differences between phases 
were not statistically 
significant. 
 
Total excretion of 13C in stool 
also varied widely across 
patients (0%-44%) and did not 
differ between study phases.  
 
Correlation between fecal fat 
and 13C (r=0.48; p<0.05) was 
observed.  
 
Lack of lipid digestion and 
absorption were assessed by 
measuring TG and FA fractions, 
respectively. Mean 13C TG 
recovery (SD) (% of 
administered dose), number of 
patients excreting TG: 
• Phase 1: 0.7% (1.6), n=3 
• Phase 2: 0.9% (2.8), n=1  
• Phase 3: no recovery from 
any subjects, differences 
between phases were NS 
 
Mean fecal fat was not 
elevated compared to 
published norms [191, 
192] during any study 
phase.  
 
There was wide variation 
in fecal fat at 
presentation, and wide 
variations in stool 13C 
across subjects. Authors 
indicate that this is the 
first such assessment in 
malnourished children; 
previous studies on 
healthy children from the 
UK demonstrated 
average excretion of 6% 
[190]. 
 
The majority of excreted 
13C was in the form of 
FA rather than TG. 
Authors interpreted this 
to reflect failure of lipid 
absorption in the face of 
adequate digestion/ 
hydrolysis. Each form 
(FA and TG) was found 
in decreasing values as 
the study phases 
progressed, suggesting 




inappropriate for a 
small sample. 
 





this might have 
affected GCA 
testing. 
Evidence Table 3. Markers of digestion.  
Biomarkers in bold are categorized as primarily markers of digestion.
Reference and 
Study Outcomes of  
Diagnostic Interest 
Location and  
Target Population 
Design and 
Sample Size Biomarker Results Conclusion Comments 
proportion of 13C in 
triglyceride (TG) and 
fatty acid (FA) 
fractions to 
distinguish excretion 
caused by impaired 
digestion (presence 




*** To assess bile 
salt deconjugation in 
the bowel caused by 
SBBO; conducted 
after the TG 
assessment and a 3 
day washout period. 
 
**** Expressed as a 
percentage of 
absorbed label (dose 
administered - label 
recovered in stool) to 
assess oxidation for 
acute energy needs. 
 
13C FA fraction in stool declined 
during rehabilitation. 
Mean 13C FA recovery (SD): 
• Phase 1: 6.0% (7.3)  
• Phase 2: 4.8% (3.7)  
• Phase 3: 3.3% (3.8),  
differences between phases 
were NS 
  
Mean FA values were ~9x (NS), 
5x (p<0.001), and 3x (p<0.05) 
higher than mean TG values in 
Phases 1, 2, and 3, respectively. 
  
Following administration of 
labeled TP, absorbed 13C label 
by breath analysis was ~5% 
(range 0%-21.2%) and similar 
across study phases.  
 
Following the administration of 
labeled GCA, there was either 
no or minimal recovery of 13C in 
stool and 13CO2 on breath (as % 
of dose administered) in all 
phases. 
results did not differ 
significantly.  
 
Fecal fat was correlated 
with concentrations of 
13C in stool.  
There was no evidence 
of SBBO or bile acid 
malabsorption.  
 
13CO2 excretion following 
administration of 13C TP 
was minimal, suggesting 
a propensity for 
deposition in adipose 
tissues rather than 
oxidation for immediate 
energy needs. The 
authors report that this 
breath test has not been 
widely used, but that 
healthy UK children 
have breath excretion 
values from 15%-43% 
[190], compared to a 
mean of 5% and range 
0%-21% in this cohort; 
the latter findings were 
more similar to results 
from kwashiorkor 
patients where 13C-
labeled oleic acid was 
used as substrate [193]. 
2000 
 
Nichols B et al. 
 
Contribution of 
villous atrophy to 
reduced intestinal 
maltase in infants 
with malnutrition 
 
Sao Paulo, Brazil 
 
Cases were children 
(mean age 9.9 mo, 
SD 8.1) hospitalized 
with malnutrition 








n=24 cases  
 














Mean villous atrophy score (SD): 
• Cases: 2.6 (0.8) 
• Controls: 1.2 (0.5), p=0.006) 
 
WAZ score was correlated with 
villous atrophy (r=0.65, p- value 
not reported).  
 
13/25 [sic] cases and 0/5 
controls had subnormal (defined 
The malnourished 
children had significantly 
greater villous atrophy 
than the younger 
controls. 
 
Among the subset tested 
for mRNA messages, 
maltase activity as well 











Evidence Table 3. Markers of digestion.  
Biomarkers in bold are categorized as primarily markers of digestion.
Reference and 
Study Outcomes of  
Diagnostic Interest 
Location and  
Target Population 
Design and 
Sample Size Biomarker Results Conclusion Comments 
Jejunal biopsy, 







maltase and villous 
atrophy and other 
mucosal intestinal 
markers indicative of 
loss of enterocytes 
and enterocytic 
function. 
children (mean age 
3.6 mo, SD 1.0) with 
HAZ and WAZ 
scores >-2 and 
normal intestinal 
mucosa on biopsy, 
hospitalized for 





























* Mucosal atrophy 
was scored on a 
scale of 1 (absence 
of atrophy compared 
to an organ donor) to 
4 (similar to children 
with active CD). 
 
Histology among 
controls was on 
surgically resected 
tissue. 
as <94 U/g protein) of maltase 
activity; mean maltase was 34% 
lower among cases (p=0.11). 
Maltase activity did not appear 
to decrease with WAZ score 
(further details not provided). 
 
However, in sub-analyses 
among those samples with an 
adequate β-actin, a 
housekeeping gene message, 
(n=10 cases, n=9 controls), 
cases’ findings expressed as a 
mean percent of controls' (SD) 
included: 
• Villous length (reciprocal of 
atrophy score): 38.9 (41.6), 
p=0.004 
• Maltase activity: 37.1 (23.2), 
p=0.001 
• MGA mRNA: 45.1 (36.4), 
p=0.016 
• Villin mRNA: 52.5 (22.6), 
p=0.003 
• SGLT mRNA: 66.6 (23.1), 
p=0.057 
• β-actin: 88.2 (15.8), p=0.189 
 
Both villous length and maltase 
activity in a subset of cases 
were less than 40% of control 
values.  
 
MGA, villin, and SGLT mRNA 
abundances were correlated 
with villous atrophy score 
(r=0.73), (r=0.76), and (r=0.54), 
respectively (p-values not 
reported)1.  
 
MGA mRNA abundance was 
abundances for MGA, 
villin and SGLT were 
significantly correlated 
with case status and 
were correlated with 
villous atrophy. 
 
While maltase deficiency 
has been reported in 
malnutrition in other 
studies, authors assert 
that these are the first 
results that directly 
support the hypothesis 
that reductions in 
maltase activity are due 
to villous atrophy. This 
study also nicely 
correlates mRNA 





they mocked up ex 
vivo mucosal 
biopsies in these 
controls, resections 




compared to cases’ 
samples derived 
from mucosal 
biopsies. While this 
probably doesn’t 







will bring in more 
diverse populations 
of cells; only some 
of them might have 
transcripts of 
interest. However, 
the bias is likely in a 
direction that would 
reduce effect size. 
 
It was unclear if 
control inclusion 
criteria included 
absence of atrophy 





                                                          
1 Villin and SGLT1 were assessed as a ratio with housekeeper gene β-actin. 
Evidence Table 3. Markers of digestion.  
Biomarkers in bold are categorized as primarily markers of digestion.
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Study Outcomes of  
Diagnostic Interest 
Location and  
Target Population 
Design and 
Sample Size Biomarker Results Conclusion Comments 
correlated with maltase activity 
(r=0.32). 
might not have 
adequately taken 
into account the 




Subsets of subjects 
were investigated 
for various tests. 
For example, 10 
cases had mRNA 
analyses based on 
β-actin adequacy. 
Another instance of 
selected testing 
was the subset of 
22 and 15 cases 
that had WAZ score 




Rationale for subset 





Ritchie et al. 
 
13C-sucrose breath 






Sucrose breath test 
(SBT) as a marker of 




4 mo-5 yr old 
Aboriginal children 
admitted to hospital 
with diarrhea. 
 
Two control groups: 










cases with AD 
 
n=25 controls: 








cases and controls 
tested) 
• C-reactive protein 
(CRP) 






13C sucrose breath 
20/32 (63%) of Aboriginal 
children had abnormal L:R 
ratios. 
 
Mean1 L:R (CI): 
• Diarrhea cases: 31.8 (24.9, 
40.7)  
• Aboriginal controls without 




SBT Mean (CI): 
• Diarrhea cases: 1.9% (0.9, 
SBT values were 
significantly lower and 
L:R values were 
significantly higher 
among Aboriginal 
children with diarrhea 
than among those 
without GI symptoms. 
SBT was also 
significantly lower 
among Aboriginal 
controls than among 
non-Aboriginal children 
without diarrhea. This is 
Abnormal L:R ratios 
were defined as 
>16; no reference 
or derivation was 
provided for this 
cut-point.  
 







                                                          
1 Geometric mean. 
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Biomarkers in bold are categorized as primarily markers of digestion.
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Study Outcomes of  
Diagnostic Interest 
Location and  
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Design and 
Sample Size Biomarker Results Conclusion Comments 
damage vis a vis 
sucrase activity 
among an Australian 
Aboriginal 
population. Also 









test (SBT) 3.0), p<0.0001 compared to 
non-Aboriginal controls and 
p=0.004 compared to 
Aboriginal controls 
• Aboriginal controls: 4.1% (3.0, 
5.2), p=0.032 compared to 
non-Aboriginal controls 
• Non-Aboriginal controls: 6.1% 
(4.8, 7.3) 
Significant differences were 
observed between all three 
groups.  
 
SBT results were not associated 
with wasting or with patient age 
or breastfeeding status. 
 
SBT and L:R were inversely 
correlated (r=0.67; CI: 0.42, 
0.62; p<0.0001). L:R explained 
45% of the variance in SBT; 
diarrhea explained 28% of 
variance. 
 
SBT was associated with 
increased MCV, relative risk 
(CI)=3.9 (2.8, 5.0). SBT was not 
associated with hemoglobin or 
CRP. 
consistent with previous 
reports of high 
prevalence of clinically 
silent TE in this 
population.  
 
SBT was significantly 
inversely correlated with 
L:R. 
was based on data 
for Aboriginal cases 
and controls 
combined; stratified 
analysis was not 
reported and could 
be of interest 
considering the 






MCV, CRP, and 
hemoglobin with 
SBT after adjusting 
for potentially 
confounding 
variables were not 
reported. 
Notes: Some studies included subjects ≥5 yr of age. Where these studies provided data separately for children <5 yr, we present results for only those subjects. 
Where these studies did not stratify results by age, but did report the number of children <5 yr included in the study, we provide a breakdown of under-5s. 
All studies reporting lactulose:rhamnose ratio results presented values multiplied by a factor of 100 for ease of reporting. 
 
Abbreviations: AD=acute diarrhea, ALT=alanine aminotransferase, AST=aspartate aminotransferase, CBC=complete blood count, CD=celiac disease, CI=95% confidence interval, 
Cr=creatinine, ∆=change in, EED=environmental enteric dysfunction, FTT=failure to thrive, GI=gastrointestinal, HAZ=height-for-age Z-(score), HDL=high density lipoproteins, 
HIV=human immunodeficiency virus, HLA=human leukocyte antigen, IEL=intraepithelial lymphocytes, IgA=immunoglobulin A, IgE=immunoglobulin E, IgG=immunoglobulin G, 
IgM=immunoglobulin M, IL=interleukin, IFN=interferon, LDL=low density lipoproteins, L:M=lactulose:mannitol ratio, mo=month(s), NS=not statistically significant, PD=persistent 
diarrhea, RCT=randomized controlled trial, SBBO=small bowel bacterial overgrowth, SD=standard deviation, SE=standard error, SES=socioeconomic status, Tc-99m=technetium 
99, T3=triiodothyronine, T4=thyroxine, TE=tropical enteropathy, TGF=transforming growth factor, TNF=tumor necrosis factor, TS=tropical sprue, WAZ=weight-for-age Z-(score), 
WBC=white blood cell count, WFA=weight-for-age, WHZ=weight-for-height Z-(score), wk=week(s), yr=year(s) 
 
Evidence Table 3. Markers of digestion.  
Biomarkers in bold are categorized as primarily markers of digestion.
5.4.1 Sucrose and Lactose Breath Tests 
Three studies used breath tests to detect the presence of lactose (n=2) [102, 147] or sucrose 
(n=1) [159] in the intestines after administration of a loading dose activity. These disaccharides should, in 
normal intestinal health, be split by the brush border enzymes lactase or sucrase to glucose and 
galactose or fructose, respectively. While these breath tests also reflect intestinal capacity to absorb these 
monosaccharides, we classified them as markers of digestive function first and foremost, because 
enzymatic cleavage of the ingested sugars is a cardinal intestinal process required for absorption to take 
place. Breath tests can measure various molecules in exhaled breath, most commonly hydrogen. 
Normally, very little hydrogen is detected in breath after an overnight fast; however, hydrogen is produced 
when undigested substances such as lactose are fermented by intestinal bacteria. The sucrose breath 
test (SBT) assessed in this review measured exhaled CO2, a normal by-product of disaccharide 
metabolism which will be found in reduced amounts if there is reduced sucrase activity. Because 
genetically ordained age-associated lactose intolerance becomes common beyond infancy in many 
populations irrespective of intestinal mucosal health, the possibility exists that sucrase activity might serve 
as a better marker of overall intestinal function because such age-related decline in tolerances are not 
known to be associated with sucrose.  
CO2 exhalation in the SBT was significantly lower among Aboriginal children with diarrhea 
compared to those without gastrointestinal symptoms, as well as among Aboriginal controls compared to 
non-Aboriginal children without diarrhea. SBT results were not associated with age, breastfeeding status, 
or wasting [159]. SBT results were significantly inversely correlated with L:R values (r=0.67), but this was 
assessed among all Aboriginal subjects (cases and controls) combined. L:R values differed largely 
between these groups; it would be useful to investigate the relationship between SBT and L:R stratified on 
diarrhea status. SBT results were also associated with one other marker, mean corpuscular volume, but 
were not associated with blood C-reactive protein, an index of systemic inflammation, or with hemoglobin, 
concentrations of which can be reduced for a variety of reasons, including acute and chronic systemic 
inflammation. While this study suggests that SBT is a promising diagnostic test for EED, this was the only 
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publication that analyzed the SBT in children in a developing country setting or among marginalized 
populations during the time period under review.  
Two studies utilized hydrogen breath tests (HBT) to assess lactase function [102, 147]. Each study 
also assessed either lactulose or D-xylose as substrates using the HBT. These two substrates for breath 
hydrogen analyses are primarily used to identify small bowel bacterial overgrowth (SBBO) and 
malabsorption, respectively, and as such they are discussed in those sections. Prevalence of abnormal 
lactose absorption differed between these two studies. Lactose absorption among indigenous Brazilian 
children with mild malnutrition was abnormal in more than one fourth of the subjects [102]. In well-
nourished Mexican children, HBT values in cases with asymptomatic giardiasis were only mildly elevated 
but remained below concentrations that have been used as criteria for lactose malabsorption [147]. Cases 
had HBTs before and after anti-giardiasis treatment. The pre-treatment HBT excretion was significantly 
higher compared to controls without giardiasis and to post-treatment values. The clinical relevance of 
such mildly elevated HBT results in asymptomatically infected children remains unclear, however.  
The discrepancy in results between the studies was unexpected, and the reason for it remains 
unclear. Both studies used the same cutoff for normal values, but the proportions of children with lactase 
deficiency were quite different. The differences might reflect numerous factors including differences in 
age, nutritional status, and age-related lactose intolerance. Another potential contributing factor is the 
exclusion of children with SBBO from the Mexican study but not from the Brazilian study, in which greater 
than 10% of the subjects had SBBO by lactulose HBT. An additional complication in assessing mucosal 
function, at least in children four years of age and older, is that there is a high prevalence of genetic 
lactase deficiency in many of the populations at risk for enteropathy, including in Latin America, Africa and 
Asia [259] and among Native Americans [260]. 
Neither of the HBT studies assessed the relationship of the test with growth outcomes in a 
statistically interpretable manner. While the Mexican study found normal D-xylose absorption by breath 
hydrogen testing in case (and control) subjects, neither this study nor the Brazilian study statistically 
analyzed the association between growth and the lactose HBT.  
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5.4.2 Stool Reducing Substances 
Reducing substances are those that reduce copper salts in a hot solution to a chromogenic less 
oxidized state. These substances include glucose, lactose, fructose, galactose, and pentose. Like breath 
tests, reducing substances can indicate malabsorption, but also primarily identify maldigestion. This test 
has been used for decades to differentiate diarrhea secondary to infection from that caused by 
noninfectious intestinal dysfunction, particularly lactose intolerance. A condition of the test is that it must 
be performed on liquid stool.  
Four studies [43, 58, 132, 138] assessed the prevalence of stool reducing substances to 
investigate digestive pathology. The proportion of positive tests for stool reducing substances among 
subjects varied widely across studies. Only 3.3% of Brazilian children hospitalized with malnutrition or 
persistent diarrhea had positive tests for stool reducing substances (definition of positive not provided) 
[138]. In contrast, tests in Haitian children with and without diarrhea were positive for stool reducing 
substances in one-third of those with diarrhea and cryptosporidiosis, in two-thirds of those with diarrhea 
but no evidence of Cryptosporidium infection, and in nearly half of controls without diarrhea [132], though 
the accuracy of this test on non-diarrheal stools is assumed to be inadequate because the non-absorbed 
sugars reportedly partition to the aqueous phase [261]. Hence, finding these sugars in solid stools, while 
unexpected, probably indicates of some degree of maldigestion. Again, cutoff points defining positivity 
were not provided, and there was no statistical difference between groups for this parameter (p=0.2).  
Two studies investigated reducing substances among Aboriginal and non-Aboriginal Australian 
children with diarrhea; a positive result was defined as stool containing sugar concentrations >0.5 %. In 
the first of these, one-quarter of Aboriginal diarrheal cases tested positive for stool reducing substances 
[58]. In the subsequent study by the same authors almost one-fifth of children with profuse diarrhea tested 
positive [43].  
Only one study of reducing substances examined its association with clinical outcomes, and this 
study found that the marker was associated with severity of diarrheal illness [58]. The same study found 
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that among subjects with diarrhea, a positive test for reducing substances was associated with high L:R 
by univariate analysis, but the association did not hold up in their multivariate model. Another study also 
examined the association between reducing substances and urinary nitric oxide among Aboriginal and 
non-Aboriginal children with acute diarrhea, but found none [43]. 
5.4.3 Intestinal Disaccharidases 
Two studies assessed intestinal disaccharidase activity as a marker of digestive pathology on 
jejunal specimens obtained by capsule biopsy--Bolivian children with persistent diarrhea and malnutrition 
[109] and Brazilian children with refractory malnutrition [53]. Of note, the latter study utilized a unique 
control group, children without severe malnutrition undergoing intestinal resection as part of the 
management of their biliary atresia. Both studies assessed the proportion of children with maltase 
activities that were below normal, and the Bolivian study also measured sucrase-isomaltase and lactase 
activities. Both studies reported similar prevalences of abnormally low maltase activity in approximately 
half of the subjects with enteric dysfunction, but only one of these studies provided a defined cut point for 
abnormal (<94U/g protein) [53]. The deficiency in other disaccharidase activities was not as prevalent as 
that of maltase. In addition to maltase activity, the Brazilian study also measured abundance of 
messenger RNA for maltase-glucoamylase (MGA) and sucrase-isomaltase in small intestinal tissue, and 
found that they were correlated with the activity of maltase at the messenger RNA abundance.  
The Brazilian study found no association between WAZ score and tissue maltase activity (no other 
details were provided), while the Bolivian study found that intestinal lactase concentrations were 
significantly and positively associated with WAZ and less strongly associated with HAZ at admission. 
Unfortunately, they did not detail the magnitude of these associations or report if they assessed maltase 
and sucrase-isomaltase association with growth parameters. Because intestinal disaccharidase activity is, 
by its nature, measured on intestinal tissue, it was relatively straightforward for these studies to assess 
marker association with intestinal histopathology. Maltase-glucoamylase (MGA) mRNA abundances were 
strongly correlated with both maltase activity and villous atrophy. The Bolivian study did not attempt to 
correlate disaccharidase activity with histopathology. 
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5.4.4 13C Assessment in Stool after Lipid Administration 
Two studies by the same group of investigators in the same setting [148, 149] with a total sample 
size of 32 severely malnourished children assessed digestion by administering radiolabeled lipids. They 
then measured the amount of radiolabel excreted in the stool in the forms of triglyceride (TG) and fatty 
acid (FA), with recovery of fatty acids interpreted to indicate adequate lipid breakdown but poor absorption 
while recovery of triglycerides marked poor digestive function. Both studies found widely varying 13C in 
stool, although the variation was less marked in their later study; however the sample size was only eight 
patients [148].  
In both of these studies, the majority of excreted 13C was in the form of FA rather than TG, 
reflecting a failure of lipid absorption in the face of adequate digestion. Each labeled lipid form (FA and 
TG) was found in decreasing concentrations as the study progressed, suggesting improved digestion and 
absorption, although concentrations did not differ significantly with time.  
The two studies differed in their findings related to small bowel bacterial overgrowth; the first study 
[149] found no evidence for bacterial overgrowth while the second [148] did, as measured by the recovery 
of label in the stool after ingestion of 13C glycocholate.  
The first of these studies [149] additionally investigated fecal fat as a marker and found that it was 
associated with concentrations of 13C in stool. 
5.4.5 Urinary Lactose:Lactulose Ratio 
We considered serum and urinary lactose to be primarily measures of gut permeability, as 
described above. As a large molecule, lactose should not enter the system unless there is a permeability 
defect. It should be recognized, however, that presence of lactose in the serum or urine could be 
complicated by lactase deficiency. However, lactase deficiency without a permeability defect would not be 
expected to result in the presence of lactose in the blood or urine. When urinary lactose is normalized 
against another marker for permeability, the lactose:lactulose ratio is primarily a marker of lactose 
digestion. One study assessed this marker and found that nearly half of subjects had low lactase activity, 
176
defined as lactose:lactulose ratio >0.4 [124]. Urinary lactose and lactose:lactulose ratios significantly 
decreased with age and were significantly elevated among breast-fed compared to non-breastfed infants, 
adjusting for age, despite similar intestinal permeability values as measured by L:M. The markers were 
not associated with sex, ethnicity, or location. Lactose and lactose:lactulose ratios were not associated 
with L:M.  
5.4.6 Summary of Markers of Digestion 
A broad range of markers was used to assess digestive function in children in resource-limited 
settings. Intestinal disaccharidases were affected in subjects with persistent diarrhea and/or malnutrition. 
The sucrose and lactose HBTs showed varying degrees of digestive disturbance across studies with 
subjects of differing health conditions. Results for maltase activities were consistent across the two 
studies in which they were sought in intestinal tissues. Several different methods were used to assess 
intestinal enzyme capacity, and results between methods were consistent where comparable.  
Few markers of digestion were investigated in relation to biopsy or tests of intestinal permeability. 
Breath tests in particular lacked comparison to other standard markers.  
Varying associations were observed between markers of digestion and growth parameters. The 
sucrose breath test was not associated with growth [159]. The studies of intestinal disaccharidases found 
different results for different enzymes; one study found no association between maltase and wasting while 
the other found an association between lactase and growth parameters [53, 109]. The relationship 
between abnormal markers of digestion and growth outcomes was not reported for either hydrogen breath 
tests or stool reducing substances. 
The sucrose breath test results were significantly associated with the L:R; the concentration of 
exhaled hydrogen was inversely associated with the L:R [159]. This test might be useful as a noninvasive 
marker of enteric dysfunction, although replication of these results is needed before a judgment as to their 
value can be made.  
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5.5 Markers of Intestinal Inflammation and Intestinal 
Immune Activation 
Eighteen studies utilized a variety of markers that reflect intestinal inflammation or immune 
activation among children in resource-limited settings. The data relevant to this review are listed for each 
of these studies in Evidence Table 4. Eight types of markers were assessed across the studies, most of 
which were examined in stool. Lactoferrin was the most commonly assessed marker among these 
reports; nine studies utilized it to assess intestinal inflammation. Additionally, fecal cytokines, leukocytes, 
and neopterin were measured in five [101, 131, 132, 137, 140], four [104, 138, 158, 169], and one [15] 
studies, respectively. Two studies by the same group of investigators assessed fecal IgE [142, 143]. 
Intestinal tissue cytokines, immune and inflammatory cell markers, and duodenal aspirate 






Study Outcomes of  
Diagnostic Interest 
Location and  
Target Population 
Design and 
Sample Size Biomarker Results Conclusion Comments 
2003 
 













Fecal cytokines and 
lactoferrin as 
markers of intestinal 
inflammation among 







3-43 mo olds 
recruited from a 
shantytown 
community who 
were screened for 
enteric pathogens. 
 







exposed to C. 
parvum by 
ingestion were also 
studied; these data 
were not included 





n=17 cases with C. 
parvum:  
• 4 with no 
diarrhea 
• 10 with AD 
• 3 with PD 
 
n=15 controls with 
no diarrhea or 
enteric pathogens 
and comparable 
HAZ and WAZ 
scores to cases 
Stool tests: 
• Lactoferrin  
(17 cases and 15 controls 
tested) 
• IL-8  
(13 cases and 15 controls 
tested) 
• TNF-α  






• 12/17 cases 
• 1/4 cases without 
diarrhea 
• 8/10 AD cases 
• 3/3 PD cases 
• 3/15 controls (p=0.006 
compared to cases) 
 
IL-8 detectable: 
• 3/13 all cases 
• 0/2 cases without 
diarrhea 
• 3/10 AD cases 
• 0/1 PD cases 
• 6/16 controls (p=0.435 
compared to cases) 
 
TNF-α detectable:  
• 0/10 cases 
The proportion of 
children who tested 
positive for fecal 
lactoferrin was 





diarrhea, than in 
uninfected controls, 
although 20% of 
the control group 
tested positive. 
 
Fecal IL-8 did not 
differ between 











stool tests were 
not reported.  
 
Lactoferrin results 




dilution and were 
considered 
negative if there 
was no reaction at 
1:25.  
 
Four subjects were 










occurs in Zambian 
children with 






intestinal markers in 
children with PD and 
Lusaka, Zambia 
 
12.2-19.8 mo olds 
with PD and 
malnutrition 
admitted to the 
malnutrition ward of 





n=41 cases with 
PD and 
malnutrition:  
• 18 with 
marasmus 
• 8 with marasmic 
kwashiorkor 









• Densities in lamina propria 
and crypt epithelium: 
• Cell proteins:  
• Glycosaminoglycan 
(GAG) 
• Enterocyte heparan 
sulfate proteoglycan 
(HSPG) 
• Syndecan-1  
• Inflammatory cell 
markers: 
• CD3 IEL 
• Ki67 
• Human leukocyte 
Biopsy findings among the 
Zambian compared to the UK 
children: 
• Villous height reduced 
• Crypt depth increased  
• ~50% reduction in 
crypt:villous ratio 
• Values for lamina propria cell 
densities were not reported 
for UK subjects 
 
No significant differences in 
crypt or villous measures or 
lamina propria cell densities 
were observed between 





compared to UK 










compared to UK 
children and 
showed different 
27 subjects were 
HIV positive; 
incidence was 
lower in the 
kwashiorkor group. 
Evidence Table 4. Markers of intestinal inflammation and intestinal immune activation.  
Biomarkers in bold are primarily markers of gut inflammation and/or immune activation.
Reference and 
Study Outcomes of  
Diagnostic Interest 
Location and  
Target Population 
Design and 
Sample Size Biomarker Results Conclusion Comments 




* UK subjects are 
presented in this 
table due to 
comparisons of 
interest made in 
the review. 
However we do not 
include these 
subjects in the 






• Inflammatory markers were 
seen in higher densities 
compared to the UK children. 
There were significant 
differences between the 
different nutritional groups in 
the specific types of 
inflammatory markers. 
• There was a significant 
reduction in GAGs and HSPG 
in the kwashiorkor group 
compared to UK children, but 
no significant differences 
between kwashiorkor and 
other presentations of 
malnutrition.  
• There was no difference in 
epithelial syndecan-1 protein 
expression between the 
malnutrition groups (data not 
available for UK controls). 












markers did not 




Azim T et al. 
 
Immune response of 
Bangladeshi 






tests, as well as 
transferrin and 
albumin as markers 
of nutritional status 
among children with 
and without PD 
Dhaka, Bangladesh 
 
7-12 mo olds with 
6-8 days of watery 
diarrhea attending 
the International 
Centre for Diarrheal 
Disease Research.  
 
Cases were those 
who went on to 
develop PD, 
controls were those 
who did not.  
 
An additional group 
of subjects without 
diarrhea were 










• 85 with AD 











• Immune function tests: 
• Neutrophil polarization 
response to chemotactic 
factor 
• Neutrophil opsonization 
to yeast 
• Mononuclear cell 
proliferation, 
spontaneous and in 
response to stimuli with 
WBC total and differential, 
immunoglobulin subtypes, 
cytokines, transferrin, and 
albumin did not differ between 
cases with diarrhea or controls, 
nor did stool leukocyte or 
erythrocyte counts.  
 
The percentages of neutrophils 
that polarized in response to 
stimulation were significantly 
higher in subjects with AD or 
PD compared to those without 
diarrhea; there was no 
difference between the two 
diarrhea groups. 
 
Opsonization did not vary 
between any groups. 
 











progression to PD 
was a negative 
DTH response to 
tuberculin antigen 
(odds ratio=3.8, CI: 
1.4, 9.9). This was 
calculated from a 
logistic regression 
analysis that only 
The number of 
controls was 
relatively small and 
their nutritional 
status was not 
reported. 
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(DTH) to tuberculin, 
tetanus, diphtheria, 
Streptococcus, Proteus, 





• Red blood cells 
Monocyte spontaneous 
proliferation counts were less 
than half among children with 
no diarrhea compared to those 
with AD (p<0.001) or with PD 
(p=0.011); there was no 
difference between the two 
diarrhea groups.  
 
Monocyte proliferation in 
response to stimulation did not 
differ between the 3 groups.  
 
The proportion with DTH 
responses differed among the 
three groups only in response 
to tuberculin (p=0.021). More 
PD subjects had a negative 
tuberculin response than did 









infections in children 







Fecal lactoferrin as 






favela in Fortaleza, 
Brazil 
 
All newborns from 
an urban 
shantytown were 
recruited at birth 
and followed for up 
to 4 yr.  
 
This study included 










collected at regular 
intervals as well as 





68.3% were lactoferrin- 
positive; there were no 
differences in positivity 
between subjects with C. 
hominis and C. parvum spp. 
 
67.9% of lactoferrin-positive 
subjects had very high titers. 
 
Younger children were more 
often lactoferrin-positive 
(p=0.03). The difference was 
mediated by C. parvum; 87.5% 
of ≤1 year olds compared to 
40.0% of older children with C. 
parvum were lactoferrin-
positive (p=0.04). There was no 
difference among those 
infected with C. hominis. 
 
Lactoferrin was correlated with 
symptomatic infection among 
those with C. parvum: 78.6% of 
Lactoferrin was 
correlated with 
younger age and 
symptomatic 
infection among 
those infected with 
C. parvum.  
 









In contrast to C. 










dilution and were 
considered 
negative if there 
was no reaction at 
1:50 and highly 
positive at >1:400. 
 
Data were part of a 
larger study; 




published by A. 
Kohli, et al. (also 
included in this 
review), using a 
slightly different 
Evidence Table 4. Markers of intestinal inflammation and intestinal immune activation.  
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symptomatic children 
compared to no asymptomatic 
children had a positive test 
(r=0.67, p=0.0041).  
 
Lactoferrin was not correlated 
with degree of oocyst shedding 
(p=0.28). 
 
Lactoferrin was correlated with 
∆HAZ score among those with 
C. parvum, although this 
observation was not statistically 






children with C. 
hominis had high 
fecal lactoferrin 
titers as had 
undetectable 
results. 
grading scale for 
reporting 
lactoferrin results 
[133]. Rather than 
exclude breastfed 
children, Bushen et 
al. stratified results 
on breastfeeding 
status and found 





and older children. 
2004 
 














Fecal neopterin and 





their correlation with 
growth status and 
Keneba, Gambia 
 
2 mo olds from 
rural area followed 


























Mean neopterin concentration 
was negatively correlated with 
long-term height (r=-0.29, 
p<0.009) and weight (r=-0.36, 
p<0.007) gain, but not with 
giardiasis. 
 
Mean3 L:M (CI): 0.31 (0.26, 
0.34). 
 
Mean excretion of lactulose 
(CI): 0.20 (0.18, 0.23).  
 
Mean excretion of mannitol 
(CI): 3.0 (2.8, 3.2).  
 
Mean L:M was negatively 
correlated with long-term height 
gain (r value not provided, 
p<0.0001), but was not 
correlated with presence of 
Giardia. 
 
L:M and fecal neopterin were 





Mean L:M in the 
Gambian children 
was substantially 
higher than normal 
values in children in 
the UK. These high 
L:M ratios appear 
to be driven by 
mannitol excretion. 
Study population 
might have some 
overlap with that of 
Campbell et al. 
also included in 
this review [110]. 
                                                          
1 Reported results were adjusted for confounding variables, unless otherwise noted. 
2 Lactulose and mannitol results were expressed as % of dose administered. 
3 Geometric mean. 
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Giardia recovery in 
the stool 
not correlated (p=0.11). 
2003 
 












L:M as a marker of 
intestinal 
permeability, small 














Fajara and Sibanar, 
The Gambia 
 
6 mo-3 yr old 
hospital- and clinic-
based cases from 
rural communities. 
 
Case groups based 
on differences in 
nutritional status:  
• WAZ score >-2, 
with GI 
complaints other 
than diarrhea  









with or without 
diarrhea 
• Grade II PEM 
(WAZ score <-4) 
with or without 
diarrhea  
 
Controls from UK* 
who were well 
nourished children 
with GI complaints 
other than diarrhea 





• Group 1: n=4  
• Group 2: n=11 (7 
with diarrhea) 










• Group 1: n=3 
• Group 2: n=8 
• Group 3: n=23 
Endoscopic 
small bowel biopsy, site not 
specified: 
• Histopathology 
• Morphometric assessment 
by computer analysis*  
• Intestinal tissue cytokines 
and immune markers:  





















* Biopsy involved 
morphometric assessment 
by computer analysis of 
villous height, crypt depth, 
villous:crypt ratio, and 
intraepithelial lymphocyte 
(IEL) density (per 100 
epithelial cells). 
Crypt-hyperplasia and villous 
atrophy were observed among 
all Gambian subjects, and the 
degree of histopathology did 
not differ among cases with 
differing nutritional status, nor 
was there a correlation with 
diarrhea. 
 
IEL2 means were ~3-fold 
higher in Gambian than UK 
children. 
 
Median CD3, CD4, CD8, 
CD19, and CD25 cell counts 
were significantly higher (2-5x 
higher) among each case 
group compared to the UK 
controls.  
 
IEL, γδ, syndecan-1, HLA-DR, 
and perforin were detected 
among the Gambian children in 
varying degrees but were not 
reported for UK controls. 
Syndecan, CD3, and CD8 
displayed a gradient 
proportional to malnutrition 
severity. 
 
All Gambian groups showed 
higher lamina propria cytokine-
immunoreactive mononuclear 
cell density (~200-450/mm2) 
than UK controls (30-80/mm2). 
 
Among subjects with elevated 






and villous atrophy, 
and mean IELs >2 
SD above UK 
norms, independent 










present across the 





L:M ratios were 
elevated in all 
Gambian groups, 
without apparent 
























and L:M results 
were not stratified 
by history of 
diarrhea. 
                                                          
1 Lactulose and mannitol results were expressed as % of dose administered. 
2 These figures are presumed to represent IEL means; however, this was not explicitly stated. 
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were also studied. 
 
 
* UK subjects are 
presented in this 
table due to 
comparisons of 
interest made in the 
review. However 
we do not include 
these subjects in 
the sample size for 
this review. 
were seen for both pro-
inflammatory (IFN-γ and TNF-
α) and putative regulatory (IL-
10 and TGF-β) cytokines. 
Epithelial expression of TGF-β 
was also enhanced compared 
to UK controls, but subjects 
with poorer nutritional status 
had lower densities of mucosal 
TGF-β+ cells, with median 
densities of 420 and 250 
cells/mm2 in the grade I and 
grade II PEM groups, 
respectively. 
 
L:M values1:  
• Group 1: 0.53 (0.4-1.3)  
• Group 2: 0.47 (0.02-2.20) 
• Group 3: 0.73 (0.14-2.2) 
• Not assessed among the UK 
controls 
 
Nutritional status was not 
associated with L:M, recoveries 
of lactulose or mannitol.  
 
L:M was correlated with 
mucosal B lymphocyte density 
(r=0.57, p<0.05), IEL (r=0.51, 












New Delhi, India 
 
<12 yr olds 
admitted to hospital 
with PD and 
Giardia.  
 
Controls had no 






n=30 cases with 














Higher mean concentrations of 
IgM were found in duodenal 
aspirates of cases compared to 
controls (p<0.05).  
 
Mean concentrations of 
duodenal IgA and IgG did not 





were limited among 
children with PD 
infected with 
Giardia compared 
to children without 
such conditions. 
 
The number of 
controls was small 






                                                          
1 Not clearly indicated if these figures represent mean (CI) or another measure of central tendency. 
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duodenal fluid and 
serum among 
children with PD and 
Giardia infection 




Most cases were 
<7 yr old, with n=19 
<3 yr old. Ages of 















Fecal cytokines and 
lactoferrin as 
markers of intestinal 
mucosal 
inflammation among 













healthy controls.  
 
Subjects were 
followed-up at 6 
and 9 months after 
infection resolved.  
 
HIV status of 
subjects varied.  
 
There was a high 
prevalence of 























• IL-4  




• Cases: 51.2% 
• Controls: 4.0% 
 
Cases had higher 
concentrations of TNF-α than 
controls at enrollment (p=0.04), 
but no difference was observed 
at follow-up. 
 
Controls had almost 2x higher 
fecal IFN-γ at enrollment 
(p=0.1); the magnitude of 
difference increased (to almost 
3x) and was statistically 
significant at the 6- and 9-
month follow-up (p=0.01 and 
p=0.03, respectively). 
 
No differences in fecal 
concentrations of TGF-β, IL-8, 
IL-4, or IL-10 were noted 
between groups. 
Lactoferrin was 
present among half 







Fecal TNF-α was 
higher among 
cases at enrollment 







higher fecal IFN-γ 
increased in both 
magnitude and 




Of the remaining 
fecal cytokines 
assessed, there 
were no differences 
between cases and 
controls. 
Cut-off values for 
lactoferrin positivity 
were not provided.  
 
Breastfed children 
(>85% of cases 
and controls) were 
included in testing. 
Proportions at 
follow-up were not 
reported.  
 
The association of 




of PD, and HIV 
status were not 
reported, nor was 
their association 
with each other.  
 











                                                          
1 The Haitian Group for the Study of Kaposi's Sarcoma and Opportunistic Infections. 
Evidence Table 4. Markers of intestinal inflammation and intestinal immune activation.  
Biomarkers in bold are primarily markers of gut inflammation and/or immune activation.
Reference and 
Study Outcomes of  
Diagnostic Interest 
Location and  
Target Population 
Design and 


















markers of intestinal 
inflammation of 







<18 mo olds from a 
low SES setting 
recruited from the 

















n=17 cases with 
Cryptosporidium 
and diarrhea (5 





• 17 with diarrhea 
(5 with PD) 
• 15 healthy 
 
Stool Tests: 
• Reducing substances (RS) 
• Lactoferrin 
• Cytokines: 









• WBC  
 
Proportion RS-positive:  
• 33.3% cases 
• 64.7% diarrhea controls 
• 46.7% healthy controls, 
(p=0.2) 
 
Proportion lactoferrin-positive:  
• 83.3% cases  
• 60.0% diarrhea controls 
• 28.6% healthy controls, 
(p=0.01) 
 
IFN-γ was not recovered in any 
stools. 
 
All other fecal cytokines were 
significantly associated with 
Cryptosporidium cases 
compared to diarrhea and 
healthy controls.  
 
Additionally, TNF-α receptor I, 
IL-8, and IL-13 were found in 
diarrhea and healthy controls, 
while IL-4 and IL-10 were not.  
 
Fecal lactoferrin was 
associated with the presence of 
TNF-α receptor I (point 
estimate not provided, p=0.03). 
 
Mean WBC counts were within 
normal range in all 3 groups. 
Fecal lactoferrin 
was identified most 
often in children 
with diarrhea, 
especially in those 
with 
Cryptosporidium. 
While some fecal 
cytokines were 
detected in as 
many as 40% of 
healthy controls 
and 70% of controls 




infection. The other 






were not stratified 










children who were 
breastfeeding were 










favela in Fortaleza, 
Brazil 
 










Stool Test:  
Lactoferrin 
Proportion of positive 
lactoferrin results decreased 
with each new Giardia 
infection, p=0.015: 
1.1st infection: 74.0% (15.2% of 
those testing positive had 














following scale was 
                                                          
1 The Haitian Group for the Study of Kaposi's Sarcoma and Opportunistic Infections. 
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Fecal lactoferrin as 








recruited at birth 
and followed for up 
to 4 yr. Those with 
Giardia recovered 
from stools were 
included in this 
study. 
collected at regular 
intervals as well as 
during episodes of 
diarrhea. 
2.2nd infection: 40.0% (5.3% of 
those testing positive had 
high titers)  
3.3rd infection: 1 (20.0%) tested 
positive (at a high titers) 
 
Increasing titers of lactoferrin 
were associated with longer 
duration of diarrhea, p=0.017: 
• Negative: 2.2 days 
• Low: 9.7 days 
• High: 14.6 days 
 
Lactoferrin results did not differ 
between symptomatic and 
asymptomatic children at first 
infection, but those with 
symptoms had positive results 
with recurrent infections with 
greater frequency (75.0% vs. 0 




with longer duration 
of diarrhea, 
although these 
results were not 
presented 





might be useful in 
predicting duration 




• High = positive 
at 1:400-1:3200 
dilution  
• Low = positive at 
1:25-1:200 
• Negative = no 
reaction at 1:25 
 
Stools from 
children who were 
breastfeeding were 
not tested.  
 
Data were part of a 
larger study; 




were published by 
O.Y. Bushen, et al. 
(also included in 
this review); 
however, Bushen 
et al. used a 
slightly different 






Lima AA et al.  
 




total parasitic, and 
specific Giardia spp 
Fortaleza, Brazil 
 
2 mo-9 yr olds 
(mean 43 mo) from 
an impoverished 
urban community, 
eligible if HAZ 
score was <median 






















Median L:M at baseline was 
0.089. There was no significant 
change in L:M at 4 mo follow-
up within either treatment 
group. 
 
No significant difference in L:M 
was observed between 
treatment groups. 
 









it was also 
Authors did not 







fecal cytokines, or 
between these 
                                                          
1 For lactulose and mannitol results, excretion measurement was not specified. 
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infections in 






L:M as a marker of 
intestinal barrier 

























Both median lactulose and 
mannitol excretions decreased 
at 4 mo follow-up among the 
vitamin A compared to the 
placebo group: 
• Lactulose: 0.21 to 0.74, 
p=0.042  
• Mannitol: 3.06 to 8.25, 
p=0.008  
 
Overall proportion of lactoferrin 
was 23% initially. At 1 mo 
follow-up, there was no 
difference in prevalence 
between vitamin A (33%) and 
placebo (31%) groups. 
 
Cytokine concentrations did not 
significantly differ between 
placebo and vitamin A groups. 
associated with 
reduced mannitol 
excretion, with no 





was not associated 













abnormal L:M were 











Lima AA et al. 
 
Intestinal barrier 
function and weight 






L:M as a marker of 
intestinal 
permeability and 
various stool tests 
among children with 
malnutrition or PD 
who received either 
glycine or glutamine 
Fortaleza, Brazil 
 
2-60 mo olds 
hospitalized with 
WAZ score <-2, 









• 27 with glycine 












• Lactoferrin  
• Leukocytes  
• Occult blood 
• Reducing substances (RS) 
 
 
* n=80 tested at enrollment, 
n=65 tested at day 10. 
 
** n=60 tested. 
Mean2 L:M (SE):  
• Glutamine group: 
• Baseline: 0.31 (0.10) 
(similar in all three 
groups) 
• Day 10: 0.10 (0.02); 
significant decrease, 
(p=0.01) 
• No significant decrease in 
L:M in glycine and 
nonsupplemented formula 
groups at day 10 
 
Mean lactulose (SE):  
• Glutamine group: 
• Baseline: 0.97 (0.46) 
(similar in all three 
groups) 
• Day 10: NS decrease in 
all 3 groups 
L:M significantly 









RS, and occult 
blood were 





markers and L:M 
was not reported.  
 
Data were not 
stratified by history 
of PD. 
 
Fecal fat was 
assessed, but 
results were not 
reported. 
 






                                                          
1 Lactulose and mannitol results were expressed as % of dose administered. 
2 Type of mean not specified. 
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supplemented 
formula or placebo 
 
Mean mannitol (SE):  
• Glutamine group: 
• Baseline: 3.42 (0.64) 
(similar in all three 
groups) 
• Day 10: NS decrease in 
all 3 groups 
 
Proportion of stool markers at 
baseline among all subjects:  
• Lactoferrin: 53.3% 
• Leukocytes: 11.7% 
• RS: 3.3% 










Long KZ et al. 
 
The effect of vitamin 
A supplementation 
on the intestinal 
immune response in 





Fecal cytokines as 
markers of intestinal 
mucosal immune 
activation in children 
with and without GI 
pathogens receiving 




All 5-15 mo olds 
within a periurban 
community were 
























was tracked and 







Positive tests for fecal 
cytokines: 
• IL-4: ~55% 
• IFN-γ: ~50% 
• IL-6: ~40%  
 
There were no significant 
differences in proportions of 
these fecal cytokines between 




children with diarrhea had 
lower median IFN-γ 
concentrations (odds 
ratio1=0.51; CI: 0.26, 0.99) and 
higher IL-4 concentrations 
(odds ratio=2.14; CI: 0.94, 
4.87) compared to children with 
diarrhea in the placebo group 
in a nonrandomized analysis. 
IL-6 concentrations did not 
differ in this analysis. There 
were no differences between 
the two groups among those 
Differences in fecal 
cytokine 
concentrations due 
to vitamin A 
supplementation 
were observed only 
in the subset of 








were not reported. 
Differences in fecal 
cytokines between 
all subjects with 
and without GI 
infections or 
history of diarrhea 
were not directly 
reported; all 
differences were 
described in terms 
of vitamin A 
interaction. 
                                                          
1 The odds ratios represent odds that a cytokine (categorized into three levels: undetectable, <median, >median) will have a higher value among vitamin A-supplemented children.   
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without diarrhea. 
 
Differences in median 
concentrations of fecal 
cytokines by types of enteric 
pathogens were also observed. 
2001 
 




clinical risk factors 
for developing 
persistent diarrhea 
among infants in a 
rural community of 
Egypt 
 
Stool IgE as a 
marker of 
gastrointestinal 
allergy and its 
association with 





at birth from a rural 
village and followed 







diarrhea, 41 (11%) 
of which were 
persistent. 
Nested case-
control within a 
cohort study  
 
n=392 episodes of 
diarrhea (including 





* Stool samples 
from each PD 
episode were 
counted as a case 
for analysis and 
compared to 
randomly selected 





Fecal IgE was detected more 
frequently in stools from 
episodes of PD compared to 
episodes of AD: odds ratio 
(CI)1=3.3 (1.0, 10.9). 
 
Fecal IgE was detected more 
frequently in stools from 
episodes of PD than in stools 
from children without diarrhea: 
odds ratio (CI)=4.84 (1.1, 21.7). 
Fecal IgE was 
detected 3 times 
more frequently 
during episodes of 
PD than AD and 5 
times more 
frequently in PD 
stools than in stools 
from those without 
diarrhea. 
Sampling was 
based on episodes 
of diarrhea within a 




than one diarrheal 
episode. 
Additionally, it 
appears that an 
individual could 
also have been 
included as a case 
of PD, a control 
with AD, or a non-
diarrhea stool 




appears to be the 
same as in another 
Mahmud, et al. 
study also included 
in this review 
which reported the 
prevalence of fecal 
IgE by gender and 




Mahmud MA et al. 
 
Bilbeis, Egypt        
 
Newborns recruited 




followed for 29,036 
Stool Test: 
IgE 
Overall incidence of fecal IgE: 
0.39/child-year 
 
By age group:  
Substantial 
incidence of fecal 
IgE was observed 
in this setting in 
Study population 
appears to be the 
same population 
as in another 
                                                          
1 Reported results were adjusted for confounding variables, unless otherwise noted. 
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Increased fecal IgE 
among infants in a 
rural community of 




Fecal IgE as a 




village and followed 
for the first year of 
life. 






• < 3 mo: 0.28/child-yr  
•  3-6 mo: 0.42/child-yr  
•  6-9 mo: 0.16/child-yr  
• >9 mo: 0.12/child-yr  
 
Relative risks (CI): 
•  3-6 compared to >9 mo olds: 
3.28 (1.03, 13.60)  





peaked at 3-6 mo 
of age. 
 
Male gender was 
associated with 
fecal IgE. 
Mahmud, et al. 
reference also 




between fecal IgE 
and PD [142]. 
2001 
 
Rabbani GH et al. 
 
Increased nitrite and 
nitrate 
concentrations in 
sera and urine of 
patients with cholera 
or shigellosis 
 
To assess and 
compare nitric oxide 
as a marker of 
intestinal 
inflammation among 
children with cholera 
or shigellosis or 
healthy controls. 
Evaluated to assess 
nitric oxide 
production during 
infection of small 
bowel without 
inflammatory lesion 








2-6 yr olds with 
cholera or 
shigellosis admitted 
to the hospital. 
 
Controls were 
recruited from the 
healthy attendants 
of patients or from 
children of hospital 
staff. 
 
Mean age (SD) in 
yr: 
• Shigellosis 
cases: 3.8 (1.2) 
• Cholera cases: 
4.2 (1.4)  







• 24 with cholera 













10 days of 
treatment). 
Urine Test: 




• Nitrite (NO2) 
• Nitrate (NO3) 







* Nitric oxide (NO) is an 
unstable free radical that is 
converted to nitrite and 
nitrate. Urine NO2 + NO3 
were expressed as a ratio 
with urine creatinine in order 
to account for differences in 
urine concentration. 
In children with shigellosis, 
median serum NO was ~8x 
higher at baseline than in 
controls and significantly 
differed from convalescent 
concentrations (p<0.01). 
Concentrations declined by 
52% of baseline during the 
recovery period but did not 
return to values found in the 
controls (measure of statistical 
significance not reported).  
 
In children with cholera, 
median serum NO 
concentrations at baseline 
were ~4x higher than in control 
subjects. Recovery 
concentrations decreased 52% 
from baseline (p<0.01); 
convalescent values did not 
differ from the values in 
controls (p<0.4).  
 
Median urinary NO ratios were 
similar among those with 
Shigella and V. cholerae 
infection, both upon admission 
and discharge. Initial values 
were ~2x higher than upon 
discharge (p<0.05 and 0.01, 
NO as measured 
by both serum and 






compared to 7-10 
days after 
hospitalization in 
both cholera and 
shigellosis.  
 
Median serum NO 
concentrations in 
cholera patients 




upon discharge and 
concentrations 
were much higher 
in cases than in 
controls, Such 
striking differences 
were not observed 




reported in table 
format conflict with 
the text; columns 




NO correlation with 
fecal leukocyte 
counts was not 
reported, nor was 
the correlation 
between urinary 
NO and total blood 
WBC. 
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Reference and 
Study Outcomes of  
Diagnostic Interest 
Location and  
Target Population 
Design and 
Sample Size Biomarker Results Conclusion Comments 
respectively). Control median 
NO was of an intermediate 
concentration between cases’ 
admission and discharge 
median concentrations; the 
difference between control and 
case admission values was 
NS. 
 
Mean blood WBC counts (SD): 
• Shigellosis: 19.6 (3.3)  
• Cholera: 8.3 (2.8) 
• Controls: 7.1 (1.8) 
 
Mean fecal WBC/high power 
field (SD): 
• Shigellosis: 38 (17) 
• Cholera: 5 (2) 
• Controls: 3 (1)  
 
Serum NO correlated with 
blood WBC count in shigellosis 
cases at baseline (r2=0.92, 
p<0.01), but only to a slight 
degree upon discharge 
(r2=0.26, no p-value reported) 
and there was no correlation 
among the cholera cases. 
Serum NO correlated with stool 
volume at presentation 
(r2=0.85, statistically significant 
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diarrhea or other GI 
complaints as well 
Cross-sectional 
 
n=26 <5 yr old: 
• 22 hospital-
based subjects 




16/22 patients and 0/4 students 
were lactoferrin positive. 
 
While examination of lactoferrin 
association with history of 
diarrhea or with 
Cryptosporidium infection was 
not reported, only 3/22 and 
16/22 hospitalized patients and 











Among the entire 
study cohort of all 
ages, lactoferrin 





status (influence of 
HIV infection was 
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children and hospital 





Stool lactoferrin as a 
marker of intestinal 
inflammation among 
hospitalized patients 




were positive for 
Cryptosporidium and had a 
history of diarrhea, 
respectively. 
 
Lactoferrin was not 
found among 
school-recruited 
children, most of 
whom did have a 
history of diarrhea. 









frequently found to 
be positive among 
those infected with 
Cryptosporidium; 
statistical testing 
was not reported. 
 
Lactoferrin results 




dilution and was 
considered 
negative if there 




were breastfed and 
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and intestinal barrier 











2 mo-9 yr olds 




if HAZ score 
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• C-reactive protein (CRP)  
48.5% had abnormal L:M.  
 
L:M and excretion of each 
sugar separately did not vary 
with retinol concentration. 
 
L:M was associated with levels 
of common dietary carotenoids, 
primarily driven by lactulose. 
However, the association was 
not always statistically 
significant, and the direction of 
association varied depending 
on precursor.  
 
Almost half of 
subjects had 
increased L:M, and 











that these retinol 
L:M threshold for 
abnormal values 
was defined as 
>0.0864 [214]. Cut-











                                                          
1 Lactulose and mannitol results were expressed as % of dose administered. 
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Biomarkers in bold are primarily markers of gut inflammation and/or immune activation.
Reference and 
Study Outcomes of  
Diagnostic Interest 
Location and  
Target Population 
Design and 
Sample Size Biomarker Results Conclusion Comments 
markers of intestinal 
inflammation, and 
CRP and AGP as 
acute phase 
reactants among 
children with varying 
vitamin A status 
• α-1-acid glycoprotein 
(AGP) 
40% of stool samples were 
positive for lactoferrin. 
 
1% of stool samples were 
positive for fecal leukocytes. 
 
30% of stool samples were 
positive for parasites but this 
had no impact on L:M results, 
lactoferrin, or acute phase 
reactants. 















between L:M and 
lactoferrin or fecal 
leukocytes as well 
as those between 
retinol or 
carotenoids and 
lactoferrin or fecal 
leukocytes were 






participation due to 
assessment of 
stool lactoferrin. 
Notes: Some studies included subjects ≥5 yr of age. Where these studies provided data separately for children <5 yr, we present results for only those subjects. 
Where these studies did not stratify results by age, but did report the number of children <5 yr included in the study, we provide a breakdown of under-5s. 
All studies reporting lactulose:rhamnose ratio results presented values multiplied by a factor of 100 for ease of reporting. 
 
Abbreviations: AD=acute diarrhea, ALT=alanine aminotransferase, AST=aspartate aminotransferase, CBC=complete blood count, CD=celiac disease, CI=95% confidence interval, 
Cr=creatinine, ∆=change in, EED=environmental enteric dysfunction, FTT=failure to thrive, GI=gastrointestinal, HAZ=height-for-age Z-(score), HDL=high density lipoproteins, 
HIV=human immunodeficiency virus, HLA=human leukocyte antigen, IEL=intraepithelial lymphocytes, IgA=immunoglobulin A, IgE=immunoglobulin E, IgG=immunoglobulin G, 
IgM=immunoglobulin M, IL=interleukin, IFN=interferon, LDL=low density lipoproteins, L:M=lactulose:mannitol ratio, mo=month(s), NS=not statistically significant, PD=persistent 
diarrhea, RCT=randomized controlled trial, SBBO=small bowel bacterial overgrowth, SD=standard deviation, SE=standard error, SES=socioeconomic status, Tc-99m=technetium 
99, T3=triiodothyronine, T4=thyroxine, TE=tropical enteropathy, TGF=transforming growth factor, TNF=tumor necrosis factor, TS=tropical sprue, WAZ=weight-for-age Z-(score), 
WBC=white blood cell count, WFA=weight-for-age, WHZ=weight-for-height Z-(score), wk=week(s), yr=year(s) 
 
 
Evidence Table 4. Markers of intestinal inflammation and intestinal immune activation.  
Biomarkers in bold are primarily markers of gut inflammation and/or immune activation.
5.5.1 Fecal Lactoferrin 
Fecal lactoferrin reflects infiltration of intestinal mucosa by polymorphonuclear 
neutrophils. The lactoferrin test might be more sensitive than assays for detection of leukocytes 
in stool because the former does not rely on the detection of whole cells, or on visualizing 
technology and trained observers. Its usefulness as a marker is enhanced by its relative stability 
in feces at room temperature. 
We reviewed nine studies that utilized stool lactoferrin as a measure of intestinal 
inflammation. Populations in two of these studies appear to overlap [108, 133].  
5.5.1.1 Prevalence of Fecal Lactoferrin 
The proportion of lactoferrin-positive stools varied widely across publications whose 
study populations also varied in terms of nutritional status and health conditions such as 
diarrhea symptoms and infection with enteric parasites. The proportion of subjects whose stools 
tested positive for lactoferrin ranged from 13 to 74% [132, 133]. 
Two studies assessed stools of children whose HAZ scores were below the median and 
found that 23 to 40% were lactoferrin-positive [137, 169]. Another study found that 53% of 
subjects with malnutrition or persistent diarrhea had lactoferrin in their stools [138]. Samie et al. 
measured lactoferrin in 26 stools of children hospitalized with diarrhea or other gastrointestinal 
complaints and in stools of four primary school children, three of whom had diarrhea at the time 
of testing [162]. None of the schoolchildren and 73% of the inpatients had lactoferrin in their 
stools. 
Several studies measured stool lactoferrin in children with parasitic infections. The 
proportion of Brazilian children infected with Giardia whose stools tested lactoferrin-positive 
decreased with each subsequent infection [133]. At first infection, 74% of subjects’ stools were 
lactoferrin positive, 15% of which had high lactoferrin concentrations, defined as 1:400-1:3200 
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dilution in an agglutination reaction. At second infection, 40% were positive, of which 5% had 
high concentrations of this marker. At third infection, 20% tested positive, all of which had a high 
concentration of lactoferrin. Interestingly, lactoferrin results did not differ between symptomatic 
and asymptomatic children at first colonization by these parasites, but those with symptoms 
were more likely to produce stools that tested positive with recurrent infections. In a study 
among children from an impoverished Brazilian community with HAZ scores less than the 
median, nearly one-third of stools were positive for parasites, but parasitic infection was not 
associated with presence of stool lactoferrin [169].  
Four studies measured stool lactoferrin in children with Cryptosporidium infection. One 
study tested stool lactoferrin in infants and children with Cryptosporidium parvum diarrhea, 
controls with diarrhea of different etiology, and healthy controls [132]. Lactoferrin was detected in 
60% of stools from C. parvum-infected cases, 35% of diarrhea control stools, and 13% of 
healthy control stools. This difference across groups was statistically significant. Two other 
studies also found that the proportion of subjects with lactoferrin-positive stools was about 50 
percentage points higher among cases compared to controls [101, 131]. Bushen et al. reported 
lactoferrin results only on Cryptosporidium-infected children; 68% were positive for lactoferrin 
and 68% of these subjects tested positive at a high titer, defined as positive at >1:400 dilution 
[108]. There were no differences in prevalence of lactoferrin-positivity between subjects with C. 
hominis and C. parvum spp. 
5.5.1.2 Associations between Fecal Lactoferrin and Growth or Other 
Outcomes 
Fecal lactoferrin did not significantly predict growth outcomes in the one study that 
assessed this relationship [108]. This was also the only study to assess the marker’s relationship 
to breastfeeding and age. While there was no association with breastfeeding, younger subjects’ 
stools were significantly more likely to be lactoferrin-positive. This difference, however, was 
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mediated by C. parvum; there was no age-associated difference among those infected with C. 
hominis. 
Three studies found significant associations between fecal lactoferrin and 
cryptosporidiosis [101, 131, 132]. A fourth study reported a high proportion of positive stools 
from infected subjects but did not enroll uninfected children, so assessment of association with 
presence of infection was not possible [108]. That study did, however, test the relationship of 
fecal lactoferrin with oocyst shedding and found no association. A fifth study that had a small 
proportion of subjects infected with Cryptosporidium species did not report examining for 
association with fecal lactoferrin and infection, but based on the numerical data presented such 
an association was not mathematically possible [162].  
Fecal lactoferrin was used as an outcome measure in one intervention trial testing the 
efficacy of vitamin A supplementation on intestinal barrier function, growth, and intestinal 
parasite infections [137]. No difference was observed in fecal lactoferrin results among treatment 
and placebo groups.  
5.5.1.3 Association between Fecal Lactoferrin and Other Markers 
Despite the number of studies that utilized fecal lactoferrin, only one study examined the 
association between fecal lactoferrin and another biomarker and found that fecal lactoferrin was 
significantly associated with the presence of tumor necrosis factor-α receptor I (TNF-αRI). 
Although the investigators also tested for other fecal cytokines, leukocytes and reducing 
substances, they did not report attempts to associate lactoferrin presence or concentration and 
these other markers in these subjects [132].  
5.5.1.4 Methodological Issues with the Fecal Lactoferrin Test 
The stool lactoferrin assay was generally performed with commercial kits. Methods 
described were similar across studies and results graded based on agglutination reaction 






[131, 132, 137, 138, 162, 169]. Two studies defined a positive threshold as a titer of >1:50 [101, 
108], another as >1:25 [133]. Two studies defined high titers of positivity to be values >1:400 
[108, 133].  
Ingestion of breast milk might cause lactoferrin to be detected in the stool, in the absence 
of intestinal inflammation. Most of the lactoferrin studies in this review did not discuss this 
potential issue within the context of their research. One study that tested a wide age range of 
subjects did not mention the breastfeeding status of those being tested [162]. Five of the studies 
excluded breastfeeding subjects from lactoferrin testing [132, 133, 137, 138, 169]. Several 
studies, however, tested fecal lactoferrin in subjects known to be breast feeding [101, 108, 131], 
and one of these studies assessed the association between breastfeeding and stool lactoferrin 
but found none [108]. 
5.5.2 Fecal Cytokines 
Five studies [101, 131, 132, 137, 140] measured concentrations of stool cytokines as 
indicators of intestinal inflammation; four of these studies investigated fecal cytokines in relation 
to gastrointestinal infection [101, 131, 132, 140]. The most commonly measured fecal cytokines 
were IFN-γ, TNF-α or TNF-αRI, and IL-4; each was assessed in four studies. IL-8 and IL-10 
were each measured in three studies, while TGF-β, IL-6 and IL-13 were each measured in one.  
5.5.2.1 Prevalence of Fecal Cytokines 
Three of the five studies of fecal cytokines reported the proportion of subjects with 
positive tests. The proportion of samples with detectable cytokines in stool varied widely by 
cytokine and by study, ranging from 3% for IL-4 [132] to 55%, also for IL-4 [140]. In a study of 
children with and without gastrointestinal pathogens, about half of the stool samples were 
positive for IL-4, IFN-γ, and/or IL-6, respectively [140]. In contrast, in a study that measured a 
panel of cytokines in the stools of children with and without diarrhea, IFN-γ was not recovered in 
any stools and IL-4 was only detected in 3% of samples [132]. Only IL-13 and TNF-αRI were 
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detected in a substantial proportion of these subjects’ stools; the former was detected in 32% 
and the latter in 52%. IL-8 was detected in 15% and IL-10 in 12% of stools. At 4-month follow-up 
in a subset of subjects, IL-8 was found in 6% and IFN-γ, IL-4, and IL-10 were not found in any 
stools. Among subjects in whom TNF-αRI was detected in stool during acute infection, this 
cytokine persisted at lower concentrations in stools of 50% of cases but was not detected in 
stools of controls. Some subjects previously negative for fecal TNF-αRI were positive at follow-
up. In a study of fecal IL-8 and TNF-α in children with or without C. parvum infection, IL-8 was 
detectable in 31% of subjects without significant differences based on infection status [101]. 
TNF-α was only investigated in infected children and was detected in stools of 40%, all of whom 
had acute diarrhea; however, none had high fecal concentrations of the cytokine.  
5.5.2.2 Associations between Fecal Cytokines and Growth or Other 
Outcomes 
None of the studies of fecal cytokines reported assessment of their relationship to growth 
outcomes in the children studied.  
Three studies investigated the relationship between fecal cytokines and Cryptosporidium 
infection. While IFN-γ was not identified in any stools in a Haitian study, fecal TNF-αRI, IL-8, IL-
13, IL-4 and IL-10 were significantly associated with C. parvum infection [132]. Interestingly, 
some of these cytokines (TNF-αRI, IL-8, IL-13) were found in children with non-Cryptosporidium 
diarrhea and in children without diarrhea while other cytokines (IL-4 & IL-10) were not. Fecal 
cytokines were not associated with presence of co-pathogens in the stool. A subsequent study 
by the same investigators measured concentrations of IFN-γ, TNF-α, TGF-β, IL-4, IL-8, and IL-
10 at multiple time points over nine months in stools of children with and without 
Cryptosporidium infection [131]. In contrast to their previous study, there were no differences in 
fecal concentrations of TGF-β, IL-8, IL-4 or IL-10 between those children with and without 
Cryptosporidium infection. Also, in contrast to their previous study, IFN-γ was detected and 
concentrations in stools of controls were almost double those of cases at enrollment, but this 
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difference was not statistically significant. At six- and nine-month follow-up, however, 
concentrations in stools of controls increased to almost triple that of cases and the difference 
was significant. Fecal TNF-α was only assessed in the second study; those with 
cryptosporidiosis had significantly higher concentrations at enrollment, but this did not persist at 
follow-up, i.e., after infection had resolved. A Brazilian study only measured TNF-α among 10 C. 
parvum-infected children and found no samples with elevated concentrations. IL-8 was 
measured among those with and without C. parvum infection, but the proportions of those with 
detectable serum concentrations did not differ between the groups [101].  
Two randomized, controlled trials of vitamin A supplementation used fecal cytokines as 
outcome measures [137, 140]. In one, IL-4, IL-6 and IFN-γ were measured as the primary 
endpoints of the intervention in children with and without gastrointestinal pathogens [140]. 
Overall no significant difference was observed in stool cytokine concentrations between vitamin 
A-supplemented and placebo subjects. However the relationship between fecal cytokine 
concentrations and vitamin A supplementation was modified by both gastrointestinal infection 
and diarrhea. Similarly in the second study, vitamin A supplementation was not associated with 
an intestinal cytokine response [137]. 
5.5.2.3 Associations between Fecal Cytokines and Other Markers 
Fecal cytokines were compared to other markers in only one of these studies, finding that 
TNF-αRI was significantly associated with fecal lactoferrin [132]. 
5.5.3 Fecal Leukocytes 
Four studies collected data on stool leukocytes. Two of these studies reported the 
proportion of tests positive for the presence of leukocytes. These values ranged from 1% among 
children with HAZ scores below the local median [169] to 11.7% among children hospitalized 
with malnutrition or persistent diarrhea [138]. Two studies compared fecal leukocytes across 
subject groups with different gastrointestinal conditions. In one study, where neither proportions 
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of positive nor fecal leukocyte counts were reported, the investigators found that fecal leukocytes 
did not differ between children with acute diarrhea, some of whom went on to develop persistent 
diarrhea, and controls without diarrhea [104]. The second of these two studies found that mean 
fecal leukocyte counts were nearly eight times higher in shigellosis cases than in cholera cases 
and nearly 13 times higher in shigellosis than in healthy controls [158].  
5.5.4 Fecal Neopterin 
One study measured fecal neopterin as an indicator of intestinal inflammation, following 
subjects from 2-15 months of age [15]. No association was observed between L:M and fecal 
neopterin. Mean neopterin concentrations were negatively associated with long-term height gain, 
but were not associated with Giardia recovery in stools.  
5.5.5 Fecal IgE 
Two studies assessed fecal IgE as a marker of intestinal inflammation; both appear to 
have been conducted on the same population. The first was a community-based cohort study 
that investigated incidence of fecal IgE by gender and age group [143]. The incidence of fecal 
IgE was substantial, at 0.39/child-years, and peaked at 3-6 months of age. The second study 
assessed the relationship between stool IgE and persistent and/or acute diarrhea [142]. Fecal 
IgE was detected greater than three times more frequently among stools from episodes of 
persistent diarrhea compared to stool from episodes of acute diarrhea (OR (95% CIs) =3.3 (1.0, 
10.9)) and nearly five times more frequently in persistent diarrhea stools than in stools from 
those without diarrhea (OR (95% CIs) =4.8 (1.07, 21.7)).  
5.5.6 Inflammatory Intestinal Cell Markers 
One study assessed inflammatory cell markers in intestinal tissue [103]. Densities of cell 
proteins and inflammatory markers in the lamina propria and crypt epithelium in Zambian 
children with persistent diarrhea and different forms of malnutrition were compared across 
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groups and to those in healthy controls from the UK. Immunohistochemistry was performed on 
intestinal tissue obtained by endoscopic biopsy. The intestinal cell proteins studied were 
glycosaminoglycans (GAG), heparan sulfate proteoglycan (HSPG), and syndecan-1. The 
inflammatory cell markers measured were CD3+ intraepithelial lymphocytes (IEL), human 
leukocyte antigen DR-1 (HLA-DR), and Ki67, a crypt epithelial nuclear proliferative marker.  
Inflammatory markers were observed at higher concentrations in the Zambian subjects 
than in the UK controls. There were significant differences in specific types of inflammatory 
markers across malnutrition groups. There was a significant reduction in intestinal GAG and 
HSPG in the kwashiorkor group compared to UK children, but there were no significant 
differences in these values between the children with kwashiorkor and those with other types of 
malnutrition. There was no difference in epithelial syndecan-1 protein expression between the 
malnutrition groups; data for this marker were not reported for the UK controls.  
These markers were not compared to other types of markers of intestinal function. 
5.5.7 Intestinal Tissue Cytokines and Immune Markers 
 While scintigraphy and counts of intraepithelial white blood cells (WBCs) and leukocyte 
presence in the lamina propria provide assessments of intestinal inflammation, scintigraphy can 
be used more broadly to study intestinal pathology and as such is listed in section VII on 
nonspecific markers of intestinal injury. Because WBCs are sought in biopsies along with 
assessments of intestinal architecture, histopathology, including assessment of WBC infiltration, 
is listed in section VII as well.  
Only one study assessed intestinal tissue cytokines and immune markers. Markers were 
compared between rural Gambian children with differing degrees of malnutrition and UK control 
subjects with normal endoscopic results [111]. They assessed cytokine immunohistochemistry of 
intestinal tissue using antibodies against syndecan-1, perforin, γδ T-cell receptor, CD-3, CD-4, 
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CD-8, CD-19, CD-25, HLA-DR, TNF-α, IFN-γ, TGF-β, and IL-10. Median CD3+, CD4+, CD8+, 
CD19+, and CD25+ cell counts were 2-5 times higher among each case group compared to the 
UK controls; these differences were statistically significant. IEL, γδ, syndecan-1, HLA-DR, and 
perforin were detected among the Gambian children in varying degrees but were not reported for 
UK controls. Syndecan, CD3, and CD8 displayed a gradient proportional to malnutrition severity. 
All Gambian groups had greater density of cytokine-immunoreactive mononuclear cells in the 
lamina propria than UK controls. Among subjects with elevated cytokines, similar densities were 
seen for both pro-inflammatory (IFN-γ and TNF-α) and putative regulatory (IL-10 and TGF-β) 
cytokines. Epithelial expression of TGF-β in Gambian subjects was also enhanced compared to 
UK controls, but subjects with poorer nutritional status had lower densities of mucosal TGF-β+ 
cells. A marker of intestinal permeability, L:M was significantly associated with mucosal B 
lymphocyte, IEL, and perforin-positive IEL densities. 
5.5.8 Duodenal Aspirates for Immunoglobulins 
One study measured immunoglobulin concentrations in duodenal fluid as a marker of 
intestinal inflammation [128]. Concentrations of duodenal immunoglobulin were compared in 
hospitalized children with both persistent diarrhea and Giardia infection and controls without 
diarrhea or gastrointestinal infection. Significantly higher mean concentrations of IgM were found 
in duodenal aspirates of cases compared to controls. Mean concentrations of duodenal IgA and 
IgG did not differ between cases and controls, however. 
5.5.9 Summary of Markers of Intestinal Inflammation 
A variety of markers were assessed with a preponderance of studies using fecal 
lactoferrin. Lactoferrin was measured among study populations with varying characteristics. 
Lactoferrin results varied considerably as did results of other measures of intestinal 
inflammation.  
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Of note, among studies that met our review inclusion criteria, there was a complete 
absence of research utilizing fecal calprotectin (a protein produced by neutrophils and 
monocytes). This marker has been found in stools of patients with inflammatory bowel diseases 
in developed country settings during the time period of this review [262-264], but we found no 
analyses of its prevalence and potential role as a diagnostic tool in children with EED.  
A threshold for normal for tests of intestinal inflammation was often not defined by 
authors. Generally data on these markers were not collected longitudinally so it is not clear how 
much intra-individual variation exists. Only one study statistically compared markers of intestinal 
inflammation to each other, and found a relationship between TNF-αR1 and lactoferrin [132]. 
None of the intestinal inflammation studies compared these markers to biopsy results or to other 
tests of intestinal dysfunction such as permeability or absorption. 
An important consideration in evaluating these tests is the overall feasibility of performing 
them, especially in resource-limited settings. For example, stool is a somewhat easier analyte to 
obtain than blood (especially non-capillary assessments) and even urine among young children. 
Duodenal aspirates are, of course, more invasive tests and examination of intestinal tissue can 
only be performed on biopsy specimens, limiting their feasible use. Nonetheless, stool is an 
imperfect analyte. Production of sample cannot be scheduled, and the mechanics of obtaining 
the specimen are sometimes challenging, necessitating using adhesive bags or collection from 
diapers. In addition, stool is probably more biohazardous than blood, and certainly more than 
urine, and often elicits handling concerns by laboratory staff and couriers. 
5.6 Markers of Systemic Inflammation and Systemic 
Immune Activation 
Markers of systemic immune function and inflammatory response might provide 
informative indirect evidence of precursors to, or consequences of, small intestinal injury. 
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Indeed, the hypothesis that local inflammation could be reflected in systemic markers is 
intriguing. There is precedent for associations between markers of organ-specific inflammation 
and systemic inflammation, with the best studied being coronary artery and inflammatory bowel 
diseases. The atherosclerotic lesion in coronary artery disease and the small and/or large bowel 
inflammation in Crohn’s disease and ulcerative colitis are characterized by acute and chronic 
inflammatory changes, and, as such, could be analogous to the lesions found in EED. By 
extension, there is ample evidence of an association between systemic markers of inflammation 
and acute coronary artery events, including myocardial infarction, sudden cardiac death, and 
cerebrovascular accidents, and of intestinal disease activity in inflammatory bowel diseases. 
Concentrations of circulating C-reactive protein (CRP) have, indeed, emerged as strong 
predictors of such events in adults, and complement the use of lipid profiles, which are a more 
specific biomarker of coronary artery disease [265-267]. Systemic CRP or erythrocyte 
sedimentation rates are indices of inflammatory bowel disease activity [268, 269].  
In the case of EED, there is justification for seeking evidence of systemic inflammation as 
a biomarker, based on the precedent of coronary artery disease and inflammatory bowel 
diseases. However, there are additional justifications: the pathophysiology of environmental 
enteric dysfunction might result in, or be associated with, a hyperpermeable gut. Such increased 
bowel permeability would expose the host to a variety of injurious substances, most particularly 
microbial inflammatory drivers, and the host response could either be a surrogate for 
inflammation, or reflect the process that leads to enteric dysfunction. For example, one or more 
bacterial molecules could be absorbed, leading to a pro-inflammatory host response, as 
manifested by elevated CRP, but such a response could be an appropriate reaction to the gut 
that enables the molecules to be absorbed.  
To hone in on assessments of systemic inflammation and immune function that could be 






among children with presentations such as persistent diarrhea, or investigations of the markers 
in relationship to markers of intestinal inflammation or dysfunction.  
It should be noted that there can be considerable overlap between the primary 
assignment of many of these markers of systemic inflammation and nutrient testing (e.g., serum 
albumin, total protein, hemoglobin, and blood counts.) For example, while hypoalbuminemia, 
hypo- or hypergammaglobulinemia, and impaired erythropoiesis are indicators of nutritional 
status, they can also reflect systemic immune activation [270-273]; as such, they were assigned 
to this section. For purposes of this review, if a test could be related to inflammatory activation 
and measured the product of a nutrient (such as hemoglobin) and not the nutrient itself (such as 
iron), then we included the test in our review. 
We identified a diverse set of markers from 23 studies that we assigned to the category 
of systemic inflammation but which could serve as biomarkers for intestinal inflammation. 
Relevant data for each of the studies in this category can be found in Evidence Table 5. The 
most commonly employed markers were CRP, albumin, hemoglobin, transferrin, and varying 
total and immunoglobulin class concentrations. Additional markers included circulating cytokines 
and/or chemokines, total oxidant status, circulating α-1-acid glycoprotein (AGP), serum 
mannose-binding lectin, and urinary neopterin. Three studies assessed nitric oxide [43, 158] and 
plasma endotoxin and IgG endotoxin-core antibody [110], which are markers that could reflect 
systemic inflammation driven by intestinal processes. One study also included data on multiple 
markers of cellular, as well as humoral, immunity [104].  
Although we did not systematically seek studies that assessed systemic marker 
association with nutritional status, among the studies that used markers of systemic 
inflammation or immune activation that were included in this review, seven assessed systemic 
inflammatory markers in relation to anthropometric indices [43, 110, 122, 123, 130, 150, 151]. 
The relationships varied widely across markers and sometimes across different growth 
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parameters for the same marker. Some data associated circulating markers of systemic 
inflammation and stunting; the markers with the strongest associations were albumin and α-1-
acid glycoprotein, each in an inverse relationship [123].  
Six studies investigated association of systemic markers with persistent diarrhea [104, 
106, 107, 114, 130, 166]. Those identified at significantly lower concentrations in children with 
persistent diarrhea relative to children without diarrhea included: serum total protein [106, 107], 
hemoglobin [106, 166], mean corpuscular volume (MCV) and mean corpuscular hemoglobin 
(MCH) [166], lymphocyte counts [166], and anti-oxidant concentrations [107]. Albumin 
concentrations were also lower in children with persistent diarrhea; this relationship was 
statistically significant in one study [106] but not in another [166]. Sample size differences could 
explain the effect discrepancy with six 6-24 month olds with persistent diarrhea in the latter [166] 
compared to 96 6-36 month olds in the former [106]. While albumin concentrations are known to 
increase with increasing age, the slightly older cohort in the study that found an association is 
unlikely to explain the discrepancy in results. 
Markers found at higher levels in children with persistent diarrhea compared to those with 
no diarrhea were total oxidant status, thiobarbituric reactive substances, and DNA damage 
[107]. In addition, assays of neutrophil polarization and monocyte spontaneous proliferation 
showed increased responsiveness in children with acute or persistent diarrhea relative to those 
without diarrhea [104]. A negative delayed-type hypersensitivity response to tuberculin antigen 
was also associated with progression from acute to persistent diarrhea [104]. 
Only one study utilizing markers of systemic inflammation investigated both growth 
outcomes and persistent diarrhea; this was in relation to serum mannose-binding lectin [130], 
which was not significantly associated with either.  
Five studies investigated the relationship of systemic inflammatory markers to gut 
permeability. Associations were found between IgG, IgA, IgM, and IgG endotoxin core antibody 
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and intestinal function as measured by the L:M ratio [110] and between hemoglobin 
concentration and the lactose:creatinine ratio [151]. Additionally a correlation was observed 
between urinary nitric oxide and the serum L:R ratio [43]. In contrast, anemia and mean 
corpuscular volume (MCV) were not associated with serum L:R [58], and associations were not 
found between the L:M ratio and other markers such as α-1-acid glycoprotein (AGP), total IgG, 
albumin, or hemoglobin concentrations [123]. Furthermore, only one of these studies included 
biopsy, but the authors did not report assessing the relationship between markers of systemic 
inflammation and histology [146]. 
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Reference and 
Study Outcomes of  
Diagnostic Interest 
Location and  
Target Population 
Design and 
Sample Size Biomarker Results Conclusion Comments 
2000 
 
Azim T et al. 
 
Immune response of 
Bangladeshi children 






tests, as well as 
transferrin and 
albumin as markers 
of nutritional status 
among children with 
and without PD 
Dhaka, Bangladesh 
 
7-12 mo olds with 6-
8 days of watery 
diarrhea attending 
the International 
Centre for Diarrheal 
Disease Research.  
 
Cases were those 
who went on to 
develop PD, controls 
were those who did 
not.  
 
An additional group 
of subjects without 
diarrhea were 





malnutrition was high 









• 85 with AD 





















• Mononuclear cell 
proliferation, 
spontaneous and 



















• Red blood cells 
WBC total and differential, 
immunoglobulin subtypes, cytokines, 
transferrin, and albumin did not differ 
between cases with diarrhea or 
controls, nor did stool leukocyte or 
erythrocyte counts.  
 
The percentages of neutrophils that 
polarized in response to stimulation 
were significantly higher in subjects 
with AD or PD compared to those 
without diarrhea; there was no 
difference between the two diarrhea 
groups. 
 
Opsonization did not vary between 
any groups. 
 
Monocyte spontaneous proliferation 
counts were less than half among 
children with no diarrhea compared 
to those with AD (p<0.001) or with 
PD (p=0.011); there was no 
difference between the two diarrhea 
groups.  
 
Monocyte proliferation in response to 
stimulation did not differ between the 
3 groups.  
 
The proportion with DTH responses 
differed among the three groups only 
in response to tuberculin (p=0.021). 
More PD subjects had a negative 
tuberculin response than did 
subjects with AD (p=0.024). 







The only marker that 
was significantly 
associated with 
progression to PD 
was a negative DTH 
response to 
tuberculin antigen 
(odds ratio=3.8, CI: 
1.4, 9.9). This was 
calculated from a 
logistic regression 
analysis that only 
included children 
with diarrhea. 
The number of 
controls was 
relatively small and 
their nutritional 
status was not 
reported. 
Evidence Table 5. Markers of systemic inflammation and systemic immune activation.  
Biomarkers in bold are primarily markers of systemic inflammation and/or immune activation.
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2003 
 
Bitarakwate E et al. 
 
Serum zinc status of 
children with 
persistent diarrhoea 
admitted to the 
diarrhoea 







children with and 
without PD 
Kampala and Mpigi, 
Uganda 
 
6-36 mo olds with 
PD, recruited from 
hospital, and healthy 
controls recruited 













• Total protein 
• Hemoglobin 
PD cases:  
7.47.9% low serum protein  
8.69.7% low serum albumin 
9.Low mean hemoglobin (10.5 g/dL) 
 
For controls, means of all three 
laboratory values were within normal 
range; percent of subjects with 
abnormal values are not reported. 
 
All three test results were 
significantly lower in children with PD 
than in controls (p< 0.01 for each 
comparison). 
Decreased albumin, 
serum total protein 
and hemoglobin 
concentrations were 




Bukhari AS et al. 
 













levels of DNA 
damage among 




3-6 yr olds admitted 
to hospital with PD 
















• Total protein 
• Total cholesterol, 
HDL, LDL, 
triglycerides 
• AST, ALT 
• T3, T4 
• Total oxidant 







• DNA damage to 
lymphocytes 
Mean values significantly higher 








Mean values significantly lower 














speculate that zinc 
deficiency, more 
commonly found in 
the children with PD, 




play an important 
role in mediating 
DNA damage. 
Control recruitment 
strategy was not 
well described. 
 






differed by gender 
in both the case 








did not appear to 
address potential 
confounding. 
Evidence Table 5. Markers of systemic inflammation and systemic immune activation.  
Biomarkers in bold are primarily markers of systemic inflammation and/or immune activation.
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Sample Size Biomarker Results Conclusion Comments 
2003 
 
Campbell DI et al. 
 
Growth faltering in 
rural Gambian 
infants is associated 
with impaired small 
intestinal barrier 





L:M as a marker of 
intestinal 








All 2-11 mo olds 
were recruited from 
this rural village and 

















• C-reactive  
protein (CRP) 
• IgA  
• IgM  
• IgG 
• Plasma endotoxin 
• IgG endotoxin-
core antibody 
At 8 wk of age:  
• Mean2 L:M: 0.169 (CI: 0.145, 
0.198; range: 0.058-0.657) 
• Mean lactulose recovery: 0.202 
(SD=0.159; range: 0.009-0.640) 
• Mean mannitol recovery: 3.80 
(SD=2.35; range: 0.52-8.58) 
 
L:M more than doubled between 12 
wk-1 yr of age (r=0.44, p<0.001) and 
was driven by both increasing 
lactulose (r=0.18, p<0.001) and 
decreasing mannitol (r=-0.14, 
p<0.01) excretion with age.  
 
WAZ and HAZ scores were 
negatively correlated with L:M (r=-
0.41, p<0.001), and primarily driven 
by lactulose excretion (r=-0.39, 
p<0.001). 
 
Laboratory values were consistent 
with chronic, low level 
immunostimulation: 
• 50% of platelet and 39% of 
leukocyte counts were elevated, 
especially mean lymphocyte 
counts which were almost twice 
expected values [198]. 
• While the mean3 CRP was within 
the normal range, 25% of values 
were above the upper limit of 
normal (5 mg/L), and 17% were 
>10 mg/L [198]. 
• Mean IgG, IgA and IgM 
concentrations were near normal 
at 8 wk of age, but increased 
rapidly; all three were elevated 
above expected values in all other 
Mean L:M ratios 
were elevated at 8 
weeks of age, and 
more than doubled 
in the first year of 
life. 
 








Poor growth was 
significantly 
correlated with L:M 









ascribed to a gut 
source, endotoxin 
and its related core 
antibody are 
potentially a direct 
measure of intestinal 
inflammation due to 
gut gram negatives 
as a primary source 
of endotoxin release 
among subjects 
without sources of 
Presence of malaria 
parasites was 
assessed by blood 
smear at each 
study visit; the only 
parameter 
associated with 
malaria was CRP.  










might have overlap 
with that of 
Campbell et al. 
2004 also included 
in this review [15]. 
                                                          
1 For lactulose and mannitol results, excretion measurement was not specified. 
2 Geometric mean. 
3 Geometric mean. 
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age groups [198, 199]. 
• Mean1 free plasma endotoxin 
concentration was twice the upper 
limit of normal [200] and IgG 
endotoxin-core antibody 
concentrations were also elevated 
[198]. 
• However, mean albumin 
concentrations (and 
concentrations within SD) were 
generally within normal range 
[198]. 
 
L:M was correlated with 
IgG and IgA (r=0.41 and 0.41, 
respectively, p<0.001), and IgM 
(r=0.28, p<0.02). 
 
IgG and IgA were also correlated 
with lactulose recovery (r=0.26 and 
0.25, respectively, p<0.02). 
 
IgG endotoxin core antibody 
concentration was correlated with 
L:M and driven by lactulose 
recovery, (r=0.35, p<0.005 for both).  
 
Endotoxin concentrations were 
correlated with lactulose recovery 





Clark TD et al. 
 
Risk factors and 
cumulative incidence 




children in Uganda 
Kampala, Uganda 
 
9 mo old HIV-
infected children 
followed at Mulago 
hospital until 36 mo 
of age.  
 








While chronic diarrhea was 
associated with moderate anemia in 
a univariate analysis (odds ratio=2.5, 
CI: 1.0, 6.3), it was either not 
associated with moderate anemia 
(hemoglobin <9 g/dL) in a 
multivariate model or not included in 
the model 
While there was a 
high prevalence of 
anemia (<11 g/dL) 
and moderate 
anemia (<9 g/dL) 
(92% and 35% at 9 
months, 
respectively) among 









degree of anemia, 
mean corpuscular 
volume, and mean 
corpuscular 
hemoglobin 
                                                          
1 Geometric mean. 
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Association of 
chronic diarrhea with 




appears to have not 
been associated 
with anemia in the 
multivariate analysis. 
However, the text 
did not specifically 
state whether 
chronic diarrhea was 











treatment on infant 
growth and intestinal 






L:M as a marker of 
intestinal 
permeability, IgG as 
a marker of chronic 
immune stimulation, 
and α-1-acid 
glycoprotein as an 












3-15 mo olds from a 
rural area were 
enrolled and 
followed in a 9-mo 
trial.  
 
There was a high 
prevalence of 



















* Those who fully 
participated and 
for whom data 
were analyzed 












Mean L:M1 (SD) at baseline was 
0.18 (0.24) in treatment groups, with 
no significant difference in placebo 
group or in testing post-intervention. 
 
Proportion with elevated L:M at any 
study time point varied between 
58%-74%. >57% consistently 
elevated L:M ratios. 
 
Seasonal variation in L:M was 
observed (p <0.001), with highest 
mean values in the monsoon 
season.  
 
L:M was associated with ∆WAZ and 
∆WHZ scores at 24 weeks (p=0.001 
and p<0.001, respectively, point 
estimates not provided.) 
 
Serum immune marker values were 
similar in all groups and did not 
change substantially with 
interventions. 
 
AGP concentrations were negatively 
associated with ∆WAZ score at 24 
weeks (p=0.004, point estimate not 
provided), and were associated with 
∆WHZ score at 12 weeks but not at 
24 weeks. 






Interventions did not 





weight with better 
L:M values, the 
degree to which this 
occurred was not 
reported. 
High L:M ratios 
were defined as 
greater than the 





reported by this 
group in another 
study also included 
in this review [123]. 
                                                          
1 Geometric mean. 
Evidence Table 5. Markers of systemic inflammation and systemic immune activation.  
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Goto R et al. 
 




infections on infant 
growth faltering in 
rural Bangladesh 
 
L:M as a marker of 
intestinal 
permeability, IgG as 
a marker of chronic 
immune stimulation, 
and α-1-acid 










3-15 mo olds from a 
rural area were 
enrolled and 
followed in a 9-mo 
trial.  
 
There was a high 
prevalence of 
malnutrition in the 
study population. 
Longitudinal data 
extracted from an 





Urine and blood 
samples were 


















Mean1 L:M: 0.15 
 
L:M showed a decreasing trend with 
age (p=0.003), and was associated 
with female gender (p=0.004), HAZ 
score (p=0.039), and WAZ score 
(p=0.019), but not with giardiasis or 
any of the serum immune markers. 
 
IgG, AGP, and albumin were 
associated with giardiasis, but 
hemoglobin was not. 
 
Mean circulating albumin 
concentration was normal for age 
[203]. Compared to UK age-matched 
reference [199], rate of rise in IgG 
with increasing age was similar, but 
concentrations were consistently 
~3g/L higher.  
 
IgG was not associated with growth 
parameters. Albumin was associated 
with HAZ score only (p=0.016). AGP 
was inversely associated with HAZ 
(p=0.011) and WAZ (p=0.005) 
scores 
Mean L:M was 
elevated. L:M was 
not associated with 
any of the tested 
serum markers of 
inflammation or with 
giardiasis. 
 
IgG rose with 
increasing age at the 
rate expected 
(compared to UK 
norms) [199] but at 
higher 
concentrations 




very low; testing for 
association with 











reported by this 
group in another 
study also included 






have not been 
determined for 
AGP. UK norms for 
10 mo olds-adults 
are 0.88 g/L mean 
(0.21 SD) [204]. 
2007 
 
Jain S et al. 
 
Fecal occult blood 
































Fecal occult blood test was positive 
in 30/50 (60%) cases and 0/30 
controls.  
 
Among cases positive for fecal 
occult blood, 20 (66.7%) were found 
to have hemoglobin <8 g/dL.  
 
Enteric infections: 
• Parasitic infections were detected 
A high proportion of 
severely 
malnourished 
children had a 
positive fecal occult 
blood test, 
compared with no 
positives among 
healthy controls.  
 
Among cases, half 
had a presenting 
complaint of 
diarrhea (duration 
not specified), but 
the authors did not 
report results 
stratified by 
diarrhea duration.  
 
                                                          
1 Geometric mean. 
Evidence Table 5. Markers of systemic inflammation and systemic immune activation.  
Biomarkers in bold are primarily markers of systemic inflammation and/or immune activation.
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Diagnostic Interest 
Location and  
Target Population 
Design and 
Sample Size Biomarker Results Conclusion Comments 
among severely 
malnourished 
children compared to 
healthy controls 
 
 in 14/50 (28%) of cases, 12 
(85.7%) of whom tested positive for 
fecal occult blood.  
• Bacterial infections were detected 
in 18/50 (36%) of cases, 13 
(72.2%) of whom tested positive for 
fecal occult blood. 
• Of the remaining 18 for whom an 
enteric pathogen was not 
identified, 5 (27.8%) tested positive 
for fecal blood. 
 
Among the 30 cases with fecal 
occult blood, 16 were breastfed, 11 






often tested positive 
for fecal occult 
blood, although 
approximately 25% 
of those without an 
identifiable pathogen 
also tested positive.  
 
Presence of fecal 
blood did not appear 
to vary by feeding 
mode (e.g. breast 
milk, cow’s milk, or 
formula), although 
data presented were 
limited. 
Authors did not 
provide differences 
in proportions of 
occult blood among 





was not provided; 
data were reported 
as proportions only.  
 
Matching scheme 
was not defined. 
2001 
 








duodenal fluid and 
serum among 
children with PD and 
Giardia infection 
compared to those 
without diarrhea 
New Delhi, India 
 
<12 yr olds admitted 
to hospital with PD 
and Giardia.  
 
Controls had no 




Most cases were <7 
yr old, with n=19 <3 
yr old. Ages of 







n=30 cases with 

















Higher mean concentrations of IgM 
were found in duodenal aspirates of 
cases compared to controls 
(p<0.05).  
 
Mean concentrations of duodenal 
IgA and IgG did not differ between 






children with PD 




The number of 
controls was small 














<36 mo old inner-city 
residents recruited 
from the rehydration 










Serum MBL concentrations were 
lower in cases than in healthy 






was associated with 
MBL deficiency, 
MBL concentrations 
were not significantly 
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lectin as a marker of 
innate immune 
activation among 





or from GHESKIO 
HIV Center1.  
 
All subjects were 
HIV-negative. 
infection  












• 36.7% cases 
• 9.8% healthy controls 
• 0 diarrhea controls 
 
Cryptosporidiosis was associated 
with MBL deficiency (odds 
ratio=22.4; CI: 3.1, 160.82). 
 
Among cases, the proportion of 
those with PD was nearly double 
among those with MBL deficiency 
compared to those without MBL 
deficiency, but these results were 
not significant (p=0.13). MBL 
deficiency was not associated with 
duration of diarrhea (p=0.37) among 
those with cryptosporidiosis nor with 
anthropometric status among either 
cases or controls. 
associated with 
mean duration of 


















markers of intestinal 
inflammation of 




<18 mo olds from a 
low SES setting 
recruited from the 

















n=17 cases with 
Cryptosporidium 
and diarrhea (5 





• 17 with 
diarrhea (5 with 
PD) 


















Proportion RS-positive:  
• 33.3% cases 
• 64.7% diarrhea controls 
• 46.7% healthy controls, (p=0.2) 
 
Proportion lactoferrin-positive:  
• 83.3% cases  
• 60.0% diarrhea controls 
• 28.6% healthy controls, (p=0.01) 
IFN-γ was not recovered in any 
stools. 
 
All other fecal cytokines were 
significantly associated with 
Cryptosporidium cases compared to 
diarrhea and healthy controls.  
 
Additionally, TNF-α receptor I, IL-8, 
IL-13 were found in diarrhea and 
healthy controls, while IL-4 and IL-10 
Fecal lactoferrin was 
identified most often 
in children with 
diarrhea, especially 
in those with 
Cryptosporidium. 
While some fecal 
cytokines were 
detected in as many 
as 40% of healthy 
controls and 70% of 
controls with 




infection. The other 




were not stratified 




Cut-off values for 
lactoferrin positivity 
were not described.  
 
Stools from children 
who were 
breastfeeding were 
not tested for 
lactoferrin. 
                                                          
1 The Haitian Group for the Study of Kaposi's Sarcoma and Opportunistic Infections. 
2 Reported results were adjusted for confounding variables, unless otherwise noted. 
3 The Haitian Group for the Study of Kaposi's Sarcoma and Opportunistic Infections. 
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Cryptosporidium 
infection 
were not.  
 
Fecal lactoferrin was associated with 
the presence of TNF-α receptor I 
(point estimate not provided, 
p=0.03). 
 
Mean WBC counts were within 





Kukuruzovic R et al. 
 
Increased nitric 
oxide production in 









Nitric oxide (NO) as 




ratio (L:R) as a 
marker of intestinal 
permeability and the 
relationship between 
NO and L:R, growth 
parameters, mean 
corpuscular volume 
(as a surrogate of 
iron deficiency), and 
stool reducing 
substances among 





1-6 yr old Aboriginal 
and non-Aboriginal 
hospital inpatients.  
 
Subjects were 
grouped as follows: 
• Children with AD 
• Children with no 
diarrhea but with 
non-GI infectious 
conditions  












• 73 with non-GI 
infections (49 
Aboriginal)  








•  L:R  
•  Mean 
corpuscular 






(169 cases tested)  
 
 
* NO is an unstable 
free radical and is 
converted to nitrite 
and nitrate. Urine 
nitrate (NO3)+ nitrite 
(NO2) was expressed 
as a ratio with urine 
creatinine (NO2 + 
NO3:Cr) in order to 
account for 
differences in urine 
concentration. 
 
** Measured only 
among children with 
profuse diarrhea. 
NO among Aboriginal children with 
diarrhea was >3x higher than any 
other group and >5x higher than in 
non-Aboriginal controls. 
• NO was >3x and >2x higher 
among Aboriginal than non-
Aboriginal children in the 
diarrhea (p<0.001) and no 
infections groups (p<0.001), 
respectively, but there was no 
difference between them in the 
non-GI infections group.  
• NO was >3x and ~2x higher in 
the diarrhea compared to the no 
infections group among 
Aboriginals (p<0.001) and non-
Aboriginals (p<0.03), 
respectively.  
• NO was virtually the same 
among the Aboriginal non-GI 
infections and no infections 
groups, as well as among the 
non-Aboriginal diarrhea and 
non-GI infections groups.  
 
112/152 (74%) and 31/169 (18%) of 
children with AD had abnormal L:R 
ratios and positive stool RS, 
respectively. 
 
NO and L:R were measured at 
“convalescence” on Day 5 among 
those with diarrhea: the mean 
improvement in NO was 21.7% 
NO2 + NO3:Cr ratio, 
as a measure of 
endogenous nitric 
oxide production, 
was used as a 
marker of gut 
permeability and 
inflammation, with 
an attempt to identify 
how much more it 
reflects as response 
to inflammation from 





NO production was 
the same among 
those with diarrhea 
and non-GI 
infections (and 
higher compared to 
controls). NO was 




to any other group. 





Positive stool RS 
was defined as 
>0.5%.  
 
Abnormal L:R was 
defined as >7.6; no 
reference or 
derivation was 




appears to be the 
same as in another 
Kukuruzovic, et al. 
study also included 
in this review which 
assessed serum 
lactulose:rhamnose 
as a marker of 
intestinal 
permeability [58]. 
Evidence Table 5. Markers of systemic inflammation and systemic immune activation.  
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compared with 54.6% for L:R 
(p=0.01). 
 
NO and L:R were correlated (n=193, 
r=0.37, p<0.001)1; the correlation 
was stronger for lactulose (effect 
ratio=1.47, p<0.001) than for 
rhamnose (effect ratio=0.80, 
p=0.022).  
 
NO was not correlated with stool 
RS3 or MCV, but was correlated with 
lower WAZ score (effect ratio=0.88, 
p=0.05). 
due to (clinically 
silent) enteropathy 
could explain the 
concentrations seen 
among Aboriginal 
controls in this 
study. 
 
NO appeared to 
decrease 
significantly more 




NO was found to 
correlate with L:R. 
NO was more 
strongly correlated 















(L:R), serum lactose, 
and stool reducing 
substances as 































• L:R  
• Hemoglobin  









L:R testing was 
27/75 (36%) of Aboriginal controls 
and 0 non-Aboriginal controls had 
abnormal L:R ratios. 
 
Mean5 L:R at baseline: 
Cases: 
• Aboriginal: 16.4  
• Non-Aboriginal: 7.9, p=0.002 
compared to Aboriginal cases 
Controls: 
1.Aboriginal: 4.6 
2.Non-Aboriginal: 2.5, p=0.02 
compared to Aboriginal controls  
 
Mean improvement1 in L:R (CI) at 
day 5 among those with repeat 
testing: 
Mean L:R ratios of 
Aboriginal children 
were approximately 
double those of non-
Aboriginal children 
both among those 











Positive stool RS 
was defined as 
>0.5%.  
 
Abnormal L:R was 
defined as >5.6, 
derived from 2 SD 
above the 
arithmetic mean for 
non-Aboriginal 
controls in this 
study. The rationale 
for the choice of 2 
SD above the 
arithmetic, instead 
of the geometric, 
mean is not clear. 
                                                          
1 Reported results appear to have been adjusted for age and race. 
2 Reported results were adjusted for age and race. 
3 Reported results among children with diarrhea were adjusted for age and race. 
4 Lactulose and rhamnose results were expressed as % of dose administered. 
5 Geometric mean. 
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with and without 
diarrhea 
repeated on day 5 for 
a subset of Aboriginal 
subjects: 
• 174/264 admissions 
for acute diarrhea  




* Measured only 




tested not provided. 
• Aboriginal cases: 14.6 (11.2, 
18.0)  
• Aboriginal controls: -0.63 (-4.0, 
2.7)  
 
Mean lactulose recovery2: 
• Cases day 1: 0.085 (0.070–
0.103)  
• Cases day 5: 0.039 (0.033–
0.046) 
• Controls: 0.024 (0.019–0.029) 
All 3 values significantly differed 
from one another. 
 
Mean rhamnose recovery: 
• Cases day 1: 0.479 (0.424–0.542) 
• Cases day 5: 0.555 (0.498–0.616) 
• Controls: 0.585 (0.500–0.685) 
These values did not significantly 
differ from one another. 
 
Confidence intervals (CIs) in the 
authors' graphical representation of 
mean L:R at admission did not 
overlap, and the difference in means 
was particularly evident between 
Aboriginal and non-Aboriginal 
subjects. 
 
Factors associated with L:R among 
cases were3:  
• Acidosis (p=0.007) 
• Hypokalemia (p=0.035) 
• Diarrhea severity (p=0.001)  
 
Age and malnutrition were not 
associated with L:R. 
 
improved over 5 
days among 
Aboriginal cases. 
Children with severe 
diarrhea had higher 
mean L:R. 
 
Higher case L:R was 
driven more by high 
lactulose than by low 
rhamnose.  
Similarly, 
improvement in L:R 
among cases was 
primarily due to 
decreased lactulose.  
 
Stool RS and serum 













were not reported. 
 
Analysis included 







analysis methods.  
Repeat L:R testing 
was conducted on 
controls of both 
racial groups, but 
among cases it was 
only conducted on 
Aboriginal cases. 
 
This study appears 
to report on the 
same population as 
in the Kukuruzovic, 
et al. 2003 
reference also 







the advantages of 
serum over timed 
                                                                                                                                                                                                                                                                                               
1 Improvement in L:R appears to have been calculated as baseline L:R minus repeat L:R, as described in another publication in this review; however, this was not expressly stated. 
Reference 134. Kukuruzovic RH, Brewster DR. Milk formulas in acute gastroenteritis and malnutrition: a randomized trial. J Paediatr Child Health. 2002. 38(6):571-577. 
2 Figures reported parenthetically after the mean percent recoveries of lactulose and rhamnose were not specified as ranges or CIs. 
3 Reported results were adjusted for confounding variables, unless otherwise noted. 
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38% and 27% of Aboriginal cases 
had positive serum lactose and stool 
RS, respectively. 12% of Aboriginal 
and non-Aboriginal controls 
combined had lactosemia.  
 
Presence of lactosemia was 
associated with L:R, adjusted 
relative risk (CI)=1.06 (1.03, 1.10)1. 
Stool RS, anemia, and MCV were 
not associated with L:R. 
urine collection for 
assessment of L:R, 
as discussed in 
another publication 
in this review [125]. 
2001 
 
Mittal SK et al. 
 
Tropical sprue in 
north Indian children 
 
D-xylose and 
duodenal biopsy as 




0-15 yr old 
gastroenterology 
clinic patients with 
PD.  
 
Those with abnormal 
morphology on 
biopsy, abnormal D-
xylose test, and 
clinical response to 
antibiotics were 
diagnosed as having 
TS.  
 
Those with abnormal 
morphology and 
response to gluten-
free diet were 
diagnosed with CD. 
We include data on 






(38 with repeat 
biopsies) 
 
<5 yr old: n=44 
Duodenal biopsy, 





•  Hemoglobin 
•  D-xylose*  
 
 
* Not specified 
whether from urine or 
serum, and units of 
measurement not 
provided. 
36 (38.3%) were diagnosed with TS 
including 14/44 (31.8%) who were 
under 5 years of age.  
 
18 (19.1%) were diagnosed with CD.  
 
Degree of villous atrophy among TS 
vs. CD patients:  
• Mild in 8/36 (22.2%) vs. 0 
• Moderate in 23/36 (63.9%) vs. 4/18 
(22.2%) 
• Severe in 5/36 (13.9%) vs. 14/18 
(77.8%)  
 
Mean hemoglobin concentration 
(range) among TS patients was 8.3 
g/dL (5.5-11) and did not differ from 
values of those with CD.  
 
Among the 22 TS patients, repeat 
biopsies showed: 
• 16 with normalization 
• 5 with improvement  
• 1 worsened despite marked clinical 
improvement  
 
The D-xylose test was abnormal in 
all TS patients by diagnostic 
definition. 
More than half of the 
GI clinic patients 
with PD had some 
degree of villous 
atrophy.  
 
More than one-third 
and almost one-fifth 
of subjects were 




By study diagnostic 
definition, all TS 
patients improved 
with treatment.  
Among those who 




histology, while 23% 
had partial 
improvement and 1 
patient had 
worsened pathology. 
Biopsy results were 
not provided for 
patients without TS 
or CD.  
 
It was unclear if 
there were patients 
with abnormal D-
xylose and 
histology who did 
not respond to 
antibiotic therapy 
and therefore were 
not diagnosed with 
TS. 
 
Cut-off points used 
to define abnormal 
D-xylose tests were 
not provided. 
                                                          
1 Reported results were adjusted for severity of diarrhea, acidosis, hypokalemia, and age. 
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treatment of rural 
Bangladeshi 





L:M as a marker of 
intestinal 
permeability, and α 
1-antichymotrypsin 
as a marker of 
inflammation and 









2-5 yr olds from poor 
rural villages, 
sampled randomly 






















* Randomized at 





• Albumin  







Among 93 subjects 
with L:M at baseline:  
• 46 received 
treatment 
• 47 received 
placebo 
 
Among 66 subjects 
with repeated L:M 
testing: 
• 34 received 
treatment 
• 32 received 
placebo 
Mean L:M1 at baseline: 
• Treatment: 0.22 
• Placebo: 0.25 
 
Seasonal variation in L:M was 
observed, with highest values 
following the monsoon season.  
 
Within-subject L:M analysis showed 
no significant association with 
intestinal helminthiasis and no 
significant improvement in treatment 
or placebo groups over 1 yr. L:M 
was generally not associated with 
giardiasis (with the exception of one 
group at one study interval). 
 
L:M was inversely correlated with 
∆HAZ and ∆WAZ scores at some of 
the follow-up intervals (r=-0.22, 
p<0.02 and r=-0.21, p<0.05, 
respectively, at 12 mo follow-up 
visit).  
 
Mean serum ACT, albumin and total 
protein were within normal ranges 
and were not associated with growth 
parameters. ACT and albumin 
concentrations did not significantly 
change with treatment, whereas total 
protein concentrations did (p<0.001). 
L:M ratios were high 
overall and 
demonstrated 
seasonal variation.  
 
Intra-individual L:M 
values did not 
change significantly 
over time, nor were 







were seen between 
L:M and growth 
parameters. 
 
Serum markers were 
within normal range. 
The only significant 
change in these 
markers was a 
decrease in total 
protein in the 
treatment group 
without concomitant 
change in albumin; 




perhaps due to 
decreased 
inflammation. 
Baseline study data 
were lost, so 
analysis began with 











Panter-Brick C et al. 
Kathmandu, Nepal 
 







Mean2 Lactose:Cr (CI): 
• Squatter: 0.14 (0.12, 0.16) 
• Middle Class: 0.08 (0.07, 0.10) 
Authors speculate 
that Lactose:Cr 




                                                          
1 Geometric mean. 
2 Geometric mean. 
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Pathways leading to 
early growth 
faltering: An 










ratio (Lactose:Cr) as 





IgG as markers of 
immunostimulation. 
The latter were also 




• All children in 
target age range 









n=48 in squatter 
cohort  
 







• Statistically significant difference 
between the 2 groups among the 
6-12 mo olds (p=0.007) and 18-24 
mo olds (p=0.002), but not among 
12-18 mo olds.  
• For both SES groups, Lactose:Cr 
values decreased with increasing 
age (p<0.001). 
 
HAZ, WAZ, WHZ, and ∆WAZ scores 
were strongly associated with mean 
Lactose:Cr (p<0.001 each) as was 
∆HAZ score (p=0.004); ∆WHZ score 
was not. The strength and 
magnitude of association between 
∆WAZ score and Lactose:Cr was 
most pronounced among the 
wealthier cohort and there was no 
association between ∆HAZ score 
and Lactose:Cr among the squatter 
children.  
 
Hemoglobin concentrations were 
inversely related to Lactose:Cr 
(r2=0.018, p<0.001). 
the deterioration in 
nutritional status 
among the squatter 




that impact the 
nutritional status of 
children with lower 
socio-economic 
status. 
urinary creatinine to 
control for variation 





not be as accurate 
as L:M, it might be 
a more field-friendly 
assessment of 
mucosal damage 
compared to L:M, 
requiring only spot 
urine collection and 
no substrate 
dosing. However, 
L:M was not 
assessed in this 
study; direct 
comparison of the 





inversely related to 
Lactose:Cr, testing 
for associations of 
other measured 
blood markers (IgG, 
AGP and albumin) 
with Lactose:Cr 
was not reported. 
2001 
 
Rabbani GH et al. 
 
Increased nitrite and 
nitrate 
concentrations in 
sera and urine of 




2-6 yr olds with 
cholera or shigellosis 









• 24 with cholera 








• Nitrite (NO2) 
• Nitrate (NO3) 
• WBC  
 
In children with shigellosis, median 
serum NO was ~8x higher at 
baseline than in controls and 
significantly differed from 
convalescent concentrations 
(p<0.01). Concentrations declined by 
52% of baseline during the recovery 
period but did not return to values 
found in the controls (measure of 
NO as measured by 
both serum and 




during acute illness 
compared to 7-10 
days after 
Some values 
reported in table 
format conflict with 
the text; columns of 
data appear to be 
transposed. 
 
Assessment for NO 
correlation with 
Evidence Table 5. Markers of systemic inflammation and systemic immune activation.  
Biomarkers in bold are primarily markers of systemic inflammation and/or immune activation.
Reference and 
Study Outcomes of  
Diagnostic Interest 
Location and  
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Design and 
Sample Size Biomarker Results Conclusion Comments 
or shigellosis 
 
To assess and 
compare nitric oxide 
as a marker of 
intestinal 
inflammation among 
children with cholera 
or shigellosis or 
healthy controls. 
Evaluated to assess 
nitric oxide 
production during 
infection of small 
bowel without 
inflammatory lesion 





recruited from the 
healthy attendants of 
patients or from 
children of hospital 
staff. 
 
Mean age (SD) in yr: 
• Shigellosis cases: 
3.8 (1.2) 
• Cholera cases: 4.2 
(1.4)  


















* Nitric oxide (NO) is 
an unstable free 
radical that is 
converted to nitrite 
and nitrate. Urine 
NO2 + NO3 were 
expressed as a ratio 
with urine creatinine 
in order to account 
for differences in 
urine concentration. 
statistical significance not reported).  
 
In children with cholera, median 
serum NO concentrations at 
baseline were ~4x higher than in 
control subjects. Recovery 
concentrations decreased 52% from 
baseline (p<0.01); convalescent 
values did not differ from the values 
in controls (p<0.4).  
 
Median urinary NO ratios were 
similar among those with Shigella 
and V. cholerae infection, both upon 
admission and discharge. Initial 
values were ~2x higher than upon 
discharge (p<0.05 and 0.01, 
respectively). Control median NO 
was of an intermediate concentration 
between cases’ admission and 
discharge median concentrations; 
the difference between control and 
case admission values was NS. 
 
Mean blood WBC counts (SD): 
• Shigellosis: 19.6 (3.3)  
• Cholera: 8.3 (2.8) 
• Controls: 7.1 (1.8) 
 
Mean fecal WBC/high power field 
(SD): 
• Shigellosis: 38 (17) 
• Cholera: 5 (2) 
• Controls: 3 (1)  
 
Serum NO correlated with blood 
WBC count in shigellosis cases at 
baseline (r2=0.92, p<0.01), but only 
to a slight degree upon discharge 
(r2=0.26, no p-value reported) and 
there was no correlation among the 
cholera cases. Serum NO correlated 
with stool volume at presentation 
hospitalization in 
both cholera and 
shigellosis.  
 
Median serum NO 
concentrations in 
cholera patients 
were ~half of those 
with shigellosis both 
upon admission and 
upon discharge and 
concentrations were 
much higher in 
cases than in 
controls, Such 
striking differences 
were not observed 





correlated with total 
blood WBC in 
shigellosis cases. 
fecal leukocyte 
counts was not 
reported, nor was 
the correlation 
between urinary NO 
and total blood 
WBC. 
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(r2=0.85, statistically significant per 
authors, p-value not reported). 
2009 
 
Ritchie BK et al. 
 
13C-sucrose breath 






Sucrose breath test 
(SBT) as a marker of 
small bowel mucosal 
damage vis a vis 
sucrase activity 
among an Australian 
Aboriginal 
population. Also 







4 mo-5 yr old 
Aboriginal children 
admitted to hospital 
with diarrhea. 
 
Two control groups: 















cases with AD 
 
n=25 controls: 








cases and controls 
tested) 
• C-reactive protein 
(CRP) 






13C sucrose breath 
test (SBT) 
20/32 (63%) of Aboriginal children 
had abnormal L:R ratios. 
 
Mean1 L:R (CI): 
• Diarrhea cases: 31.8 (24.9, 
40.7)  
• Aboriginal controls without 
diarrhea: 11.4 (8.5, 15.5),  
• significant difference 
(p<0.0001) 
 
SBT Mean (CI): 
• Diarrhea cases: 1.9% (0.9, 
3.0), p<0.0001 compared to 
non-Aboriginal controls and 
p=0.004 compared to 
Aboriginal controls 
• Aboriginal controls: 4.1% 
(3.0, 5.2), p=0.032 
compared to non-Aboriginal 
controls 
• Non-Aboriginal controls: 
6.1% (4.8, 7.3) 
• Significant differences were 
observed between all three 
groups.  
 
SBT results were not associated with 
wasting or with patient age or 
breastfeeding status. 
 
SBT and L:R were inversely 
correlated (r=0.67; CI: 0.42, 0.62; 
p<0.0001). L:R explained 45% of the 
variance in SBT; diarrhea explained 
28% of variance. 
 
SBT was associated with increased 
MCV, relative risk (CI)=3.9 (2.8, 5.0). 
SBT values were 
significantly lower 




diarrhea than among 
those without GI 







This is consistent 
with previous reports 
of high prevalence of 
clinically silent TE in 






Abnormal L:R ratios 
were defined as 
>16; no reference 
or derivation was 
provided for this 
cut-point.  
 






analysis was based 




analysis was not 
reported and could 
be of interest 
considering the 






MCV, CRP, and 
hemoglobin with 
SBT after adjusting 
for potentially 
confounding 
variables were not 
reported. 
                                                          
1 Geometric mean. 
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SBT was not associated with 
hemoglobin or CRP. 
2001 
 






A longitudinal study 




L:M as a marker of 
gut mucosal integrity 
and urinary 
neopterin excretion 
as a marker of cell-
mediated immunity 
in infants with and 
without HIV infection 
Durban, South Africa 
 
1, 6, and 14 wk old 








• L:M  
• Neopterin 
Mean2 L:M (CI): 
• HIV-infected subjects: 
• 1 wk: 0.12 (0.06, 0.27)  
• 6 wk: 0.24 (0.15, 0.38) 
• 14 wk: 0.24 (0.14, 0.44) 
• Uninfected subjects:  
• 1 wk: 0.13 (0.09, 0.19) 
• 6 wk: 0.08 (0.06, 0.11) 
• 14 wk: 0.09 ( 0.07, 0.13) 
 
HIV-infection by 14 wk of age was 
significantly associated with 
increased L:M. 
 
A non-significant, positive trend in 
neopterin excretion was observed 
among HIV-infected infants. 
L:M was generally 
normal (compared to 






after 6 weeks. 
 
The increased L:M 
in HIV-infected 
infants was primarily 
driven by lactulose 




infected infants was 
observed but this 




between L:M and 











timing for improving 
biochemical and 
clinical recovery and 
subsequent vitamin 
A status 
Durban, South Africa 
 






















• L:M  




• C-reactive protein 
(CRP) 





• Group 1:  
• Day 0: ~1.8 
• Day 3: ~2.4  
• Group 2:  
• Day 0: ~1.2 
• Day 3: ~0.7 
 
There were no differences in mean 
L:M between groups or within groups 
between days 0 and 3, although 
there was a significant difference in 
paired analysis within individuals at 
the two time points (data not 
Mean L:M ratios 
were very high 
(~10x) (at baseline 
and at day 3 in both 
groups) compared to 





that this could have 
been due to the 
severity of illness in 
the sample 
Urine testing could 
only be conducted 
in the laboratory on 
certain days; hence 
only a subset of 
subjects underwent 
those tests.  
 




WBCs and AGP, 
and lower retinol 
                                                          
1 Lactulose and mannitol results were expressed in mg. 
2 Geometric mean. 
3 For lactulose, mannitol, and neopterin results, excretion measurement was not specified. 
4 Geometric mean. 
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serum α-1 acid 
glycoprotein, and C-
reactive protein as 
markers of 
inflammation among 





involved vitamin A 
supplementation 
either on the day 





49 subjects received 
urine testing: 
• Group 1: n=25 
• Group 2: n=24  
 
 
Blood and urine were 
tested on days 0 and 
3. 
presented, and direction, magnitude 
and degree of significance not 
reported). 
  
Lactulose and mannitol excretion 
were assessed only in the paired 
analysis. Lactulose excretion 
decreased between days 0 and 3 
(magnitude of effect and degree of 
significance not reported), while 
mannitol excretion showed no 
change.  
 
Mean1 neopterin and AGP 
concentrations did not differ between 
groups or within groups on the 
different study days or in the paired 
analysis. When initial CRP (~2x 
higher in Group 2 compared to 
Group 1, p<0.004) was taken into 
account, mean CRP on day 3 did not 
differ between the 2 groups. 
However in the paired analysis, CRP 
concentrations were significantly 







not result in 
significant 
improvement in L:M, 
neopterin, or AGP 
regardless of timing 





compared to group 
1 at baseline. 
Authors note that 
these parameters 
suggest that Group 
2 patients might 
have been more ill 
at baseline. For the 
subset of 49 
patients undergoing 
urine testing, the 
mean2 L:M and 
neopterin 
concentrations 
were lower among 
Group 2 than Group 
1 subjects (NS). 
However, baseline 
differences in acute 
phase and vitamin 
A markers at 
baseline were not 
reported separately 
for these 49 
subjects. 
 
Data for lactulose 
and mannitol 




of these molecules 
expressed as ratios 
with creatinine was 
not explained.  
 
                                                          
1 Geometric mean. 
2 Geometric mean. 
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Authors suggest 
that their 3-day 
testing period 
(based on their 
previous work in a 
different setting 
[207] might have 
been too short to 
identify effect as 
demonstrated by 
McCullough et al. at 




Soliman SM et al. 
 
Role of micronutrient 
mixture in acute and 
persistent diarrhea in 
infants and its 
impact on nutritional 
status 
 
Blood cell and 
albumin markers 
among infants with 
acute, persistent or 
no diarrhea, and 
effects on these 





vitamin A, zinc and 
other micronutrients) 
among subjects with 











5/6 PD cases and 
10/14 AD cases had 
some degree of 
malnutrition.  
 
Infants with PD had 
significantly lower 
vitamin A and zinc 
stores compared to 
controls. Those with 
AD had significantly 







• 6 with PD 











• Complete blood 
count and 
differential 

















Mean baseline hemoglobin was 
significantly lower in infants with AD 
and PD (p<0.05 for each group) than 
in controls  
 
Mean MCV and MCH were lower in 
those with AD (p<0.025 and p<0.01, 
respectively) and PD (p<0.01 for 
both markers) compared to controls.  
 
Mean lymphocyte counts among PD 
cases were low compared to those 
of controls (p<0.01). 
 
Other markers did not vary 
significantly at baseline. However, 
among infants with PD, mean 
albumin was abnormally low, 
although it was not significantly 
different compared to controls or 
those with AD. 
Mean albumin (g/dL) (SE): 
• PD: 2.9 (0.27)  
• AD: 3.29 (0.25)  
• Controls: 3.37 (0.21) 
 
Following micronutrient 
supplementation, mean hemoglobin, 
MCV, lymphocyte counts and 
albumin increased in both diarrhea 
Albumin and many 
hematologic markers 
were low at baseline 
among infants with 
diarrhea, especially 
in those with PD, 
compared to those 
without diarrhea; 












were not specified. 
 





for PD cases (n=6). 
Controls were 
reported to have 
been matched to 
cases, yet there 
were half the 
number of controls 
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groups to concentrations on par with 
control baseline concentrations 
(albeit increases were NS except 
within the PD group). MCH improved 
to concentrations on par with the 




Vieira MM et al. 
 
Carotenoids, retinol, 
and intestinal barrier 









markers of intestinal 
inflammation, and 
CRP and AGP as 
acute phase 
reactants among 
children with varying 
vitamin A status 
Fortaleza, Brazil 
 
2 mo-9 yr olds 
(mean age 41 mo) 
from an 
impoverished urban 
community, eligible if 
HAZ score <median  

























48.5% had abnormal L:M.  
 
L:M and excretion of each sugar 
separately did not vary with retinol 
concentration. 
 
L:M was associated with levels of 
common dietary carotenoids, 
primarily driven by lactulose. 
However, the association was not 
always statistically significant, and 
the direction of association varied 
depending on precursor.  
 
40% of stool samples were positive 
for lactoferrin. 
 
1% of stool samples were positive 
for fecal leukocytes. 
 
30% of stool samples were positive 
for parasites but this had no impact 
on L:M results, lactoferrin, or acute 
phase reactants. 
Almost half of 
subjects had 
increased L:M, and 




While serum retinol 
concentrations were 
not associated with 
L:M, serum 
carotenoids were; 
authors suggest that 
these retinol 












L:M threshold for 
abnormal values 
was defined as 
>0.0864 [214]. Cut-
off values for 
lactoferrin positivity 











between L:M and 
lactoferrin or fecal 
leukocytes as well 
as those between 
retinol or 
carotenoids and 
lactoferrin or fecal 





were excluded from 
study participation 
due to assessment 
of stool lactoferrin. 
 
                                                          
1 Lactulose and mannitol results were expressed as % of dose administered. 
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2007 
 









L:M and plasma 
immunoglobulins 







enrolled in a 
glutamine trial 
 
West Kiang region, 
Gambia 
 
4-10 mo olds from a 
rural area followed 
during the 5-month 
rainy season and for 








amino acids was 
orally 
administered 
twice daily during 






















Mean2 L:M (CI):  
• Baseline:  
• Glutamine group: 0.33 (0.25, 
0.43) 
• Placebo group: 0.33 (0.26, 
0.41) 
• Post-intervention: 
• Glutamine group: 0.29 (0.23, 
0.35) 
• Placebo group: 0.26 (0.21, 
0.32) 
 
Mean excretion of lactulose (CI):  
• Baseline:  
• Glutamine group: 0.21 (0.16, 
0.28) 
• Placebo group: 0.20 (0.15, 
0.26) 
• Post-intervention: 
• Glutamine group: 0.17 (0.13, 
0.21) 
• Placebo group: 0.14 (0.11, 
0.18) 
 
Mean excretion of mannitol (CI):  
• Baseline:  
• Glutamine group: 2.65 (2.02, 
3.48) 
• Placebo group: 2.50 (1.87, 
3.36) 
• Post-intervention: 
• Glutamine group: 2.48 (1.99, 
3.11) 
• Placebo group: 2.14 (1.62, 
2.82) 
 
L:M values did not differ significantly 
between treatment groups before or 
following intervention. However, a 
L:M values were 
elevated in this 









and placebo groups, 
either at baseline or 








between L:M and 
growth parameters, 
immuno-globulins, 
and acute phase 
proteins were not 
reported. 
                                                          
1 Lactulose and mannitol results were expressed as % of dose administered. 
2 Geometric mean. 
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repeated measures ANOVA showed 
that during supplementation, L:M 
values were borderline elevated 
among the glutamine-supplemented 
group relative to the placebo group 
(p=0.05), counter to expectation. 
 
Neither ACT, CRP, albumin, nor 
immunoglobulins IgA, IgG, or IgM 
differed significantly between 
treatment and placebo groups, either 
at baseline or at the end of 
supplementation. 
 
Mean levels of IgA and IgG 
increased during the study 
(p<0.001), while IgM levels did not. 
Concentrations of each of these 
immunoglobulins did not differ 
between treatment and placebo 
groups. 
 
Plasma albumin, ACT, 
and CRP values showed no change 
over the course of the study. 
 
Proportions of children with elevated 
CRP ranged from 30-41% at 
different collection time points. The 
glutamine intervention had no effect 
on proportion of children with 
elevated CRP. 
 
Treatment and placebo groups 
experienced decreases in WAZ, 
HAZ, and MUAC coinciding with the 
rainy season; however, there was no 
significant difference observed 
between the groups for any of these 
parameters.  
 
Treatment and placebo groups did 
not differ in morbidity indices (i.e. 
Evidence Table 5. Markers of systemic inflammation and systemic immune activation.  
Biomarkers in bold are primarily markers of systemic inflammation and/or immune activation.
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percentage of time reported with a 
particular illness or illness overall). 
Notes: Some studies included subjects ≥5 yr of age. Where these studies provided data separately for children <5 yr, we present results for only those subjects. 
Where these studies did not stratify results by age, but did report the number of children <5 yr included in the study, we provide a breakdown of under-5s. 
All studies reporting lactulose:rhamnose ratio results presented values multiplied by a factor of 100 for ease of reporting. 
 
Abbreviations: AD=acute diarrhea, ALT=alanine aminotransferase, AST=aspartate aminotransferase, CBC=complete blood count, CD=celiac disease, CI=95% confidence interval, 
Cr=creatinine, ∆=change in, EED=environmental enteric dysfunction, FTT=failure to thrive, GI=gastrointestinal, HAZ=height-for-age Z-(score), HDL=high density lipoproteins, 
HIV=human immunodeficiency virus, HLA=human leukocyte antigen, IEL=intraepithelial lymphocytes, IgA=immunoglobulin A, IgE=immunoglobulin E, IgG=immunoglobulin G, 
IgM=immunoglobulin M, IL=interleukin, IFN=interferon, LDL=low density lipoproteins, L:M=lactulose:mannitol ratio, mo=month(s), NS=not statistically significant, PD=persistent 
diarrhea, RCT=randomized controlled trial, SBBO=small bowel bacterial overgrowth, SD=standard deviation, SE=standard error, SES=socioeconomic status, Tc-99m=technetium 
99, T3=triiodothyronine, T4=thyroxine, TE=tropical enteropathy, TGF=transforming growth factor, TNF=tumor necrosis factor, TS=tropical sprue, WAZ=weight-for-age Z-(score), 
WBC=white blood cell count, WFA=weight-for-age, WHZ=weight-for-height Z-(score), wk=week(s), yr=year(s) 
 
 
Evidence Table 5. Markers of systemic inflammation and systemic immune activation.  
Biomarkers in bold are primarily markers of systemic inflammation and/or immune activation.
5.7 Markers of Microbial Drivers 
Markers of microbial environments, such small bowel bacterial overgrowth (SBBO), were 
reviewed, while markers for specific enteric organisms were beyond the scope of this review. The 
data from each of the studies relevant to this review are listed in Evidence Table 6.
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Reference and 
Study Outcomes of  
Diagnostic Interest 
Location and  
Target Population 
Design and 
Sample Size Biomarker Results Conclusion Comments 
2002 
 
Alves GM et al. 
 
Nutritional status 
and breath hydrogen 
test with lactose and 




breath test (HBT) as 
a marker of lactase 
activity, and 
lactulose HBT as a 
marker of SBBO 
Limão Verde and 
Córrego Seco, Mato 
Grosso du Sul, Brazil 
 
All children <10 yr 
old were recruited 






<5 yr old: n=145  
 
(However results 
were provided by 
<4 and >4 yr old 
age groups.) 
Breath Tests: 
• Lactose HBT 
(251 tested) 
• Lactulose HBT  
(252 tested) 
Lactose HBT: 
• Elevated: 27.1% among all 
subjects 
• Borderline: 43.0% among all 
subjects 
• 0% of subjects <4 yr had elevated 
or borderline results 
 
Lactulose HBT positive: 
• 11.5% of all subjects 
• 8.6% of subjects <4 yr 
The prevalence of 
lactase deficiency as 
measured by lactose 
HBT was >25%, but 
non-existent among 
those <4 yr of age. 
 
Prevalence of SBBO 
as assessed by 










Fagundes-Neto U et 
al. 
 
Studies of the small 
bowel surface by 
scanning electron 






and light microscope 
(LM) analyses of 
small intestinal 
biopsy among 
infants with PD with 
and without SBBO 
Sao Paulo, Brazil 
 
2-10 mo olds with 
PD and protein 
calorie malnutrition 
consecutively 




















68.7% had bacterial overgrowth 
(concentration >104 colonies/mL): 3 
had enteropathogenic E. coli while 
the rest had colonic microflora. 
 
All small intestine specimens had 
morphological abnormalities on LM: 
• 43.7% moderate villous atrophy 
• 56.3% subtotal villous atrophy  
 
SEM revealed abnormalities of 
varying intensity:  
• Among the 11 with SBBO, villous 
atrophy ranged from Grade II 
(n=4), Grade III (n=2), to Grade IV 
(n=3).  
• For the 5 subjects without SBBO, 
villous atrophy ranged from Grade 
I (n=1) to Grade 2 (n=4).  
• A mucous-fibrinoid pseudo-
membrane over enterocytes was 
noted in 7 of the 11 with SBBO 
and none of the others.  
 
• Other abnormalities noted on 
SEM included:  
• Mucus and debris covered large 
Histological 
abnormalities were 
noted in all subjects 
by LM and SEM.  
 
Degree of villous 
atrophy noted on 
SEM seemed to be 
correlated with 
SBBO (no statistical 







is consistent with a 
malabsorptive 
process, with the 
findings of fat 
droplets on 
enterocytes 
surfaces, and with 
the state of 






findings among all 







findings was not 
possible. 
 
Evidence Table 6. Markers of microbial drivers.  
Biomarkers in bold are primarily markers of microbial drivers.
Reference and 
Study Outcomes of  
Diagnostic Interest 
Location and  
Target Population 
Design and 
Sample Size Biomarker Results Conclusion Comments 
areas of the villous surface 
• Derangement of the enterocytes 
(in some cases cell borders were 
not clearly defined)  
• Reduced height and number (or 
absence in some places) of 
microvilli  
• Lymphocytes and fat droplets 
were observed over the surface of 
enterocytes (18%)1 
 
10 subjects had colitis on rectal 
biopsy; this was not associated with 
SBBO or degree of small intestinal 
pathology on SEM. 
2002 
 








Stool recovery of 
radiolabeled 
products as markers 
of lipid digestion and 
absorption, and bile 
salt deconjugation 
as a marker of 
SBBO among 




5-23 mo olds 
admitted to the 
Tropical Metabolism 
Research Unit of the 
University of the 








divided into 3 
groups of 8 
children, each 





collected in three 
separate phases 
as described 
above in JL 
Murphy et al. 
2001 [149]. 
Stool Tests: 
• Total and 
fractionated 13C 
following ingestion 





• 13C stool assay 
following 
administration of 
labeled fatty acid 
13C glycocholate**  
 
 
* To assess fat 
excretion as a % of 
dose administered. 
Also assessed 
proportion of 13C in 
triglyceride (TG) and 
fatty acid (FA) 
fractions to 
distinguish excretion 
Median total stool excretion of 13C in 
phase 1 was 9% (range: 1%-29%) 
and did not vary between TG 
groups.  
Median 13C excretion dropped 33%-
99% in phase 2 and 86%-95% in 
phase 3 compared to phase 1 
(p<0.05 each). 
 
Over the study period, there were 
significant associations between 
total lipid and the amount of 13C 
labeled TGs in stool for some 
groups, but not for others. 
 
Median 13C in TG and FA was 
similar across TG groups in all 
phases. 13C FA recovery was 
similar and reduced by ~2/3 
compared to Phase 1. 13C TG was 
not detectable in Phases 2 or 3. 
Statistical comparisons between 
phases were not reported.  
 
13C after radiolabeled glycocholate 
High concentrations 
of 13C (compared to 
healthy UK children) 
[190] were observed 
in half of the 
subjects at 
admission, reflecting 
impaired digestion or 
absorption.  
 
The differences in 
stool 13C were wide 
but not as extreme 
as in a previous 
study by same 
investigators (also 
examined in this 





13C excretion did not 
significantly differ 
between TG groups 
Authors state that 
the study was not 
powered to 
compare the 
different TGs, but 
they contend that 
medium chain 
trilaurin did not 
appear to be 
processed 
differently than the 




Authors did not 
describe the 
method used to 
assign subjects to 
different TG groups.  
 
While it was noted 
that some subjects 
had positive stool 
cultures, details 
                                                          
1 These SEM results were not presented separately for those with and without SBBO. 
Evidence Table 6. Markers of microbial drivers.  
Biomarkers in bold are primarily markers of microbial drivers.
Reference and 
Study Outcomes of  
Diagnostic Interest 
Location and  
Target Population 
Design and 
Sample Size Biomarker Results Conclusion Comments 
caused impaired 
digestion (presence 




** To assess bile salt 
deconjugation in the 
bowel caused by 
SBBO; conducted 
after the TG 
assessment and a 3 
day washout period. 
administration was detected in stool 
at quantities considered to be in 
excess of the 7% recovery of dose 
administered upper limit of normal in 
U.S. adults in [189]: 
• Phase 1: 13/24 (54%) 
• Phase 2: 5/24 (20.8%)  
• Phase 3: 3/24 (12.5%) 




Similar to their 
previous study, 
significantly more 
13C in stool was 
recovered as FA 
than TG, reflecting 
impaired absorption 
over poor lipid 
digestion/ hydrolysis. 
Unlike in their 
previous study, there 
was evidence of 
SBBO as measured 
post-ingestion of 13C 
glycocholate. 
were not provided 















Fecal fat, stool 
recovery of 
radiolabeled 
products, and breath 
tests as markers of 
lipid digestion and 
absorption and bile 
salt deconjugation 
as a marker of 
SBBO among 
children with severe 
Kingston, Jamaica 
 
7-23 mo olds with 
malnutrition admitted 
to the University of 







collected in three 
separate phases 
(each lasting 9 
days): 
• Within 48 hours 
of admission 
• During early 
rehabilitation 
• During late 
rehabilitation 
Stool Tests: 
• Fecal fat* 





















* In 72 hour stool 
Mean fecal fat (SD): 
• Phase 1: 2.4 g/day (3.6) or 5.9% 
(9.4) of dietary lipid intake 
• Phase 2: 1.7 (0.9) g/day, or 3.3% 
(2.4) of intake  
• Phase 3: 0.9 (0.6) g/day, or 1.4% 
(0.7) of intake 
• Differences between phases were 
not statistically significant. 
 
Total excretion of 13C in stool also 
varied widely across patients (0%-
44%) and did not differ between 
study phases.  
 
Correlation between fecal fat and 13C 
(r=0.48; p<0.05) was observed.  
 
Lack of lipid digestion and 
absorption were assessed by 
measuring TG and FA fractions, 
respectively. Mean 13C TG recovery 
(SD) (% of administered dose), 
number of patients excreting TG: 




[191, 192] during 
any study phase.  
 
There was wide 
variation in fecal fat 
at presentation, and 
wide variations in 
stool 13C across 
subjects. Authors 
indicate that this is 




studies on healthy 
children from the UK 
demonstrated 





inappropriate for a 
small sample. 
 





this might have 
affected GCA 
testing. 
Evidence Table 6. Markers of microbial drivers.  
Biomarkers in bold are primarily markers of microbial drivers.
Reference and 
Study Outcomes of  
Diagnostic Interest 
Location and  
Target Population 
Design and 
Sample Size Biomarker Results Conclusion Comments 
malnutrition collection (measured 
as total grams and as 
% of dietary fat 
intake). 
 
** To assess fat 
excretion as a % of 
dose administered. 
Also assessed 
proportion of 13C in 
triglyceride (TG) and 
fatty acid (FA) 
fractions to 
distinguish excretion 
caused by impaired 
digestion (presence 




*** To assess bile 
salt deconjugation in 
the bowel caused by 
SBBO; conducted 
after the TG 
assessment and a 3 
day washout period. 
 
**** Expressed as a 
percentage of 
absorbed label (dose 
administered - label 
recovered in stool) to 
assess oxidation for 
acute energy needs. 
• Phase 1: 0.7% (1.6), n=3 
• Phase 2: 0.9% (2.8), n=1  
• Phase 3: no recovery from any 
subjects, differences between 
phases were NS 
 
13C FA fraction in stool declined 
during rehabilitation. 
Mean 13C FA recovery (SD): 
• Phase 1: 6.0% (7.3)  
• Phase 2: 4.8% (3.7)  
• Phase 3: 3.3% (3.8),  
differences between phases were 
NS 
  
Mean FA values were ~9x (NS), 5x 
(p<0.001), and 3x (p<0.05) higher 
than mean TG values in Phases 1, 
2, and 3, respectively. 
  
Following administration of labeled 
TP, absorbed 13C label by breath 
analysis was ~5% (range 0%-21.2%) 
and similar across study phases.  
 
Following the administration of 
labeled GCA, there was either no or 
minimal recovery of 13C in stool and 
13CO2 on breath (as % of dose 
administered) in all phases. 
The majority of 
excreted 13C was in 
the form of FA rather 
than TG. Authors 
interpreted this to 
reflect failure of lipid 
absorption in the 
face of adequate 
digestion/hydrolysis. 
Each form (FA and 
TG) was found in 
decreasing values 





results did not differ 
significantly.  
 
Fecal fat was 
correlated with 
concentrations of 
13C in stool.  
There was no 
evidence of SBBO 





administration of 13C 





rather than oxidation 
for immediate 
energy needs. The 
authors report that 
this breath test has 
not been widely 
Evidence Table 6. Markers of microbial drivers.  
Biomarkers in bold are primarily markers of microbial drivers.
Reference and 
Study Outcomes of  
Diagnostic Interest 
Location and  
Target Population 
Design and 
Sample Size Biomarker Results Conclusion Comments 
used, but that 




[190], compared to a 
mean of 5% and 
range 0%-21% in 
this cohort; the latter 
findings were more 
similar to results 
from kwashiorkor 
patients where 13C-
labeled oleic acid 
was used as 
substrate [193]. 
Notes: Some studies included subjects ≥5 yr of age. Where these studies provided data separately for children <5 yr, we present results for only those subjects. 
Where these studies did not stratify results by age, but did report the number of children <5 yr included in the study, we provide a breakdown of under-5s. 
All studies reporting lactulose:rhamnose ratio results presented values multiplied by a factor of 100 for ease of reporting. 
 
Abbreviations: AD=acute diarrhea, ALT=alanine aminotransferase, AST=aspartate aminotransferase, CBC=complete blood count, CD=celiac disease, CI=95% confidence interval, 
Cr=creatinine, ∆=change in, EED=environmental enteric dysfunction, FTT=failure to thrive, GI=gastrointestinal, HAZ=height-for-age Z-(score), HDL=high density lipoproteins, 
HIV=human immunodeficiency virus, HLA=human leukocyte antigen, IEL=intraepithelial lymphocytes, IgA=immunoglobulin A, IgE=immunoglobulin E, IgG=immunoglobulin G, 
IgM=immunoglobulin M, IL=interleukin, IFN=interferon, LDL=low density lipoproteins, L:M=lactulose:mannitol ratio, mo=month(s), NS=not statistically significant, PD=persistent 
diarrhea, RCT=randomized controlled trial, SBBO=small bowel bacterial overgrowth, SD=standard deviation, SE=standard error, SES=socioeconomic status, Tc-99m=technetium 
99, T3=triiodothyronine, T4=thyroxine, TE=tropical enteropathy, TGF=transforming growth factor, TNF=tumor necrosis factor, TS=tropical sprue, WAZ=weight-for-age Z-(score), 
WBC=white blood cell count, WFA=weight-for-age, WHZ=weight-for-height Z-(score), wk=week(s), yr=year(s) 
 
 
Evidence Table 6. Markers of microbial drivers.  




5.7.1 Lactulose Hydrogen Breath Test (HBT) 
Alves et al. utilized the lactose hydrogen breath test (HBT) to measure of lactose absorption 
and the lactulose HBT as a measure of SBBO in a community-based study of indigenous children in 
Brazil [102]. Prevalence of SBBO in the study subjects was 12% among subjects below four years of 
age, and overall 9% had SBBO. The authors did not report on the relationship between lactulose and 
lactose absorption. 
In a study of intestinal function among well-nourished children with asymptomatic giardiasis 
and healthy controls in Mexico, Moya-Camarena et al. utilized the lactulose HBT and the indican test 
to exclude subjects with SBBO. No further data were reported on results of the lactulose HBT; 
therefore we did not include this study in this section of our review [147]. 
5.7.2 13CO2 in Breath or Stool after Administration of                       
13C Glycocholate as Marker for SBBO 
Murphy et al. [149] assessed gastrointestinal function by stool tests with [149] or without [148] 
breath tests in children hospitalized for rehabilitation of malnutrition. The 13CO2 breath test was 
performed after administering 13C glycocholate (GCA) to assess bile salt deconjugation in the bowel 
caused by SBBO. The test was conducted after a similar assessment with triglyceride and a 
subsequent 3-day washout period. Results were expressed as percent of administered dose. In their 
initial study, following the administration of labeled GCA, there was no or minimal recovery of 13C in 
stool and 13CO2 on breath in all study phases. The authors interpreted these results to indicate that 
the GCA was not malabsorbed and that the subjects did not show evidence of bile salt 
deconjugation. In the subsequent larger study, however, 13C from labeled GCA was recovered in the 
stool in more than one-third of the children, indicating the presence of SBBO [148].  
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5.7.3 Intestinal Aspirates for Bacterial Concentrations 
Fagundes-Neto et al. analyzed jejunal aspirates and small intestinal biopsies of hospitalized 
infants with persistent diarrhea and malnutrition by scanning electron microscopy (SEM) and light 
microscopy [118]. Based on bacterial concentration in jejunal aspirates, more than two-thirds of 
subjects had bacterial overgrowth (concentration >104 colonies/mL), and three were infected with 
enteropathogenic E. coli while the rest had colonic microflora in their small bowel. Histological 
abnormalities were noted in all subjects by light microscopy and SEM. The degree of villous atrophy 
noted on SEM seemed to correlate with SBBO, but statistical testing was not provided.  
Fagundes-Neto et al. also reported a mucous-fibrinoid pseudo-membrane that partially 
covered enterocytes [118]. They speculated that it could indicate a malabsorptive process, based on 
the findings of fat droplets on enterocyte surfaces and the malnourished condition of the subjects. 
Reporting of proportions of histopathologic findings among all subjects and by SBBO status, 
as well as statistical assessment of potential correlation with SBBO between different histologic 
findings, would have benefitted the analysis. 
5.8 Markers of Nonspecific Intestinal Injury 
The matter of small bowel biopsies and EED is complex. From initial investigations nearly five 
decades ago, the histopathologic appearance of the small bowel defined the entity. Sentinel papers 
from Southeast Asia and elsewhere formed the basis of our understanding of the entity on which we 
have focused in this review [274, 275]. Also, there is an extensive tradition of pathological 
assessments of the bowel and other organs in a variety of syndromes and diseases, and histological 
assessment is often considered the gold standard to which biomarkers are compared. Histology 
certainly can inform the nature of lesions. In the digestive system, microscopic evaluation of tissue 
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can often help differentiate infectious from noninfectious inflammations, assess the degree of allergic 
reaction if present, suggest the principal effector cells, and identify malignant potential (rare in these 
subjects). Specific diagnoses can also be made by histologic evaluation of the small bowel; well-
known examples are celiac disease and Crohn’s disease.  
In view of the potential value of relating biopsies to biomarkers, we sought to find any relation 
between this putatively definitive test (small bowel biopsy) and any laboratory test or abnormality. 
The data relevant to this review are listed for each of these 18 biopsy studies in Evidence Table 7. 
We also include other markers of non-specific intestinal injury in Evidence Table 7, including three 




Study Outcomes of  
Diagnostic Interest 
Location and  
Target Population 
Design and 
Sample Size Biomarker Results Conclusion Comments 
2009 
 





occurs in Zambian 
children with 






intestinal markers in 
children with PD and 




12.2-19.8 mo olds 
with PD and 
malnutrition 
admitted to the 
malnutrition ward of 





n=41 cases with 
PD and 
malnutrition:  
• 18 with 
marasmus 
• 8 with marasmic 
kwashiorkor 





from UK  
 
 
* UK subjects are 
presented in this 
table due to 
comparisons of 
interest made in 
the review. 
However we do not 
include these 
subjects in the 





• Densities in lamina 
propria and crypt 
epithelium: 
• Cell proteins:  
• Glycosaminoglyca
n (GAG) 




• Syndecan-1  
• Inflammatory cell 
markers: 
• CD3 IEL 
• Ki67 
• Human leukocyte 
antigen DR-1 (HLA-
DR) 
Biopsy findings among the 
Zambian compared to the UK 
children: 
• Villous height reduced 
• Crypt depth increased  
• ~50% reduction in crypt:villous 
ratio 
• Values for lamina propria cell 
densities were not reported for 
UK subjects 
 
No significant differences in crypt 
or villous measures or lamina 
propria cell densities were 
observed between nutritional 




• Inflammatory markers were 
seen in higher densities 
compared to the UK children. 
There were significant 
differences between the 
different nutritional groups in 
the specific types of 
inflammatory markers. 
• There was a significant 
reduction in GAGs and HSPG 
in the kwashiorkor group 
compared to UK children, but 
no significant differences 
between kwashiorkor and other 
presentations of malnutrition.  
• There was no difference in 
epithelial syndecan-1 protein 
expression between the 
malnutrition groups (data not 




compared to UK 










compared to UK 
children and 
showed different 












markers did not 
differ amongst the 
malnutrition groups. 
27 subjects were 
HIV positive; 
incidence was 








7-12 mo olds with 6-








• WBC (total and 
WBC total and differential, 
immunoglobulin subtypes, 
cytokines, transferrin, and 
albumin did not differ between 




The number of 
controls was 
relatively small and 
their nutritional 
Evidence Table 7. Markers of non-specific intestinal injury.  
Biomarkers in bold are primarily markers of non-specific intestinal injury.
Reference and 
Study Outcomes of  
Diagnostic Interest 
Location and  
Target Population 
Design and 
Sample Size Biomarker Results Conclusion Comments 
Immune response of 
Bangladeshi children 






tests, as well as 
transferrin and 
albumin as markers 
of nutritional status 
among children with 
and without PD 
diarrhea attending 
the International 
Centre for Diarrheal 
Disease Research.  
 
Cases were those 
who went on to 
develop PD, 
controls were those 
who did not.  
 
An additional group 
of subjects without 
diarrhea were 






high in all groups. 




• 85 with AD 








• Immune function tests: 
• Neutrophil polarization 
response to 
chemotactic factor 
• Neutrophil opsonization 
to yeast 
• Mononuclear cell 
proliferation, 
spontaneous and in 

















• Red blood cells 
cases with diarrhea or controls, 
nor did stool leukocyte or 
erythrocyte counts.  
 
The percentages of neutrophils 
that polarized in response to 
stimulation were significantly 
higher in subjects with AD or PD 
compared to those without 
diarrhea; there was no difference 
between the two diarrhea 
groups. 
 
Opsonization did not vary 
between any groups. 
 
Monocyte spontaneous 
proliferation counts were less 
than half among children with no 
diarrhea compared to those with 
AD (p<0.001) or with PD 
(p=0.011); there was no 
difference between the two 
diarrhea groups.  
 
Monocyte proliferation in 
response to stimulation did not 
differ between the 3 groups.  
 
The proportion with DTH 
responses differed among the 
three groups only in response to 
tuberculin (p=0.021). More PD 
subjects had a negative 
tuberculin response than did 








progression to PD 
was a negative 
DTH response to 
tuberculin antigen 
(odds ratio=3.8, CI: 
1.4, 9.9). This was 
calculated from a 
logistic regression 
analysis that only 
included children 
with diarrhea.  
 





Bhatnagar S et al. 
 
Celiac disease with 




1-18 yr olds with a 
presentation 









70 had normal histology (defined 
as crypt:villous ratio 1:2-3, 
absence of lymphoid lamina 
propria infiltration, and minimal 
intraepithelial lymphocytes (IEL). 
 
37 had mild changes (defined as 
More than one 





at follow-up their 
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Design and 
Sample Size Biomarker Results Conclusion Comments 
is a common cause 
of chronic diarrhea 
in Indian children 
 
Duodenal biopsy 













antibodies were of 
interest for this 
review. 
mild blunting of villi with 
crypt:villous ratio of 1:1*). A 
specific etiology was identified in 
only n=5: 
• 2 with giardiasis 
• 1 with lymphangiectasia 
• 2 with chronic pancreatitis 
 
Only children with CD had 
moderate or severe histologic 
changes. 
 
* Along with increased IEL and 
lymphocytic lamina propria 
infiltration. 
growth had 






reached for 86% of 
subjects with 
abnormal histology 




Bustos M et al. 
 
Disaccharidase 




Jejunal biopsy and 
disaccharidase 
activities in children 
with PD and different 




3-34 mo old 
Amerindians 
hospitalized with PD 
and moderate or 
severe malnutrition 
in an urban setting. 
Cohort 
 
n=42 cases with 
PD and 
malnutrition: 
• 2 with 
kwashiorkor 
• 20 with 
marasmus 







admission and at 





Jejunal tethered capsule 
biopsy: 
• Histopathology 






Histology was scored on a 
scale of 1 (normal) to 4 
(severe morphological 
damage or flat mucosa). 
Most subjects had mild to 
moderate (score of 2-3) 
histological abnormalities, with 
one kwashiorkor patient having 
completely flat villi.  
 
Second biopsy showed a trend 
of improved mucosa, but 
difference was not significant 
based on histology score, 
intraepithelial lymphocyte 
density, or degree of infiltration 
of lamina propria. 
 
Percentages with enzymatic 
activity below normal at baseline, 
discharge:  
• Lactase: 64%, 59% 
• Sucrase-isomaltase: 97%, 90% 
• Maltase: 45%, 52% 
All changes were statistically 
significant.  
 
Lactase recovery was 
associated with admission HAZ 










biopsy at admission 












activity were not 
provided. 
 




was not reported. 
Authors did not 
report whether they 
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Despite continued high 
disaccharidase deficiency 
prevalence at discharge, all 
children tolerated the lactose-
containing formula challenge. 
2003 
 












L:M as a marker of 
intestinal 
permeability, small 














Fajara and Sibanar, 
The Gambia 
 
6 mo-3 yr old 
hospital- and clinic-
based cases from 
rural communities. 
 
Case groups based 
on differences in 
nutritional status:  
1. WAZ score >-2, 
with GI complaints 
other than diarrhea  
2. Grade I protein 
energy malnutrition 
(PEM) (WAZ score -




with or without 
diarrhea 
3. Grade II PEM 
(WAZ score <-4) 
with or without 
diarrhea  
 
Controls from UK* 
who were well 
nourished children 
with GI complaints 
other than diarrhea 





• Group 1: n=4  
• Group 2: n=11 (7 
with diarrhea) 
• Group 3: n=25 
(18 with diarrhea) 
 






• Group 1: n=3 
• Group 2: n=8 
• Group 3: n=23 
Endoscopic 





computer analysis*  
• Intestinal tissue 
cytokines and immune 
markers:  





















* Biopsy involved 
morphometric assessment 
by computer analysis of 
Crypt-hyperplasia and villous 
atrophy were observed among 
all Gambian subjects, and the 
degree of histopathology did not 
differ among cases with differing 
nutritional status, nor was there 
a correlation with diarrhea. 
 
IEL2 means were ~3-fold higher 
in Gambian than UK children. 
 
Median CD3, CD4, CD8, CD19, 
and CD25 cell counts were 
significantly higher (2-5x higher) 
among each case group 
compared to the UK controls.  
 
IEL, γδ, syndecan-1, HLA-DR, 
and perforin were detected 
among the Gambian children in 
varying degrees but were not 
reported for UK controls. 
Syndecan, CD3, and CD8 
displayed a gradient proportional 
to malnutrition severity. 
 
All Gambian groups showed 
higher lamina propria cytokine-
immunoreactive mononuclear 
cell density (~200-450/mm2) than 
UK controls (30-80/mm2). 
 
Among subjects with elevated 
cytokines, similar densities were 






and villous atrophy, 
and mean IELs >2 
SD above UK 
norms, independent 








present across the 





L:M ratios were 
elevated in all 
Gambian groups, 
without apparent 








(e.g. type of central 
tendency measure 
and variance 
calculations for L:M 












and L:M results not 
stratified by history 
of diarrhea. 
                                                          
1 Lactulose and mannitol results were expressed as % of dose administered. 
2 These figures are presumed to represent IEL means, however, this was not explicitly stated. 
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were also studied. 
 
 
* UK subjects are 
presented in this 
table due to 
comparisons of 
interest made in the 
review. However we 
do not include these 
subjects in the 
sample size for this 
review. 
villous height, crypt depth, 
villous:crypt ratio, and 
intraepithelial lymphocyte 
(IEL) density (per 100 
epithelial cells). 
(IFN-γ and TNF-α) and putative 
regulatory (IL-10 and TGF-β) 
cytokines. Epithelial expression 
of TGF-β was also enhanced 
compared to UK controls, but 
subjects with poorer nutritional 
status had lower densities of 
mucosal TGF-β+ cells, with 
median densities of 420 and 250 
cells/mm2 in the grade I and 
grade II PEM groups, 
respectively. 
 
L:M values1:  
• Group 1: 0.53 (0.4-1.3)  
• Group 2: 0.47 (0.02-2.20) 
• Group 3: 0.73 (0.14-2.2) 
• Not assessed among the UK 
controls 
 
Nutritional status was not 
associated with L:M, recoveries 
of lactulose or mannitol.  
 
L:M was correlated with mucosal 
B lymphocyte density (r=0.57, 
p<0.05), IEL (r=0.51, p<0.02), 




El Mouzan MI et al. 
 
Endoscopic 










1.5 mo-18 yr olds 
referred to hospital 
for endoscopy with 
duodenal biopsy. 
 
78% of subjects 
were <12 yr old; 
results not 





• 102 with PD 
• 116 with 
unexplained 
short stature  
• 11 with refractory 
rickets 




• Gross endoscopic 
visualization 
• Histopathology 
14% had abnormalities on 
endoscopic visualization: 
• 1% had esophagitis 
• 6% had gastritis, 7 (47%) of 
which were H. pylori positive 
• 7% had duodenitis 
 
Biopsy results: 
• PD:  
• 26% normal 
• 29% chronic non-specific 
duodenitis 
Villous atrophy was 
identified not only 
among 40% of 
children with PD, 
but also among 
22%, 9%, and 17% 
of those with short 




Authors argue that 
Specific results for 





For 27% of cases, 
the only 
histopathology 
finding was chronic 
non-specific 
duodenitis; the 
                                                          
1 Not clearly indicated if these figures represent mean (CI) or another measure of central tendency. 
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(including 2 with 
protein losing 
enteropathy) 
• 40% villous atrophy 
• 5% other* 
 
• Short stature: 
• 56% normal 
• 22% chronic non-specific 
duodenitis 
• 22% villous atrophy 
 
• Rickets: 
• 55% normal 
• 36% chronic non-specific 
duodenitis 
• 9% villous atrophy 
 
• Other: 
• 25% normal 
• 50% chronic non-specific 
duodenitis 
• 17% villous atrophy 
• 8% other* 
 
* 3 lymphangiectasia, 2 Giardia, 
1 Mycobacterium avium 
intracellulare. Findings were 
reported according to presenting 
symptoms. 
endoscopic biopsy 
is superior to “blind” 
capsule biopsy in 
developing country 
settings and allows 
for visualization of 




were not reported 
by condition nor in 
relation to 
histopathology 
results; it is difficult 
to assess the value 









Fagundes-Neto U et 
al. 
 
Studies of the small 








and light microscope 
(LM) analyses of 
Sao Paulo, Brazil 
 
2-10 mo olds with 
PD and protein 
calorie malnutrition 
consecutively 











Jejunal tethered capsule 
biopsy: 




Rectal tethered capsule 
biopsy: 
Histopathology 
68.7% had bacterial overgrowth 
(concentration >104 
colonies/mL): 3 had 
enteropathogenic E. coli while 
the rest had colonic microflora. 
 
All small intestine specimens 
had morphological abnormalities 
on LM: 
• 43.7% moderate villous 
atrophy 
• 56.3% subtotal villous atrophy  
 
SEM revealed abnormalities of 
varying intensity:  
• Among the 11 with SBBO, 
Histological 
abnormalities were 
noted in all subjects 
by LM and SEM.  
 
Degree of villous 
atrophy noted on 













findings among all 







findings was not 
possible. 
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small intestinal 
biopsy among 
infants with PD with 
and without SBBO 
villous atrophy ranged from 
Grade II (n=4), Grade III (n=2), 
to Grade IV (n=3).  
• For the 5 subjects without 
SBBO, villous atrophy ranged 
from Grade I (n=1) to Grade 2 
(n=4).  
• A mucous-fibrinoid pseudo-
membrane over enterocytes 
was noted in 7 of the 11 with 
SBBO and none of the others.  
 
Other abnormalities noted on 
SEM included:  
• Mucus and debris covered 
large areas of the villous 
surface 
• Derangement of the 
enterocytes (in some cases cell 
borders were not clearly 
defined)  
• Reduced height and number 
(or absence in some places) of 
microvilli  
• Lymphocytes and fat droplets 
were observed over the 
surface of enterocytes (18%)1 
 
10 subjects had colitis on rectal 
biopsy; this was not associated 
with SBBO or degree of small 




consistent with a 
malabsorptive 
process, with the 
findings of fat 
droplets on 
enterocytes 
surfaces, and with 
the state of 












6 mo-13 yr olds with 
acute, persistent or 
chronic diarrhea, 
and/or malnutrition 





Jejunal capsule biopsy: 
Histopathology 
30/31 (96.8%) had abnormal 
histopathology: 
• Suggesting non-specific 
inflammatory abnormalities in 
27 (87.1%) subjects. 
• Demonstrating grade 3 
mucosal abnormalities in all 
malnourished 1 yr olds 





some degree of 
abnormality on 
jejunal biopsy. 
Biopsies of interest 




the 27 children with 
non-specific 
inflammation were 
                                                          
1 These SEM results were not presented separately for those with and without SBBO. 
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diarrhea and 








service of a 
university hospital 







antibodies were of 
interest for this 
review. 







Hafeez A et al. 
 






among children with 




2 mo-12 yr olds 
referred from 
various hospitals to 
KRL Hospital 
Islamabad for 
abdominal pain, PD, 
short stature, FTT, 
GI bleeding, or 
anemia. The 
subjects of interest 
for this review were 





• 28 with PD 
• 9 with FTT 









Positive histopathologic findings 
were identified in:  
• 21/28 with PD  
• 7/9 with FTT 
• 3/4 with short stature 
 
More abnormalities were found 
via histology than visualization, 
and findings did not necessarily 
correlate. 
75% of the PD and 











endoscopy, due to 
lack of correlation 





There was possible 
bias in the manner 
of selection for 
endoscopy. 14 
biopsies were 
unable to be 
analyzed (from 100 
endoscopies). 
 
Authors did not 
report the 
endoscopic 








patients), not by 
condition or by 
patient, so specific 
results could not be 
interpreted in 












Occult blood  
 
Fecal occult blood test was 
positive in 30/50 (60%) cases 
and 0/30 controls.  
A high proportion of 
severely 
malnourished 
Among cases, half 
had a presenting 
complaint of 
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Fecal occult blood 














recruited from an 
immunization clinic. 
 









Among cases positive for fecal 
occult blood, 20 (66.7%) were 




• Parasitic infections were 
detected in 14/50 (28%) of 
cases, 12 (85.7%) of whom 
tested positive for fecal occult 
blood.  
• Bacterial infections were 
detected in 18/50 (36%) of 
cases, 13 (72.2%) of whom 
tested positive for fecal occult 
blood. 
• Of the remaining 18 for whom 
an enteric pathogen was not 
identified, 5 (27.8%) tested 
positive for fecal blood. 
 
Among the 30 cases with fecal 
occult blood, 16 were breastfed, 
11 were fed cow’s milk, and 3 
were fed formula. 
children had a 
positive fecal occult 
blood test, 
compared with no 
positives among 











of those without an 
identifiable 
pathogen also 
tested positive.  
 
Presence of fecal 
blood did not 
appear to vary by 
feeding mode (e.g. 
breast milk, cow’s 





not specified), but 
the authors did not 
report results 
stratified by 
diarrhea duration.  
 
Authors did not 
provide differences 
in proportions of 
occult blood among 





was not provided; 





was not defined. 
2002  
 




by Tc-99m dextran 




scintigraphy as a 
marker of protein-
New Delhi, India 
 











n=3 <5 yr old 
Tc-99m dextran 
scintigraphy 
Abnormal Tc-99m dextran 
uptake was positive in one child 
found to have subtotal villous 
atrophy on biopsy and another 
thought to have abdominal 
tuberculosis. 
  
The child with the negative scan 
had marasmus and partial villous 
atrophy on biopsy. 
 
Scintigraphy might 





This pilot study had 
a small sample 
size of 8 children, 
and only 3 were 
younger than 5 
years. 
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antibodies in the 
diagnosis of celiac 
disease in children: 











symptoms of CD 
(not specified).  
 
Subjects of interest 
for this review were 
those who tested 
negative for CD-
specific serology 
and who did not 
meet the study 
diagnostic criteria 
for CD--subtotal or 
total villous atrophy 
consistent with 
Marsh stages 3 or 4. 
 
Controls were aged 









Of 99 subjects not meeting 
diagnostic criteria for CD, 
endoscopic biopsies revealed: 
• 76 had normal morphology of 
the intestinal mucosa 
• 7 had elevated densities of 
intraepithelial lymphocytes  
• 10 had partial villous atrophy 
(Marsh stage 2)  
• 6 had various other conditions 
such as giardiasis or gastritis 
Among 169 
children with 
symptoms of CD, 
41% had subtotal 
or total villous 




findings, and 45% 
had normal 
biopsies. 
Article in French. 
 
Prevalence of CD 
antibodies did not 
clearly align with 
case/control 
designation. 
Because of the 
way the results 
were reported, we 
could not extract 
data on those who 
tested negative for 
CD-specific 
serology and who 
had Marsh stages 






while results and 
conclusion sections 
















Sao Paulo, Brazil 
 
5 mo-12 yr old 
(median 24 mo) 
HIV-infected 
subjects recruited 
from a hospital and 
clinic. 
 
All subjects had 







n=5 patients with 
current or recent 
episode of diarrhea  
 
n=6 patients with 
no diarrhea in the 








Biopsy of small intestine 
by tethered capsule or 
endoscopy: 
Histopathology 




100% had low D-xylose 
absorption: 
• Mean: 15.6 mg/dL 
• SD: 5 
• Range: 8.9-24.4 
• Median: 14.2  
 
Small intestinal biopsy:  
• 100% had some degree of 
villous atrophy based on a I-IV 
grading system: 
• Grade I: 3 
• Grade I/II: 2  






of diarrhea status.  
 
All patients also 
had cellular 
infiltration of the 
lamina propria and 
varying degrees of 
Portuguese 
language article.  
 
D-xylose <25 
mg/dL was defined 
as indicative of 
malabsorption. 
This value is higher 
than what some 
references have 
noted as a cut-
point [186].  
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Small intestinal and 
rectal biopsy to 
assess morphology 







• Grade II: 1 
• Grade II/III: 1 
• Grade III/IV: 1 
• 2 samples were too 
superficial to assess 
• Intraepithelial lymphocytes 
were increased in half of the 
biopsies. 
• Lymphocytic and 
polymorphonuclear (PMN) 
infiltration of the lamina 
propria were present in 10/10 




• 100% had normal architecture 
• Lymphocytic and PMN 
infiltration were present in 6/6 
and 4/6, respectively. 
villous atrophy. 
 
There was no 
correlation between 
D-xylose and 
degree of villous 
atrophy on biopsy. 
Investigators used 
a well-articulated 
system of grading 
villous atrophy.  
 
Results were not 
presented by 
diarrhea status, 
perhaps due to 
small sample size. 
2005 
 
Lima AA et al. 
 
Intestinal barrier 
function and weight 






L:M as a marker of 
intestinal 
permeability and 
various stool tests 
among children with 
malnutrition or PD 
who received either 
glycine or glutamine 
Fortaleza, Brazil 
 
2-60 mo olds 
hospitalized with 
WAZ score <-2, 









• 27 with glycine 












• Lactoferrin  
• Leukocytes  
• Occult blood 




* n=80 tested at 
enrollment, n=65 tested at 
day 10. 
 
** n=60 tested. 
Mean2 L:M (SE):  
• Glutamine group: 
• Baseline: 0.31 (0.10) 
(similar in all three groups) 
• Day 10: 0.10 (0.02); 
significant decrease, 
(p=0.01) 
• No significant decrease in L:M 
in glycine and 
nonsupplemented formula 
groups at day 10 
 
Mean lactulose (SE):  
• Glutamine group: 
• Baseline: 0.97 (0.46) 
(similar in all three groups) 













RS, and occult 
blood were 





markers and L:M 
was not reported.  
 
Data were not 
stratified by history 
of PD. 
 
Fecal fat was 
assessed, but 
results were not 
reported. 
 






                                                          
1 Lactulose and mannitol results were expressed as % of dose administered. 
2 Type of mean not specified. 
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supplemented 
formula or placebo 
Mean mannitol (SE):  
• Glutamine group: 
• Baseline: 3.42 (0.64) 
(similar in all three groups) 
• Day 10: NS decrease in all 
3 groups 
 
Proportion of stool markers at 
baseline among all subjects:  
• Lactoferrin: 53.3% 
• Leukocytes: 11.7% 
• RS: 3.3% 















with chronic diarrhea 
 
Duodenal biopsy 






1-5 yr olds with PD 
selected randomly 
from an outpatient 
population in a 
urban setting. 
 
A high proportion of 
the children had 

















7 (23.3%) had grossly abnormal 
endoscopic findings: 
• 5 (16.7%) with chronic 
duodenitis  
• 1 with duodenitis with multiple 
erosions  
• 1 with duodenitis with 
hemorrhagic gastritis  
 
22 (73.3%) had abnormal 
histopathology: 
1. 17 (56.7%) with villous atrophy 
with mononuclear cell 
infiltration  
• 1 (3.3%) with villous atrophy 
and eosinophilic infiltration  
• 2 (6.7%) with villous atrophy 
and mononuclear and 
eosinophilic infiltration 
• 2 (6.7%) with only 
mononuclear cell infiltration 
 
Mean duration of diarrhea (SD) 
was not associated with gross 
endoscopic findings but did vary 
by histopathology: 
• Normal histopathology: 9.0 wk 
(6.0), n=8 
• Mononuclear cell infiltration: 











More than half had 
villous atrophy with 
mononuclear cell 
infiltration; these 
patients had >1 
month longer 
duration of diarrhea 












not associated with 








Number of patients 




infiltration was very 
small (n=2), yet 
authors report a 
significant 
difference in their 
duration of diarrhea 
relative to those 
with normal 
histopathology. 
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• Villous atrophy with 
mononuclear cell infiltration: 
14.9 wk (5.3), n=17, p<0.02 
compared to normal 
histopathology 
• Villous atrophy with 
mononuclear and eosinophilic 
infiltration: 21.5 wk (2.1), n=2, 
p<0.02 compared to normal 
histopathology 
• Villous atrophy with 
eosinophilic infiltration: 6.0 wk, 
n=1 
 
No consistent pattern was 
observed between gross 
endoscopic findings or 
histopathological lesions and 
age, WFA, or type of 







Mittal SK et al. 
 
Tropical sprue in 
north Indian children 
 
D-xylose and 
duodenal biopsy as 






0-15 yr old 
gastroenterology 







xylose test, and 
clinical response to 
antibiotics were 
diagnosed as 









(38 with repeat 
biopsies) 
 












• D-xylose*  
 
 
* Not specified whether 
from urine or serum, and 
units of measurement not 
provided. 
36 (38.3%) were diagnosed with 
TS including 14/44 (31.8%) who 
were under 5 years of age.  
 
18 (19.1%) were diagnosed with 
CD.  
 
Degree of villous atrophy among 
TS vs. CD patients:  
• Mild in 8/36 (22.2%) vs. 0 
• Moderate in 23/36 (63.9%) vs. 
4/18 (22.2%) 
• Severe in 5/36 (13.9%) vs. 
14/18 (77.8%)  
 
Mean hemoglobin concentration 
(range) among TS patients was 
8.3 g/dL (5.5-11) and did not 
differ from values of those with 
CD.  
 
Among the 22 TS patients, 
More than half of 
the GI clinic 
patients with PD 
had some degree 
of villous atrophy.  
 
More than one-third 
and almost one-fifth 
of subjects were 




By study diagnostic 
definition, all TS 
patients improved 
with treatment.  





Biopsy results were 
not provided for 
patients without TS 
or CD.  
 
It was unclear if 
there were patients 
with abnormal D-
xylose and 
histology who did 
not respond to 
antibiotic therapy 
and therefore were 
not diagnosed with 
TS. 
 
Cut-off points used 
to define abnormal 
D-xylose tests 
were not provided. 
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free diet were 
diagnosed with CD. 
We include data on 
these subjects for 
comparative 
reasons. 
repeat biopsies showed: 
• 16 with normalization 
• 5 with improvement  
• 1 worsened despite marked 
clinical improvement  
 
The D-xylose test was abnormal 




23% had partial 







Nichols B et al. 
 
Contribution of 
villous atrophy to 
reduced intestinal 











maltase and villous 
atrophy and other 
mucosal intestinal 
markers indicative of 




Sao Paulo, Brazil 
 
Cases were children 
(mean age 9.9 mo, 
SD 8.1) hospitalized 
with malnutrition 




children (mean age 
3.6 mo, SD 1.0) with 
HAZ and WAZ 
scores >-2 and 
normal intestinal 
mucosa on biopsy, 
hospitalized for 
Kasai procedure for 







n=24 cases  
 




matched on height 





Jejunal capsule biopsy: 
• Histopathology* 
• Maltase activity  







• Villin, a structural 
protein expressed 





(SGLT), a functional 
protein expressed 




* Mucosal atrophy was 
scored on a scale of 1 
(absence of atrophy 
compared to an organ 
donor) to 4 (similar to 
children with active CD). 
 
Histology among controls 
was on surgically resected 
tissue.  
 
Mean villous atrophy score (SD): 
• Cases: 2.6 (0.8) 
• Controls: 1.2 (0.5), p=0.006) 
 
WAZ score was correlated with 
villous atrophy (r=0.65, p- value 
not reported).  
 
13/25 [sic] cases and 0/5 
controls had subnormal (defined 
as <94 U/g protein) of maltase 
activity; mean maltase was 34% 
lower among cases (p=0.11). 
Maltase activity did not appear to 
decrease with WAZ score 
(further details not provided). 
 
However, in sub-analyses 
among those samples with an 
adequate β-actin, a 
housekeeping gene message, 
(n=10 cases, n=9 controls), 
cases’ findings expressed as a 
mean percent of controls' (SD) 
included: 
• Villous length (reciprocal of 
atrophy score): 38.9 (41.6), 
p=0.004 
• Maltase activity: 37.1 (23.2), 
p=0.001 
• MGA mRNA: 45.1 (36.4), 
p=0.016 









Among the subset 
tested for mRNA 
messages, maltase 
activity as well as 
the mRNA 
abundances for 




case status and 
were correlated 
with villous atrophy. 
 
While maltase 
deficiency has been 
reported in 
malnutrition in other 
studies, authors 
assert that these 
are the first results 
that directly support 
the hypothesis that 
reductions in 
maltase activity are 
due to villous 













they mocked up ex 
vivo mucosal 
biopsies in these 
controls, resections 




compared to cases’ 
samples derived 
from mucosal 
biopsies. While this 
probably doesn’t 







will bring in more 
diverse populations 
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• SGLT mRNA: 66.6 (23.1), 
p=0.057 
• β-actin: 88.2 (15.8), p=0.189 
 
Both villous length and maltase 
activity in a subset of cases were 
less than 40% of control values.  
 
MGA, villin, and SGLT mRNA 
abundances were correlated with 
villous atrophy score (r=0.73), 
(r=0.76), and (r=0.54), 
respectively (p-values not 
reported)1.  
 
MGA mRNA abundance was 








with function.  
 
 
of cells; only some 
of them might have 
transcripts of 
interest. However, 
the bias is likely in 
a direction that 
would reduce effect 
size. 
 
It was unclear if 
control inclusion 
criteria included 
absence of atrophy 





might not have 
adequately taken 
into account the 




Subsets of subjects 
were investigated 
for various tests. 
For example, 10 
cases had mRNA 
analyses based on 
β-actin adequacy. 
Another instance of 
selected testing 
was the subset of 
22 and 15 cases 
that had WAZ 




                                                          
1 Villin and SGLT1 were assessed as a ratio with housekeeper gene β-actin. 
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analysis of small 











intestine biopsy in 
subjects with PD 
Porto Alegre, Brazil 
 
6 mo-5 yr old 
inpatients from an 
urban setting who 
underwent biopsy 
as part of a work-up 
for PD. 
 
There was a high 
proportion of 
children with 






Small intestinal biopsies, 
site and method not 
specified*:  
• Mucosal morphometric 
assessment by computer 
analysis (62 tested):  
• Villous height 
• Crypt depth  
• Villous:crypt ratio 
• Mucosal thickness 
• Digital assessment (500x 
magnification) (65 
tested): 
• Enterocyte height  
• Enterocyte nucleus 
height 
• Brush border 
height  
• Stereological analysis 
to assess mucosal 
surface area (62 tested) 
 
 
* From stored specimens 
previously assessed by 
micrometer. 
Computerized mucosal 
measures were similar to those 
by micrometer and were not 
associated with nutritional status. 
 
Digitally assessed enterocyte 
height, enterocyte brush border, 
and enterocyte nucleus height 
correlations:  
• WAZ score: r=0.25 (p=0.038), 
r=0.26 (p=0.03), and r=0.24, 
(p=0.05), respectively  
• WHZ score: r=0.29 (p=0.02), 
r=0.27 (p=0.03), and r=0.16 
(p=0.19), respectively 
• HAZ score: r=0.16 (0.18), 
r=0.23 (p=0.06), r=0.23 (0.06)  
 
There was no correlation 
between mucosal surface area 




with WAZ and WHZ 





were not correlated 












best for diagnosing 






<14 yr (mean age 
6.9 yr) presenting 
with symptoms 
consistent with CD 




for CD were of 




• 22 with giardiasis  
• 1 with TS 




Duodenal biopsy of those with 
giardiasis showed nonspecific 
chronic inflammation of lamina 
propria; there was no evidence 







Authors did not 
report the biopsy 
findings in the TS 
or SBBO patients. 
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Duodenal biopsies in 
controls with 





Poddar U et al. 
 
Celiac disease in 
India: Are they true 




xylose, and fecal fat 
in children with 
symptoms of CD but 
normal mucosal 
biopsy results  
Chandigarh, India 
 
18 mo-14 yr olds 
with PD, FTT, or 






ratio on biopsy were 
















* In 72-hour stool 
collection. 
 
** Not specified whether 
from urine or serum, and 




38% had chronic inflammatory 
cell infiltrates in the lamina 
propria.  
 
55% had abnormal D-xylose 
concentrations. 
 
20% had abnormal fecal fat test. 
 
No results beyond proportion 
positive were reported for any of 






biopsy, more than 
one-third had PD. 
 
D-xylose and fecal 
fat might not 




between fecal fat, 
D-xylose and 
biopsy results were 
not reported. 
 
While 38% of 
controls had PD, 
results for the 
markers studied 
were not stratified 
by PD for this 
group.  
 
Seven children with 
biopsies consistent 
with CD did not 
respond to gluten-
free diet and were 
excluded from the 
study.  
 
Cut-off points used 
to define abnormal 
D-xylose tests 




Sherwani K et al. 
 
Prevalence of iron 
deficiency anemia in 
chronic diarrhoea 
and celiac disease - 
A western UP 
experience 
 
Duodenal biopsy in 
Aligarh, India  
 
1-12 yr olds (mean 
age 51.2 mo) from 
an urban setting 
with PD recruited 
from pediatric 
outpatient and 
inpatient units.  
 
Those with negative 





Duodenal biopsy, method 
not specified: 
Histopathology 
Six patients had partial villous 
atrophy and non-specific 





of patients who did 
not have CD, but 
did not identify PD 
etiology in the 
remainder who did 
not have CD. 
The 6 children with 
partial villous 
atrophy were 
thought to have 





Evidence Table 7. Markers of non-specific intestinal injury.  
Biomarkers in bold are primarily markers of non-specific intestinal injury.
Reference and 
Study Outcomes of  
Diagnostic Interest 
Location and  
Target Population 
Design and 
Sample Size Biomarker Results Conclusion Comments 
patients with PD  subjects of interest 
for this review. 
2003 
 
Tassara O et al. 
 
Gastrointestinal 
diseases in children 










0-12 yr old (median 
9 mo) HIV-infected 
children treated in 
hospital. A high 







upper GI biopsy including 
esophagus, stomach, 
and/or duodenum: 






changes were observed on 
endoscopy in the esophagus, 
stomach or duodenum in 2 
subjects.  
 
Biopsies of esophagus, stomach 
or duodenum showed 
inflammatory changes of varying 













in the digestive 
system were not 










Notes: Some studies included subjects ≥5 yr of age. Where these studies provided data separately for children <5 yr, we present results for only those subjects. 
Where these studies did not stratify results by age, but did report the number of children <5 yr included in the study, we provide a breakdown of under-5s. 
All studies reporting lactulose:rhamnose ratio results presented values multiplied by a factor of 100 for ease of reporting. 
 
Abbreviations: AD=acute diarrhea, ALT=alanine aminotransferase, AST=aspartate aminotransferase, CBC=complete blood count, CD=celiac disease, CI=95% confidence interval, 
Cr=creatinine, ∆=change in, EED=environmental enteric dysfunction, FTT=failure to thrive, GI=gastrointestinal, HAZ=height-for-age Z-(score), HDL=high density lipoproteins, 
HIV=human immunodeficiency virus, HLA=human leukocyte antigen, IEL=intraepithelial lymphocytes, IgA=immunoglobulin A, IgE=immunoglobulin E, IgG=immunoglobulin G, 
IgM=immunoglobulin M, IL=interleukin, IFN=interferon, LDL=low density lipoproteins, L:M=lactulose:mannitol ratio, mo=month(s), NS=not statistically significant, PD=persistent 
diarrhea, RCT=randomized controlled trial, SBBO=small bowel bacterial overgrowth, SD=standard deviation, SE=standard error, SES=socioeconomic status, Tc-99m=technetium 
99, T3=triiodothyronine, T4=thyroxine, TE=tropical enteropathy, TGF=transforming growth factor, TNF=tumor necrosis factor, TS=tropical sprue, WAZ=weight-for-age Z-(score), 
WBC=white blood cell count, WFA=weight-for-age, WHZ=weight-for-height Z-(score), wk=week(s), yr=year(s) 
 
 
Evidence Table 7. Markers of non-specific intestinal injury.  
Biomarkers in bold are primarily markers of non-specific intestinal injury.
Our findings indicate a profound lack of enteric histologic data on pediatric populations in 
resource-limited settings. Specifically, only 18 of the 77 studies that we reviewed contained any 
biopsy materials, and only three of these 18 publications also included any non-intestinal tissue 
candidate biomarkers [111, 136, 155]. Furthermore, only two [111, 136] of these three studies 
attempted to statistically relate the less invasive, non-intestinal markers to histologic findings; 
the only significant association reported was between L:M and intestinal tissue inflammation on 
histopathology. Moreover, only 718 subjects aged 0-18 years were represented among the 18 
biopsy studies. Ages were mixed in many studies, such that it was impossible to discern which 
subjects were in the age range of maximal interest in this review (i.e., under five years of age), 
and indications for the biopsies were quite diffuse (e.g., diarrhea, poorly specified abdominal 
symptoms). Therefore, the subject population and data availability were suboptimal for the 
purposes of this review. In addition, none of the studies that included biopsies related the 
findings to the outcome of most considerable interest, i.e., stunting. 
Prospectively collected small bowel biopsies may provide useful data, guide biomarker 
development and validation, and reveal information about the cause(s) and pathophysiology of 
EED. Appropriate conditions are necessary for biopsy studies to be illuminating. For example, 
the context in which subjects and controls are selected is vital. Regarding cases, a rigorous 
clinical case definition must be established that defines growth faltering and minimal extent of 
intestinal functional abnormalities. Exclusion criteria should also be established for disorders 
that might mimic EED, such as celiac disease or inflammatory bowel disease. The pathology 
associated with these disorders, however, could inform biomarker association with intestinal 
dysfunction not specific to, but nevertheless relevant to and sensitive for EED. Such markers 
could be part of a set of markers used to diagnose EED. However, the usefulness of a biopsy to 
guide biomarker development and validation depends on several factors. Ideally, the lesion 
should be from treatment-naïve hosts; this does bring up an ethical dilemma, however. For 
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example, placement of a patient on gluten free diet, even briefly, or treating a patient with 
possible inflammatory bowel disease, prior to biopsies can obscure findings and render the 
histopathologic evaluation less valuable. Second, biopsies obtained under protocol must take 
into account the distribution of the lesion, so as to confirm the negative predictive value of any 
set of biopsies. Two disorders provide some guidance in this realm. For celiac disease, the 
lesion is surprisingly non-uniform [276-279], and multiple biopsies must be sought to avoid beta 
error. A similar situation applies to gastric biopsies for Helicobacter pylori detection [280-286]. A 
comparison group is also necessary, and to date, most “normal” or “control” tissues were from 
children in developed country settings. Hence, the abnormalities noted in children’s biopsies 
cannot be attributed to the disease process (enteropathy), or its consequences (stunting, most 
particularly), rather than to residence in an area in which such disorders are common. In other 
words, biopsy association with disease is, based on the available literature, no more strong than 
EED association with geography. 
A case could be made that biopsies are part of a routine evaluation of a child with failure 
to thrive, and a recent publication from North America suggests that this diagnostic modality is 
commonly employed in the evaluation of stunting disorders [287]. However, the precise 
diagnostic yield of a biopsy is not stated in this publication, nor are the data weighted by the 
symptoms or the age of the children. At this time, it remains uncertain how generalizable the 
utility of these recommendations is in settings where EED is common. 
The safety of a biopsy also needs to be considered in pondering the value of tissue 
assessment, or of biomarker discovery or validation. If a biopsy is obtained as part of an 
evaluation of poor growth, then the small risk of the biopsy usually is less than the potential 
benefit. However, this calculus assumes that substantial pre-procedure and post-procedure care 
is available to mitigate the likelihood of complications. The use of anesthesia in inpatient or 
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outpatient settings is safe, but should conform to the highest grade of safety [288]. An additional 
concern is that endoscopy of the duodenum carries a risk of causing intramural hematomas, 
estimated at 0.08% of upper endoscopic procedures in the United States [289, 290]. This 
complication results in small bowel obstruction, severe pain, and Ampulla of Vater obstruction 
and requires management involving prolonged hospitalization and total parenteral nutrition 
and/or or naso-enteral feeds. Coagulopathies such as von Willebrand Disease, other platelet 
disorders, and vitamin K deficiency (the risk of which is increased in chronic diarrhea and 
malabsorption) [291, 292] are thought to contribute to approximately half of endoscopy-related 
duodenal hematomas [289, 290, 293-307]. Among von Willebrand Disease variants, only severe 
(type 3) disease can be readily identified by available screening tests (prothrombin time) 
although such assessments can be used to pre-endoscopically identify treatment-responsive 
vitamin D deficiency. 
If biopsies are obtained as part of a research protocol to identify markers that predict 
clinically consequential EED (and even if biopsies are only used for clinical care), it is necessary 
to assemble a panel of individuals whose tissues are evaluated in parallel, but who do not have 
the most consequential of the complications of putative enteropathy, namely, stunting 
(assuming this remains the outcome of greatest concern). It would not be possible to recruit 
healthy control children for biopsies, because the procedure would offer limited benefit—
especially in relation to potential harm. However, some surrogate controls might arise as 
adventitiously obtained tissue becomes available either during operations or other endoscopic 
procedures, and the use of small bowel obtained at time of portoenterostomy is a particularly 
inspired choice [53].  
Caveats must be attached to any histologic assessment of the guts in children being 
evaluated for enteropathy as part of a care plan. It is very unlikely that intestinal biopsies would 
261
be used as a diagnostic procedure at the beginning of an evaluation for malnutrition or poor 
growth. More likely, it would be a procedure of last resort, after less invasive evaluation failed to 
establish an etiology, and after attempts at nutritional and intestinal rehabilitation are undertaken 
and prove unsuccessful. However, as noted above, the empiric treatment of consequential 
intestinal dysfunction might change the pathology, and thereby diminish the diagnostic value of 
the procedure. Also, if biopsies are obtained, and subjected to analysis, it is critical that the 
materials be handled in a systematic manner, and processed per protocol, so as to maximize 
the data that they generate.  
In summary, there is no evidence to date that biopsies have been used to define the 
entity of childhood EED, because inadequate controls have been studied (children without 
evidence of functional impairment of gut function living in the same environment). There is no 
evidence that the biopsies relate to the outcome of greatest concern, namely, stunting. The data 
obtained from biopsies could be falsely normal, because of attempts at intestinal rehabilitation 
that will presumably precede the endoscopy. This negative assessment does not mean that 
biopsies are without worth, only that their value as providing case-defining information, or 
guiding biomarker discovery or validation, has yet to be made. However, if biopsies are 
obtained, it is critical that they be performed in a rigorous, disciplined and ethical manner, and 
that the data to be obtained are maximized.  
5.9 Markers of Extra-Small Intestinal Function 
We included markers of non-small intestinal organ function as these might provide 
important indirect assessments of precursors to or resultants of small intestinal injury. We 
reviewed those markers that were examined among children with presentations potentially 
consistent with enteropathy, such as persistent diarrhea, or were examined in relationship to 
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markers of intestinal inflammation or dysfunction. The data relevant to this review are listed for 
each of these studies in Evidence Table 8. 
263
Reference and 
Study Outcomes of  
Diagnostic Interest 
Location and  
Target Population 
Design and 
Sample Size Biomarker Results Conclusion Comments 
2010 
 
Bukhari AS et al. 
 













levels of DNA 
damage among 




3-6 yr olds admitted 
to hospital with PD 
















• Total protein 
• Total cholesterol, 
HDL, LDL, 
triglycerides 
• AST, ALT 
• T3, T4 
• Total oxidant status 
(TOS), Total anti-




DNA damage to 
lymphocytes 
Mean values significantly higher 






• DNA damage 
 
Mean values significantly lower 
among PD cases than in healthy 
controls:  












speculate that zinc 
deficiency, more 
commonly found in 






play an important 
role in mediating 
DNA damage. 
Control recruitment 
strategy was not 
well described. 
 






differed by gender 
in both the case 
and control groups:  
• Triglycerides 
• Total cholesterol 
• HDL 









Fagundes-Neto U et 
al. 
 
Studies of the small 
bowel surface by 
scanning electron 






and light microscope 
(LM) analyses of 
small intestinal 
biopsy among 
infants with PD with 
and without SBBO 
Sao Paulo, Brazil 
 
2-10 mo olds with 
PD and protein 
calorie malnutrition 
consecutively 






















68.7% had bacterial overgrowth 
(concentration >104 colonies/mL): 3 
had enteropathogenic E. coli while 
the rest had colonic microflora. 
 
All small intestine specimens had 
morphological abnormalities on LM: 
• 43.7% moderate villous atrophy 
• 56.3% subtotal villous atrophy  
 
SEM revealed abnormalities of 
varying intensity:  
• Among the 11 with SBBO, villous 
atrophy ranged from Grade II 
(n=4), Grade III (n=2), to Grade IV 
(n=3).  
• For the 5 subjects without SBBO, 
villous atrophy ranged from Grade 
I (n=1) to Grade 2 (n=4).  
• A mucous-fibrinoid pseudo-
Histological 
abnormalities were 
noted in all subjects 
by LM and SEM.  
 
Degree of villous 
atrophy noted on 
SEM seemed to be 
correlated with 
SBBO (no statistical 














findings among all 







findings was not 
possible. 
Evidence Table 8. Markers of extra-small intestinal function.  
Biomarkers in bold are primarily markers of extra-small-intestinal function.
Reference and 
Study Outcomes of  
Diagnostic Interest 
Location and  
Target Population 
Design and 
Sample Size Biomarker Results Conclusion Comments 
membrane over enterocytes was 
noted in 7 of the 11 with SBBO 
and none of the others.  
 
Other abnormalities noted on SEM 
included:  
• Mucus and debris covered large 
areas of the villous surface 
• Derangement of the enterocytes 
(in some cases cell borders were 
not clearly defined)  
• Reduced height and number (or 
absence in some places) of 
microvilli  
• Lymphocytes and fat droplets 
were observed over the surface of 
enterocytes (18%)1 
 
10 subjects had colitis on rectal 
biopsy; this was not associated with 
SBBO or degree of small intestinal 
pathology on SEM. 
process, with the 
findings of fat 
droplets on 
enterocytes 
surfaces, and with 
the state of 




Galpin L et al. 
 
Effect of 
Lactobacillus GG on 
intestinal integrity in 
Malawian children at 
risk of tropical 
enteropathy 
 
L:M and sucrose: 
lactulose ratio 
(SUC:L) as markers 
of intestinal and 
gastric permeability, 
respectively, in 
Mwenye, Malawi  
 
36-60 mo olds 
recruited from a rural 
community, 
excluding children 






considered at risk for 
EED due to 
residence in a 
location with high 





















• Sucrose (SUC) 




• 73% had L:M >0.10  
• 40% had L:M >0.20 
• Mean3 L:M (SD): 
• Treatment: 0.18 (0.16) 
• Placebo: 0.22 (0.20)  
• Mean lactulose (SD) in treatment 
group: 0.25 (0.17) 
• Mean mannitol (SD) in treatment 
group: 8.0 (4.5)  
• Mean SUC:L (SD):  
• Treatment: 0.58 (0.64)  
• Placebo: 0.60 (0.64) 
 
Mean excretion of sucrose (SD) 
increased from 0.057 (0.042) to 
0.078 (0.058) in the treatment group 
A high baseline 
prevalence of 
abnormal L:M was 





excretion (relative to 
UK norms) drove 
the abnormal L:M. 
 
There was little 
effect on SUC:L with 
intervention; 
sucrose excretion 
increased in both 
Difficult to interpret 
sucrose tests 
because there are 
limited data on 
laboratory values 
for these tests in 
young children. 
                                                          
1 These SEM results were not presented separately for those with and without SBBO. 
2 Lactulose, mannitol, and sucrose results were expressed as % of dose administered. 
3 Arithmetic mean. 
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asymptomatic 
children presumed at 
risk of EED 
Presumed that if 
SBBO is etiology for 
EED, treatment with 
Lactobacillus will 
result in improved 
gut integrity. 
Lactobacillus GG 
or placebo. Only 
the 161 subjects 
who completed 
the study had 
repeat testing. 
(p=0.01), but similar results were 
observed in the placebo group. 
Otherwise there were no changes in 
lactulose, mannitol, L:M, or SUC:L 
















Small intestinal and 
rectal biopsy to 
assess morphology 





Sao Paulo, Brazil 
 
5 mo-12 yr old 
(median 24 mo) HIV-
infected subjects 
recruited from a 
hospital and clinic. 
 
All subjects had 







n=5 patients with 




n=6 patients with 









Biopsy of small 
intestine by tethered 
capsule or endoscopy: 
Histopathology 






100% had low D-xylose absorption: 
• Mean: 15.6 mg/dL 
• SD: 5 
• Range: 8.9-24.4 
• Median: 14.2  
 
Small intestinal biopsy:  
• 100% had some degree of villous 
atrophy based on a I-IV grading 
system: 
• Grade I: 3 
• Grade I/II: 2  
• Grade II: 1 
• Grade II/III: 1 
• Grade III/IV: 1 
• 2 samples were too superficial 
to assess 
• Intraepithelial lymphocytes were 
increased in half of the biopsies. 
• Lymphocytic and 
polymorphonuclear (PMN) 
infiltration of the lamina propria 




• 100% had normal architecture 
Lymphocytic and PMN infiltration 
were present in 6/6 and 4/6, 
respectively. 






of diarrhea status.  
 
All patients also had 
cellular infiltration of 
the lamina propria 
and varying degrees 
of villous atrophy. 
 
There was no 
correlation between 
D-xylose and 
degree of villous 
atrophy on biopsy. 
Portuguese 
language article.  
 
D-xylose <25 
mg/dL was defined 
as indicative of 
malabsorption. This 
value is higher than 
what some 
references have 





system of grading 
villous atrophy.  
 
Results were not 
presented by 
diarrhea status, 
perhaps due to 
small sample size. 
2003 
 
Tassara O et al. 
 
Gastrointestinal 
diseases in children 
infected with the 
Santiago, Chile 
 
0-12 yr old (median 
9 mo) HIV-infected 
children treated in 
hospital. A high 










• Gross endoscopic 
visualization 
Macroscopic inflammatory changes 
were observed on endoscopy in the 
esophagus, stomach or duodenum 
in 2 subjects.  
 
Biopsies of esophagus, stomach or 
duodenum showed inflammatory 
Biopsy results might 
show inflammatory 
damage in cases 







in the digestive 
system were not 
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• Histopathology changes of varying degree in all 11 
subjects. 

















trial of rifaximin, a 
nonabsorbable 
antibiotic, in the 













rifaximin or placebo 
Limela, Malawi 
 
All 3-5 yr olds from 













It was presumed 
that if SBBO is 









• Sucrose (SUC) 
• Sucralose (SCL) 




ratio (SCL:L)  
 
 
Subjects were tested 
before and after 
treatment. 
At enrollment: 
• Mean mannitol (SD):  
• Treatment: 9.57 (5.24)  
• Placebo: 10.29 (6.62) 
• Mean lactulose (SD): 
• Treatment: 0.30 (0.18) 
• Placebo: 0.34 (0.25) 
• Mean SUC (SD):  
• Treatment: 0.062 (0.04)  
• Placebo: 0.074 (0.058) 
• Mean SCL (SD):  
• Treatment: 0.51 (0.29)  
• Placebo: 0.58 (0.53) 
• Mean L:M (SD): 
• Treatment: 0.18 (0.12) 
• Placebo: 0.17 (0.09) 
• Mean SUC:L (SD): 
• Treatment: 0.50 (0.34) 
• Placebo: 0.64 (0.90) 
• Mean SCL:L (SD): 
• Treatment: 0.42 (0.32) 
• Placebo: 0.39 (0.23) 
• For both groups combined:  
• 76% had L:M >0.10 
• 34% had L:M >0.20 
 
No significant post- intervention 
differences were observed in any 
fractional sugar excretion or dual 
sugar test, including among children 
There was a high 
proportion with 
elevated L:M which 





this study resembled 






SCL excretion in this 
population was 
similar to that found 
in healthy American 
children (0.4%), 
while SCL:L was 
comparatively lower 
(0.8) and driven by 
lactulose [210]. 
SCL:L might be a 
better marker of 
colonic permeability 
[211-213]. Results 






and testing, in 
particular for SCL 
excretion, might 
account for some 
differences in 
values compared to 
other studies.  
 
This was the first 
use of SCL for site-
specific absorption 
testing in a 
developing country 
setting. 
                                                          
1 Lactulose, mannitol, SUC, and SCL results were expressed as % of dose administered. 
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Sample Size Biomarker Results Conclusion Comments 
with elevated pre-intervention L:M. permeability was 
normal. 
  
Few data exist on 
SUC excretion. 
Results in this trial 
are similar to those 
found in another 
Malawian population 
(0.06% SUC 
excretion) [120] and 





0.03%) [210, 212]. 
Notes: Some studies included subjects ≥5 yr of age. Where these studies provided data separately for children <5 yr, we present results for only those subjects. Where these 
studies did not stratify results by age, but did report the number of children <5 yr included in the study, we provide a breakdown of under-5s. 
All studies reporting lactulose:rhamnose ratio results presented values multiplied by a factor of 100 for ease of reporting.  
 
Abbreviations: AD=acute diarrhea, ALT=alanine aminotransferase, AST=aspartate aminotransferase, CBC=complete blood count, CD=celiac disease, CI=95% confidence interval, 
Cr=creatinine, ∆=change in, EED=environmental enteric dysfunction, FTT=failure to thrive, GI=gastrointestinal, HAZ=height-for-age Z-(score), HDL=high density lipoproteins, 
HIV=human immunodeficiency virus, HLA=human leukocyte antigen, IEL=intraepithelial lymphocytes, IgA=immunoglobulin A, IgE=immunoglobulin E, IgG=immunoglobulin G, 
IgM=immunoglobulin M, IL=interleukin, IFN=interferon, LDL=low density lipoproteins, L:M=lactulose:mannitol ratio, mo=month(s), NS=not statistically significant, PD=persistent 
diarrhea, RCT=randomized controlled trial, SBBO=small bowel bacterial overgrowth, SD=standard deviation, SE=standard error, SES=socioeconomic status, Tc-99m=technetium 
99, T3=triiodothyronine, T4=thyroxine, TE=tropical enteropathy, TGF=transforming growth factor, TNF=tumor necrosis factor, TS=tropical sprue, WAZ=weight-for-age Z-(score), 
WBC=white blood cell count, WFA=weight-for-age, WHZ=weight-for-height Z-(score), wk=week(s), yr=year(s) 
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One study assessed markers of liver and thyroid function among hospitalized persistent 
diarrhea cases and healthy controls [107]. These authors found that thyroid hormones were 
significantly lower in children with diarrhea than in controls. Liver tests showed associations in 
conflicting directions.  
The remaining five studies examined tests related to segments of the gastrointestinal 
tract outside of the small bowel [13, 118, 120, 136, 167]. Three of these performed endoscopy 
and/or biopsy on the esophagus, stomach, and/or rectum [118, 136, 167]. In a study of 11 HIV-
infected malnourished children rectal biopsy tissue uniformly demonstrated normal architecture, 
but increased lymphocytic and neutrophilic infiltration. Duodenal biopsies were also infiltrated 
with these cells but all subjects had additionally some degree of abnormal architecture [136]. 
Another case series found macroscopic inflammatory changes in 18% of endoscopies and 
100% of biopsies of the upper gastrointestinal tract in eight children with HIV infection, many of 
whom had persistent diarrhea [167]. However, the investigators did not report whether these 
findings were identified in the esophagus, stomach and/or duodenum. A third study in this 
category found that nearly two-thirds of subjects had evidence of colitis based on rectal biopsy; 
this was not associated with small bowel bacterial overgrowth or degree of small intestinal 
pathology observed by scanning electron microscope [118].  
Tests of small intestinal permeability have been described in a previous section (5.3), 
but certain dual-sugar permeability tests are more specific for evaluating colonic or gastric 
function. These markers include urinary sucrose, urinary sucralose, the urinary 
sucrose:lactulose ratio (SUC:L), and the urinary sucralose:lactulose ratio (SCL:L). Sucrose 
excretion and sucrose:lactulose (SUC:L) were components of a panel of urinary excretion tests 
that comprised the clinical endpoints as measures of gastric permeability for two community-
based intervention studies, one of which additionally tested sucralose excretion and 
sucralose:lactulose (SCL:L) as measures of colonic permeability. The first of these studies was 
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a randomized, controlled trial of Lactobacillus GG [120]. The mean excretion of sucrose 
increased in the treatment group following treatment, but similar results were observed in the 
placebo group. Following the intervention, there was no change in the mean SUC:L in either 
group. The second of these studies was a randomized, controlled trial that assessed L:M, 
SUC:L, and SCL:L responses to treatment with rifaximin, a nonabsorbable antibiotic. The 
investigators hypothesized that if small bowel bacterial overgrowth played an etiologic role in 
enteropathy, treatment with the antibiotic would result in improvements in measurements of 
permeability [13]. Sucralose excretion in this population was similar to that found in healthy 
American children while SCL:L was comparatively lower and driven by lactulose [210]. These 
results were similar to those found in another Malawian population [120] in where excretion 
values were 2-3 fold greater than those excreted by healthy older children from developed 
countries [210, 212]. No significant post-intervention differences were observed for any of these 
markers. The authors asserted that this was the first use of sucralose for site-specific absorption 
testing in a developing country setting. Few data exist on sucrose excretion, but overall values 
for sucrose excretion were similar across the two studies.  
5.10 Relationships between Markers of EED, 
Including Histopathology 
Biomarkers provide, by definition, “read-outs” or values that are related to one or more 
host processes. Here we review inter-marker relationships, independent of host outcomes 
(which are reviewed below).  
Only four studies included assessments of “noninvasive” biomarkers (i.e., those not 
requiring the introduction of an endoscope or tube into the small bowel (e.g., for visualization, to 
obtain duodenal fluid or biopsy tissue) as well as intestinal histopathology [111, 136, 155]; only 
two of these studies compared histopathology to less invasive markers. Leite et al. assessed 
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the relationship of D-xylose and the degree of villous blunting and found no association [136]. 
Campbell et al. found that L:M was associated with various findings on scanning electronic 
microscopy (SEM) and was correlated with mucosal B lymphocyte density, intraepithelial 
lymphocyte (IEL) density, and the presence of perforin-positive IELs [111].  
An additional three studies compared endoscopic visualization or markers in intestinal 
tissue obtained by biopsy to standard light microscopic histopathology [53, 118, 126]. Neither 
endoscopic [126] nor SEM [118] findings were associated with histopathology on light 
microscopy. However, intestinal maltase activity, as well as intestinal mRNA abundances for 
maltase-glucoamylase and the enterocyte-specific proteins villin and sodium-activated luminal 
glucose-galactose transporter 1, were correlated with villous atrophy [53]. 
Twelve studies [15, 43, 58, 110, 123-125, 132, 149, 151, 158, 159] compared 15 
different non-intestinal tissue markers to each other. Four of these studies assessed serum L:R 
to other markers and found relationships with sucrose breath values [159], serum lactose [58], 
urinary nitrites [43], and urinary L:R [125], but did not demonstrate associations with stool 
reducing substances [58] or serum red blood cell markers [58]. Three other studies assessed 
urinary L:M to other markers and found no associations with fecal neopterin [15], urinary lactose 
or lactose:lactulose [124], or a variety of systemic immune/inflammatory markers including AGP, 
total IgG, albumin, and hemoglobin [123]. However, one additional study did find that L:M was 
associated with not only total serum IgM and IgA levels, but also IgG [110]. This study also 
found a correlation between L:M values and IgG endotoxin core antibody concentrations, and 
additionally found urinary lactulose excretion to correlate with circulating IgG endotoxin core 
antibody and endotoxin concentrations. Other studies found that urinary lactose:creatinine was 
inversely related to hemoglobin [151] and that fecal lactoferrin was related to TNF-α receptor I 
[132]. Others found no relationship between urinary nitrite and stool reducing substances [43] or 
between sucrose breath test and hemoglobin or C-reactive protein [159].  
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5.11 Relationships between EED Biomarkers and 
Growth or Other Outcomes of Interest  
We sought to find biomarkers of processes relevant to consequential outcomes in the 
host. In the context of EED, the outcome of greatest proximate interest is growth failure, 
specifically linear growth failure, but other potential injuries (e.g., persistent diarrhea) and distal 
consequences (e.g., delayed cognitive development) were also considered.  
Eight studies attempted to associate various markers with persistent diarrhea, six of 
which found such an association. In five of the six studies, these were systemic markers such 
as serum proteins or indices of serum white or red blood cells [106, 107, 142, 166, 308]. A sixth 
study found that concentrations of immunoglobulin in duodenal aspirates were associated with 
persistent diarrhea among children infected with Giardia [128]. A study of mannose-binding 
lectin (MBL) found that while a deficiency of the marker was associated with cryptosporidiosis, 
MBL concentrations were not significantly associated with either duration of diarrhea or 
persistent diarrhea [130]. While the eighth study did assess for hemoglobin association with 
persistent diarrhea, it was not clear from the reporting of their multivariate results if there was an 
association [114].  
Fourteen studies [101, 103, 111, 113, 117, 121, 126, 131-133, 138, 154, 155, 167] 
included subjects with and without persistent diarrhea but did not statistically assess 
relationships between markers and this outcome, although five of these studies [101, 103, 117, 
126, 155] did present data stratified by the outcome of persistent diarrhea. 
While acute diarrhea is not a cardinal EED symptom, we included it as an outcome of 
interest when looking at studies that sought its association with biomarkers of enteric 
dysfunction. Our rationale was that intestinal damage or pathophysiology resulting from acute 
enteric processes might still provide meaningful insights into the utility of various markers in 
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representing pathologic gut processes. Eight studies [43, 58, 116, 124, 125, 159, 166, 308] 
investigated the relationship between markers and acute diarrhea. It should be noted that some 
of these studies included children with persistent diarrhea, but did not stratify results according 
to acute or persistent presentations; we include all of these studies under the heading “acute 
diarrhea”. Most of these studies found associations between acute diarrhea and the markers 
investigated. One of these studies [125] found a relationship between acute diarrhea and both 
urinary and serum L:R while another [58], a study limited to serum L:R testing, found 
associations between diarrhea and serum L:R and lactulose. However, Goto et al. [124] did not 
find an association between the L:M ratio and acute diarrhea.  
Studies also found associations between acute diarrhea and other tests specific for 
intestinal function, such as the sucrose breath test [159], and fecal fat [116]. Association was 
also observed for two markers of innate immunity, neutrophil polarization in response to a 
chemotactic factor and monocyte spontaneous proliferation assays [104], as well as nitric oxide 
production [43]. While one study found associations between acute diarrhea and various red 
blood cell parameters [166], another [104] found a lack of association between acute diarrhea 
and other systemic markers such as white blood cells, transferrin, serum albumin, cytokines, 
and immunoglobulin subtypes.  
Sixteen [15, 101, 108, 121, 130-134, 136, 140, 152, 158, 162, 168, 172] studies had 
subjects with and without acute diarrhea but did not statistically analyze the relationship 
between markers and acute diarrhea, although three [101, 152, 162] presented data stratified by 
acute diarrhea status. In two studies [101, 162], a high proportion of those with acute diarrhea 
were lactoferrin positive. One of these studies [101] also found that a low proportion of cases 
with acute diarrhea were positive for stool IL-8, but all of the individuals positive for stool IL-8 
had acute diarrhea. The study [152] utilizing the D-xylose test found that of the eight children 
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with abnormal results, one had diarrhea and of 19 children with diarrhea, only one had an 
abnormal result for D-xylose.  
Thirteen studies included children with symptomatic or clinically silent giardiasis [15, 
105, 116, 117, 122-124, 128, 133, 137, 147, 150, 154]; diagnostic methods to identify Giardia 
varied between microscopy and antigen testing. Seven of these studies investigated the 
relationship between markers and giardiasis [15, 116, 123, 124, 128, 147, 150] and five found 
an association between at least one marker and the infection [116, 123, 124, 128, 147], 
although the studies commonly reported associations between one biomarker and not others. 
Some studies found serum total IgG and AGP [123], and lactose hydrogen breath test results 
[147] were significantly higher in asymptomatic, Giardia-infected children than in uninfected 
controls. Significantly higher mean concentrations of total IgM were found in duodenal aspirates 
of Giardia cases with persistent diarrhea compared to controls without diarrhea [128]. In a study 
that included subjects with and without diarrhea, giardiasis was associated with the presence of 
fecal fat, and this association held across four testing methods [116]. In contrast, a study of a 
fecal marker of inflammation, neopterin, did not find an association with Giardia infection [15]. 
The relationship between Giardia infection and a urinary marker of intestinal permeability 
differed across studies. While Goto et al. found an association between giardiasis and mean 
urinary L:M value in one study [124], they did not find this association in a subsequently 
published study [123]. Campbell et al. did not find an association between Giardia infection and 
urinary L:M [15], and another report found that urinary L:M was not consistently associated with 
giardiasis [150]. The relationship between circulating markers and Giardia infection varied by 
marker; specifically, an association was observed between infection and serum albumin but not 
hemoglobin concentrations [123]. Six studies [105, 117, 122, 133, 137, 154] that included both 
infected and uninfected subjects did not statistically investigate the relationship between Giardia 
infection and these markers, although two [105, 117] of these studies did present data stratified 
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by infection status and a third [154] provided a general description of the histopathology in 
infected subjects. These three studies investigated cases with intestinal symptoms consistent 
with celiac disease and referred for duodenal biopsy. Among the children that were not 
diagnosed as having celiac disease, the studies reported widely varying percentages of subjects 
with Giardia infection: 0.8% [117], 5.4% [105], and 78.6% [154].  
Eight studies presented data on children with asymptomatic and/or symptomatic 
cryptosporidiosis. Five of these [101, 130-132, 172] tested the association of Cryptosporidium 
infection with various markers, three of which were conducted in Haiti by the same group [130-
132]. Fecal lactoferrin [101, 132] serum mannose-binding lectin deficiency [130], and mean 
urinary L:M [172] were associated with cryptosporidiosis. A sixth study tested longitudinally 
collected stools of Brazilian children for Cryptosporidium and presented the results for the 
children with infection, finding that stool lactoferrin was strongly associated with symptomatic 
infection in children with C. parvum but not C. hominis [108].  
In the three cryptosporidiosis studies that included testing for various fecal cytokines, 
results were mixed. For example, two studies found no association between infection and IL-8 
[101, 131], IL-4 [131], or IL-10 [131], while associations were identified with each of these 
cytokines, as well as with IL-13, in one of the studies from Haiti [132]. One of the studies from 
Haiti found an association between fecal IFN-γ and control status rather than among those with 
Cryptosporidium infection [131], while the other did not detect IFN-γ in the stools of any subjects 
[132].  
In two additional studies of subjects with and without Cryptosporidium infection, 
abnormal D-xylose results were found more often among infected children [152], while fecal 
lactoferrin did not appear to be related to infection status based on the numbers reported in the 
study, although statistical testing of the relationship was not described [162].  
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Sixteen studies assessed the association of markers of intestinal function with nutritional 
status outcomes [15, 43, 53, 108-112, 122-124, 139, 145, 150, 151, 153]. The anthropometric 
assessments used in these investigations varied, and the results for given measures were 
mixed. We describe the results of the eight studies that measured the relationship between L:M 
and anthropometrics above (see Table 15) [15, 110-112, 122-124, 150].  
Urinary lactose:creatinine [151], stool neopterin [15], and intestinal lactase activity [109] 
were associated with all anthropometric indices investigated while stool lactoferrin [108] and 
intestinal maltase activity were not [53]. Results for urinary nitric oxide and WAZ correlation 
were of borderline statistical significance (effect ratio 0.88, p=0.05) [43].  
Four studies examined the association between histopathology and growth parameters 
[53, 111, 145, 153]; two studies identified no relationship between weight-for-age measures 
[111, 145], while one reported that WAZ score was correlated with degree of villous atrophy 
[53]. Examination of tissue by digital morphometry in another study produced ambiguous results 
[153]. One of these studies also examined the relationship of weight-for-age with endoscopic 
visualization of the intestine and found no association [145]. Campbell et al. found varying 
results when assessing the relationship of different intestinal tissue cytokines and immune 




Chapter 6. Conclusions and Future 
Implications 
6.1 Summary of Findings 
The 77 references from the years 2000 to 2010 provide a robust body of knowledge on 
biomarkers and diagnostic tests that could be useful in the quest to identify EED pathology, 
especially actionable EED, the entity most in need of identification to mitigate its long-term and 
life-threatening consequences. 
Markers of permeability were the most frequently utilized biomarkers in the studies that 
we reviewed and the urinary L:M test was the most common of those measures. Lactoferrin, as 
well as other stool markers of intestinal inflammation, were also frequently assessed. Marker 
results varied greatly in terms of indicating the presence of intestinal dysfunction and degree of 
dysfunction when positive. This is not unexpected given the diverse populations that were 
studied, including different settings and subject presentations (e.g., asymptomatic children as 
well as those with various symptoms). In 20 of the 25 studies using the L:M test, the 
permeability ratio was noted to be elevated. As mentioned in the L:M section in Chapter 5, 
interpretation and comparison across studies in this review were hampered by variations in the 
way data were reported. 
6.2 Future Biomarker and Diagnostics Research 
This analysis was a comprehensive attempt to identify the most promising biomarkers or 
diagnostic tests on which to base future efforts and analyses of EED. Our review found many 
different biomarkers, across a wide range of diagnostic categories that have been deployed to 
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assess enteric function in children in resource-poor settings. However, regrettably, the extant 
literature does not permit us to recommend a specific technology or biomarker that can be used 
as a standard for the diagnosis of EED. There are many reasons for this difficulty: 
1. The “tests” and the studies in which they were used were not developed with a 
biomarker concept in mind. The assays were performed chiefly to corroborate 
processes and were related to various host characteristics, but the relation to gut 
dysfunction was inferred without validation. While the preponderance of tests 
reported plausibly relate to gut dysfunction, their association with this particular 
pathophysiology was not proven. 
2. The disorder of interest is poorly defined. It is clear that there is considerable and 
convergent evidence of abnormal digestive systems in the population of interest 
(children in low-income settings), and that there is an outcome (i.e., stunting) that is 
conceivably related to dysfunction of the gut, but the link has not been made 
conclusively. 
3. Histopathological evidence of gut inflammation, which has been considered to prove 
the presence of EED, is an elusive gold standard (see discussion below on small 
bowel biopsies). Only two studies related histopathology to specific extra-intestinal 
markers. The L:M was found to correlate with intestinal inflammatory cell infiltration 
[111], while D-xylose was not associated with degree of villous atrophy [136]. 
Moreover, there is no evidence that histopathology is related to the ultimate outcome 
of interest, namely stunting, or other consequential host injury such as vaccine failure 
or increased susceptibility to infections. 
4. The data presented in the publications that we analyzed often did not reflect high-
grade subject reporting. For example, we often encountered data reported only in 
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terms of p-values and lacking reporting of effect sizes. In the field of randomized 
controlled trials, adherence to Consolidated Standards of Reporting Trials 
(CONSORT) Statement guidelines [309, 310] has improved the quality of clinical 
trials [311-313]. The effect of the non-systematic reporting of data in the biomarker 
field is that populations are not well described, methodology is not always 
discernible, and statistical tests are not completely described. The data that result 
might either obscure, or overstate, the value of the tests being assessed. We 
applaud efforts to standardize the quality of reporting of tests and biomarkers [314]. 
5. More data were certainly available than were reported. For example, there is value to 
the separate and simultaneous reporting of the lactulose and mannitol clearances, 
but such values were often not provided. Some studies reported a biomarker as 
significantly associated with an outcome of interest or correlated with another 
marker. However, often they did not mention whether other outcomes or biomarkers 
examined in the study were related to the biomarker of interest, leaving the reader 
unsure of whether these relationships were assessed at all or if only select (e.g., 
positive) findings were reported. Correlation analyses between the tests employed in 
the study were rarely reported. The publications that we reviewed did not report 
utilization of supplementary data deposition resources (e.g., supplementary or web-
linked tables). However, such on-line registries for meta-data have only recently 
been made widely available by journals, better enabling capacity for all data to be 
fully utilized to answer questions that may not have been primary to the published 
study. 
6. The biomarker studies that we analyzed, in the main, were often research project-
driven. They were rarely scrutinized in the context of modern test-development 
standards. Many potential aspects critical to the clinical usefulness of a test, and to 
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the interpretation of the reported data, were not addressed. These include matters 
pertaining to the following: specimen transport, physical condition of the specimen 
(e.g., water content of stool), specimen processing prior to assay performance, 
temperature sensitivity, dynamic range of the test result, inhibitors (or molecules that 
could cause false positives) in the analyte, durability of the assays, inter-laboratory 
variability, biologic perturbations in specimens that often contain bacteria (stool and 
possibly urine), and assessments of the distribution of values in normal groups. An 
additional concern is that the target biomarker is presumed to be stable in the body 
fluid assayed, but this is rarely documented. We would encourage the broader use of 
spiking experiments, whereby the target molecule is added to the specimen of 
interest, and, ideally, recovered quantitatively. These study design, subject 
characterization, laboratory and analyte specification, and analysis and reporting 
considerations should be well addressed in future biomarker development work. 
The multitude of test methods and procedures utilized, the disparate nature of the 
studies, and the limited testing for correlation with outcomes of interest (e.g., clinical signs of 
EED, histopathology or other markers of EED, or clinical outcomes of EED, such as stunting,) 
restrict our ability to declare any markers as clear lead candidates that warrant major or 
exclusive investment in the next phase of EED biomarker research.   
It is important to note that our analysis was focused only on literature produced during 
the last eleven years. We acknowledge that it is possible that additional information could be 
extracted from studies published during prior years. In fact, we identified more references that 
were potentially relevant to our review question from the period 1990-1999 than for the period 
2000-2010. However, a review of 10 randomly selected articles published between 1990-1999 
and relevant to our review question (Appendix 3) did not add significant information compared to 
the 77 more recent publications included in the systematic review. Also, the aforementioned 
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structural issues in the reporting of the data in the studies from the 11-year period used in this 
systematic review (e.g., small sample sizes, study design and reporting issues) were also 
evident in the earlier studies. Moreover, even though EED research was more prevalent in the 
1970s and 1980s, secular trends in nutritional, socioeconomic, and disease conditions, as well 
as laboratory, epidemiologic, and biostatistical method improvements as well as potential shifts 
in etiologies raise concerns about data comparability across large intervals of time.  
It is quite likely that combinations of complementary markers might be required for 
different purposes. For instance, specific growth measures are used for population screening 
(e.g., height-for-age Z-scores to identify prevalence of stunting within given populations), and 
differ from those used for individual clinical management (i.e., growth monitoring). Another 
paradigm might be to use a highly sensitive screen for enteropathy, followed by more specific 
reflexive testing. An example in clinical medicine would be HIV screening followed by protein 
immunoblot (Western blot) assay for specific antigenic reactivity. The situation might, however, 
be more complicated for EED, as there is unlikely to be a unifactorial process or driver. Ideally, 
forthcoming research will identify a marker or markers that can serve related but differing 
functions. The marker or set of markers might also vary according to the function desired. For 
EED, we foresee multiple potential points of testing. First, in an individual, a biomarker could be 
used to detect early pathologic or functional changes, at an actionable stage before stunting and 
its consequences ensue. Second, a biomarker could be used to monitor clinical 
progression/recovery to determine intervention effectiveness. Third, a biomarker could be used 
to measure population prevalence to determine those populations where focused attention 
could mitigate morbidity and mortality from enteropathy and stunting.  
It is possible that a marker of end-pathway processes common to non-EED forms of 
enteropathy will have more utility than EED-specific biomarkers. However, we wish to note that 
the “re-purposing” of biomarkers of other enteropathies will not result in an EED-specific marker. 
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This issue would be most relevant if there is geographic overlap between EED and other 
enteropathies of childhood, most notably celiac disease, as might be the case in South Asia as 
evidenced by recent studies from India [315].  
Different approaches probably need to be tested or developed in parallel to find the 
optimal biomarkers for enteropathy, and in particular, to identify the optimal biomarkers to detect 
enteropathy that results in adverse consequences for the host (mostly likely stunting). Such 
strategies could consist of broad screening and biomarker discovery, using agnostic 
methodologies (e.g., proteomics, genomics, and metabolomics). It is important to note that 
biomarker discovery requires disciplined approaches, strong statistical support to identify 
attributable risk to a specific biomarker and to avoid false discoveries, as well as validation 
cohorts. Underlying any such discovery and validation is the obligation to be absolutely certain 
that the core data and specimens are of the highest quality. To date, cohorts have been small, 
specimens not uniformly collected and handled, and outcomes have been nebulous. These 
problems need to be remedied before applying novel analytics to the problem of enteropathy. 
However, the MAL-ED [316] and other cohorts might provide sufficient rigor and resources to 
begin to answer these questions. 
If a perfect, or even an adequate single biomarker, cannot be found, an alternative might 
be the development of an “enteropathy index” which integrates a constellation of clinical 
symptoms and signs and/or set of markers. Variations of the “enteropathy index” might need to 
accommodate the processes of screening, diagnosing dysfunction in individual cases, and 
monitoring this condition and its consequences. For example, we divided the markers into eight 
categories, representing different enteric functions or expressions. An “enteropathy index” might 
be represented by “stacking” one marker from each of three or more categories such as 
lactoferrin (intestinal inflammation) + L:M (primarily permeability but mannitol excretion provides 
a measure of absorptive function) + lactose hydrogen breath test (digestion). We wish to note 
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that a recent publication by Kosek, et al. [317] provides data in support of this concept, 
proposing the use of three stool markers (neopterin, myeloperoxidase, and alpha-1-antitrypsin) 
reflective of inflammatory and permeability processes. 
In considering data to be obtained from biopsy specimens, it will be important to balance 
information to be gleaned against the small risk related to the procedure. Based on current state 
of knowledge, it is not known when enteric functional deficits related to environmental 
enteropathy occur in temporal relation to histopathologic changes. When EED research does 
incorporate obtaining biopsies, such issues should be considered. Given the challenges in 
obtaining pediatric biopsies, any future EED biopsy research should include ascertainment of 
the relationship between histopathology and growth, in addition to utilization of histopathology 
as a “gold standard” by which less invasive biomarker performance is gauged.  
Whichever of these biomarker discovery and validation strategies is employed, we urge 
rigorous adherence to standards for the design and reporting of biomarker studies. The 
“STAndards for the Reporting of Diagnostic accuracy studies” or “STARD” initiative provides an 
excellent framework and checklist for diagnostic accuracy studies, allowing readers to assess 
for potential bias in a study (internal validity) and to evaluate generalizability (external validity). 
The STARD initiative is akin to the CONSORT statement for randomized controlled trials [318] 
and provides an excellent structure for consideration for development of biomarker discovery 
study design and reporting guidelines [319].  
In reviewing these studies, it appears that many tests were compromised by choice of 
analyte, and independent of processes, it is important, looking forward, to consider the body 





Table 16. Analyte attributes. 
Comments on attributes of analyte, relevant to current and future biomarker assessments. 
Attribute Blood Urine Stool Breath Biopsies Saliva 
Invasiveness1 High Low Low Med High Med 
Steady state 





Yes No No No Yes No 
Schedulable4 Yes No No Yes Yes Yes 
Consent issues5 Medium Low Low Low High  Low 
Components of 




cells, red cells, 
host nucleic 
acids 













Biohazardous7 High Low Low Med High Low 
Offensive8 Med Low High Med Med Med 
Ability to collect 
and bring from 
home 9 
No Yes Yes No No Yes 
Provenance10 Good Fair Fair Good Good Fair 
1 Invasiveness is defined as "low" if analyte is produced spontaneously by subject, "medium" if a special apparatus or 
collection device is needed to obtain the specimen and "high" if mucosa or integument is breached to obtain. 
2 Steady state is assessed (“yes”) if the substance studied is likely to remain stable on an hour-to-hour basis, and not 
assessed (“no”) if substance studied is capable of changing profoundly in a short interval. 
3 Processing (e.g., physical separation by centrifugation of components) is generally performed before long-term 
storage. 
4 Schedulable samplings are those that can be arranged and obtained in advance, i.e., are not generally produced on 
command by children. 
5 Consent issues are "low" if the substance is spontaneously produced without any physical risk to the subject, 
"medium" if obtaining the substance has a degree of physical discomfort or anxiety risk such as a hematoma or pain 
from a phlebotomy, and "high" if there is any possibility of injury that could result in hospitalization. 
6 "Low" technology describes minimally expensive materials that are easily obtainable, such as needles and syringes; 
"medium" cost pertains to special-order items, such as breath hydrogen bags; and "high" cost pertains to materials 
obtained in an inpatient setting using sophisticated technology, such as endoscopic and biopsy equipment.  
7 Materials are considered to have "low" biohazard risk if the likelihood of contracting a life-threatening infection are nil 
if the substance is placed on an open cut or inhaled; "medium" if a serious but rarely life threatening infection would 
result if the substance is placed on an open cut or inhaled (breath is placed in this category because of the possibility 
of tuberculosis or other infections spread via respiratory droplets); and "high" if a life-threatening infection, most 
notably HIV, would result if the substance is placed on an open cut or inhaled. 
8 Offensiveness relates to a general reaction to a worker’s skin coming in contact with the substance accidentally. 
9 Materials can be brought from home for analysis, with a modest amount of instruction and materials. 
10 Provenance relates to low, medium, or high risk of accidental or intentional substitution by a research subject or 




As can be seen, each body substance has strengths and drawbacks in research studies 
and clinical practice, and much of the literature chose specimens to analyze based either on 
precedent or lack of suitable alternatives. In reviewing the tests, blood has many commendable 
attributes, but the requirement to breach the skin to obtain the specimen adds an extreme, and 
often limiting, constraint to sampling. We wish to propose for consideration the use of 
transcutaneous technology to evaluate blood components. These devices are quite successful 
in measuring blood gases (oxygen and carbon dioxide), bilirubin, and glucose, and their 
methodology might be adaptable to either endogenous targets (e.g., iron) or challenge 
substances (D-xylose), and therefore have a high likelihood of playing a useful role in detecting 
and monitoring enteropathy.  
In all assessments, it is important to recognize that normal or reference values are highly 
abstract concepts. Often, normal values were obtained from studying cohorts of children in 
developed countries, and there are rarely opportunities to establish normal values based on 
putatively normal subjects in the same environment, and of the same genetic makeup, as the 
subjects studied for enteropathy. Unless and until methodology and sampling of subjects are 
used to establish such norms, it will be difficult to calibrate the magnitude of abnormality. This 
problem is compounded by definitional issues in pathology. While we believe that intestinal 
inflammation is quite likely undesirable, we cannot state with certainty that an inflamed mucosa 
is wholly deleterious for children in resource-poor settings. Specifically, it is possible that low-to-
moderate-grade inflammation of the gut is a homeostatic mechanism in environments in which 
enteric pathogens are ubiquitous.  
The obstacles we encountered in this review suggest opportunities to adhere to 
publication standards in future reports of biomarker research related to EED. We were largely 
hindered by inadequate definitions and reporting incompleteness. The STARD guidelines are a 
very good basis for subsequent reports, but might need to be adapted in consideration of the 
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biomarker field. Specifically, processes that are interrogated by the biomarker should be clearly 
described, if known, and if not known, then that should be stated. Rigorous statistics should be 
applied for two overriding reasons: first, it is critical that point estimates (including percent 
attribution where study design allows for calculation) and confidence intervals should be 
reported in addition to the less informative p-values; second, in the assessment of multiple 
biomarkers identified in agnostic discovery projects, it is important to incorporate statistically 
valid safeguards against false discovery via multiple comparisons.  
We also believed that the authors of the texts we reviewed generally obtained more data 
than they reported, probably because of page limitations or focus of the paper. Very few of the 
publications reported data that were obtained exclusively in the context of biomarker 
development or evaluation; many of the reports produced biomarker data in the context of other 
studies. Also, there was sparse use of online repositories for storage of meta-data. As such, 
considerable opportunities to review relevant data for biomarkers might have been lost. 
Certainly, there are increasing capacities to archive ancillary data for interrogation by other 
investigators. We are encouraged by this trend and believe that complete data deposition 
should be considered a “best practice” of future enteropathy-biomarker projects. Furthermore, 
systematic deposition is best facilitated, for ease of input as well as extraction of data, by 
placement in the public domain.  
In addition to more rigorous and transparent provision of study design and major 
findings, it is apparent that future research in the field will be handicapped by current journal 
publication constraints. Specifically, biomarker studies in human populations are likely to 
generate volumes of data that are well in excess of the word and table limits of standard journal 
articles. This is especially regrettable, because the cost of accruing human cohorts is 
increasing, and therefore there is an obligation to make the most of the data that are produced 
henceforth. We propose that a biomarker data repository be established, and used to advance 
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research in this field, and to be accessible for future data queries. We do acknowledge, 
however, that the establishment, preservation, and curation of data require resources that are 
often not provided to the projects in which the data are generated. Nonetheless, a standardized, 
disciplined, and logical deposition and maintenance of data while studies are performed will 
reduce the expense of archiving the material after the study. Such investments will enhance and 
expedite biomarker research and application for reducing the burden of stunting.  
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APPENDICES 
Appendix 1. Search terms for EED articles of interest. 
Search terms for EED alone are in gray, malnutrition outcomes are in pink. A combined 
strategy, denoted in yellow was utilized for searches in the smaller WHO databases. 
 
 
PubMed TE/ED  
completed April 1, 2010 (24156 Citations) 
Step 1 (24875 Citations) 
("Viruses" [Mesh] OR "Bacteria" [Mesh] OR "Parasites" [Mesh]) AND "Intestinal Diseases" 
[Mesh] 
Step 2 (2789652 Citations) 
("malnutrition" OR "undernutrition" OR "micronutrient" OR "nutritional deficiency" OR "Nutrition 
Disorders" [Mesh] OR "child development" [Mesh ] OR environmental OR recurrent OR 
recurring OR persistent OR chronic OR "Communicable Disease Control" [Mesh] OR 
handwashing OR "hand washing" OR toilet* OR sanitation OR hygiene OR drinking) 
Step 3 (478234 Citations) 
(enteropathy OR enteropathies OR diarrhea OR diarrhoea OR diarrhoeal OR diarrheal OR 
"Malabsorption Syndromes" [Mesh]) 
Step 2 AND 3 combined (93491 Citations) 
Step 4 (759 Citations) 
("Diarrhea" [Mesh] AND "chronic disease" [Mesh]) 1, 378 
Step 5 
("environmental enteropathies" OR "environmental enteropathy" OR "tropical enteropathy" OR 
"tropical enteropathies" OR "sprue, tropical " [MeSH] OR "tropical sprue" OR " Idiopathic 
Tropical Malabsorption Syndromes" OR " Idiopathic Tropical Malabsorption Syndrome") 
Step 6 (37074 Citations) 
"Intestinal Absorption" [Mesh] 
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Step 1 OR (Step 2 AND 3) OR Step 4 OR Step 5 OR Step6 (148353 Citations ) 
Step 7 (1826934 Citations ) 
"Child" [Mesh] OR "Maternal-Child Health Centers" [Mesh] OR "Child Nutrition Sciences" [Mesh] 
OR "Child Health Services" [Mesh] OR "Child Nutritional Physiological Phenomena" [Mesh] OR 
"Child Nutrition Disorders" [Mesh] OR "Child Mortality" [Mesh] OR "Child Welfare" [Mesh] OR 
"Child Care" [Mesh] OR "Child Reactive Disorders" [Mesh] OR "Child Guidance" [Mesh] OR 
"Child Reactive Disorders" [Mesh] OR "Child Behavior Disorders" [Mesh] OR "Child, Orphaned" 
[Mesh] OR "Child, Institutionalized" [Mesh] OR "Child, Hospitalized" [Mesh] OR "Child 
Development" [Mesh] OR "Child Behavior" [Mesh] OR "Developmental Disabilities" [Mesh] OR 
"Mental Disorders Diagnosed in Childhood" [Mesh] OR "Disabled Children" [Mesh] OR 
"children" [TIAB] OR "newborn*" [TIAB] OR "childhood" [TIAB] OR "baby" [TIAB] OR "babies" 
[TIAB] OR "toddler" [TIAB] OR "toddlers" [TIAB] OR "infants" [TIAB] OR "infant" [TIAB] OR 
"infantile" [TIAB] OR "young patient" [TIAB] OR "young patients" [TIAB] OR "Pediatric Nursing" 
[Mesh] OR "Pediatric Assistants" [Mesh] OR "Hospitals, Pediatric" [Mesh] OR "Intensive Care 
Units, Pediatric" [Mesh] OR "Pediatrics" [Mesh] OR "Pediatricians" [TIAB] OR "paediatricians" 
[TIAB] OR "Pediatrician" [TIAB] OR "paediatrician" [TIAB] OR "Pediatrics" [TIAB] OR 
"paediatrics" [TIAB] OR "Pediatric" [TIAB] OR "paediatric" [TIAB] 
Step 1 OR (Step 2 AND 3) OR Step 4 OR Step 5 OR Step6 AND Step7 (24156 Citations)  
 
EMBASE TE/ED  
completed April 1, 2010 (20052 Citations) 
Step 1 (39771 Citations)  
'gastroenteritis'/exp OR 'gastroenteritis' OR 'protein losing gastroenteropathy'/exp OR 'protein 
losing gastroenteropathy' OR 'celiac disease'/exp OR 'celiac disease' OR 'tropical sprue'/exp 
OR 'tropical sprue' OR 'infantile gastroenteritis'/exp OR 'infantile gastroenteritis' OR 'acute 
gastroenteritis'/exp OR 'acute gastroenteritis' OR 'viral gastroenteritis'/exp OR 'viral 
gastroenteritis' OR 'persistent diarrhea' OR 'persistent diarrhoea' OR 'recurrent diarrhea' OR 
'recurrent diarrhoea' 
 Step 2 (4062 Citations) 
'intestine mucosa permeability'/exp OR 'small intestine absorption'/exp 
Step 3 (745 Citations)  
'environmental enteropathies' OR 'environmental enteropathy' OR 'tropical enteropathy' OR 
'tropical enteropathies' OR 'tropical sprue'/exp OR 'tropical sprue' OR 'idiopathic tropical 
malabsorption syndromes' OR 'idiopathic tropical malabsorption syndrome' 
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OR  
Step 4 (3611 citations)  
('chronic disease'/exp AND 'diarrhea'/exp) OR 'chronic diarrhea'/exp 
Step 5 (3156573 Citations) 
'child'/exp OR 'child' OR 'children'/exp OR 'children' OR 'youth'/exp OR 'youth' OR youth* OR 
newborn* OR 'newborn'/exp OR 'newborn' OR 'new born' OR 'childhood disease'/exp OR 
'childhood disease' OR 'baby'/exp OR 'baby' OR babies OR 'infant'/exp OR 'infant' OR infant* 
OR childhood* OR toddler* OR kid OR kids OR 'young patient' OR boy* OR girl* OR 'young age' 
OR pediatr* OR paediatr* OR 'child death'/exp OR 'child death' OR 'child health'/exp OR 'child 
health' OR 'child care'/exp OR 'child care' OR 'childhood mortality'/exp OR 'childhood mortality' 
OR 'child hospitalization'/exp OR 'child hospitalization' OR 'pediatric hospital'/exp OR 'pediatric 
hospital' OR child* 
(Step 1 OR Step 2 OR Step 3 OR Step 4) AND Step 5 (20052 Citations)  
 
Global Health TE/ED  
completed June 1, 2010 (7825 citations) 
Step 1 (232244 Citations) 
(child or children or newborn$ or childhood or baby or babies or toddler or toddlers or infants or 
infant or infantile or "young patients" or "young patient" or pediatrics or pediatric or paediatric or 
paediatrics or girls or sons or daughters or "child welfare" or "rearing practices" or unicef or 
paediatr$ or "child development" or "child nutrition" or "child health" or kid or kids or 
pediatricians or paediatricians).af. 
Step 2 (4555 Citations)  
(enteropathy or scouring).id. OR ("chronic infections" and diarrhoea).de. OR (diarrhea and 
"nutritional status").id. OR ("tropical sprue$" or "tropical enteropath$" or "environmental 
enteropath$" or "persistent diarrhea$" or "Persistent diarrhoea$" or "chronic diarrhoea$" 
or "chronic diarrhea$" or "intestinal inflamm*" or "intestinal permeability").af.  
        
Step 3 (620850 Citations) 
(undernutrition or "tropical countries" or "tropical zones" or "parasitic infections").id. or (tropics or 
"bacterial diseases").de. or (vv600 or vv210 or hh600 or ll822 or vv130).cc.  
Step 4 (28447 Citations) 
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"("intestinal mucosa" or "small intestine" or "gastroenteritis" or intestines or "intestinal diseases" 
or "intestinal absorption").de. or (Intestines or "gastrointestinal tract").id. 
Step 1 AND (Step 2 OR (Step 3 AND Step 4)) (10242 Citations) 
Step 5 (*Journals indexed by PubMed and Embase removed) (2417 Citations) 
"Journal of Pediatric Gastroenterology and Nutrition" [Journals] OR Journal of Clinical 
Microbiology" [Journals] OR"Archives of Disease in Childhood" [Journals] OR"Pediatric 
Infectious Disease Journal" [Journals] OR"Journal of Infectious Diseases" [Journals] 
OR"Journal of Pediatrics" [Journals] OR 
"Clinical Infectious Diseases" [Journals] OR"Infection and Immunity" [Journals] OR 
"Journal of Medical Virology" [Journals] OR"Transactions of the Royal Society of Tropical 
Medicine and Hygiene" [Journals] OR"Journal of Nutrition" [Journals] OR "East African Medical 
Journal" [Journals] 
"BMC Infectious Diseases" [Journals] OR"American Journal of Tropical Medicine and Hygiene" 
[Journals] OR"Pediatric Research" [Journals] OR"Archives de Pediatrie" [Journals] OR 
"Journal of Paediatrics and Child Health" [Journals] OR"Asian Pacific Journal of Allergy and 
Immunology" [Journals] OR"Journal of Tropical Pediatrics" [Journals] 
Step 1 AND (Step 2 OR (Step 3 AND Step 4) NOT Step 5 (7825 Citations)  
 
PubMed Malnutrition  
completed April 19, 2010 (23238 Citations) 
Step 1 (2540333 Citations)          
"developing country" [tiab] OR "developing countries" [tiab] OR "developing nation" [tiab] OR 
"developing nations" [tiab] OR "developing population" [tiab] OR "developing populations" [tiab] 
OR "developing world" [tiab] OR "less developed country" [tiab] OR "less developed countries" 
[tiab] OR "less developed nation" [tiab] OR "less developed nations" [tiab] OR "less developed 
population" [tiab] OR "less developed populations" [tiab] OR "less developed world" [tiab] OR 
"lesser developed country" [tiab] OR "lesser developed countries" [tiab] OR "lesser developed 
nation" [tiab] OR "lesser developed nations" [tiab] OR "lesser developed population" [tiab] OR 
"lesser developed populations" [tiab] OR "lesser developed world" [tiab] OR "under developed 
country" [tiab] OR "under developed countries" [tiab] OR "under developed nation" [tiab] OR 
"under developed nations" [tiab] OR "under developed population" [tiab] OR "under developed 
populations" [tiab] OR "under developed world" [tiab] OR "underdeveloped country" [tiab] OR 
"underdeveloped countries" [tiab] OR "underdeveloped nation" [tiab] OR "underdeveloped 
nations" [tiab] OR "underdeveloped population" [tiab] OR "underdeveloped populations" [tiab] 
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OR "underdeveloped world" [tiab] OR "middle income country" [tiab] OR "middle income 
countries" [tiab] OR "middle income nation" [tiab] OR "middle income nations" [tiab] OR "middle 
income population" [tiab] OR "middle income populations" [tiab] OR "low income country" [tiab] 
OR "low income countries" [tiab] OR "low income nation" [tiab] OR "low income nations" [tiab] 
OR "low income population" [tiab] OR "low income populations" [tiab] OR "lower income 
country" [tiab] OR "lower income countries" [tiab] OR "lower income nation" [tiab] OR "lower 
income nations" [tiab] OR "lower income population" [tiab] OR "lower income populations" [tiab] 
OR "underserved country" [tiab] OR "underserved countries" [tiab] OR "underserved nation" 
[tiab] OR "underserved nations" [tiab] OR "underserved population" [tiab] OR "underserved 
populations" [tiab] OR "underserved world" [tiab] OR "under served country" [tiab] OR "under 
served countries" [tiab] OR "under served nation" [tiab] OR "under served nations" [tiab] OR 
"under served population" [tiab] OR "under served populations" [tiab] OR "under served world" 
[tiab] OR "deprived country" [tiab] OR "deprived countries" [tiab] OR "deprived nation" [tiab] OR 
"deprived nations" [tiab] OR "deprived population" [tiab] OR "deprived populations" [tiab] OR 
"deprived world" [tiab] OR "poor country" [tiab] OR "poor countries" [tiab] OR "poor nation" [tiab] 
OR "poor nations" [tiab] OR "poor population" [tiab] OR "poor populations" [tiab] OR "poor 
world" [tiab] OR "poorer country" [tiab] OR "poorer countries" [tiab] OR "poorer nation" [tiab] OR 
"poorer nations" [tiab] OR "poorer population" [tiab] OR "poorer populations" [tiab] OR "poorer 
world" [tiab] OR "developing economy" [tiab] OR "developing economies" [tiab] OR "less 
developed economy" [tiab] OR "less developed economies" [tiab] OR "lesser developed 
economy" [tiab] OR "lesser developed economies" [tiab] OR "under developed economy" [tiab] 
OR "under developed economies" [tiab] OR "underdeveloped economy" [tiab] OR 
"underdeveloped economies" [tiab] OR "middle income economy" [tiab] OR "middle income 
economies" [tiab] OR "low income economy" [tiab] OR "low income economies" [tiab] OR "lower 
income economy" [tiab] OR "lower income economies" [tiab] OR "low gdp" [tiab] OR "low gnp" 
[tiab] OR "low gross domestic" [tiab] OR "low gross national" [tiab] OR "lower gdp" [tiab] OR 
"lower gnp" [tiab] OR "lower gross domestic" [tiab] OR "lower gross national" [tiab] OR lmic [tiab] 
OR lmics [tiab] OR "third world" [tiab] OR "lami country" [tiab] OR "lami countries" [tiab] OR 
"transitional country" [tiab] OR "transitional countries" [tiab] OR "developing country" [ot] OR 
"developing countries" [ot] OR "developing nation" [ot] OR "developing nations" [ot] OR 
"developing population" [ot] OR "developing populations" [ot] OR "developing world" [ot] OR 
"less developed country" [ot] OR "less developed countries" [ot] OR "less developed nation" [ot] 
OR "less developed nations" [ot] OR "less developed population" [ot] OR "less developed 
populations" [ot] OR "less developed world" [ot] OR "lesser developed country" [ot] OR "lesser 
developed countries" [ot] OR "lesser developed nation" [ot] OR "lesser developed nations" [ot] 
OR "lesser developed population" [ot] OR "lesser developed populations" [ot] OR "lesser 
developed world" [ot] OR "under developed country" [ot] OR "under developed countries" [ot] 
OR "under developed nation" [ot] OR "under developed nations" [ot] OR "under developed 
population" [ot] OR "under developed populations" [ot] OR "under developed world" [ot] OR 
"underdeveloped country" [ot] OR "underdeveloped countries" [ot] OR "underdeveloped nation" 
[ot] OR "underdeveloped nations" [ot] OR "underdeveloped population" [ot] OR 
"underdeveloped populations" [ot] OR "underdeveloped world" [ot] OR "middle income country" 
[ot] OR "middle income countries" [ot] OR "middle income nation" [ot] OR "middle income 
nations" [ot] OR "middle income population" [ot] OR "middle income populations" [ot] OR "low 
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income country" [ot] OR "low income countries" [ot] OR "low income nation" [ot] OR "low income 
nations" [ot] OR "low income population" [ot] OR "low income populations" [ot] OR "lower 
income country" [ot] OR "lower income countries" [ot] OR "lower income nation" [ot] OR "lower 
income nations" [ot] OR "lower income population" [ot] OR "lower income populations" [ot] OR 
"underserved country" [ot] OR "underserved countries" [ot] OR "underserved nation" [ot] OR 
"underserved nations" [ot] OR "underserved population" [ot] OR "underserved populations" [ot] 
OR "underserved world" [ot] OR "under served country" [ot] OR "under served countries" [ot] 
OR "under served nation" [ot] OR "under served nations" [ot] OR "under served population" [ot] 
OR "under served populations" [ot] OR "under served world" [ot] OR "deprived country" [ot] OR 
"deprived countries" [ot] OR "deprived nation" [ot] OR "deprived nations" [ot] OR "deprived 
population" [ot] OR "deprived populations" [ot] OR "deprived world" [ot] OR "poor country" [ot] 
OR "poor countries" [ot] OR "poor nation" [ot] OR "poor nations" [ot] OR "poor population" [ot] 
OR "poor populations" [ot] OR "poor world" [ot] OR "poorer country" [ot] OR "poorer countries" 
[ot] OR "poorer nation" [ot] OR "poorer nations" [ot] OR "poorer population" [ot] OR "poorer 
populations" [ot] OR "poorer world" [ot] OR "developing economy" [ot] OR "developing 
economies" [ot] OR "less developed economy" [ot] OR "less developed economies" [ot] OR 
"lesser developed economy" [ot] OR "lesser developed economies" [ot] OR "under developed 
economy" [ot] OR "under developed economies" [ot] OR "underdeveloped economy" [ot] OR 
"underdeveloped economies" [ot] OR "middle income economy" [ot] OR "middle income 
economies" [ot] OR "low income economy" [ot] OR "low income economies" [ot] OR "lower 
income economy" [ot] OR "lower income economies" [ot] OR "low gdp" [ot] OR "low gnp" [ot] 
OR "low gross domestic" [ot] OR "low gross national" [ot] OR "lower gdp" [ot] OR "lower gnp" 
[ot] OR "lower gross domestic" [ot] OR "lower gross national" [ot] OR lmic [ot] OR lmics [ot] OR 
"third world" [ot] OR "lami country" [ot] OR "lami countries" [ot] OR "transitional country" [ot] OR 
"transitional countries" [ot] OR Africa [pl] OR Asia [pl] OR Caribbean [pl] OR West Indies [pl] OR 
South America [pl] OR Latin America [pl] OR Central America [pl] OR Afghanistan [pl] OR 
Albania [pl] OR Algeria [pl] OR Angola [pl] OR Antigua [pl] OR Barbuda [pl] OR Argentina [pl] 
OR Armenia [pl] OR Armenian [pl] OR Aruba [pl] OR Azerbaijan [pl] OR Bahrain [pl] OR 
Bangladesh [pl] OR Barbados [pl] OR Benin [pl] OR Byelarus [pl] OR Byelorussian [pl] OR 
Belarus [pl] OR Belorussian [pl] OR Belorussia [pl] OR Belize [pl] OR Bhutan [pl] OR Bolivia [pl] 
OR Bosnia [pl] OR Herzegovina [pl] OR Hercegovina [pl] OR Botswana [pl] OR Brazil [pl] OR 
Bulgaria [pl] OR Burkina Faso [pl] OR Burkina Fasso [pl] OR Upper Volta [pl] OR Burundi [pl] 
OR Urundi [pl] OR Cambodia [pl] OR Khmer Republic [pl] OR Kampuchea [pl] OR Cameroon 
[pl] OR Cameroons [pl] OR Cameron [pl] OR Camerons [pl] OR Cape Verde [pl] OR Central 
African Republic [pl] OR Chad [pl] OR Chile [pl] OR China [pl] OR Colombia [pl] OR Comoros 
[pl] OR Comoro Islands [pl] OR Comores [pl] OR Mayotte [pl] OR Congo [pl] OR Zaire [pl] OR 
Costa Rica [pl] OR Cote d'Ivoire [pl] OR Ivory Coast [pl] OR Croatia [pl] OR Cuba [pl] OR 
Cyprus [pl] OR Czechoslovakia [pl] OR Czech Republic [pl] OR Slovakia [pl] OR Slovak 
Republic [pl] OR Djibouti [pl] OR French Somaliland [pl] OR Dominica [pl] OR Dominican 
Republic [pl] OR East Timor [pl] OR East Timur [pl] OR Timor Leste [pl] OR Ecuador [pl] OR 
Egypt [pl] OR United Arab Republic [pl] OR El Salvador [pl] OR Eritrea [pl] OR Estonia [pl] OR 
Ethiopia [pl] OR Fiji [pl] OR Gabon [pl] OR Gabonese Republic [pl] OR Gambia [pl] OR Gaza [pl] 
OR Georgia Republic [pl] OR Georgian Republic [pl] OR Ghana [pl] OR Gold Coast [pl] OR 
Greece [pl] OR Grenada [pl] OR Guatemala [pl] OR Guinea [pl] OR Guam [pl] OR Guiana [pl] 
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OR Guyana [pl] OR Haiti [pl] OR Honduras [pl] OR Hungary [pl] OR India [pl] OR Maldives [pl] 
OR Indonesia [pl] OR Iran [pl] OR Iraq [pl] OR Isle of Man [pl] OR Jamaica [pl] OR Jordan [pl] 
OR Kazakhstan [pl] OR Kazakh [pl] OR Kenya [pl] OR Kiribati [pl] OR Korea [pl] OR Kosovo [pl] 
OR Kyrgyzstan [pl] OR Kirghizia [pl] OR Kyrgyz Republic [pl] OR Kirghiz [pl] OR Kirgizstan [pl] 
OR "Lao PDR" [pl] OR Laos [pl] OR Latvia [pl] OR Lebanon [pl] OR Lesotho [pl] OR Basutoland 
[pl] OR Liberia [pl] OR Libya [pl] OR Lithuania [pl] OR Macedonia [pl] OR Madagascar [pl] OR 
Malagasy Republic [pl] OR Malaysia [pl] OR Malaya [pl] OR Malay [pl] OR Sabah [pl] OR 
Sarawak [pl] OR Malawi [pl] OR Nyasaland [pl] OR Mali [pl] OR Malta [pl] OR Marshall Islands 
[pl] OR Mauritania [pl] OR Mauritius [pl] OR Agalega Islands [pl] OR Mexico [pl] OR Micronesia 
[pl] OR Middle East [pl] OR Moldova [pl] OR Moldovia [pl] OR Moldovian [pl] OR Mongolia [pl] 
OR Montenegro [pl] OR Morocco [pl] OR Ifni [pl] OR Mozambique [pl] OR Myanmar [pl] OR 
Myanma [pl] OR Burma [pl] OR Namibia [pl] OR Nepal [pl] OR Netherlands Antilles [pl] OR New 
Caledonia [pl] OR Nicaragua [pl] OR Niger [pl] OR Nigeria [pl] OR Northern Mariana Islands [pl] 
OR Oman [pl] OR Muscat [pl] OR Pakistan [pl] OR Palau [pl] OR Palestine [pl] OR Panama [pl] 
OR Paraguay [pl] OR Peru [pl] OR Philippines [pl] OR Philipines [pl] OR Phillipines [pl] OR 
Phillippines [pl] OR Poland [pl] OR Portugal [pl] OR Puerto Rico [pl] OR Romania [pl] OR 
Rumania [pl] OR Roumania [pl] OR Russia [pl] OR Russian [pl] OR Rwanda [pl] OR Ruanda [pl] 
OR Saint Kitts [pl] OR St Kitts [pl] OR Nevis [pl] OR Saint Lucia [pl] OR St Lucia [pl] OR Saint 
Vincent [pl] OR St Vincent [pl] OR Grenadines [pl] OR Samoa [pl] OR Samoan Islands [pl] OR 
Navigator Island [pl] OR Navigator Islands [pl] OR Sao Tome [pl] OR Saudi Arabia [pl] OR 
Senegal [pl] OR Serbia [pl] OR Montenegro [pl] OR Seychelles [pl] OR Sierra Leone [pl] OR 
Slovenia [pl] OR Sri Lanka [pl] OR Ceylon [pl] OR Solomon Islands [pl] OR Somalia [pl] OR 
Sudan [pl] OR Suriname [pl] OR Surinam [pl] OR Swaziland [pl] OR Syria [pl] OR Tajikistan [pl] 
OR Tadzhikistan [pl] OR Tadjikistan [pl] OR Tadzhik [pl] OR Tanzania [pl] OR Thailand [pl] OR 
Togo [pl] OR Togolese Republic [pl] OR Tonga [pl] OR Trinidad [pl] OR Tobago [pl] OR Tunisia 
[pl] OR Turkey [pl] OR Turkmenistan [pl] OR Turkmen [pl] OR Uganda [pl] OR Ukraine [pl] OR 
Uruguay [pl] OR USSR [pl] OR Soviet Union [pl] OR Union of Soviet Socialist Republics [pl] OR 
Uzbekistan [pl] OR Uzbek OR Vanuatu [pl] OR New Hebrides [pl] OR Venezuela [pl] OR 
Vietnam [pl] OR Viet Nam [pl] OR West Bank [pl] OR Yemen [pl] OR Yugoslavia [pl] OR Zambia 
[pl] OR Zimbabwe [pl] OR Rhodesia [pl] OR Africa [tiab] OR Asia [tiab] OR Caribbean [tiab] OR 
West Indies [tiab] OR South America [tiab] OR Latin America [tiab] OR Central America [tiab] 
OR Afghanistan [tiab] OR Albania [tiab] OR Algeria [tiab] OR Angola [tiab] OR Antigua [tiab] OR 
Barbuda [tiab] OR Argentina [tiab] OR Armenia [tiab] OR Armenian [tiab] OR Aruba [tiab] OR 
Azerbaijan [tiab] OR Bahrain [tiab] OR Bangladesh [tiab] OR Barbados [tiab] OR Benin [tiab] OR 
Byelarus [tiab] OR Byelorussian [tiab] OR Belarus [tiab] OR Belorussian [tiab] OR Belorussia 
[tiab] OR Belize [tiab] OR Bhutan [tiab] OR Bolivia [tiab] OR Bosnia [tiab] OR Herzegovina [tiab] 
OR Hercegovina [tiab] OR Botswana [tiab] OR Brazil [tiab] OR Bulgaria [tiab] OR Burkina Faso 
[tiab] OR Burkina Fasso [tiab] OR Upper Volta [tiab] OR Burundi [tiab] OR Urundi [tiab] OR 
Cambodia [tiab] OR Khmer Republic [tiab] OR Kampuchea [tiab] OR Cameroon [tiab] OR 
Cameroons [tiab] OR Cameron [tiab] OR Camerons [tiab] OR Cape Verde [tiab] OR Central 
African Republic [tiab] OR Chad [tiab] OR Chile [tiab] OR China [tiab] OR Colombia [tiab] OR 
Comoros [tiab] OR Comoro Islands [tiab] OR Comores [tiab] OR Mayotte [tiab] OR Congo [tiab] 
OR Zaire [tiab] OR Costa Rica [tiab] OR Cote d'Ivoire [tiab] OR Ivory Coast [tiab] OR Croatia 
[tiab] OR Cuba [tiab] OR Cyprus [tiab] OR Czechoslovakia [tiab] OR Czech Republic [tiab] OR 
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Slovakia [tiab] OR Slovak Republic [tiab] OR Djibouti [tiab] OR French Somaliland [tiab] OR 
Dominica [tiab] OR Dominican Republic [tiab] OR East Timor [tiab] OR East Timur [tiab] OR 
Timor Leste [tiab] OR Ecuador [tiab] OR Egypt [tiab] OR United Arab Republic [tiab] OR El 
Salvador [tiab] OR Eritrea [tiab] OR Estonia [tiab] OR Ethiopia [tiab] OR Fiji [tiab] OR Gabon 
[tiab] OR Gabonese Republic [tiab] OR Gambia [tiab] OR Gaza [tiab] OR Georgia Republic 
[tiab] OR Georgian Republic [tiab] OR Ghana [tiab] OR Gold Coast [tiab] OR Greece [tiab] OR 
Grenada [tiab] OR Guatemala [tiab] OR Guinea [tiab] OR Guam [tiab] OR Guiana [tiab] OR 
Guyana [tiab] OR Haiti [tiab] OR Honduras [tiab] OR Hungary [tiab] OR India [tiab] OR Maldives 
[tiab] OR Indonesia [tiab] OR Iran [tiab] OR Iraq [tiab] OR Isle of Man [tiab] OR Jamaica [tiab] 
OR Jordan [tiab] OR Kazakhstan [tiab] OR Kazakh [tiab] OR Kenya [tiab] OR Kiribati [tiab] OR 
Korea [tiab] OR Kosovo [tiab] OR Kyrgyzstan [tiab] OR Kirghizia [tiab] OR Kyrgyz Republic [tiab] 
OR Kirghiz [tiab] OR Kirgizstan [tiab] OR "Lao PDR" [tiab] OR Laos [tiab] OR Latvia [tiab] OR 
Lebanon [tiab] OR Lesotho [tiab] OR Basutoland [tiab] OR Liberia [tiab] OR Libya [tiab] OR 
Lithuania [tiab] OR Macedonia [tiab] OR Madagascar [tiab] OR Malagasy Republic [tiab] OR 
Malaysia [tiab] OR Malaya [tiab] OR Malay [tiab] OR Sabah [tiab] OR Sarawak [tiab] OR Malawi 
[tiab] OR Nyasaland [tiab] OR Mali [tiab] OR Malta [tiab] OR Marshall Islands [tiab] OR 
Mauritania [tiab] OR Mauritius [tiab] OR Agalega Islands [tiab] OR Mexico [tiab] OR Micronesia 
[tiab] OR Middle East [tiab] OR Moldova [tiab] OR Moldovia [tiab] OR Moldovian [tiab] OR 
Mongolia [tiab] OR Montenegro [tiab] OR Morocco [tiab] OR Ifni [tiab] OR Mozambique [tiab] OR 
Myanmar [tiab] OR Myanma [tiab] OR Burma [tiab] OR Namibia [tiab] OR Nepal [tiab] OR 
Netherlands Antilles [tiab] OR New Caledonia [tiab] OR Nicaragua [tiab] OR Niger [tiab] OR 
Nigeria [tiab] OR Northern Mariana Islands [tiab] OR Oman [tiab] OR Muscat [tiab] OR Pakistan 
[tiab] OR Palau [tiab] OR Palestine [tiab] OR Panama [tiab] OR Paraguay [tiab] OR Peru [tiab] 
OR Philippines [tiab] OR Philipines [tiab] OR Phillipines [tiab] OR Phillippines [tiab] OR Poland 
[tiab] OR Portugal [tiab] OR Puerto Rico [tiab] OR Romania [tiab] OR Rumania [tiab] OR 
Roumania [tiab] OR Russia [tiab] OR Russian [tiab] OR Rwanda [tiab] OR Ruanda [tiab] OR 
Saint Kitts [tiab] OR St Kitts [tiab] OR Nevis [tiab] OR Saint Lucia [tiab] OR St Lucia [tiab] OR 
Saint Vincent [tiab] OR St Vincent [tiab] OR Grenadines [tiab] OR Samoa [tiab] OR Samoan 
Islands [tiab] OR Navigator Island [tiab] OR Navigator Islands [tiab] OR Sao Tome [tiab] OR 
Saudi Arabia [tiab] OR Senegal [tiab] OR Serbia [tiab] OR Montenegro [tiab] OR Seychelles 
[tiab] OR Sierra Leone [tiab] OR Slovenia [tiab] OR Sri Lanka [tiab] OR Ceylon [tiab] OR 
Solomon Islands [tiab] OR Somalia [tiab] OR Sudan [tiab] OR Suriname [tiab] OR Surinam [tiab] 
OR Swaziland [tiab] OR Syria [tiab] OR Tajikistan [tiab] OR Tadzhikistan [tiab] OR Tadjikistan 
[tiab] OR Tadzhik [tiab] OR Tanzania [tiab] OR Thailand [tiab] OR Togo [tiab] OR Togolese 
Republic [tiab] OR Tonga [tiab] OR Trinidad [tiab] OR Tobago [tiab] OR Tunisia [tiab] OR Turkey 
[tiab] OR Turkmenistan [tiab] OR Turkmen [tiab] OR Uganda [tiab] OR Ukraine [tiab] OR 
Uruguay [tiab] OR USSR [tiab] OR Soviet Union [tiab] OR Union of Soviet Socialist Republics 
[tiab] OR Uzbekistan [tiab] OR Uzbek OR Vanuatu [tiab] OR New Hebrides [tiab] OR Venezuela 
[tiab] OR Vietnam [tiab] OR Viet Nam [tiab] OR West Bank [tiab] OR Yemen [tiab] OR 
Yugoslavia [tiab] OR Zambia [tiab] OR Zimbabwe [tiab] OR Rhodesia [tiab] OR Africa [ot] OR 
Asia [ot] OR Caribbean [ot] OR West Indies [ot] OR South America [ot] OR Latin America [ot] 
OR Central America [ot] OR Afghanistan [ot] OR Albania [ot] OR Algeria [ot] OR Angola [ot] OR 
Antigua [ot] OR Barbuda [ot] OR Argentina [ot] OR Armenia [ot] OR Armenian [ot] OR Aruba [ot] 
OR Azerbaijan [ot] OR Bahrain [ot] OR Bangladesh [ot] OR Barbados [ot] OR Benin [ot] OR 
295
Byelarus [ot] OR Byelorussian [ot] OR Belarus [ot] OR Belorussian [ot] OR Belorussia [ot] OR 
Belize [ot] OR Bhutan [ot] OR Bolivia [ot] OR Bosnia [ot] OR Herzegovina [ot] OR Hercegovina 
[ot] OR Botswana [ot] OR Brazil [ot] OR Bulgaria [ot] OR Burkina Faso [ot] OR Burkina Fasso 
[ot] OR Upper Volta [ot] OR Burundi [ot] OR Urundi [ot] OR Cambodia [ot] OR Khmer Republic 
[ot] OR Kampuchea [ot] OR Cameroon [ot] OR Cameroons [ot] OR Cameron [ot] OR Camerons 
[ot] OR Cape Verde [ot] OR Central African Republic [ot] OR Chad [ot] OR Chile [ot] OR China 
[ot] OR Colombia [ot] OR Comoros [ot] OR Comoro Islands [ot] OR Comores [ot] OR Mayotte 
[ot] OR Congo [ot] OR Zaire [ot] OR Costa Rica [ot] OR Cote d'Ivoire [ot] OR Ivory Coast [ot] OR 
Croatia [ot] OR Cuba [ot] OR Cyprus [ot] OR Czechoslovakia [ot] OR Czech Republic [ot] OR 
Slovakia [ot] OR Slovak Republic [ot] OR Djibouti [ot] OR French Somaliland [ot] OR Dominica 
[ot] OR Dominican Republic [ot] OR East Timor [ot] OR East Timur [ot] OR Timor Leste [ot] OR 
Ecuador [ot] OR Egypt [ot] OR United Arab Republic [ot] OR El Salvador [ot] OR Eritrea [ot] OR 
Estonia [ot] OR Ethiopia [ot] OR Fiji [ot] OR Gabon [ot] OR Gabonese Republic [ot] OR Gambia 
[ot] OR Gaza [ot] OR "Georgia Republic" [ot] OR "Georgian Republic" [ot] OR Ghana [ot] OR 
Gold Coast [ot] OR Greece [ot] OR Grenada [ot] OR Guatemala [ot] OR Guinea [ot] OR Guam 
[ot] OR Guiana [ot] OR Guyana [ot] OR Haiti [ot] OR Honduras [ot] OR Hungary [ot] OR India 
[ot] OR Maldives [ot] OR Indonesia [ot] OR Iran [ot] OR Iraq [ot] OR Isle of Man [ot] OR Jamaica 
[ot] OR Jordan [ot] OR Kazakhstan [ot] OR Kazakh [ot] OR Kenya [ot] OR Kiribati [ot] OR Korea 
[ot] OR Kosovo [ot] OR Kyrgyzstan [ot] OR Kirghizia [ot] OR Kyrgyz Republic [ot] OR Kirghiz [ot] 
OR Kirgizstan [ot] OR "Lao PDR" [ot] OR Laos [ot] OR Latvia [ot] OR Lebanon [ot] OR Lesotho 
[ot] OR Basutoland [ot] OR Liberia [ot] OR Libya [ot] OR Lithuania [ot] OR Macedonia [ot] OR 
Madagascar [ot] OR Malagasy Republic [ot] OR Malaysia [ot] OR Malaya [ot] OR Malay [ot] OR 
Sabah [ot] OR Sarawak [ot] OR Malawi [ot] OR Nyasaland [ot] OR Mali [ot] OR Malta [ot] OR 
Marshall Islands [ot] OR Mauritania [ot] OR Mauritius [ot] OR Agalega Islands [ot] OR Mexico 
[ot] OR Micronesia [ot] OR Middle East [ot] OR Moldova [ot] OR Moldovia [ot] OR Moldovian [ot] 
OR Mongolia [ot] OR Montenegro [ot] OR Morocco [ot] OR Ifni [ot] OR Mozambique [ot] OR 
Myanmar [ot] OR Myanma [ot] OR Burma [ot] OR Namibia [ot] OR Nepal [ot] OR Netherlands 
Antilles [ot] OR New Caledonia [ot] OR Nicaragua [ot] OR Niger [ot] OR Nigeria [ot] OR 
Northern Mariana Islands [ot] OR Oman [ot] OR Muscat [ot] OR Pakistan [ot] OR Palau [ot] OR 
Palestine [ot] OR Panama [ot] OR Paraguay [ot] OR Peru [ot] OR Philippines [ot] OR Philipines 
[ot] OR Phillipines [ot] OR Phillippines [ot] OR Poland [ot] OR Portugal [ot] OR Puerto Rico [ot] 
OR Romania [ot] OR Rumania [ot] OR Roumania [ot] OR Russia [ot] OR Russian [ot] OR 
Rwanda [ot] OR Ruanda [ot] OR Saint Kitts [ot] OR St Kitts [ot] OR Nevis [ot] OR Saint Lucia 
[ot] OR St Lucia [ot] OR Saint Vincent [ot] OR St Vincent [ot] OR Grenadines [ot] OR Samoa [ot] 
OR Samoan Islands [ot] OR Navigator Island [ot] OR Navigator Islands [ot] OR Sao Tome [ot] 
OR Saudi Arabia [ot] OR Senegal [ot] OR Serbia [ot] OR Montenegro [ot] OR Seychelles [ot] 
OR Sierra Leone [ot] OR Slovenia [ot] OR Sri Lanka [ot] OR Ceylon [ot] OR Solomon Islands 
[ot] OR Somalia [ot] OR Sudan [ot] OR Suriname [ot] OR Surinam [ot] OR Swaziland [ot] OR 
Syria [ot] OR Tajikistan [ot] OR Tadzhikistan [ot] OR Tadjikistan [ot] OR Tadzhik [ot] OR 
Tanzania [ot] OR Thailand [ot] OR Togo [ot] OR Togolese Republic [ot] OR Tonga [ot] OR 
Trinidad [ot] OR Tobago [ot] OR Tunisia [ot] OR Turkey [ot] OR Turkmenistan [ot] OR Turkmen 
[ot] OR Uganda [ot] OR Ukraine [ot] OR Uruguay [ot] OR USSR [ot] OR Soviet Union [ot] OR 
Union of Soviet Socialist Republics [ot] OR Uzbekistan [ot] OR Uzbek OR Vanuatu [ot] OR New 
Hebrides [ot] OR Venezuela [ot] OR Vietnam [ot] OR Viet Nam [ot] OR West Bank [ot] OR 
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Yemen [ot] OR Yugoslavia [ot] OR Zambia [ot] OR Zimbabwe [ot] OR Rhodesia [ot] OR 
Developing Countries [Mesh:noexp] OR Africa [Mesh:noexp] OR Africa, Northern [Mesh:noexp] 
OR Africa South of the Sahara [Mesh:noexp] OR Africa, Central [Mesh:noexp] OR Africa, 
Eastern [Mesh:noexp] OR Africa, Southern [Mesh:noexp] OR Africa, Western [Mesh:noexp] OR 
Asia [Mesh:noexp] OR Asia, Central [Mesh:noexp] OR Asia, Southeastern [Mesh:noexp] OR 
Asia, Western [Mesh:noexp] OR Caribbean Region [Mesh:noexp] OR West Indies [Mesh:noexp] 
OR South America [Mesh:noexp] OR Latin America [Mesh:noexp] OR Central America 
[Mesh:noexp] OR Afghanistan [Mesh:noexp] OR Albania [Mesh:noexp] OR Algeria 
[Mesh:noexp] OR American Samoa [Mesh:noexp] OR Angola [Mesh:noexp] OR "Antigua and 
Barbuda" [Mesh:noexp] OR Argentina [Mesh:noexp] OR Armenia [Mesh:noexp] OR Azerbaijan 
[Mesh:noexp] OR Bahrain [Mesh:noexp] OR Bangladesh [Mesh:noexp] OR Barbados 
[Mesh:noexp] OR Benin [Mesh:noexp] OR Byelarus [Mesh:noexp] OR Belize [Mesh:noexp] OR 
Bhutan [Mesh:noexp] OR Bolivia [Mesh:noexp] OR Bosnia-Herzegovina [Mesh:noexp] OR 
Botswana [Mesh:noexp] OR Brazil [Mesh:noexp] OR Bulgaria [Mesh:noexp] OR Burkina Faso 
[Mesh:noexp] OR Burundi [Mesh:noexp] OR Cambodia [Mesh:noexp] OR Cameroon 
[Mesh:noexp] OR Cape Verde [Mesh:noexp] OR Central African Republic [Mesh:noexp] OR 
Chad [Mesh:noexp] OR Chile [Mesh:noexp] OR China [Mesh:noexp] OR Colombia 
[Mesh:noexp] OR Comoros [Mesh:noexp] OR Congo [Mesh:noexp] OR Costa Rica 
[Mesh:noexp] OR Cote d'Ivoire [Mesh:noexp] OR Croatia [Mesh:noexp] OR Cuba [Mesh:noexp] 
OR Cyprus [Mesh:noexp] OR Czechoslovakia [Mesh:noexp] OR Czech Republic [Mesh:noexp] 
OR Slovakia [Mesh:noexp] OR Djibouti [Mesh:noexp] OR "Democratic Republic of the Congo" 
[Mesh:noexp] OR Dominica [Mesh:noexp] OR Dominican Republic [Mesh:noexp] OR East 
Timor [Mesh:noexp] OR Ecuador [Mesh:noexp] OR Egypt [Mesh:noexp] OR El Salvador 
[Mesh:noexp] OR Eritrea [Mesh:noexp] OR Estonia [Mesh:noexp] OR Ethiopia [Mesh:noexp] 
OR Fiji [Mesh:noexp] OR Gabon [Mesh:noexp] OR Gambia [Mesh:noexp] OR "Georgia 
(Republic)" [Mesh:noexp] OR Ghana [Mesh:noexp] OR Greece [Mesh:noexp] OR Grenada 
[Mesh:noexp] OR Guatemala [Mesh:noexp] OR Guinea [Mesh:noexp] OR Guinea-Bissau 
[Mesh:noexp] OR Guam [Mesh:noexp] OR Guyana [Mesh:noexp] OR Haiti [Mesh:noexp] OR 
Honduras [Mesh:noexp] OR Hungary [Mesh:noexp] OR India [Mesh:noexp] OR Indonesia 
[Mesh:noexp] OR Iran [Mesh:noexp] OR Iraq [Mesh:noexp] OR Jamaica [Mesh:noexp] OR 
Jordan [Mesh:noexp] OR Kazakhstan [Mesh:noexp] OR Kenya [Mesh:noexp] OR Korea 
[Mesh:noexp] OR Kosovo [Mesh:noexp] OR Kyrgyzstan [Mesh:noexp] OR Laos [Mesh:noexp] 
OR Latvia [Mesh:noexp] OR Lebanon [Mesh:noexp] OR Lesotho [Mesh:noexp] OR Liberia 
[Mesh:noexp] OR Libya [Mesh:noexp] OR Lithuania [Mesh:noexp] OR Macedonia [Mesh:noexp] 
OR Madagascar [Mesh:noexp] OR Malaysia [Mesh:noexp] OR Malawi [Mesh:noexp] OR Mali 
[Mesh:noexp] OR Malta [Mesh:noexp] OR Mauritania [Mesh:noexp] OR Mauritius [Mesh:noexp] 
OR Mexico [Mesh:noexp] OR Micronesia [Mesh:noexp] OR Middle East [Mesh:noexp] OR 
Moldova [Mesh:noexp] OR Mongolia [Mesh:noexp] OR Montenegro [Mesh:noexp] OR Morocco 
[Mesh:noexp] OR Mozambique [Mesh:noexp] OR Myanmar [Mesh:noexp] OR Namibia 
[Mesh:noexp] OR Nepal [Mesh:noexp] OR Netherlands Antilles [Mesh:noexp] OR New 
Caledonia [Mesh:noexp] OR Nicaragua [Mesh:noexp] OR Niger [Mesh:noexp] OR Nigeria 
[Mesh:noexp] OR Oman [Mesh:noexp] OR Pakistan [Mesh:noexp] OR Palau [Mesh:noexp] OR 
Panama [Mesh:noexp] OR Papua New Guinea [Mesh:noexp] OR Paraguay [Mesh:noexp] OR 
Peru [Mesh:noexp] OR Philippines [Mesh:noexp] OR Poland [Mesh:noexp] OR Portugal 
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[Mesh:noexp] OR Puerto Rico [Mesh:noexp] OR Romania [Mesh:noexp] OR Russia 
[Mesh:noexp] OR "Russia (Pre-1917)" [Mesh:noexp] OR Rwanda [Mesh:noexp] OR "Saint Kitts 
and Nevis" [Mesh:noexp] OR Saint Lucia [Mesh:noexp] OR "Saint Vincent and the Grenadines" 
[Mesh:noexp] OR Samoa [Mesh:noexp] OR Saudi Arabia [Mesh:noexp] OR Senegal 
[Mesh:noexp] OR Serbia [Mesh:noexp] OR Montenegro [Mesh:noexp] OR Seychelles 
[Mesh:noexp] OR Sierra Leone [Mesh:noexp] OR Slovenia [Mesh:noexp] OR Sri Lanka 
[Mesh:noexp] OR Somalia [Mesh:noexp] OR South Africa [Mesh:noexp] OR Sudan 
[Mesh:noexp] OR Suriname [Mesh:noexp] OR Swaziland [Mesh:noexp] OR Syria [Mesh:noexp] 
OR Tajikistan [Mesh:noexp] OR Tanzania [Mesh:noexp] OR Thailand [Mesh:noexp] OR Togo 
[Mesh:noexp] OR Tonga [Mesh:noexp] OR "Trinidad and Tobago" [Mesh:noexp] OR Tunisia 
[Mesh:noexp] OR Turkey [Mesh:noexp] OR Turkmenistan [Mesh:noexp] OR Uganda 
[Mesh:noexp] OR Ukraine [Mesh:noexp] OR Uruguay [Mesh:noexp] OR USSR [Mesh:noexp] 
OR Uzbekistan [Mesh:noexp] OR Vanuatu [Mesh:noexp] OR Venezuela [Mesh:noexp] OR 
Vietnam [Mesh:noexp] OR Yemen [Mesh:noexp] OR Yugoslavia [Mesh:noexp] OR Zambia 
[Mesh:noexp] OR Zimbabwe [Mesh:noexp] OR "tropical climate" OR "tropical climate" [MeSH] 
OR "Vulnerable Populations" [Mesh] OR "American Native Continental Ancestry Group" [Mesh] 
OR "Oceanic Ancestry Group" [Mesh] OR "aboriginals" [all fields] OR "aboriginals" [all fields] OR 
"native americans" [all fields] OR "native american" [all fields] OR "first nations" [all fields] OR 
inuit [all fields] OR eskimo [all fields] OR eskimos [all fields] OR maori [all fields] OR "Health 
Services, Indigenous" [MeSH] 
Step 2 (53847 Citations)  
"Growth Disorders" [Mesh:NoExp] OR "Body Weight Changes" [Mesh] OR "Child Nutrition 
Disorders" [Mesh] OR "Infant Nutrition Disorders" [Mesh] 
Step 1 AND Step 2 (7592 Citations) 
Step 3 (73672 Citations) 
"Failure to Thrive" [Mesh] OR "Body Height" [Mesh]OR "Thinness" [Mesh] OR "Starvation" 
[Mesh] OR "Protein Deficiency" [Mesh] OR "Malnutrition" [Mesh] OR "Malnutrition" 
[Mesh] or "stunting" [all fields] OR "stunted" [all fields] OR "wasted" [TIAB] OR "wasting" 
[TIAB] OR "height for age" [all fields] OR "weight for age" [all fields] OR "weight for 
height" [all fields] OR "growth faltering" [all fields] OR "underweight" [all fields] OR "under 
weight" [all fields] OR "short stature" [all fields] 
(Step 1 AND Step 2) OR Step 3 (79085 Citations) 
Step 4 (1848948 Citations) 
'Child' [Mesh] OR 'Maternal-Child Health Centers' [Mesh] OR 'Child Nutrition Sciences' [Mesh] 
OR 'Child Health Services' [Mesh] OR 'Child Nutritional Physiological Phenomena' [Mesh] OR 
'Child Nutrition Disorders' [Mesh] OR 'Child Mortality' [Mesh] OR 'Child Welfare' [Mesh] OR 
'Child Care' [Mesh] OR 'Child Reactive Disorders' [Mesh] OR 'Child Guidance' [Mesh] OR 'Child 
Reactive Disorders' [Mesh] OR 'Child Behavior Disorders' [Mesh] OR 'Child, Orphaned' [Mesh] 
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OR 'Child, Institutionalized' [Mesh] OR 'Child, Hospitalized' [Mesh] OR 'Child Development' 
[Mesh] OR 'Child Behavior' [Mesh] OR 'Developmental Disabilities' [Mesh] OR 'Mental Disorders 
Diagnosed in Childhood' [Mesh] OR 'Disabled Children' [Mesh] OR 'children' [TIAB] OR 
'newborn*' [TIAB] OR 'childhood' [TIAB] OR 'baby' [TIAB] OR 'babies' [TIAB] OR 'toddler' [TIAB] 
OR 'toddlers' [TIAB] OR 'infants' [TIAB] OR 'infant' [TIAB] OR 'infantile' [TIAB] OR 'young patient' 
[TIAB] OR 'young patients' [TIAB] OR 'Pediatric Nursing' [Mesh] OR 'Pediatric Assistants' 
[Mesh] OR 'Hospitals, Pediatric' [Mesh] OR 'Intensive Care Units, Pediatric' [Mesh] OR 
'Pediatrics' [Mesh] OR 'Pediatricians' [TIAB] OR 'paediatricians' [TIAB] OR 'Pediatrician' [TIAB] 
OR 'paediatrician' [TIAB] OR 'Pediatrics' [TIAB] OR 'paediatrics' [TIAB] OR 'Pediatric' [TIAB] OR 
'paediatric' [TIAB]  
Step 4 AND ((Step 1 AND Step 2) OR Step 3(34445 Citations)) 
Step 5 (2329420 Citations) 
"Congenital Abnormalities" [Mesh] OR "Genetic Diseases, Inborn" [Mesh] OR "Endocrine 
System Diseases" [Mesh]OR "Hormones, Hormone Substitutes, and Hormone Antagonists" 
[Mesh] OR "Kidney Diseases" [Mesh] 
(Step 4 AND ((Step 1 AND Step 2) OR Step 3)) NOT Step 5 23238 Citations 
  
 
EMBASE Malnutrition  
completed April 19, 2010 (17,634 Citations) 
Step 1 (3,164,283 citations) 
'child'/exp OR 'child' OR 'children'/exp OR 'children' OR 'youth'/exp OR 'youth' OR youth* OR 
newborn* OR 'newborn'/exp OR 'newborn' OR 'new born' OR 'childhood disease'/exp OR 
'childhood disease' OR 'baby'/exp OR 'baby' OR babies OR 'infant'/exp OR 'infant' OR infant* 
OR childhood* OR toddler* OR kid OR kids OR 'young patient' OR boy* OR girl* OR 'young age' 
OR pediatr* OR paediatr* OR 'child death'/exp OR 'child death' OR 'child health'/exp OR 'child 
health' OR 'child care'/exp OR 'child care' OR 'childhood mortality'/exp OR 'childhood mortality' 
OR 'child hospitalization'/exp OR 'child hospitalization' OR 'pediatric hospital'/exp OR 'pediatric 
hospital' OR child* 
 Step 2 (4,437,122 Citations) 
Afghanistan or Albania or Algeria or Angola or Antigua or Barbuda or Argentina or Armenia or 
Armenian or Aruba or Azerbaijan or Bahrain or Bangladesh or Barbados or Benin or Byelarus or 
Byelorussian or Belarus or Belorussian or Belorussia or Belize or Bhutan or Bolivia or Bosnia or 
Herzegovina or Hercegovina or Botswana or Brazil or Bulgaria or 'Burkina Faso' or 'Burkina 
Fasso' or 'Upper Volta' or Burundi or Urundi or Cambodia or 'Khmer Republic' or Kampuchea or 
Cameroon or Cameroons or Cameron or Camerons or 'Cape Verde' or 'Central African 
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Republic' or Chad or Chile or China or Colombia or Comoros or 'Comoro Islands' or Comores or 
Mayotte or Congo or Zaire or 'Costa Rica' or 'Cote d Ivoire' or 'Ivory Coast' or Croatia or Cuba or 
Cyprus or Czechoslovakia or 'Czech Republic' or Slovakia or 'Slovak Republic' or Djibouti or 
'French Somaliland' or Dominica or 'Dominican Republic' or 'East Timor' or 'East Timur' or 
'Timor Leste' or Ecuador or Egypt or 'United Arab Republic' or 'El Salvador' or Eritrea or Estonia 
or Ethiopia or Fiji or Gabon or 'Gabonese Republic' or Gambia or Gaza or 'Georgia Republic' or 
'Georgian Republic' or Ghana or 'Gold Coast' or Greece or Grenada or Guatemala or Guinea or 
Guam or Guiana or Guyana or Haiti or Honduras or Hungary or India or Maldives or Indonesia 
or Iran or Iraq or Jamaica or Jordan or Kazakhstan or Kazakh or Kenya or Kiribati or Korea or 
Kosovo or Kyrgyzstan or Kirghizia or Kyrgyz or Kirghiz or Kirgizstan or 'Lao PDR' or Laos or 
Latvia or Lebanon or Lesotho or Basutoland or Liberia or Libya or Lithuania or Macedonia or 
Madagascar or Malagasy or Malaysia or Malaya or Malay or Sabah or Sarawak or Malawi or 
Nyasaland or Mali or Malta or 'Marshall Islands' or Mauritania or Mauritius or 'Agalega Islands' 
or Mexico or Micronesia or 'Middle East' or Moldova or Moldovia or Moldovian or Mongolia or 
Montenegro or Morocco or Ifni or Mozambique or Myanmar or Myanma or Burma or Namibia or 
Nepal or 'Netherlands Antilles' or 'New Caledonia' or Nicaragua or Niger or Nigeria or 'Mariana 
Islands' or Oman or Muscat or Pakistan or Palau or Palestine or Panama or Paraguay or Peru 
or Philippines or Philipines or Phillipines or Phillippines or Poland or Portugal or 'Puerto Rico' or 
Romania or Rumania or Roumania or Russia or Russian or Rwanda or Ruanda or 'Saint Kitts' 
or 'St Kitts' or Nevis or 'Saint Lucia' or 'St Lucia' or 'Saint Vincent' or 'St Vincent' or Grenadines 
or Samoa or 'Samoan Islands' or 'Navigator Island' or 'Navigator Islands' or 'Sao Tome' or 
'Saudi Arabia' or Senegal or Serbia or Montenegro or Seychelles or 'Sierra Leone' or Slovenia 
or 'Sri Lanka' or Ceylon or 'Solomon Islands' or Somalia or Sudan or Suriname or Surinam or 
Swaziland or Syria or Tajikistan or Tadzhikistan or Tadjikistan or Tadzhik or Tanzania or 
Thailand or Togo or Togolese or Tonga or Trinidad or Tobago or Tunisia or Turkey or 
Turkmenistan or Turkmen or Uganda or Ukraine or Uruguay or USSR or 'Soviet Union' or 'Union 
of Soviet Socialist Republics' or Uzbekistan or Uzbek or Vanuatu or 'New Hebrides' or 
Venezuela or Vietnam or 'Viet Nam' or 'West Bank' or Yemen or Yugoslavia or Zambia or 
Zimbabwe or Rhodesia OR ((developing or 'less developed' or 'under developed' or 
underdeveloped or 'middle income' or 'low income' or 'lower income' or underserved or 'under 
served' or deprived or poor*) and (countr* or nation* or population* or world)) OR ((developing 
or 'less developed' or 'lesser developed' or 'under developed' or underdeveloped or middle 
income or 'lower income' or 'lower income') AND (economy or economies)) OR (low* NEAR 
(gdp or gnp or gross domestic or gross national )) OR ( low NEAR/3 middle ) OR (lmic OR lmics 
OR third AND world OR 'lami countries' OR 'lami country') OR ( transitional AND countr*) OR 
'tropic climate'/exp OR 'aborigine'/exp OR 'American Indian'/exp OR 'Eskimo'/exp OR 
'Maori'/exp OR 'indigenous people'/exp 
Step 3 (141,231 Citations) 
'thinness' OR 'stunted' OR 'stunting' OR 'growth faltering' OR 'wasted' OR 'height for age' OR 
'weight for age' OR 'weight for height' OR 'underweight' OR 'under weight' OR 'growth failure' 
OR 'protein deficiency'/exp OR 'starvation'/exp OR 'underweight'/exp OR 'lean body weight'/exp 
OR 'weight change'/exp OR 'growth curve'/exp OR 'growth inhibition'/exp OR 'growth rate'/exp 
OR 'postnatal growth'/exp OR 'failure to thrive'/exp OR 'wasting syndrome'/exp OR 
'malnutrition'/de or 'developmental, age and growth parameters'/de OR 'growth disorder'/de OR 
'body height'/exp OR 'body height'/exp 
Step 1 AND Step 2 AND Step 3 (24,575 Citations) 
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Step 4  
'genetic and familial disorders'/exp OR 'congenital disorder'/exp OR 'endocrine disease'/exp OR 
'hormones and agents acting on the endocrine system'/exp OR 'urogenital tract disease'/exp OR 
'neoplasm'/exp 
 (Step 1 AND Step 2 AND Step 3) NOT Step 4 (16,833 Citations) 
Step 5 (13,130 Citations) 
'growth retardation'/exp 
    
Step 1 and Step 2 and Step 5 (2,321 Citations) 
Step 6 (5,6000,005) 
'genetic and familial disorders'/exp OR 'congenital disorder'/exp OR 'hormones and agents 
acting on the endocrine system'/exp OR 'urogenital tract disease'/exp OR 'neoplasm'/exp 
(Step 1 and Step 2 and Step 3) NOT Step 6 (801 Citations) 
 
 ((Step 1 AND Step 2 AND Step 3) NOT Step 4) OR ((Step 1 and Step 2 and Step 5) NOT Step 
6) (17,634 Citations)  
 
WHO LILACS Database (TE/ED and Malnutrition)  
completed June 17, 2010 (1617 Citations) 
("tropical sprue" OR "tropical enteropathy" OR "environmental enteropathy" OR "persistent 
diarrhea" OR "Persistent diarrhoea" or "chronic diarrhoea" or "chronic diarrhea" OR "tropical 
malabsorption syndrome" OR Stunting OR wasting OR underweight OR "height for age" OR 
"weight for height" OR "weight for age" OR malnutrition) and ( Child OR Children OR newborn 
OR childhood OR baby OR babies OR toddler OR toddlers OR infants OR infant OR infantile 
OR young patient OR young patients OR Pediatricians OR paediatricians OR Pediatrician OR 
paediatrician OR Pediatrics OR paediatrics OR Pediatric OR paediatric )  
 
WHO SE Asia Database (IMSEAR) (TE/ED and Malnutrition)  
completed June 17, 2010 (1335 Citations) 
(("tropical sprue" OR "tropical enteropathy" OR "environmental enteropathy" OR "persistent 
diarrhea" OR "Persistent diarrhoea" or "chronic diarrhoea" or "chronic diarrhea" OR "tropical 
malabsorption syndrome" OR Stunting OR wasting OR underweight OR "height for age" OR 
"weight for height" OR "weight for age" OR malnutrition) AND (Child OR Children OR newborn 
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OR childhood OR baby OR babies OR toddler OR toddlers OR infants OR infant OR infantile 
OR young patient OR young patients OR Pediatricians OR paediatricians OR Pediatrician OR 
paediatrician OR Pediatrics OR paediatrics OR Pediatric OR paediatric)) 
 
 
WHO Western Pacific Region Index Medicus (WPRIM) (TE/ED and Malnutrition)  
completed June 17, 2010 (685 Citations) 
"tropical sprue" OR "tropical enteropathy" OR "environmental enteropathy" OR "persistent 
diarrhea" OR "Persistent diarrhoea" or "chronic diarrhoea" or "chronic diarrhea" OR "tropical 
malabsorption syndrome" OR Stunting OR wasting OR underweight OR "height for age" OR 
"weight for height" OR "weight for age" OR malnutrition  
 
WHO EMRO (IMEMR) (TE/ED and Malnutrition)  
completed June 17, 2010 (459 Citations) 
Child OR Children OR newborn OR childhood OR baby OR babies OR toddler OR toddlers OR 
infants OR infant OR infantile OR young patient OR young patients OR Pediatricians OR 
paediatricians OR Pediatrician OR paediatrician OR Pediatrics OR paediatrics OR Pediatric OR 
paediatric [KeyWords] and "tropical sprue" OR "tropical enteropathy" OR "environmental 
enteropathy" OR "persistent diarrhea" OR "Persistent diarrhoea" or "chronic diarrhoea" or 
"chronic diarrhea" OR "tropical malabsorption syndrome" OR Stunting OR wasting OR 
underweight OR "height for age" OR "weight for height" OR "weight for age" OR malnutrition 
[KeyWords]  
 
WHO African Index Medicus (TE/ED and Malnutrition)  
completed June 17, 2010 (70 Citations) 
"tropical sprue" OR "tropical enteropathy" OR "environmental enteropathy" OR "persistent 
diarrhea" OR "Persistent diarrhoea" or "chronic diarrhoea" or "chronic diarrhea" OR "tropical 
malabsorption syndrome" OR Stunting OR wasting OR underweight OR "height for age" OR 
"weight for height" OR "weight for age" OR malnutrition 
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Appendix 2. References used to test systematic search. 
These papers were used to confirm inclusiveness in search criteria, and to confirm that filters do 
not inadvertently exclude relevant work. 
Reference Setting and why selected 
Brown KH, Khatun M, Ahmed G. Relationship of the xylose 
absorption status of children in Bangladesh to their 
absorption of macronutrients from local diets. Am J Clin Nut. 
1981;34(8):1540-7. 
Setting: Bangladesh 
Reason for selection: Biomarker and 
physiologic test studied 
Fagundes-Neto U, Viaro T, Wehba J, Patrício FR, Machado 
NL. Tropical enteropathy (environmental enteropathy) in 
early childhood: a syndrome caused by contaminated 
environment. J Trop Pediatr. 1984;30(4):204-9. 
Setting: Brazil 
Reason for selection: Biomarkers, 
pathophysiologic correlates 
Solomons NW, Mazariegos M, Brown KH, Klasing K. The 
underprivileged, developing country child: environmental 
contamination and growth failure revisited. Nutr Rev 
1993;51(11):327-32. 
Setting: Review 
Reason for selection: Addresses 
pathophysiology and epidemiology 
Fagundes-Neto U, Martins MC, Lima FL, Patricio FR, Toledo 
MR. Asymptomatic environmental enteropathy among slum-
dwelling infants. J Am Coll Nutr 1994;13(1):51-6. 
Setting: Brazil 
Reason for selection: Pathophysiology 
Bhutta ZA, Hendricks KM. Nutritional management of 
persistent diarrhea in childhood: a perspective from the 
developing world. J Pediatr Gastroenterol Nutr 
1996;22(1):17-37. 
Setting: Review 
Reason for selection: Therapy and 
epidemiology 
Menzies IS, Zuckerman MJ, Nukajam WS, Somasundaram 
SG, Murphy B, Jenkins AP, et al. Geography of intestinal 
permeability and absorption. Gut 1999;44(4):483-91. 
Setting: Qatar  
Reason for selection: Pathophysiology 
Campbell DI, Elia M, Lunn PG. Growth faltering in rural 
Gambian infants is associated with impaired small intestinal 
barrier function, leading to endotoxemia and systemic 
inflammation. J Nutr. 2003;133(5):1332-8. 
Setting: Gambia 
Reason for selection: Biomarkers related to 
stunting 
Kukuruzovic R, Brewster DR, Gray E, Anstey NM. Increased 
nitric oxide production in acute diarrhoea is associated with 
abnormal gut permeability, hypokalaemia and malnutrition in 
tropical Australian aboriginal children. Trans R Soc Trop Med 
Hyg. 2003;97(1):115-20. 
Setting: Australian Aboriginal children  
Reason for selection: Relates a relevant 
biomarker (NO production) to 
lactulose/rhamnose test of intestinal 
permeability  
Solomons NW. Environmental contamination and chronic 
inflammation influence human growth potential. J Nutr 
2003;133(5):12372. 
Setting: Commentary 
Reason for selection: Risk factors 
1 The reference was not captured in the umbrella search of multiple databases with both TE/ED and stunting search 
terms (i.e., PubMed + EMBASE + GH—TE/ED + stunting). 
2 The reference was captured in the PubMed stunting search but lost when the child filter was added. 
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Reference Setting and why selected 
Campbell DI, McPhail G, Lunn PG, Elia M, Jeffries DJ. 
Intestinal inflammation measured by fecal neopterin in 
Gambian children with enteropathy: association with growth 
failure, Giardia lamblia, and intestinal permeability. J Pediatr 
Gastroenterol Nutr. 2004;39(2):153-7.  
Setting: Gambia 
Reason for selection: Marker of gut 
inflammation in children and inflammation is 
related to another biomarker 
(lactulose:mannitol ratio) and growth of 
children in study 
Salazar-Lindo E, Allen S, Brewster DR, Elliott EJ, Fasano A, 
Phillips AD, et al. Intestinal infections and environmental 
enteropathy: Working Group report of the second World 
Congress of Pediatric Gastroenterology, Hepatology, and 
Nutrition. J Pediatr Gastroenterol Nutr 2004;39 Suppl 
2:S662-9. 
Setting: Review 
Reason for selection: Broadly inclusive of 
topics of interest 
Lima AA, Brito LF, Ribeiro HB, Martins MC, Lustosa AP, 
Rocha EM, et al. Intestinal barrier function and weight gain in 
malnourished children taking glutamine supplemented 
enteral formula. J Pediatr Gastroenterol Nutr 2005;40(1):28-
35. 
Setting: Brazil 
Reason for selection: Pathophysiology and 
treatment 
Bhutta ZA. Effect of infections and environmental factors on 
growth and nutritional status in developing countries. J 
Pediatr Gastroenterol Nutr 2006;43 Suppl 3:S13-213. 
Setting: Review 
Reason for selection: Epidemiology and 
causative factors 
Bhutta ZA, Nelson EA, Lee WS, Tarr PI, Zablah R, Phua KB, 
et al. Recent advances and evidence gaps in persistent 
diarrhea. J Pediatr Gastroenterol Nutr 2008;47(2):260-5. 
Setting: Review 
Reason for selection: Broadly inclusive data 
Botero-Garcés JH, García-Montoya GM, Grisales-Patiño D, 
Aguirre-Acevedo DC, Alvarez-Uribe MC. Giardia intestinalis 
and nutritional status in children participating in the 
complementary nutrition program, Antioquia, Colombia, May 
to October 2006.Rev Inst Med Trop Sao Paulo. 
2009;51(5):155-62.  
Setting: Colombia 
Reason for selection: Studies relation 
between a specific agent and nutritional 
status  
Goto R, Mascie-Taylor CG, Lunn PG. Impact of intestinal 
permeability, inflammation status and parasitic infections on 
infant growth faltering in rural Bangladesh 2009:Br J Nutr. 
2009;101(10):1509-16.  
Setting: Rural Bangladesh 
Reason for selection: Biomarkers 
associated with stunting  
Humphrey JH. Child undernutrition, tropical enteropathy, 
toilets, and handwashing. Lancet 2009;374(9694):1032-5. 
Setting: Review 
Reason for selection: Environmental factors 
Ritchie BK, Brewster DR, Davidson GP, Tran CD, McNeil Y, 
Hawkes JS, et al. 13C-sucrose breath test: novel use of a 
noninvasive biomarker of environmental gut health. 
Pediatrics. 2009;124(2):620-6.  
Setting: Australian Aboriginal children 
Reason for selection: Novel biomarker 




3 The reference was captured in the search with only the stunting term. 
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Appendix 3. Summary of sampled references published between 1990-1999. 
Method: An index of records determined to be relevant to this systematic review was sorted by 
year. From this ordering, every 10th article was sampled. 
 
1. Khoshoo V, Bhan MK, Jain R, Jayashree S, Bhandari N, Sazawal S, et al. Intestinal glucoamylase and 
other disaccharidases in children with protracted diarrhoea. Indian J Med Res. 1990;92:1-4. 
Sample size: 42 (all < 5 years of age) 
Subjects: Persistent or chronic diarrhea and malnutrition 
Markers: Jejunal biopsy, brush border disaccharidase activity, and correlation of latter with degree of 
mucosal injury 
Relevance to 2000-2010 set: Disaccharidase activity was investigated in one study from the previous 
decade; this study adds assessment of its relationship with histology. 
 
2. Saavedra JM, Brown KH. Nonabsorbable marker and single, random stool samples used for 
measuring intestinal absorption of macronutrients in infants and children. Am J Clin Nutr. 1991;53(3):790-
94. 
Sample size: 21 (all < 5 years of age) 
Subjects: Malnourished 
Markers: Fecal excretion of polyethylene glycol as a marker of intestinal absorption and in comparison to 
standard balance test 
Relevance to 2000-2010 set: These tests of absorption were not included in the previous decade article 
set.  
 
3. Sullivan PB, Lunn PG, Northrop-Clewes C, Crowe PT, Marsh MN, Neale G. Persistent diarrhea and 
malnutrition--the impact of treatment on small bowel structure and permeability. J Pediatr Gastroenterol 
Nutr. 1992;14(2):208-15. 
Sample size: 20 (all < 5 years of age) 
Subjects: Persistent or chronic diarrhea, most also malnourished 
Markers: Lactulose and mannitol fractional excretion, L:M, and jejunal biopsy; compared L:M with biopsy 
results  
Relevance to 2000-2010 set: The L:M test was reported in 25 studies in later decade, but none compared 
it to histology. 
 
4. Baqui AH, Sack RB, Black RE, Chowdhury HR, Yunus M, Siddique AK. Cell-mediated immune 
deficiency and malnutrition are independent risk factors for persistent diarrhea in Bangladeshi children. 
Am J Clin Nutr. 1993;58(4):543-48. 
Sample size: 705 (all < 5 years of age) 
Subjects: Persistent diarrhea, malnutrition, or asymptomatic 
Markers: Cell-mediated immune response with multiple-antigen skin test  
Relevance to 2000-2010 set: A similar study was published in the 2000-2010 publication set. 
 
5. Roy SK, Akramuzzaman SM, Haider R, Khatun M, Akbar MS, Eeckels R. Persistent diarrhoea: efficacy 
of a rice-based diet and role of nutritional status in recovery and nutrient absorption. Br J Nutr. 
1994;71(1):123-34. 
Sample size: 51 (all < 5 years of age) 
Subjects: Persistent diarrhea (many also malnourished) and controls with previous history of acute 
diarrhea 
Markers: Comparison of nutrient absorption in cases and controls determined by 72-hour balance study 
and recovery of cases following rice-based diet therapy 




6. Kallas MR, Patricio FR, Fagundes-Neto U. [Morphometrics of the small intestine in children with 
diarrhea due to classical enteropathogenic Escherichia coli and to environmental asymptomatic 
enteropathy]. Rev Assoc Med Bras. 1995;41(3):162-166. Portuguese. 
Sample size: 46 (likely most or all subjects < 5 years of age; mean age was under 7 months) 
Subjects: Acute or persistent diarrhea with stool culture positive for EPEC (cases) or asymptomatic 
children negative for EPEC (controls) 
Markers: Small intestine biopsy and morphometry 
Relevance to 2000-2010 set: Histology was examined in 18 studies in the 2000-2010 set with one study 
also using morphometric assessment.  
 
7. Cooper ES, Ramdath DD, Whyte-Alleng C, Howell S, Serjeant BE. Plasma proteins in children with 
trichuris dysentery syndrome. J Clin Pathol. 1997;50(3):236-240. 
Sample size: 89 (many older than 5 years of age) 
Subjects: Chronic diarrhea with and without Trichuris dysentery syndrome and healthy controls 
Markers: Blood markers: alpha-1-antitrypsin, ceruloplasmin, albumin, globulin, fibrinogen, fibronectin, 
ferritin, transferrin, plasma viscosity, hemoglobin, leukocytes, and CRP 
Relevance to 2000-2010 set: Primarily assessed markers of systemic inflammation that were reviewed in 
assessments of articles from the previous decade. The remaining markers are primarily assessments of 
hepatic function and were not assessed in the 2000-2010 set. 
 
8. Brooks SE, Reid WA. Scanning electron microscopy of the jejunum in children with protein-energy 
malnutrition. West Indian Med J. 1997;46(1):15-21. 
Sample size: 7 (all < 5 years of age) 
Subjects: Fatal severe kwashiorkor or marasmic kwashiorkor 
Markers: Scanning electron microscopy (SEM) and light microscopy on jejunal biopsy sections taken by 
autopsy and fixed within 75 minutes after death 
Relevance to 2000-2010 set: In the later decade publications, SEM and light microscopy were used in 
one study to investigate jejunal morphology in 16 infants with persistent diarrhea, many of whom also had 
small bowel bacterial overgrowth (as measured by jejunal secretion) and/or exhibited some degree of 
malnutrition. 
 
9. Abbas KA, Bilal R, Sajjad MI, Latif Z, Mirza NH. Fat absorption in persistent diarrhoea using 13C-
labelled trioctanoin breath test. J Trop Pediatr. 1999;45(2):87-94. 
Sample size: 10 (all < 5 years of age) 
Subjects: Persistent diarrhea (some with malnutrition) and asymptomatic controls 
Markers: Fat absorption by breath test after 13C-labelled trioctanoin administration 
Relevance to 2000-2010 set: 2 studies in the 1990-1999 publication set assessed fat absorption although 
not by breath test with this specific medium chain fatty acid. 
 
10. Taniguchi K, Rikimaru T, Yartey JE, Akpedonu P, Armar-Klemesu MA, Nkrumah FK, et al. 
Immunological background in children with persistent diarrhea in Ghana. Pediatr Int. 1999;41(2):162-167. 
Sample size: 85 (all < 5 years of age) 
Subjects: Persistent or acute diarrhea 
Markers: A variety of serum markers of systemic inflammation and immune response were compared 
between persistent and acute diarrhea cases, including: albumin, pre-albumin, total protein, transferrin, 
IgA & IgG subclass fractions, natural killer cells, lymphocyte immunophenotypes, and T-cell activation.  
Relevance to 2000-2010 set: Many of these systemic markers were examined in the 2000-2010 set, 
although some were not.  
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Appendix 5. Highly considered but excluded references. 
Reference Country Reason for exclusion 
Altuntas B, Filik B, Ensari A, Zorlu 
P, Teziç T. Can zinc deficiency be 
used as a marker for the diagnosis 
of celiac disease in Turkish 
children with short stature? Pediatr 
Int. 2000;42(6):682-684. 
Turkey Biopsy data were the same as previously reported 
in a 1998 publication1 that was included in this 
review. This 2000 publication adds no new data of 
relevance to this review. 
Bahia M, Rabello A, Brasileiro 
Filho G, Penna FJ. Serum 
antigliadin antibody levels as a 
screening criterion before jejunal 
biopsy indication for celiac disease 
in a developing country. Braz J 
Med Biol Res. 2001;34(11):1415-
1420. 
Brazil The only outcomes of interest to this review that 
were reported on for subjects of interest (controls 
that did not have celiac disease) were that their 
jejunal biopsy results were “normal,” and no other 
data or specific information was reported that 
pertained to this review. 
Bay A, Oner AF, Celebi V, Uner A. 
Evaluation of vitamin K deficiency 
in children with acute and 
intractable diarrhea. Adv Ther. 
2006;23(3):469-474. 
Turkey Outcomes were primarily related to micronutrient 
(vitamin K) deficiency or malabsorption. 
Cooke ML, Goddard EA, Brown 
RA. Endoscopy findings in HIV-
infected children from sub-




Most subjects had upper gastrointestinal 
conditions that were not of interest to this review. 
Only 3 subjects had diarrhea, and it was unlikely 
that they were all under 5 yr. 
Kelly P, Musuku J, Kafwembe E, 
Libby G, Zulu I, Murphy J, et al. 
Impaired bioavailability of vitamin 
A in adults and children with 
persistent diarrhoea in Zambia. 
Aliment Pharmacol Ther. 
2001;15(7):973-979. 
Zambia Change in serum retinol status was assessed 
following administration of oral vitamin A to adult 
cases (males hospitalized with persistent diarrhea 
(PD)) (n=15), controls (males hospitalized with 
conditions other than PD) (n=24) and cases under 
2 yr hospitalized with PD and malnutrition (n=11). 
While the children with PD did have similar 
degrees of change in serum retinol after vitamin A 
administration compared to the adult controls, the 
study did not include childhood controls. Without 
childhood controls and with limited sample size of 
children, interpretation and generalization of 
findings to childhood enteric function is limited. 
Kukuruzovic R, Robins-Browne 
RM, Anstey NM, Brewster DR. 
Enteric pathogens, intestinal 
permeability and nitric oxide 
Australia Data on outcomes of interest to this review were 
not reported.  
1 Altuntas B, Kansu A, Ensari A, Girgin N. Celiac disease in Turkish short-statured children and the value 
of antigliadin antibody in diagnosis. Acta Paediatr Jpn. 1998;40(5):457-460. 
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Reference Country Reason for exclusion 
production in acute gastroenteritis. 
Pediatr Infect Dis J. 
2002;21(8):730-739. 
Kumar R, Marwaha N, Marwaha 
RK, Garewal G. Vitamin K 
deficiency in diarrhoea. Indian J 
Pediatr. 2001;68(3):235-238. 
India Outcomes were primarily related to micronutrient 
(vitamin K) deficiency or malnutrition. 
Manary MJ, Hotz C, Krebs NF, 
Gibson RS, Westcott JE, Arnold T, 
et al. Dietary phytate reduction 
improves zinc absorption in 
Malawian children recovering from 
tuberculosis but not in well 
children. J Nutr. 
2000;130(12):2959-2964. 
Malawi Subjects ranged in age from 3-13 yr, but based on 
the group means and standard deviations for age, 
there were likely to be few subjects under age 5 
years. 
 
Thacher TD, Obadofin MO, 
O'Brien KO, Abrams SA. The 
effect of vitamin D2 and vitamin D3 
on intestinal calcium absorption in 
Nigerian children with rickets. J 
Clin Endocrinol Metab. 
2009;94(9):3314-3321. 
 Nigeria Study assessed differences in calcium uptake with 
varying vitamin D preparations and was not an 
assessment of intestinal function.  
Ukarapol N, Lertprasertsuk N, 
Fuchs GJ, Wongsawasdi L, 
Sirisanthana V. Impact of 
gastrointestinal endoscopy on HIV-
infected children. Dig Endosc. 
2004;16(1):26-29. 
Thailand Study described 13 colonoscopy or 
sigmoidoscopy and 10 gastroduodenoscopy 
sessions for 14 patients resulting in 7 possible 
assessments of the small intestine. However 
results were aggregated across gastrointestinal 
anatomical sites, and it was difficult to extract 
results of interest to this review.  
Walkowiak J, Herzig KH. Fecal 
elastase-1 is decreased in villous 
atrophy regardless of the 
underlying disease. Eur J Clin 
Invest. 2001;31(5):425-430. 
Poland The age range of all subjects (n=54) was 2-16 yr 
with a mean of 7.0 yr, SE=0.5. The sample size of 
children of any age with presentations of interest 
to this review was n=18. The high mean age of 
subjects coupled with small sample size suggest 
that few children with presentations meeting 
inclusion criteria were likely under 5 yr. In addition, 
it was unclear if the study setting met developing 
country setting inclusion criteria. 
Yachha SK, Aggarwal R, Srinivas 
S, Srivastava A, Somani SK, Itha 
S. Antibody testing in Indian 
children with celiac disease. Indian 
J Gastroenterol. 2006;25(3):132-
135. 
India While some subjects in this study were under 5 yr 
of age, the subjects of interest to this review (i.e., 
the children without celiac disease who had small 
intestinal biopsies) were all aged >5 yr. 
 
309
Appendix 6. Review articles with information of relevance to the systematic review. 
Bhatnagar S. Laboratory diagnosis of persistent and chronic diarrhea. IJPP. 2003;5(2):125-132. 
Bhutta ZA, Nelson EA, Lee WS, Tarr PI, Zablah R, Phua KB, et al. Recent advances and evidence 
gaps in persistent diarrhea. J Pediatr Gastroenterol and Nutr. 2008;47(2):260-265.  
Bhutta ZA. Effect of infections and environmental factors on growth and nutritional status in 
developing countries. J Pediatr Gastroenterol Nutr. 2006 Dec;43: Suppl 3:S13-21. 
Bickler SW. Tropical enteropathy protects against Western diseases in environments of poor 
sanitation. Med Hypotheses. 2006;67(1):146-150. 
Brewster DR. Critical appraisal of the management of severe malnutrition: 3. Complications. J 
Paediatr Child Health. 2006;42(10):583-593. 
Brewster DR, Manary MJ, Menzies IS, O'Loughlin EV, Henry RL. Intestinal permeability in 
kwashiorkor. Arch Dis Child. 1997; Mar;76(3):236-41. 
Butler RN. Non-invasive tests in animal models and humans: a new paradigm for assessing efficacy 
of biologics including prebiotics and probiotics. Curr Pharm Des. 2008;14(14):1341-50. 
Davidson G, Kritas S, Butler R. Stressed mucosa. Nestle Nutr Workshop Ser Pediatr Program. 
2007;59:133-142; discussion 143-146. 
Gibbons T, Fuchs GJ. Chronic enteropathy: clinical aspects. Nestle Nutr Workshop Ser Pediatr 
Program. 2007;59:89-101; discussion 102-104. 
Guerrant RL, Oriá RB, Moore SR, Oriá MO, Lima AA. Malnutrition as an enteric infectious disease 
with long-term effects on child development. Nutr Rev. 2008;66(9):487-505. 
Humphrey JH. Child undernutrition, tropical enteropathy, toilets, and handwashing. Lancet. 
2009;374(9694):1032-35. 
Mehta S. Celiac disease in India. Indian J Gastroenterol. 2008;27(1):43. 
Petri WA Jr, Miller M, Binder HJ, Levine MM, Dillingham R, Guerrant RL. Enteric infections, diarrhea, 
and their impact on function and development. J Clin Invest. 2008;118(4):1277-90. 
Prentice AM, Darboe MK, Growth and host-pathogen interactions. Nestle Nutr Workshop Ser Pediatr 
Program. 2007;61:197-210. 
Ramakrishna BS, Venkataraman S, Mukhopadhya A. Tropical malabsorption. Postgrad Med J. 2006; 
82(974):779-787. 
Solon JA, Morgan G, Prentice A. Mucosal immunity in severely malnourished Gambian children. J 
Pediatr. 2006; 149(5) Suppl:S100-S106. 
Sondheimer JM. Glutamine for childhood malnutrition: Probably not needed. J Pediatr Gastroenterol 
and Nutr. 2005;40(1):24-25. 
Sullivan PB. Studies of the small intestine in persistent diarrhea and malnutrition: the Gambian 
experience. J Pediatr Gastroenterol Nutr. 2002;34 Suppl 1:S11-13. 
Taren DL. Diarrhea and other gastrointestinal diseases. In: Gershwin ME, Nestel P, Keen CL, editors. 
Handbook of Nutrition and Immunity. Humana Press; 2004;287-302. 
Velasco-Benitez CA. Digestive, hepatic, and nutritional manifestations in Latin American children with 









Target Population  
Design and 
Sample Size  Biomarker Results Conclusion Comments 
2003 
 












Fecal cytokines and 
lactoferrin as markers 
of intestinal 
inflammation among 








3-43 mo olds 
recruited from a 
shantytown 
community who 
were screened for 
enteric pathogens. 
 
There was a high 
prevalence of 
malnutrition 








these data were 







with C. parvum:  
• 4 with no 
diarrhea 
• 10 with AD 








HAZ and WAZ 
scores to cases 
 
Stool tests: 
• Lactoferrin  
(17 cases and 15 
controls tested) 
• IL-8  
(13 cases and 15 
controls tested) 
• TNF-α  
(10 cases and 0 






• 12/17 cases 
• 1/4 cases without 
diarrhea 
• 8/10 AD cases 
• 3/3 PD cases 
• 3/15 controls (p=0.006 
compared to cases) 
 
IL-8 detectable: 
• 3/13 all cases 
• 0/2 cases without 
diarrhea 
• 3/10 AD cases 
• 0/1 PD cases 
• 6/16 controls (p=0.435 
compared to cases) 
 
TNF-α detectable:  
• 0/10 cases 
 
The proportion of 
children who tested 
positive for fecal 
lactoferrin was 





diarrhea, than in 
uninfected controls, 
although 20% of 
the control group 
tested positive. 
 
Fecal IL-8 did not 
differ between 












stool tests were 











negative if there 
was no reaction 








Alves GM et al. 
 
Nutritional status and 
breath hydrogen test 
with lactose and 




breath test (HBT) as a 
marker of lactase 
activity, and lactulose 
HBT as a marker of 
Limão Verde and 
Córrego Seco, 
Mato Grosso du 
Sul, Brazil 
 
All children <10 yr 
old were recruited 


















• Lactose HBT 
(251 tested) 
• Lactulose HBT  
(252 tested) 
Lactose HBT: 
• Elevated: 27.1% among all 
subjects 
• Borderline: 43.0% among 
all subjects 
• 0% of subjects <4 yr had 
elevated or borderline 
results 
 
Lactulose HBT positive: 
• 11.5% of all subjects 
• 8.6% of subjects <4 yr 
The prevalence of 
lactase deficiency 
as measured by 
lactose HBT was 
>25%, but non-
existent among 
those <4 yr of age. 
 
Prevalence of 
SBBO as assessed 
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Target Population  
Design and 




Amadi B et al. 
 
Reduced production of 
sulfated 
glycosaminoglycans 
occurs in Zambian 
children with 





of intestinal markers in 
children with PD and 




12.2-19.8 mo olds 
with PD and 
malnutrition 
admitted to the 
malnutrition ward 







with PD and 
malnutrition:  
• 18 with 
marasmus 
• 8 with 
marasmic 
kwashiorkor 
• 15 with 




from UK  
 
 
* UK subjects 
are presented 




in the review. 
However we do 
not include 
these subjects 
in the sample 





• Densities in lamina 
propria and crypt 
epithelium: 







• Syndecan-1  
• Inflammatory cell 
markers: 
• CD3 IEL 
• Ki67 
• Human leukocyte 
antigen DR-1 
(HLA-DR) 
Biopsy findings among the 
Zambian compared to the UK 
children: 
• Villous height reduced 
• Crypt depth increased  
• ~50% reduction in 
crypt:villous ratio 
• Values for lamina propria 
cell densities were not 
reported for UK subjects 
 
No significant differences in 
crypt or villous measures or 
lamina propria cell densities 
were observed between 




• Inflammatory markers were 
seen in higher densities 
compared to the UK 
children. There were 
significant differences 
between the different 
nutritional groups in the 
specific types of 
inflammatory markers. 
• There was a significant 
reduction in GAGs and 
HSPG in the kwashiorkor 
group compared to UK 
children, but no significant 
differences between 
kwashiorkor and other 
presentations of 
malnutrition.  




compared to UK 










compared to UK 
children and 
showed different 












markers did not 
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Target Population  
Design and 
Sample Size  Biomarker Results Conclusion Comments 
epithelial syndecan-1 
protein expression between 
the malnutrition groups 




Azim T et al. 
 
Immune response of 
Bangladeshi children 






tests, as well as 
transferrin and 
albumin as markers of 
nutritional status 
among children with 




7-12 mo olds with 







Cases were those 
who went on to 
develop PD, 
controls were 
those who did not.  
 
An additional 
group of subjects 
without diarrhea 
were recruited 
from a nutrition 














• 85 with AD 























• Mononuclear cell 
proliferation, 
spontaneous and in 












and Trichophyton  
WBC total and differential, 
immunoglobulin subtypes, 
cytokines, transferrin, and 
albumin did not differ 
between cases with diarrhea 
or controls, nor did stool 
leukocyte or erythrocyte 
counts.  
 
The percentages of 
neutrophils that polarized in 
response to stimulation were 
significantly higher in subjects 
with AD or PD compared to 
those without diarrhea; there 
was no difference between 
the two diarrhea groups. 
 
Opsonization did not vary 
between any groups. 
 
Monocyte spontaneous 
proliferation counts were less 
than half among children with 
no diarrhea compared to 
those with AD (p<0.001) or 
with PD (p=0.011); there was 
no difference between the 
two diarrhea groups.  
 
Monocyte proliferation in 
response to stimulation did 
not differ between the 3 
groups.  
 
The proportion with DTH 











progression to PD 
was a negative 
DTH response to 
tuberculin antigen 
(odds ratio=3.8, CI: 
1.4, 9.9). This was 
calculated from a 
logistic regression 
analysis that only 
included children 
with diarrhea.  
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Target Population  
Design and 





• Red blood cells 
responses differed among the 
three groups only in response 
to tuberculin (p=0.021). More 
PD subjects had a negative 
tuberculin response than did 
subjects with AD (p=0.024).  
2005 
 
Bhatnagar S et al. 
 
Celiac disease with 
mild to moderate 
histological changes is 
a common cause of 


























antibodies were of 










70 had normal histology 
(defined as crypt:villous ratio 
1:2-3, absence of lymphoid 




37 had mild changes (defined 
as mild blunting of villi with 
crypt:villous ratio of 1:1*). A 
specific etiology was 
identified in only n=5: 
• 2 with giardiasis 
• 1 with lymphangiectasia 
• 2 with chronic pancreatitis 
 
Only children with CD had 
moderate or severe histologic 
changes. 
 
* Along with increased IEL 
and lymphocytic lamina 
propria infiltration. 
More than one 





at follow-up their 
growth had 






reached for 86% of 
subjects with 
abnormal histology 






Bitarakwate E et al. 
 
Serum zinc status of 
children with 
persistent diarrhea 
admitted to the 
diarrhea management 






6-36 mo olds with 

















• Total protein 
• Hemoglobin 
PD cases:  
• 47.9% low serum protein  
• 69.7% low serum albumin 
• Low mean hemoglobin 
(10.5 g/dL) 
 
For controls, means of all 
three laboratory values were 
within normal range; percent 
of subjects with abnormal 
values are not reported. 
Decreased 
albumin, serum 
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Target Population  
Design and 




children with and 
without PD 
 
All three test results were 
significantly lower in children 
with PD than in controls (p< 
0.01 for each comparison). 
2010 
 
Bukhari AS et al. 
 
DNA damage and 
plasma homocysteine 
concentrations are 
associated with serum 
metabolites and 
mineral constituents' 





levels of DNA damage 
among children with 




3-6 yr olds 
admitted to 


















• Total protein 
• Total cholesterol, 
HDL, LDL, 
triglycerides 
• AST, ALT 
• T3, T4 
• Total oxidant status 
(TOS), Total anti-




• DNA damage to 
lymphocytes 
Mean values significantly 
higher among PD cases than 





• DNA damage 
 
Mean values significantly 
lower among PD cases than 
in healthy controls:  












speculate that zinc 
deficiency, more 
commonly found in 
the children with 





play an important 
role in mediating 
DNA damage.  
Control 
recruitment 










gender in both 
the case and 
















Bushen OY et al. 
 
Heavy cryptosporidial 







All newborns from 
an urban 
shantytown were 












68.3% were lactoferrin- 
positive; there were no 
differences in positivity 
between subjects with C. 
hominis and C. parvum spp. 
 
67.9% of lactoferrin-positive 
subjects had very high titers. 
Lactoferrin was 
correlated with 
younger age and 
symptomatic 
infection among 
those infected with 
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Target Population  
Design and 






Fecal lactoferrin as a 




and followed for 
















Younger children were more 
often lactoferrin-positive 
(p=0.03). The difference was 
mediated by C. parvum; 
87.5% of ≤1 year olds 
compared to 40.0% of older 
children with C. parvum were 
lactoferrin-positive (p=0.04). 
There was no difference 
among those infected with C. 
hominis. 
 
Lactoferrin was correlated 
with symptomatic infection 
among those with C. parvum: 
78.6% of symptomatic 
children compared to no 
asymptomatic children had a 
positive test (r=0.67, 
p=0.0041).  
 
Lactoferrin was not correlated 
with degree of oocyst 
shedding (p=0.28). 
 
Lactoferrin was correlated 
with ∆HAZ score among 
those with C. parvum, 
although this observation was 













In contrast to C. 
parvum, there was 
no association 
between lactoferrin 







children with C. 
hominis had high 
fecal lactoferrin 





negative if there 
was no reaction 
at 1:50 and 
highly positive at 
>1:400. 
 
Data were part 






published by A. 
Kohli, et al. (also 
included in this 
review), using a 
slightly different 












status and found 








                                                          
1 Reported results were adjusted for confounding variables, unless otherwise noted. 
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Target Population  
Design and 
Sample Size  Biomarker Results Conclusion Comments 
2003 
 
Bustos M et al. 
 
Disaccharidase 




Jejunal biopsy and 
disaccharidase 
activities in children 
with PD and different 




3-34 mo old 
Amerindians 
hospitalized with 
PD and moderate 
or severe 





with PD and 
malnutrition: 
• 2 with 
kwashiorkor 
• 20 with 
marasmus 


























Histology was scored 
on a scale of 1 (normal) 
to 4 (severe 
morphological damage 
or flat mucosa). 
 
Most subjects had mild to 
moderate (score of 2-3) 
histological abnormalities, 
with one kwashiorkor patient 
having completely flat villi.  
 
Second biopsy showed a 
trend of improved mucosa, 
but difference was not 
significant based on histology 
score, intraepithelial 
lymphocyte density, or 
degree of infiltration of lamina 
propria. 
 
Percentages with enzymatic 
activity below normal at 
baseline, discharge:  
• Lactase: 64%, 59% 
• Sucrase-isomaltase: 97%, 
90% 
• Maltase: 45%, 52% 
All changes were statistically 
significant.  
 
Lactase recovery was 
associated with admission 
HAZ (p=0.05) and WAZ 
(p=0.03) scores.  
 
Despite continued high 
disaccharidase deficiency 
prevalence at discharge, all 
children tolerated the lactose-


































Authors did not 
report whether 














2 mo olds from 









Mean neopterin concentration 
was negatively correlated 
with long-term height (r=-
0.29, p<0.009) and weight 







overlap with that 
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Target Population  
Design and 
Sample Size  Biomarker Results Conclusion Comments 
Intestinal inflammation 
measured by fecal 




growth failure, Giardia 
lamblia, and intestinal 
permeability 
 
Fecal neopterin and 
L:M as markers of 
intestinal inflammation 
and permeability, 
respectively, and their 
correlation with growth 
status and Giardia 
recovery in the stool  












every 2 mo.  
Urine Tests: 





(r=-0.36, p<0.007) gain, but 
not with giardiasis. 
 
Mean3 L:M (CI): 0.31 (0.26, 
0.34). 
 
Mean excretion of lactulose 
(CI): 0.20 (0.18, 0.23).  
 
Mean excretion of mannitol 
(CI): 3.0 (2.8, 3.2).  
 
Mean L:M was negatively 
correlated with long-term 
height gain (r value not 
provided, p<0.0001), but was 
not correlated with presence 
of Giardia. 
 
L:M and fecal neopterin were 
not correlated (p=0.11). 
 
Mean L:M in the 
Gambian children 
was substantially 
higher than normal 
values in children 
in the UK. These 
high L:M ratios 
appear to be driven 
by mannitol 
excretion. 
of Campbell et 
al. also included 




Campbell DI et al. 
 
Growth faltering in 
rural Gambian infants 
is associated with 
impaired small 
intestinal barrier 









All 2-11 mo olds 
were recruited 
from this rural 
village and 
followed up to 14 


















• C-reactive  
protein (CRP) 
• IgA 
At 8 wk of age:  
• Mean5 L:M: 0.169 (CI: 
0.145, 0.198; range: 0.058-
0.657) 
• Mean lactulose recovery: 
0.202 (SD=0.159; range: 
0.009-0.640) 
• Mean mannitol recovery: 
3.80 (SD=2.35; range: 
0.52-8.58) 
 
L:M more than doubled 
between 12 wk-1 yr of age 
(r=0.44, p<0.001) and was 
driven by both increasing 
Mean L:M ratios 
were elevated at 8 
weeks of age, and 
more than doubled 
in the first year of 
life. 
 












blood smear at 







Authors did not 
report 
investigating 
                                                          
2 Lactulose and mannitol results were expressed as % of dose administered. 
3 Type of mean not specified. 
4 For lactulose and mannitol results, excretion measurement was not specified. 
5 Geometric mean. 
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Target Population  
Design and 
Sample Size  Biomarker Results Conclusion Comments 
and its relationship 
with various 
inflammatory markers 
and endotoxin  
• IgM 
• IgG 
• Plasma endotoxin 
• IgG endotoxin-core 
antibody 
 
lactulose (r=0.18, p<0.001) 
and decreasing mannitol (r=-
0.14, p<0.01) excretion with 
age.  
 
WAZ and HAZ scores were 
negatively correlated with L:M 
(r=-0.41, p<0.001), and 
primarily driven by lactulose 
excretion (r=-0.39, p<0.001). 
 
Laboratory values were 
consistent with chronic, low 
level immunostimulation: 
• 50% of platelet and 39% of 
leukocyte counts were 
elevated, especially mean 
lymphocyte counts which 
were almost twice 
expected values [198]. 
• While the mean6 CRP was 
within the normal range, 
25% of values were above 
the upper limit of normal (5 
mg/L), and 17% were >10 
mg/L [198]. 
• Mean IgG, IgA and IgM 
concentrations were near 
normal at 8 wk of age, but 
increased rapidly; all three 
were elevated above 
expected values in all other 
age groups [198, 199]. 
• Mean7 free plasma 
endotoxin concentration 
was twice the upper limit of 
normal [200] and IgG 
endotoxin-core antibody 
concentrations were also 
Poor growth was 
significantly 
correlated with L:M 










ascribed to a gut 
source, endotoxin 
and its related core 
antibody are 
potentially a direct 
measure of 
intestinal 
inflammation due to 
gut gram negatives 
as a primary 




















with that of 
Campbell et al. 
2004 also 
included in this 
review [15]. 
                                                          
6 Geometric mean. 
7 Geometric mean. 
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Target Population  
Design and 
Sample Size  Biomarker Results Conclusion Comments 
elevated [198]. 
• However, mean albumin 
concentrations (and 
concentrations within SD) 
were generally within 
normal range [198]. 
 
L:M was correlated with 
IgG and IgA (r=0.41 and 
0.41, respectively, p<0.001), 
and IgM (r=0.28, p<0.02). 
 
IgG and IgA were also 
correlated with lactulose 
recovery (r=0.26 and 0.25, 
respectively, p<0.02). 
 
IgG endotoxin core antibody 
concentration was correlated 
with L:M and driven by 
lactulose recovery, (r=0.35, 
p<0.005 for both).  
 
Endotoxin concentrations 
were correlated with lactulose 








in rural west African 
children: relationship 













• Group 1: n=4  
• Group 2: 
n=11 (7 with 
diarrhea) 
• Group 3: 
n=25 (18 
Endoscopic 





computer analysis*  
• Intestinal tissue 
cytokines and 
Crypt-hyperplasia and villous 
atrophy were observed 
among all Gambian subjects, 
and the degree of 
histopathology did not differ 
among cases with differing 
nutritional status, nor was 







and villous atrophy, 
and mean IELs >2 









(e.g. type of 
central tendency 
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Target Population  
Design and 
Sample Size  Biomarker Results Conclusion Comments 




L:M as a marker of 
intestinal permeability, 






among rural Gambian 










nutritional status:  














with or without 
diarrhea 
3. Grade II PEM 
(WAZ score <-
4) with or 
without diarrhea  
 
Controls from UK* 
who were well 
nourished children 
with GI complaints 
other than 
diarrhea and with 
normal endoscopy 




* UK subjects are 










ivity tests:  
• Group 1: 
n=3 
• Group 2: 
n=8 




immune markers:  





















* Biopsy involved 
morphometric 
assessment by 
computer analysis of 
villous height, crypt 
depth, villous:crypt 
ratio, and intraepithelial 
lymphocyte (IEL) 
density (per 100 
epithelial cells).  
 
 
IEL9 means were ~3-fold 
higher in Gambian than UK 
children. 
 
Median CD3, CD4, CD8, 
CD19, and CD25 cell counts 
were significantly higher (2-5x 
higher) among each case 
group compared to the UK 
controls.  
 
IEL, γδ, syndecan-1, HLA-
DR, and perforin were 
detected among the Gambian 
children in varying degrees 
but were not reported for UK 
controls. Syndecan, CD3, 
and CD8 displayed a gradient 
proportional to malnutrition 
severity. 
 
All Gambian groups showed 
higher lamina propria 
cytokine-immunoreactive 
mononuclear cell density 
(~200-450/mm2) than UK 
controls (30-80/mm2). 
 
Among subjects with elevated 
cytokines, similar densities 
were seen for both pro-
inflammatory (IFN-γ and 
TNF-α) and putative 
regulatory (IL-10 and TGF-β) 
cytokines. Epithelial 
expression of TGF-β was 
also enhanced compared to 












present across the 





L:M ratios were 
elevated in all 
Gambian groups, 
without apparent 
correlation to host 


















y, and L:M 





                                                          
8 Lactulose and mannitol results were expressed as % of dose administered. 
9 These figures are presumed to represent IEL means; however, this was not explicitly stated. 
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Target Population  
Design and 
Sample Size  Biomarker Results Conclusion Comments 
table due to 
comparisons of 
interest made in 
the review. 
However we do 
not include these 
subjects in the 




poorer nutritional status had 
lower densities of mucosal 
TGF-β+ cells, with median 
densities of 420 and 250 
cells/mm2 in the grade I and 
grade II PEM groups, 
respectively. 
 
L:M values10:  
• Group 1: 0.53 (0.4-1.3)  
• Group 2: 0.47 (0.02-2.20) 
• Group 3: 0.73 (0.14-2.2) 
• Not assessed among the 
UK controls 
 
Nutritional status was not 
associated with L:M, 
recoveries of lactulose or 
mannitol.  
 
L:M was correlated with 
mucosal B lymphocyte 
density (r=0.57, p<0.05), IEL 
(r=0.51, p<0.02), and 




Campbell DI et al. 
 
Age-related 
association of small 
intestinal mucosal 
enteropathy with 














<5 yr old:  
n=26 








Mean12 L:M (SE) in 2-5 yr old 
group: 0.353 (0.022).  
 
Mean lactulose and mannitol 
% recovery was ~0.45 and 
~0.65, respectively. 
  
L:M was highest in 2-5 yr age 
group and decreased with 
Mean L:M in 
asymptomatic 2 to 
5 yr olds was high 
and decreased 
significantly with 
increasing age, but 
never fell within 





symptoms for at 
least one week 




                                                          
10 Not clearly indicated if these figures represent mean (CI) or another measure of central tendency. 
11 Lactulose and mannitol results were expressed as % of dose administered. 
12 Type of mean not specified. 
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Target Population  
Design and 
Sample Size  Biomarker Results Conclusion Comments 
rural Gambian children 
 
L:M and urinary 
lactulose and mannitol 
recovery as a marker 
of intestinal 
permeability and its 
association with 
nutritional status at 
varying ages. Also 
assessed correlation 
of change in L:M with 
nutritional status at 3.5 
mo re-visit. 
 
increasing age (up to age 20) 
(p<0.001), but never fell 
within referenced UK normal 
ranges [201]. 
 
Most of the improvement in 
L:M was driven by a 
reduction in lactulose 
excretion (p<0.001), which 
fell within expected UK 
ranges by age 10 yr. 
 
In contrast, although mannitol 
excretion slightly decreased 
with age, this trend did not 
reach statistical significance. 
In fact, excretion proportions 
were at all times ½ - ⅓ of 
expected UK values [201]. 
 
L:M was inversely correlated 
with HAZ score13 (r=-0.31, 
p<0.001), but not with WAZ 
or body mass index (BMI) Z 
scores. The correlation with 
HAZ score was mainly due to 
the higher lactulose excretion 
in subjects with poorer HAZ 
scores (r=-0.22, p=0.001) and 
held across all age groups.  
 
There was a small 
improvement in mean L:M 
(SE) between the two study 
time points from 0.198 
(0.018) to 0.172 (0.010) 
(p=0.026 for change in L:M), 
driven by an improvement in 
mannitol recovery with no 
change in lactulose excretion.  
 





tests conducted 3.5 
months apart.  
 
Among all age 
groups, L:M was 
significantly 
inversely correlated 
with HAZ score, 
primarily driven by 





mean L:M of the 









                                                          
13 Reported results were adjusted for age, sex, and visit. 
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Target Population  
Design and 
Sample Size  Biomarker Results Conclusion Comments 
 
Indices of intestinal 
permeability within subjects 
showed a high degree of 
correlation between the two 
visits:  
• Lactulose: r=0.55, p<0.001 
• Mannitol: r=0.24, p<0.05 
• L:M: r=0.66, p<0.001 
 
Change in measures 
between visits (analysis not 
stratified by age): 
• Mean L:M (SD):  
• Visit 1: -1.62 (0.66) 
• Visit 2: -1.76 (0.55), 
(p=0.026) 
• Mean mannitol recovery 
(SD): 
• Visit 1: 5.25 (2.69) 
• Visit 2: 6.28 (3.03), 
(p=0.006) 
• Mean lactulose recovery 
(SD):  
• Visit 1: 0.28 (0.20)  
• Visit 2: 0.29 (0.18),  




Chen P et al. 
 
Association of vitamin 
A and zinc status with 
altered intestinal 
permeability: analyses 




Fortaleza, Brazil  
 
2-97 mo olds 
recruited from an 







L:M and retinol 
concentrations 
measured: 









Baseline mean (SD): 
• L:M15: 0.29 (0.16) 
• Lactulose: 0.54 (0.29) 
• Mannitol: 2.07 (0.88) 
 
L:M was not correlated with 
age. L:M was inversely 
correlated with retinol (r=-
0.55, p<0.0005), including 
after adjustment for zinc 
Supplementation of 




L:M among the 
cohort of children 
with a history of PD 
or low WAZ score 
who received post-
Longitudinal 









                                                          
14 For lactulose and mannitol results, excretion measurement was not specified. 
15 Type of mean not specified. 
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Target Population  
Design and 
Sample Size  Biomarker Results Conclusion Comments 
 
L:M as a marker of 
intestinal permeability 
pre- and post-vitamin 
A and zinc 
supplementation 
among children with 











history of PD 








dose of vitamin 
A and a 2-wk 





stratification on retinol 
concentrations.  
 
Retinol was correlated with 
mannitol (r=0.28, p=0.017) 
and lactulose (r=-0.22, 
p<0.063) excretion.  
 
Lactulose, mannitol and their 
combined ratio were not 
correlated with zinc 
concentrations.  
  
L:M improved after 
supplementation for the 
cohort of 20 children followed 
longitudinally with PD or low 
WAZ score: 
L:M mean (SD):  
• Pre-treatment: 0.28 (0.12) 
• Post-treatment: 0.19 (0.07) 
However, lactulose and 




than one-third of 




on L:M were not 
provided for the 
children with 
normal WAZ 
score or no 





the L:M testing 




L:M results in 










Clark TD et al. 
 
Risk factors and 
cumulative incidence 






Association of chronic 
diarrhea with 








until 36 mo of age.  
 











While chronic diarrhea was 
associated with moderate 
anemia in a univariate 
analysis (odds ratio=2.5, CI: 
1.0, 6.3), it was either not 
associated with moderate 
anemia (hemoglobin <9 g/dL) 
in a multivariate model or not 
included in the model 
  
While there was a 
high prevalence of 
anemia (<11 g/dL) 
and moderate 
anemia (<9 g/dL) 
(92% and 35% at 9 
months, 
respectively) 
among this cohort 
of HIV-infected 
children, chronic 
diarrhea appears to 
have not been 
associated with 
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Target Population  
Design and 
Sample Size  Biomarker Results Conclusion Comments 
analysis. However, 
the text did not 
specifically state 
whether chronic 
diarrhea was tested 




Darboe MK et al. 
 
Effectiveness of an 
early supplementation 
scheme of high-dose 
vitamin A versus 
standard WHO 
protocol in Gambian 




L:M as a marker of 
intestinal epithelial 
integrity among infants 
receiving high-dose 
vitamin A or standard 





at birth from rural 
community. Age 
range during 

























Mean16 L:M and proportion 
with values >0.30 among 
those receiving standard 
doses of vitamin A, by age: 
• 2 mo: 0.195, 12% 
• 5 mo: 0.197, 13% 
• 7 mo: 0.212, 22% 
• 9 mo: 0.286, 30% 
• 12 mo: 0.322, 34% 
 
Mean L:M differed between 
the two groups only at 7 mo 
(0.276 in high-dose vitamin A 
group, p=0.014), although 
there was no difference in 




L:M values rose by 
~50% from age 2 
mo to 1 yr and 
were not affected 
by dosing of 
vitamin A.  
The L:M normal 
cutoff was 
defined higher 
than for most 
other L:M 
studies, as 0.30. 
This was 
derived from the 
mean plus 2 SD 
from a study of 




Dini E et al. 
 
Sudan III and 
steatocrit in the 
detection of fecal fat in 
malnourished children 
 
Fecal fat by four 
different testing 




6 mo-9 yr olds 











• 30 with 
subclinical 
malnutrition 
• 34 with mild 
malnutrition  
• 30 with 
moderate 
Stool Test: 
Fecal fat, by method: 
• Sudan III classic 
• Sudan III 
modified 
• Steatocrit classic 




underwent testing for 
Proportions testing positive 
for fecal fat ranged from 33%-
41% overall, depending on 
test method used. 
 
The proportion testing 
positive varied by nutritional 
status across testing 
methods: 
• 80%-100% of severely 
malnourished subjects had 
a positive test 
A majority of 
children studied 
tested negative for 




positive was in 
those with severe 
malnutrition, 











positive for fecal 
fat by history of 
diarrhea (current 
                                                          
16 Geometric mean. 
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Target Population  
Design and 
Sample Size  Biomarker Results Conclusion Comments 
of malabsorption 







• 5 with severe 
malnutrition  
 
n=30 controls  
 
all four methods. • Similar proportions of 
subjects with subclinical, 
mild or moderate 
malnutrition tested positive, 
ranging from 30%-47%  
• 13%-27% of controls tested 
positive 
These differences appeared 
to be significant, but 
statistical comparison results 
were not entirely clear. 
 
Fecal fat did not vary based 
on quantity of fat intake. 
  
By all four methods, a high 
percentage of children with 
parasites tested positive 
(~60%) compared to children 
without parasites (25%).  
 
Associations were observed 
between infection with 
Giardia lamblia or 
Blastocystis hominis and 
fecal fat (p<0.05); this held 
true across diagnostic 
methods.  
 
The presence of diarrhea at 
time of testing was positively 
associated with fecal fat by all 
test methods (p<0.02 for all 
except steatocrit classic, 
p=0.06).  
 
The relationship between 
fecal fat and history of 
diarrhea in the year prior to 
testing varied by test method:  
• Sudan III classic: p=0.134 
moderate 
malnutrition. 
Controls had the 
lowest percent 
testing positive.  
 
Subjects with 
enteric parasites or 
those experiencing 
diarrhea at time of 







difference was not 
reported.  
 
There was some 
variation between 
the different testing 
methods, for 
example their 
relationship with a 
history of diarrhea 









but did not 
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Target Population  
Design and 
Sample Size  Biomarker Results Conclusion Comments 
• Sudan III modified: p<0.001 
• Steatocrit classic: p=0.14 
• Steatocrit acid: p=0.015  
 
Agreement between all four 
methods was 72%. 
Agreement between at least 
three was 91.5%. 
2006 
 
El Mouzan MI et al. 
 
Endoscopic duodenal 
biopsy in children 
 
Duodenal biopsy 












78% of subjects 
were <12 yr old; 
results not 






• 102 with PD 
• 116 with 
unexplained 
short stature  
• 11 with 
refractory 
rickets 








• Gross endoscopic 
visualization 
• Histopathology 
14% had abnormalities on 
endoscopic visualization: 
• 1% had esophagitis 
• 6% had gastritis, 7 (47%) of 
which were H. pylori 
positive 
• 7% had duodenitis 
 
Biopsy results: 
• PD:  
• 26% normal 
• 29% chronic non-
specific duodenitis 
• 40% villous atrophy 
• 5% other* 
 
• Short stature: 
• 56% normal 
• 22% chronic non-
specific duodenitis 
• 22% villous atrophy 
 
• Rickets: 
• 55% normal 
• 36% chronic non-
specific duodenitis 
• 9% villous atrophy 
 
• Other: 
• 25% normal 
• 50% chronic non-
specific duodenitis 
Villous atrophy was 
identified not only 
among 40% of 
children with PD, 
but also among 
22%, 9%, and 17% 
of those with short 




Authors argue that 
endoscopic biopsy 




settings and allows 
for visualization of 




were not reported 
by condition nor in 
relation to 
histopathology 
results; it is difficult 
to assess the value 











For 27% of 
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Target Population  
Design and 
Sample Size  Biomarker Results Conclusion Comments 
• 17% villous atrophy 
• 8% other* 
 
* 3 lymphangiectasia, 2 
Giardia, 1 Mycobacterium 
avium intracellulare. Findings 




Fagundes-Neto U et 
al. 
 
Studies of the small 
bowel surface by 
scanning electron 






and light microscope 
(LM) analyses of small 
intestinal biopsy 
among infants with PD 
with and without 
SBBO 
 
Sao Paulo, Brazil 
 
2-10 mo olds with 




























68.7% had bacterial 
overgrowth (concentration 
>104 colonies/mL): 3 had 
enteropathogenic E. coli 
while the rest had colonic 
microflora. 
 
All small intestine specimens 
had morphological 
abnormalities on LM: 
• 43.7% moderate villous 
atrophy 
• 56.3% subtotal villous 
atrophy  
 
SEM revealed abnormalities 
of varying intensity:  
• Among the 11 with SBBO, 
villous atrophy ranged from 
Grade II (n=4), Grade III 
(n=2), to Grade IV (n=3).  
• For the 5 subjects without 
SBBO, villous atrophy 
ranged from Grade I (n=1) 
to Grade 2 (n=4).  
• A mucous-fibrinoid pseudo-
membrane over enterocytes 
was noted in 7 of the 11 
with SBBO and none of the 
others.  
 
Other abnormalities noted on 
SEM included:  
Histological 
abnormalities were 
noted in all 
subjects by LM and 
SEM.  
 
Degree of villous 
atrophy noted on 












consistent with a 
malabsorptive 
process, with the 
findings of fat 
droplets on 
enterocytes 
surfaces, and with 
the state of 







all subjects and 
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Target Population  
Design and 
Sample Size  Biomarker Results Conclusion Comments 
• Mucus and debris covered 
large areas of the villous 
surface 
• Derangement of the 
enterocytes (in some cases 
cell borders were not clearly 
defined)  
• Reduced height and 
number (or absence in 
some places) of microvilli  
• Lymphocytes and fat 
droplets were observed 
over the surface of 
enterocytes (18%)17 
 
10 subjects had colitis on 
rectal biopsy; this was not 
associated with SBBO or 
degree of small intestinal 
pathology on SEM.  
2001 
 
Filteau SM et al. 
 
The effect of antenatal 
vitamin A and (beta)-
carotene 
supplementation on 
gut integrity of infants 
of HIV-infected South 
African women 
 
L:M as a marker of 
intestinal permeability 







between 28-32 wk 
gestation recruited 
from antenatal 
clinic. Infants were 
followed until 14 


















• Lactulose18  





• 1 wk: 
• Treatment: n=104 
• Placebo: n=104 
• 6 wk: 
• Treatment: n=100 
• Placebo: n=105 
• 14 wk: 
• Treatment: n=99 
Mean L:M19 (CI) at 1 wk 
among infants without reports 
of illness was 0.12 (0.08, 
0.17). L:M did not change 
with increasing age and did 
not significantly increase with 
reported morbidity. 
 
While a history of ever having 
been breastfed was an 
important contributor to L:M 
at 1 wk (ΔR2=0.22, p=0.008), 
a significant effect was not 
seen at 6 and 14 weeks20. 
Current feeding status had a 
modest effect on L:M only at 
Mean L:M overall 
was within normal 
range. However, 
mean L:M for 
placebo-treated, 
HIV-infected infants 
by 14 weeks was 
significantly 
elevated to almost 
0.5.  
 
While HIV infection 
did not affect 
mannitol excretion, 












                                                          
17 These SEM results were not presented separately for those with and without SBBO. 
18 For lactulose and mannitol results, excretion measurement was not specified. 
19 Geometric mean. 
20 Reported results were adjusted for confounding variables, unless otherwise noted. 
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Target Population  
Design and 
Sample Size  Biomarker Results Conclusion Comments 











at delivery.  
• Placebo: n=95 
 
14 wk (ΔR2=0.06, p=0.04).  
 
Birth weight contributed 
significantly at 1 wk 
(ΔR2=0.07, p=0.02), but 
current weight did not 
contribute significantly to L:M 
at any time point.  
 
HIV infection status by 14 wk 
was the major factor 
contributing to L:M at 6 wk 
(ΔR2=0.22, p=0.008) and 14 
wk (ΔR2=0.21, p=0.01). 
 
Maternal HIV viral load during 
pregnancy was not 
consistently significantly 
correlated with infant L:M. 
Maternal lymphocyte counts 
and plasma retinol 
concentrations were not 
associated with infant L:M. 
 
While maternal vitamin A 
supplementation had no 
effect on L:M of uninfected 
infants, it appeared to prevent 
the increase in L:M of HIV-
infected infants21: 
Mean22 L:M (CI):  
• Uninfected: 
• Vitamin A group: 0.11 
(0.08, 0.15)  
• Placebo group: 0.09 





                                                          
21 Reported results were adjusted for confounding variables included an interaction with HIV infection. 
22 Geometric mean. 
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Target Population  
Design and 
Sample Size  Biomarker Results Conclusion Comments 
• Vitamin A group: 0.17 
(0.13, 0.23) 
• Placebo group: 0.50 
(0.37, 0.68)  
  
Mannitol was not affected by 
vitamin A. HIV infection was 
not consistently significantly 
associated with mannitol 
across age groups. 
 
Lactulose also did not 
consistently differ between 
treatment groups or by HIV-
status, although vitamin A 
prevention of increase in 
lactulose among HIV-infected 
infants neared significance at 
14 wk (p=0.058)23.  
2005 
 
Galpin L et al. 
 
Effect of Lactobacillus 
GG on intestinal 
integrity in Malawian 
children at risk of 
tropical enteropathy 
 
L:M and sucrose: 
lactulose ratio (SUC:L) 
as markers of 




presumed at risk of 
Mwenye, Malawi  
 
36-60 mo olds 
recruited from a 
rural community, 
excluding children 






considered at risk 
for EED due to 
residence in a 
























• Sucrose (SUC) 





• 73% had L:M >0.10  
• 40% had L:M >0.20 
• Mean25 L:M (SD): 
• Treatment: 0.18 (0.16) 
• Placebo: 0.22 (0.20)  
• Mean lactulose (SD) in 
treatment group: 0.25 (0.17) 
• Mean mannitol (SD) in 
treatment group: 8.0 (4.5)  
• Mean SUC:L (SD):  
• Treatment: 0.58 (0.64)  
• Placebo: 0.60 (0.64) 
 
Mean excretion of sucrose 
(SD) increased from 0.057 
(0.042) to 0.078 (0.058) in the 
treatment group (p=0.01), but 
A high baseline 
prevalence of 
abnormal L:M was 






to UK norms) drove 
the abnormal L:M. 
 
There was little 
effect on SUC:L 
with intervention; 
sucrose excretion 






are limited data 
on laboratory 
values for these 
tests in young 
children. 
                                                          
23 P-values are from reported results that were adjusted for confounding variables. 
24 Lactulose, mannitol, and sucrose results were expressed as % of dose administered. 
25 Arithmetic mean. 
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Target Population  
Design and 
Sample Size  Biomarker Results Conclusion Comments 
EED  
Presumed that if 








GG or placebo. 





similar results were observed 
in the placebo group. 
Otherwise there were no 
changes in lactulose, 
mannitol, L:M, or SUC:L after 
treatment or placebo.  
control groups.  
2001 
 
Gandolfi L et al. 
 
Antiendomysial 
antibody test reliability 
in children with 
frequent diarrhea and 
malnutrition: is it celiac 
disease 
 
Jejunal biopsy among 
children with PD 
and/or malnutrition  
Brasilia, Brazil 
 






seen at the 
pediatric 
gastroenterology 
service of a 
university hospital 







antibodies were of 











30/31 (96.8%) had abnormal 
histopathology: 
• Suggesting non-specific 
inflammatory abnormalities 
in 27 (87.1%) subjects. 
• Demonstrating grade 3 
mucosal abnormalities in all 
malnourished 1 yr olds 
negative for enteric 
parasites. 
 



























R. Goto, et al. 
 
Impact of anti-Giardia 
and anthelminthic 




3-15 mo olds from 
a rural area were 
enrolled and 












Blood Tests:  
• α-1-acid glycoprotein 
(AGP) 
Mean L:M26 (SD) at baseline 
was 0.18 (0.24) in treatment 
groups, with no significant 
difference in placebo group or 
in testing post-intervention. 
 
Proportion with elevated L:M 







High L:M ratios 
were defined as 
greater than the 




                                                          
26 Geometric mean. 
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Target Population  
Design and 
Sample Size  Biomarker Results Conclusion Comments 
growth and intestinal 
permeability in rural 
Bangladesh: a 
randomised double-
blind controlled study 
 
L:M as a marker of 
intestinal permeability, 
IgG as a marker of 
chronic immune 
stimulation, and α-1-
acid glycoprotein as 











There was a high 
prevalence of 













* Those who 
fully 
participated 
and for whom 
data were 
analyzed are 







at any study time point varied 
between 58%-74%. >57% 
consistently elevated L:M 
ratios. 
 
Seasonal variation in L:M 
was observed (p <0.001), 
with highest mean values in 
the monsoon season.  
 
L:M was associated with 
∆WAZ and ∆WHZ scores at 
24 weeks (p=0.001 and 
p<0.001, respectively, point 
estimates not provided.) 
 
Serum immune marker 
values were similar in all 




AGP concentrations were 
negatively associated with 
∆WAZ score at 24 weeks 
(p=0.004, point estimate not 
provided), and were 
associated with ∆WHZ score 
at 12 weeks but not at 24 
weeks. 
Interventions did 






weight with better 
L:M values, the 
degree to which 
this occurred was 




reported by this 
group in another 
study also 




Goto R et al. 
 








3-15 mo olds from 
a rural area were 
enrolled and 





















Mean27 L:M: 0.15 
 
L:M showed a decreasing 
trend with age (p=0.003), and 
was associated with female 
gender (p=0.004), HAZ score 
(p=0.039), and WAZ score 
(p=0.019), but not with 
giardiasis or any of the serum 
Mean L:M was 
elevated. L:M was 
not associated with 
any of the tested 




IgG rose with 
Helminthiasis 
prevalence was 







                                                          
27 Geometric mean. 
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Target Population  
Design and 
Sample Size  Biomarker Results Conclusion Comments 
growth faltering in 
rural Bangladesh 
 
L:M as a marker of 
intestinal permeability, 
IgG as a marker of 
chronic immune 
stimulation, and α-1-
acid glycoprotein as 




with giardiasis and 
growth parameters.  
There was a high 
prevalence of 
















IgG, AGP, and albumin were 
associated with giardiasis, 
but hemoglobin was not. 
 
Mean circulating albumin 
concentration was normal for 
age [203]. Compared to UK 
age-matched reference [199], 
rate of rise in IgG with 
increasing age was similar, 
but concentrations were 
consistently ~3g/L higher.  
 
IgG was not associated with 
growth parameters. Albumin 
was associated with HAZ 
score only (p=0.016). AGP 
was inversely associated with 
HAZ (p=0.011) and WAZ 
(p=0.005) scores.  
increasing age at 
the rate expected 
(compared to UK 
norms) [199] but at 
higher 
concentrations 












reported by this 
group in another 
study also 







have not been 
determined for 
AGP. UK norms 
for 10 mo olds-
adults are 0.88 




Goto R et al. 
 
Poor intestinal 
permeability in mildly 
stunted Nepali 
children: Associations 
with weaning practices 
and Giardia lamblia 
infection 
 




0-5 yr olds (mean 
























• 92% had values >UK norms 
• Mean30 L:M (SD, range): 
0.26 (0.21, 0.04-1.71).  
• Giardia-infected versus 
uninfected means: 0.43 vs. 
0.25, p=0.014 
 
The duration of ingestion of 
solid foods (with or without 
concurrent breastfeeding) 
was not associated with L:M 
in multivariate analysis.  

















ratio >0.4.  
 
Specific L:M 
data by WAZ 





                                                          
28 Lactulose and mannitol results were expressed as % of dose administered. 
29 Lactose results were expressed in mg/L. 
30 Geometric mean. 
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Target Population  
Design and 
Sample Size  Biomarker Results Conclusion Comments 
intestinal permeability, 





and growth status.  
respectively.   
L:M was correlated with 
longer duration of 
breastfeeding (r=0.27, 
p<0.019). Specifically, 
children who breastfed for >2 
yr had higher L:M ratios than 
children who breastfed for 
shorter times (data not 
provided).  
 
L:M was not associated with:  
• History of diarrhea in the 
week preceding testing 
• Helminthiasis 
• Age 
• WAZ or HAZ scores 
 
Lactulose excretion ranged 
from 0.02–15.00. Mannitol 
excretion ranged from 0.5–
15.00. 
 
47% showed low lactase 
activity. Lactose values and 
lactose:lactulose ratios 
decreased with age (R2=28%, 
p<0.0001), but were not 
associated with sex, ethnicity, 
and location nor were they 
associated with L:M.  
 
Mean31 urinary lactose 
concentrations (mg/L) by 
feeding mode: 
• Breastfed: 172.5  
• Non-breastfed: 44.5, 
p<0.0001 corrected for 







subjects than in 











not the timing of 
introduction of solid 
foods, was 
correlated with L:M, 
and the correlation 
was direct, not 
inverse. Authors 
speculate that this 
could be due to 
higher mean age of 
their cohort 
compared to 
another study that 
demonstrated 
beneficial effect of 
duration of 
breastfeeding on 
reduced L:M in 
Guatemala [205]. 





                                                          
31 Geometric mean. 
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Target Population  
Design and 
Sample Size  Biomarker Results Conclusion Comments 
 
Mean32 lactose:lactulose ratio 
by feeding mode:  
• Breastfed: 2.76 
• Non-breastfed: 0.31,  
p<0.0001 corrected for 
infant age 
 
Mean L:M by feeding mode: 
• Breastfed: 0.23 
• Non-breastfed: 0.28, non-




Haase A et al. 
 
Dual sugar 




ratio (L:R) as a marker 
of intestinal 
permeability in 
children with or 
without diarrhea. Also 
directly compared 
blood and urine 
methods of L:R testing 





Cases were >4 
mo olds admitted 





GI illness.  
 






























• 24 had both blood 
and urine L:R 
• 98 had blood L:R only 
• 28 had urine L:R only 
  
Among controls: 
• 25 had both blood 
and urine L:R 
• 36 had blood L:R only 
• 53 had urine L:R only 
 
A total of 49 subjects 
were tested with both 
blood and urine L:R 
methods to allow direct 
Among the subset with both 
blood and urine specimens: 
• Urine L:R: 
• Mean33 (CI): 
• Cases: 12.4 (9.3, 
16.5) 
• Controls: 6.7 (5.0, 
8.8), p=0.004 
• Distribution across 
ratios:  
• Low: n=31 
• Intermediate: n=9 
• High: n=9 
• Blood L:R: 
• Mean34 (CI): 
• Cases: 9.4 (6.7, 13.1) 
• Controls: 5.9 (4.4, 
7.8), p=0.04  
• Distribution across 
ratios: 
• Low: n=27 
• Intermediate: n=11 




L:R ratios by both 
blood and urine 
testing compared 
with controls 





between urine and 
blood L:R tests in 
the same subjects. 
 
Urine has been an 
established 
substrate for sugar 
excretion 











for L:R ratios 
used in this 
study:  
• Blood L:R: 





• Urinary L:R: 
• Low= <10 
• Intermediat
e= 10-18 




                                                          
32 Geometric mean. 
33 Geometric mean. 
34 Geometric mean. 
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Target Population  
Design and 
Sample Size  Biomarker Results Conclusion Comments 
comparison of values. 
 
 
Among subjects with only 
urine tested: 
Mean35 urine L:R (CI):  
• Cases: 15.7 (12.6, 19.6)  
• Controls: 6.7 (5.7, 8.0), 
p<0.0001  
 
Among subjects with only 
blood tested: 
Mean36 blood L:R (CI):  
• Cases: 12.8 (10.3, 16.0) 
• Controls: 3.7 (2.8, 4.9), 
p<0.0001   
 
Even though blood L:R was 
consistently lower than urine 
L:R by a geometric mean (CI) 
of 1.09 (1.02, 1.16), there 
was strong correlation 
between L:R ratios in blood 
and urine as measured by:  
• Concordance correlation 
coefficient for agreement 
(CI) of 0.76 (0.64, 0.88) 
• Kappa statistic (CI) of 0.71 
(0.51, 0.92) (when L:R 
ratios are divided into 3 
ordered categories) 
• Sensitivity and specificity of 
blood tests of 81% (25/31) 
and 89% (16/18), 
respectively, when using 
the urine testing as the 
standard. 
 
The failure rate* for serum 
However, timed 
collection of urine 









the much lower 
concentrations of 
probe sugars in 
blood compared to 
urine had posed a 
challenge to 
sensitive detection 




as used in this 
study, now provide 





The failure rate of 
L:R blood testing 
was significantly 
lower than that of 
urine testing.  
 
 














test failure rate 
calculations 







who had both 






those with and 
without diarrhea 
would have 
been of interest. 
One would 
expect children 
with diarrhea to 
have higher 
rates of urine 
                                                          
35 Geometric mean. 
36 Geometric mean. 
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Target Population  
Design and 
Sample Size  Biomarker Results Conclusion Comments 
L:R testing (20/197, 10%) 
was lower than for urine 




* Defined as emesis with 
rhamnose/lactulose oral 
challenge (same dose for 
urine and serum testing), 
urine leakage or 
contamination with stool, or 
plasma quantity from blood 
draw of insufficient quantity 
for analysis.  
test failure due 
to contamination 




analytes due to 




testing might be 
more feasible 
than timed urine 
collections, but 
HPLC might not 






report on the 
same population 
as two other 
studies in this 
review which 
also assessed 







Hafeez A et al. 
 







2 mo-12 yr olds 
referred from 
various hospitals 





• 28 with PD 
• 9 with FTT 










findings were identified in:  
• 21/28 with PD  
• 7/9 with FTT 
• 3/4 with short stature 
 
More abnormalities were 
found via histology than 
75% of the PD and 






Authors assert the 
There was 
possible bias in 




unable to be 
analyzed (from 
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Target Population  
Design and 
Sample Size  Biomarker Results Conclusion Comments 
Duodenal biopsy 
among children with 
PD or growth 
problems 
abdominal pain, 
PD, short stature, 
FTT, GI bleeding, 
or anemia. The 
subjects of 
interest for this 
review were those 
with PD or growth 
problems. 
visualization, and findings did 







endoscopy, due to 
lack of correlation 





















not by condition 
or by patient, so 
specific results 
could not be 
interpreted in 
regards to this 
review.  
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Target Population  
Design and 
Sample Size  Biomarker Results Conclusion Comments 
2007 
 
Jain S et al. 
 
Fecal occult blood 




Fecal occult blood 
among severely 
malnourished children 





































Fecal occult blood test was 
positive in 30/50 (60%) cases 
and 0/30 controls.  
 
Among cases positive for 
fecal occult blood, 20 (66.7%) 
were found to have 
hemoglobin <8 g/dL.  
 
Enteric infections: 
• Parasitic infections were 
detected in 14/50 (28%) of 
cases, 12 (85.7%) of whom 
tested positive for fecal 
occult blood.  
• Bacterial infections were 
detected in 18/50 (36%) of 
cases, 13 (72.2%) of whom 
tested positive for fecal 
occult blood. 
• Of the remaining 18 for 
whom an enteric pathogen 
was not identified, 5 
(27.8%) tested positive for 
fecal blood. 
 
Among the 30 cases with 
fecal occult blood, 16 were 
breastfed, 11 were fed cow’s 
milk, and 3 were fed formula.  
 
A high proportion of 
severely 
malnourished 
children had a 
positive fecal occult 
blood test, 
compared with no 
positives among 











of those without an 
identifiable 
pathogen also 
tested positive.  
 
Presence of fecal 
blood did not 
appear to vary by 
feeding mode (e.g. 
breast milk, cow’s 



































scheme was not 
defined. 
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 Reference and 
Study Outcomes of 
Diagnostic Interest 
Location and 
Target Population  
Design and 
Sample Size  Biomarker Results Conclusion Comments 
2002  
 














New Delhi, India 
 












n=3 <5 yr old 
Tc-99m dextran 
scintigraphy 
Abnormal Tc-99m dextran 
uptake was positive in one 
child found to have subtotal 
villous atrophy on biopsy 
and another thought to have 
abdominal tuberculosis. 
  
The child with the negative 
scan had marasmus and 











This pilot study had 
a small sample 
size of 8 children, 
and only 3 were 












duodenal fluid and 
serum among 
children with PD 
and Giardia 
infection compared 
to those without 
diarrhea  
New Delhi, India 
 
<12 yr olds 
admitted to 
hospital with PD 
and Giardia.  
 
Controls had no 




Most cases were 
<7 yr old, with 
n=19 <3 yr old. 
Ages of controls 





n=30 cases with 




















Higher mean concentrations 
of IgM were found in 
duodenal aspirates of cases 
compared to controls 
(p<0.05).  
 
Mean concentrations of 
duodenal IgA and IgG did 















The number of 
controls was small 



















<36 mo old inner-
city residents 
recruited from the 






n=49 cases with 
Cryptosporidium 
infection  




Serum MBL concentrations 
were lower in cases than in 
healthy controls (p=0.002) 














was defined as 
concentrations <70 
ng/mL. 
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 Reference and 
Study Outcomes of 
Diagnostic Interest 
Location and 
Target Population  
Design and 






lectin as a marker of 
innate immune 
response among 





or from GHESKIO 
HIV Center37.  
 













• 9.8% healthy controls 
• 0 diarrhea controls 
 
Cryptosporidiosis was 
associated with MBL 
deficiency (odds ratio=22.4; 
CI: 3.1, 160.838). 
 
Among cases, the 
proportion of those with PD 
was nearly double among 
those with MBL deficiency 
compared to those without 
MBL deficiency, but these 
results were not significant 
(p=0.13). MBL deficiency 
was not associated with 
duration of diarrhea 
(p=0.37) among those with 
cryptosporidiosis nor with 
anthropometric status 
among either cases or 
controls. 
associated with 
mean duration of 
diarrhea or history 
of PD.  
2006 
 









Fecal cytokines and 
lactoferrin as 










healthy controls.  
 
Subjects were 
followed-up at 6 





















• IL-4  
• IL-8  
• IL-10 
Proportion lactoferrin-
positive at enrollment: 
• Cases: 51.2% 
• Controls: 4.0%  
 
Cases had higher 
concentrations of TNF-α 
than controls at enrollment 
(p=0.04), but no difference 
was observed at follow-up. 
 
Controls had almost 2x 
higher fecal IFN-γ at 
enrollment (p=0.1); the 
Lactoferrin was 
present among 








Fecal TNF-α was 
higher among 
cases at 
enrollment but did 
Cut-off values for 
lactoferrin positivity 
were not provided.  
 
Breastfed children 
(>85% of cases 
and controls) were 
included in testing. 
Proportions at 
follow-up were not 
reported.  
 
The association of 
fecal cytokines and 
                                                          
37 The Haitian Group for the Study of Kaposi's Sarcoma and Opportunistic Infections. 
38 Reported results were adjusted for confounding variables, unless otherwise noted. 
39 The Haitian Group for the Study of Kaposi's Sarcoma and Opportunistic Infections. 
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 Reference and 
Study Outcomes of 
Diagnostic Interest 
Location and 
Target Population  
Design and 
Sample Size  Biomarker Results Conclusion Comments 
mucosal 
inflammation among 




infection resolved.  
 
HIV status of 
subjects varied.  
 
There was a high 
prevalence of 
malnutrition in the 
study population. 
negative magnitude of difference 
increased (to almost 3x) and 
was statistically significant 
at the 6- and 9-month 
follow-up (p=0.01 and 
p=0.03, respectively). 
 
No differences in fecal 
concentrations of TGF-β, IL-
8, IL-4, or IL-10 were noted 
between groups. 
not persist when 





higher fecal IFN-γ 













and controls.  
lactoferrin with 
growth parameters, 
history of PD, and 
HIV status were 
not reported, nor 
was their 
association with 
each other.  
 










not reported.  
2002 
 



















<18 mo olds from 
a low SES setting 
recruited from the 
















n=17 cases with 
Cryptosporidium 
and diarrhea (5 





• 17 with diarrhea 
(5 with PD)  



















Proportion RS-positive:   
• 33.3% cases 
• 64.7% diarrhea controls 





• 83.3% cases  
• 60.0% diarrhea controls 
• 28.6% healthy controls, 
(p=0.01) 
 
IFN-γ was not recovered in 
any stools. 
 










While some fecal 
cytokines were 
detected in as 
many as 40% of 
healthy controls 






were not stratified 










children who were 
breastfeeding were 
not tested for 
lactoferrin.  
 
                                                          
40 The Haitian Group for the Study of Kaposi's Sarcoma and Opportunistic Infections. 
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 Reference and 
Study Outcomes of 
Diagnostic Interest 
Location and 
Target Population  
Design and 
Sample Size  Biomarker Results Conclusion Comments 










compared to diarrhea and 
healthy controls.  
 
Additionally, TNF-α receptor 
I, IL-8, and IL-13 were found 
in diarrhea and healthy 
controls, while IL-4 and IL-
10 were not.  
 
Fecal lactoferrin was 
associated with the 
presence of TNF-α receptor 
I (point estimate not 
provided, p=0.03). 
 
Mean WBC counts were 






















Fecal lactoferrin as 









favela in Fortaleza, 
Brazil 
 
All newborns from 
an urban 
shantytown were 
recruited at birth 
and followed for up 
to 4 yr. Those with 
Giardia recovered 
from stools were 


















Stool Test:  
Lactoferrin 
Proportion of positive 
lactoferrin results decreased 
with each new Giardia 
infection, p=0.015: 
• 1st infection: 74.0% 
(15.2% of those testing 
positive had high titers)  
• 2nd infection: 40.0% (5.3% 
of those testing positive 
had high titers)  
• 3rd infection: 1 (20.0%) 
tested positive (at a high 
titers) 
 
Increasing titers of 
lactoferrin were associated 
with longer duration of 
diarrhea, p=0.017: 
• Negative: 2.2 days 
• Low: 9.7 days 













these results were 
not presented 





might be useful in 
predicting 
Lactoferrin results 





following scale was 
used: 
• High = positive 
at 1:400-1:3200 
dilution  
• Low = positive at 
1:25-1:200 
• Negative = no 
reaction at 1:25 
 
Stools from 
children who were 
breastfeeding were 
not tested.  
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 Reference and 
Study Outcomes of 
Diagnostic Interest 
Location and 
Target Population  
Design and 
Sample Size  Biomarker Results Conclusion Comments 
 
Lactoferrin results did not 
differ between symptomatic 
and asymptomatic children 
at first infection, but those 
with symptoms had positive 
results with recurrent 
infections with greater 









Data were part of a 
larger study; similar 
data on lactoferrin 
in Cryptosporidium-
infected children 
were published by 
O.Y. Bushen, et al. 
(also included in 
this review); 
however, Bushen 
et al. used a 
slightly different 
grading scale for 
reporting lactoferrin 
results [108].  
2003 
 




oxide production in 









Nitric oxide (NO) as 





ratio (L:R) as a 
marker of intestinal 





1-6 yr old 
Aboriginal and 
non-Aboriginal 





1. Children with 
AD 
2. Children with no 
diarrhea but with 
non-GI infectious 
conditions  
3. Children without 












• 73 with non-GI 
infections (49 
Aboriginal)  


















(169 cases tested)  
 
 
* NO is an unstable 
free radical and is 
converted to nitrite 
and nitrate. Urine 
nitrate (NO3)+ nitrite 
(NO2) was expressed 
as a ratio with urine 
creatinine (NO2 + 
NO3:Cr) in order to 
account for 
NO among Aboriginal 
children with diarrhea was 
>3x higher than any other 
group and >5x higher than 
in non-Aboriginal controls. 
• NO was >3x and >2x 
higher among Aboriginal 
than non-Aboriginal 
children in the diarrhea 
(p<0.001) and no 
infections groups 
(p<0.001), respectively, 
but there was no 
difference between them 
in the non-GI infections 
group.  
• NO was >3x and ~2x 
higher in the diarrhea 
compared to the no 
infections group among 
Aboriginals (p<0.001) and 
non-Aboriginals (p<0.03), 
respectively.  
• NO was virtually the same 
among the Aboriginal non-
GI infections and no 
NO2 + NO3:Cr 




was used as a 
marker of gut 
permeability and 
inflammation, with 
an attempt to 
identify how much 
more it reflects as 
response to 
inflammation from 







the same among 
those with 
diarrhea and non-
GI infections (and 
higher compared 
Positive stool RS 
was defined as 
>0.5%.  
 
Abnormal L:R was 
defined as >7.6; no 
reference or 
derivation was 




appears to be the 
same as in another 
Kukuruzovic, et al. 
study also included 
in this review which 
assessed serum 
lactulose:rhamnose 
as a marker of 
intestinal 
permeability [58].  
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 Reference and 
Study Outcomes of 
Diagnostic Interest 
Location and 
Target Population  
Design and 
Sample Size  Biomarker Results Conclusion Comments 




(as a surrogate of 
iron deficiency), and 
stool reducing 
substances among 
children with and 
without diarrhea  
differences in urine 
concentration. 
 
** Measured only 
among children with 
profuse diarrhea. 
 
infections groups, as well 
as among the non-
Aboriginal diarrhea and 
non-GI infections groups.  
 
112/152 (74%) and 31/169 
(18%) of children with AD 
had abnormal L:R ratios and 
positive stool RS, 
respectively. 
 
NO and L:R were measured 
at “convalescence” on Day 
5 among those with 
diarrhea: the mean 
improvement in NO was 
21.7% compared with 
54.6% for L:R (p=0.01). 
 
NO and L:R were correlated 
(n=193, r=0.37, p<0.001)41; 
the correlation was stronger 
for lactulose (effect 
ratio=1.47, p<0.001) than 
for rhamnose (effect 
ratio=0.80, p=0.0242).  
 
NO was not correlated with 
stool RS43 or MCV, but was 
correlated with lower WAZ 
score (effect ratio=0.88, 
p=0.05). 
to controls). NO 




compared to any 
other group. 
Authors suggest 











controls in this 
study. 
 
NO appeared to 
decrease 
significantly more 




NO was found to 
correlate with L:R. 





                                                          
41 Reported results appear to have been adjusted for age and race. 
42 Reported results were adjusted for age and race. 
43 Reported results among children with diarrhea were adjusted for age and race. 
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2002 
 
Kukuruzovic RH et 
al. 
 
Milk formulas in 
acute gastroenteritis 




ratio (L:R) as a 












<3 yr old with AD 
and/or WAZ score 
<-2. 
 
60% of subjects 
had low WAZ 



























free formula  







L:R testing was 
repeated in 150 
subjects at day 5: 
• De-Lact: n=48  
• O-Lac: n=52 
• Alfaré: n=50 
Baseline mean44 L:R (CI) in 
De-Lact group was 14.9 
(10.4, 21.5), with no 
difference between groups. 
 
The mean improvement* in 
L:R (CI) was 13.0 (9.3, 16.6) 
with some significant 
differences between the 
various formulas: 
• De-Lact: 18.6 (10.6, 26.6)  
• O-Lac: 12.0 (7.5, 16.6), 
p=0.15 compared to De-
Lact  
• Alfaré: 8.5 (2.1, 14.9), 




* Improvement in L:R was 
calculated as baseline L:R 





with all of the low-
lactose formulas 
studied resulted in 
improved L:R 
among this 





most marked with 






did not appear to 











The study did not 
include a control 
arm (of standard 
care) to which 





the advantages of 
serum over timed 
urine collection for 
assessment of L:R 
as discussed in 
another publication 
in this review [125]. 
                                                          
44 Geometric mean. 
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2002 
 












lactose, and stool 
reducing 
substances as 












































• L:R  
• Hemoglobin  









L:R testing was 
repeated on day 5 for 
a subset of Aboriginal 
subjects: 
• 174/264 admissions 
for acute diarrhea  




* Measured only 




tested not provided. 
 
 
27/75 (36%) of Aboriginal 
controls and 0 non-
Aboriginal controls had 
abnormal L:R ratios. 
 
Mean46 L:R at baseline: 
Cases: 
• Aboriginal: 16.4  
• Non-Aboriginal: 7.9, 
p=0.002 compared to 
Aboriginal cases 
Controls: 
• Aboriginal: 4.6 
• Non-Aboriginal: 2.5, 
p=0.02 compared to 
Aboriginal controls  
 
Mean improvement47 in L:R 
(CI) at day 5 among those 
with repeat testing: 
• Aboriginal cases: 14.6 
(11.2, 18.0)  
• Aboriginal controls: -0.63 
(-4.0, 2.7)  
 
Mean lactulose recovery48: 
• Cases day 1: 0.085 
(0.070–0.103)  
• Cases day 5: 0.039 
(0.033–0.046) 
• Controls: 0.024 (0.019–
0.029) 
All 3 values significantly 
differed from one another. 
 
Mean rhamnose recovery: 




double those of 
non-Aboriginal 
children both 



















had higher mean 
L:R. 
 
Higher case L:R 
was driven more 
by high lactulose 




Positive stool RS 
was defined as 
>0.5%.  
 
Abnormal L:R was 
defined as >5.6, 
derived from 2 SD 
above the 
arithmetic mean for 
non-Aboriginal 
controls in this 
study. The 
rationale for the 
choice of 2 SD 
above the 
arithmetic, instead 
of the geometric, 





were not reported. 
 
Analysis included 







analysis methods.  
 
Repeat L:R testing 
was conducted on 
                                                          
45 Lactulose and rhamnose results were expressed as % of dose administered. 
46 Geometric mean. 
47 Improvement in L:R appears to have been calculated as baseline L:R minus repeat L:R, as described in another publication in this review; however, this was not expressly stated. 
Reference 134. Kukuruzovic, R.H. and D.R. Brewster, Milk formulas in acute gastroenteritis and malnutrition: a randomized trial. J Paediatr Child Health, 2002. 38(6): p. 571-577. 
48 Figures reported parenthetically after the mean percent recoveries of lactulose and rhamnose were not specified as ranges or CIs. 
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• Cases day 1: 0.479 
(0.424–0.542) 
• Cases day 5: 0.555 
(0.498–0.616) 
• Controls: 0.585 (0.500–
0.685) 
These values did not 
significantly differ from one 
another. 
 
Confidence intervals (CIs) in 
the authors' graphical 
representation of mean L:R 
at admission did not 
overlap, and the difference 
in means was particularly 
evident between Aboriginal 
and non-Aboriginal subjects.  
 
Factors associated with L:R 
among cases were49:  
• Acidosis (p=0.007) 
• Hypokalemia (p=0.035) 
• Diarrhea severity 
(p=0.001)  
 
Age and malnutrition were 
not associated with L:R. 
 
38% and 27% of Aboriginal 
cases had positive serum 
lactose and stool RS, 
respectively. 12% of 
Aboriginal and non-
Aboriginal controls 
combined had lactosemia.  
 
Presence of lactosemia was 
associated with L:R, 
L:R among cases 




Stool RS and 
serum lactose 










controls of both 
racial groups, but 





This study appears 
to report on the 
same population as 
in the Kukuruzovic, 
et al. 2003 
reference also 







the advantages of 
serum over timed 
urine collection for 
assessment of L:R, 
as discussed in 
another publication 
in this review [125]. 
                                                          
49 Reported results were adjusted for confounding variables, unless otherwise noted. 
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Design and 
Sample Size  Biomarker Results Conclusion Comments 
adjusted relative risk 
(CI)=1.06 (1.03, 1.10)50. 
Stool RS, anemia, and MCV 
were not associated with 
L:R.  
                                                          
50 Reported results were adjusted for severity of diarrhea, acidosis, hypokalemia, and age. 
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2004 
 





antibodies in the 
diagnosis of celiac 
disease in children: 




among patients with 








symptoms of CD 
(not specified).  
 
Subjects of interest 
for this review 
were those who 
tested negative for 
CD-specific 
serology and who 
did not meet the 
study diagnostic 
criteria for CD--
subtotal or total 
villous atrophy 
consistent with 




aged 3 mo-17 yr 












Of 99 subjects not meeting 
diagnostic criteria for CD, 
endoscopic biopsies 
revealed: 
• 76 had normal 
morphology of the 
intestinal mucosa 
• 7 had elevated densities 
of intraepithelial 
lymphocytes  
• 10 had partial villous 
atrophy (Marsh stage 2)  
• 6 had various other 
conditions such as 
giardiasis or gastritis 
Among 169 
children with 
symptoms of CD, 
41% had subtotal 
or total villous 








Article in French. 
 
Prevalence of CD 
antibodies did not 
clearly align with 
case/control 
designation. 
Because of the 
way the results 
were reported, we 
could not extract 
data on those who 
tested negative for 
CD-specific 
serology and who 
had Marsh stages 






while results and 
conclusion sections 
specify that jejunal 
specimens were 
obtained. 
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2006 
 











Small intestinal and 
rectal biopsy to 
assess morphology 





Sao Paulo, Brazil 
 
5 mo-12 yr old 
(median 24 mo) 
HIV-infected 
subjects recruited 
from a hospital and 
clinic. 
 
All subjects had 







n=5 patients with 




n=6 patients with 











Biopsy of small 










100% had low D-xylose 
absorption: 
• Mean: 15.6 mg/dL 
• SD: 5 
• Range: 8.9-24.4 
• Median: 14.2  
 
Small intestinal biopsy:  
• 100% had some degree 
of villous atrophy based 
on a I-IV grading system: 
• Grade I: 3 
• Grade I/II: 2  
• Grade II: 1 
• Grade II/III: 1 
• Grade III/IV: 1 
• 2 samples were too 
superficial to assess 
• Intraepithelial 
lymphocytes were 
increased in half of the 
biopsies. 
• Lymphocytic and 
polymorphonuclear 
(PMN) infiltration of the 
lamina propria were 




• 100% had normal 
architecture 
• Lymphocytic and PMN 
infiltration were present in 
6/6 and 4/6, respectively. 








diarrhea status.  
 
All patients also 
had cellular 
infiltration of the 
lamina propria 
and varying 
degrees of villous 
atrophy. 
 
There was no 
correlation 
between D-xylose 
and degree of 
villous atrophy on 
biopsy.  
Portuguese 
language article.  
 
D-xylose <25 
mg/dL was defined 
as indicative of 
malabsorption. 
This value is higher 
than what some 
references have 
noted as a cut-




system of grading 
villous atrophy.  
 
Results were not 
presented by 
diarrhea status, 
perhaps due to 
small sample size. 
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2010 
 
Lima AA et al.  
 




total parasitic, and 
specific Giardia spp 
infections in 






L:M as a marker of 
intestinal barrier 










vitamin A or placebo  
Fortaleza, Brazil 
 
2 mo-9 yr olds 
(mean 43 mo) from 
an impoverished 
urban community, 
eligible if HAZ 
score was 







































Median L:M at baseline was 
0.089. There was no 
significant change in L:M at 
4 mo follow-up within either 
treatment group.  
 
No significant difference in 
L:M was observed between 
treatment groups. 
 
Both median lactulose and 
mannitol excretions 
decreased at 4 mo follow-up 
among the vitamin A 
compared to the placebo 
group: 
• Lactulose: 0.21 to 0.74, 
p=0.042  
• Mannitol: 3.06 to 8.25, 
p=0.008  
 
Overall proportion of 
lactoferrin was 23% initially. 
At 1 mo follow-up, there was 
no difference in prevalence 
between vitamin A (33%) 
and placebo (31%) groups. 
 
Cytokine concentrations did 
not significantly differ 
between placebo and 















excretion, with no 











Authors did not 













Cut-point values for 
lactoferrin positivity 








participation due to 
assessment of 
stool lactoferrin. 
                                                          
51 For lactulose and mannitol results, excretion measurement was not specified. 
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2005 
 
Lima AA et al. 
 
Intestinal barrier 








L:M as a marker of 
intestinal 
permeability and 
various stool tests 
among children with 
malnutrition or PD 
who received either 
glycine or glutamine 
supplemented 
formula or placebo 
Fortaleza, Brazil 
 
2-60 mo olds 
hospitalized with 
WAZ score <-2, 
~70% of whom 
had PD.  
RCT 
 





• 27 with glycine 















• Lactoferrin  
• Leukocytes  





* n=80 tested at 
enrollment, n=65 
tested at day 10. 
 
** n=60 tested. 
Mean53 L:M (SE):  
• Glutamine group: 
• Baseline: 0.31 (0.10) 
(similar in all three 
groups) 
• Day 10: 0.10 (0.02); 
significant decrease, 
(p=0.01) 
• No significant decrease in 
L:M in glycine and 
nonsupplemented formula 
groups at day 10 
 
Mean lactulose (SE):  
• Glutamine group: 
• Baseline: 0.97 (0.46) 
(similar in all three 
groups) 
• Day 10: NS decrease 
in all 3 groups 
 
Mean mannitol (SE):  
• Glutamine group: 
• Baseline: 3.42 (0.64) 
(similar in all three 
groups) 
• Day 10: NS decrease 
in all 3 groups 
 
Proportion of stool markers 
at baseline among all 
subjects:  
• Lactoferrin: 53.3% 
• Leukocytes: 11.7% 
• RS: 3.3% 
• Occult blood: 5.0%  
L:M significantly 









RS, and occult 
blood were 





markers and L:M 
was not reported.  
 
Data were not 
stratified by history 
of PD. 
 
Fecal fat was 
assessed, but 
results were not 
reported. 
 














                                                          
52 Lactulose and mannitol results were expressed as % of dose administered. 
53 Type of mean not specified. 
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2007 
 


























6 mo-8 yr olds 
(mean age 3.5 yr) 
from an urban 
setting with HAZ, 


















• L:M  
 
L:M median (range) at 
baseline: 
• Treatment: 0.0385 
(0.8922 [sic])  
• Placebo: 0.0302 (5.5812 
[sic]) 
 
Lactulose and mannitol 
excretion both significantly 
decreased in the treatment 
group only (p=0.05 for both 
sugars)55. L:M did not 
change significantly within 
or across groups days after 
treatment. 
 
Lactulose excretion was not 
associated with WHZ, WAZ 
or HAZ scores in either 
group56. Mannitol was not 
associated with growth 
parameters in the control 
group, but was associated 
with WHZ (r2=-0.386, 
p=0.027) and WAZ (r2=-
0.385, p=0.027) scores in 
the supplemented group. 
Data for L:M and growth 













mannitol and L:M 
did not change 
significantly in the 
placebo group. 
Authors state that 
L:M median and 
range values were 
within the 
confidence interval 
for values of 









chronic diarrhea in 
their methods, they 
did not report data 
stratified according 
to these conditions. 
 
Authors provide 




results; these likely 




Long KZ et al. 
 
The effect of vitamin 
A supplementation 




All 5-15 mo olds 
within a periurban 
community were 













Positive tests for fecal 
cytokines: 
• IL-4: ~55% 
• IFN-γ: ~50% 
• IL-6: ~40%  
 




due to vitamin A 
supplementation 
were observed 




were not reported. 
Differences in fecal 
cytokines between 
all subjects with 
                                                          
54 For lactulose and mannitol results, excretion measurement was not specified. 
55 Reported results were adjusted for age and season. 
56 Reported results were adjusted for age and season. 
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immune response in 





Fecal cytokines as 
markers of intestinal 
mucosal immune 
activation in children 
with and without GI 
pathogens receiving 




















was tracked and 
stool samples 
were tested. 
differences in proportions of 
these fecal cytokines 
between vitamin A-




children with diarrhea had 
lower median IFN-γ 
concentrations (odds 
ratio57=0.51; CI: 0.26, 0.99) 
and higher IL-4 
concentrations (odds 
ratio=2.14; CI: 0.94, 4.87) 
compared to children with 
diarrhea in the placebo 
group in a nonrandomized 
analysis. IL-6 
concentrations did not differ 
in this analysis. There were 
no differences between the 
two groups among those 
without diarrhea. 
 
Differences in median 
concentrations of fecal 
cytokines by types of enteric 
pathogens were also 
observed.  
of subjects with 
GI infection or 
diarrhea.  
and without GI 
infections or history 




described in terms 




López de Romaña 









3-4 yr olds residing 
in a poor 
community at the 
periphery of Lima 
with stunting and 
moderate anemia 
as a surrogate risk 





both initial and 
follow-up 
absorption assay 




Zinc excretion to 
measure fractional 
absorption of zinc 
(FAZ) and total 
absorbed zinc (TAZ) 
following radiolabeled 
zinc administration  
 
Mean zinc parameters (SD) 
at initial assessment: 
• FAZ:  
• Group 1: 0.34 (0.11) 
• Group 2: 0.24 (0.05) 
• Group 3: 0.13 (0.04) 
• TAZ (mg/d):  
• Group 1: 0.71 (0.18) 
• Group 2: 1.11 (0.21) 
• Group 3: 1.34 (0.47) 
Despite a 










could play a role in 
zinc (or other 
micronutrient) 
absorption; such 
factors were not 
explored in this 
study. 
 
The principal aim 
                                                          
57 The odds ratios represent odds that a cytokine (categorized into three levels: undetectable, <median, >median) will have a higher value among vitamin A-supplemented children. 
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products fortified 
with iron only or iron 






receiving zinc as 

















wheat flour with 
iron and 3mg 





n=15 wheat flour 
with iron and 9mg 







Neither mean FAZ nor TAZ 
changed significantly at 
subsequent assessments in 
any treatment group. 
 
In both the initial and 
subsequent assays, mean 
TAZ from zinc-fortified 
meals increased with 
increasing amounts of 
fortification (p< 0.001). 
However mean FAZ was 
inversely related to zinc 
intake from these meals 
(p<0.001). 
 
Nonfortified dinner FAZ and 
TAZ were significantly lower 
in the group receiving the 
most zinc-supplementation 
at the initial assay (p=0.015 
and p=0.012, respectively) 
despite no difference in zinc 
intakes from the unfortified 
dinner by treatment group. 
This relationship between 
groups was not observed at 
the second assay; however, 
a significant decrease of 
16% in mean FAZ and TAZ 
from the unfortified dinners 
was observed between 
initial and subsequent 
assays (p<0.001).  
Mean plasma zinc 
concentrations did not differ 
between treatment groups 
throughout the study period. 
The proportion with low 








be due to factors 








zinc from the zinc-
fortified breakfast 
and lunch meals 
absorbed less 
zinc from the 
unfortified 




of this study was to 
determine 
appropriate extent 
of zinc fortification 
of a staple food in 
a specific 
community; we 
present only results 
relevant to this 
review. 
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was lower at the end of the 
study (3.3% vs. 20.5% 
initially, p=0.046).  
2001 
 




clinical risk factors 
for developing 
persistent diarrhea 
among infants in a 
rural community of 
Egypt 
 
Stool IgE as a 
marker of 
gastrointestinal 
allergy and its 
association with 






recruited at birth 
from a rural village 
and followed for 






diarrhea, 41 (11%) 




control within a 










* Stool samples 
from each PD 
episode were 
counted as a 
case for analysis 
and compared to 
randomly 
selected AD 







Fecal IgE was detected 
more frequently in stools 
from episodes of PD 
compared to episodes of 
AD: odds ratio (CI)58=3.3 
(1.0, 10.9). 
 
Fecal IgE was detected 
more frequently in stools 
from episodes of PD than in 
stools from children without 
diarrhea: odds ratio 
(CI)=4.84 (1.1, 21.7).  
 
Fecal IgE was 
detected 3 times 
more frequently 
during episodes 
of PD than AD 
and 5 times more 
frequently in PD 
stools than in 




based on episodes 
of diarrhea within a 




than one diarrheal 
episode. 
Additionally, it 
appears that an 
individual could 
also have been 
included as a case 
of PD, a control 
with AD, or a non-
diarrhea stool 




appears to be the 
same as in another 
Mahmud, et al. 
study also included 
in this review which 
reported the 
prevalence of fecal 
IgE by gender and 




Mahmud MA et al. 
 
Bilbeis, Egypt         
 
Newborns 









Overall incidence of fecal 
IgE: 0.39/child-year 
 
By age group:  
Substantial 
incidence of fecal 
IgE was observed 
in this setting in 
Study population 
appears to be the 
same population as 
in another 
                                                          
58 Reported results were adjusted for confounding variables, unless otherwise noted. 
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Increased fecal IgE 
among infants in a 
rural community of 
Egypt: an analysis 
of associated risk 
factors 
 
Fecal IgE as a 




from a rural village 
and followed for 














• < 3 mo: 0.28/child-yr  
•  3-6 mo: 0.42/child-yr  
•  6-9 mo: 0.16/child-yr  
• >9 mo: 0.12/child-yr  
 
Relative risks (CI): 
• 3-6 compared to >9 mo 
olds : 3.28 (1.03, 13.60)  





peaked at 3-6 mo 
of age. 
 
Male gender was 
associated with 
fecal IgE. 
Mahmud, et al. 
reference also 




between fecal IgE 
and PD [142]. 
2002 
 
Manary ML et al. 
 






Zinc absorption in a 








2–5 yr olds (mean 
age 43.6 mo, SD 





There was a high 
prevalence of 
stunting and low 














Zinc excretion to 
measure fractional 
absorption (FAZ) and 






• FAZ: 0.24 (0.04) 
• TAZ (mg/d): 1.30 (0.33)  
• EFZ (mg/d): 1.15 (0.33) 
 
Language in the discussion 
section strongly suggests, 
but does not explicitly state, 
that TAZ and EFZ were not 
correlated. Correlation 
analysis for these 
parameters was not 
reported. 
  
EFZ was higher 
than would be 
expected for a 
zinc deficient 
cohort, and EFZ 
was not 
correlated with 




leading to poor 
zinc absorption 
might explain 
these findings, the 
authors note that 
in a previous 
study (among a 
somewhat older 
age group) there 
were no 




diets [187]. They 
note that such 
perturbations in 
EFZ have also 
Authors note that 
the lack of 
comparable 
data from children 
of the age range in 
this study limits 
data interpretation. 
They also provide 
results per body 
weight due to 
presumed 
relationship; 
validity of such 




that the methods 




accurate, but quite 
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been reported in 
children with 
enteropathy due 
to cystic fibrosis 
[188] and suggest 
that a similar 
process could be 
going on in these 
Malawian children 
due to TE.  
2001 
 


















1-5 yr olds with PD 
selected randomly 
from an outpatient 
population in an 
urban setting. 
 
A high proportion 
of the children had 

















7 (23.3%) had grossly 
abnormal endoscopic 
findings: 
• 5 (16.7%) with chronic 
duodenitis  
• 1 with duodenitis with 
multiple erosions  
• 1 with duodenitis with 
hemorrhagic gastritis  
 
22 (73.3%) had abnormal 
histopathology: 
• 17 (56.7%) with villous 
atrophy with mononuclear 
cell infiltration  
• 1 (3.3%) with villous 
atrophy and eosinophilic 
infiltration  
• 2 (6.7%) with villous 
atrophy and mononuclear 
and eosinophilic 
infiltration 




Mean duration of diarrhea 
(SD) was not associated 


















had >1 month 
longer duration of 
diarrhea than 










WFA were not 








Number of patients 




infiltration was very 
small (n=2), yet 
authors report a 
significant 
difference in their 
duration of diarrhea 
relative to those 
with normal 
histopathology. 
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findings but did vary by 
histopathology: 
• Normal histopathology: 
9.0 wk (6.0), n=8 
• Mononuclear cell 
infiltration: 9.0 wk (6.0), 
n=2 
• Villous atrophy with 
mononuclear cell 
infiltration: 14.9 wk (5.3), 
n=17, p<0.02 compared 
to normal histopathology 
• Villous atrophy with 
mononuclear and 
eosinophilic infiltration: 
21.5 wk (2.1), n=2, 
p<0.02 compared to 
normal histopathology 
• Villous atrophy with 
eosinophilic infiltration: 
6.0 wk, n=1 
 
No consistent pattern was 
observed between gross 
endoscopic findings or 
histopathological lesions 
and age, degree of 
malnutrition, or type of 
enteropathogen recovered 








Mittal SK et al. 
 
Tropical sprue in 
north Indian children 
 
D-xylose and 




0-15 yr old 
gastroenterology 







(38 with repeat 
biopsies) 
 










• D-xylose*  
 
36 (38.3%) were diagnosed 
with TS including 14/44 
(31.8%) who were under 5 
years of age.  
 
18 (19.1%) were diagnosed 
with CD.  
 
Degree of villous atrophy 
More than half of 
the GI clinic 
patients with PD 
had some degree 
of villous atrophy.  
 
More than one-
third and almost 
one-fifth of 
Biopsy results were 
not provided for 
patients without TS 
or CD.  
 
It was unclear if 
there were patients 
with abnormal D-
xylose and 
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D-xylose test, and 
clinical response to 
antibiotics were 
diagnosed as 








with CD. We 
include data on 






* Not specified 
whether from urine or 
serum, and units of 
measurement not 
provided. 
among TS vs. CD patients:  
• Mild in 8/36 (22.2%) vs. 0 
• Moderate in 23/36 
(63.9%) vs. 4/18 (22.2%) 
• Severe in 5/36 (13.9%) 




among TS patients was 8.3 
g/dL (5.5-11) and did not 
differ from values of those 
with CD.  
 
Among the 22 TS patients, 
repeat biopsies showed: 
• 16 with normalization 
• 5 with improvement  




The D-xylose test was 
abnormal in all TS patients 
by diagnostic definition. 
subjects were 
diagnosed with 





definition, all TS 
patients improved 
with treatment.  







23% had partial 
improvement and 




histology who did 
not respond to 
antibiotic therapy 
and therefore were 
not diagnosed with 
TS. 
 
Cut-off points used 
to define abnormal 
D-xylose tests 























criteria of no GI 
symptoms, no 
antibiotics in the 
preceding 3 wk, 
and no SBBO by 
















• Lactose HBT  







* Reported as parts 
per million (ppm) post-
substrate ingestion 
after subtraction of 
baseline, pre-
Mean lactose HBT (SE): 
• Cases pre-treatment: 3.6 
(0.75) ppm  
• Cases post-treatment:  -
0.85 (0.75) ppm (p<0.05 
compared to pre-
treatment) 
• Controls: 0.19 (0.81) ppm 
(p<0.05 compared to pre-
treatment cases) 
 
Mean xylose HBT (SE): 
• Cases pre-treatment: 2.2 














to controls and 
Statistical methods 
might not have 




the same group of 
subjects (cases) 




wished to exclude 
children with 
                                                          
59 D-xylose results were expressed as % of dose administered. 
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Lactose hydrogen 
breath test (HBT) as 
a marker of lactose 
absorption, and 
xylose breath test 
and urinary 
excretion as 


























positive HBT is 
considered to be a 
rise of >20ppm in 




** Investigators did 




characteristics lead us 
to assume that it was 




• Cases post-treatment:   -
4.16 (0.69) ppm (p<0.05 
compared to pre-
treatment) 
• Controls: 1.13 (0.74) ppm 
(NS compared to pre-
treatment cases) 
 
Mean urinary excretion of 
xylose (SE) among cases 
pre-treatment and post- 
treatment was 34% (3) and 
46% (11), respectively (NS), 
well above cut-offs 
indicative of malabsorption. 
 







relevance of such 
mildly elevated 
HBT results in 
asymptomatically 
infected children 
is unclear.  
 




either urinary or 
breath measures 
among any group. 
While urinary 
results did not 
differ before and 
after treatment, 






such results is not 
apparent. 






production of H2 
following ingestion 




The number of 
children excluded 
due to failure to 
meet these criteria 












5-23 mo olds 
admitted to the 
Tropical 
Metabolism 
Research Unit of 







divided into 3 
groups of 8 
Stool Tests: 
• Total and 
fractionated 13C 
following ingestion 
of one of three 13C 
labeled triglycerides 
(TG): trilaurin, 
triolein, or trilinolein* 
Median total stool excretion 
of 13C in phase 1 was 9% 
(range: 1%-29%) and did 
not vary between TG 
groups.  
Median 13C excretion 
dropped 33%-99% in phase 
2 and 86%-95% in phase 3 
High 
concentrations of 
13C (compared to 
healthy UK 
children) [190] 
were observed in 
half of the 
subjects at 
Authors state that 
the study was not 
powered to 
compare the 
different TGs, but 
they contend that 
medium chain 
trilaurin did not 
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malnutrition 
 
Stool recovery of 
radiolabeled 
products as markers 
of lipid digestion and 
absorption, and bile 
salt deconjugation 
as a marker of 
SBBO among 















collected in three 
separate phases 
as described 
above in JL 
Murphy et al. 
2001 [149].  
• 13C stool assay 
following 
administration of 




* To assess fat 
excretion as a % of 
dose administered. 
Also assessed 
proportion of 13C in 
triglyceride (TG) and 
fatty acid (FA) 
fractions to distinguish 
excretion caused 
impaired digestion 
(presence of TG) vs. 
poor absorption 
(presence of FA). 
 
** To assess bile salt 
deconjugation in the 
bowel caused by 
SBBO; conducted 
after the TG 
assessment and a 3 
day washout period. 
 
 
compared to phase 1 
(p<0.05 each). 
 
Over the study period, there 
were significant 
associations between total 
lipid and the amount of 13C 
labeled TGs in stool for 
some groups, but not for 
others. 
 
Median 13C in TG and FA 
was similar across TG 
groups in all phases. 13C 
FA recovery was similar and 
reduced by ~2/3 compared 
to Phase 1. 13C TG was not 
detectable in Phases 2 or 3. 
Statistical comparisons 
between phases were not 
reported.  
 
13C after radiolabeled 
glycocholate administration 
was detected in stool at 
quantities considered to be 
in excess of the 7% 
recovery of dose 
administered upper limit of 
normal in U.S. adults in 
[189]: 
• Phase 1: 13/24 (54%) 
• Phase 2: 5/24 (20.8%)  







or absorption.  
 
The differences in 
stool 13C were 
wide but not as 
extreme as in a 
previous study by 
same 
investigators (also 
examined in this 





13C excretion did 
not significantly 






Similar to their 
previous study, 
significantly more 
13C in stool was 








in their previous 
study, there was 
evidence of 
SBBO as 
appear to be 
processed 
differently than the 




Authors did not 
describe the 
method used to 




While it was noted 
that some subjects 
had positive stool 
cultures, details 
were not provided 
on the nature of the 
enteric infections. 
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measured post-



















breath tests as 
markers of lipid 
digestion and 
absorption and bile 
salt deconjugation 
as a marker of 
SBBO among 







7-23 mo olds with 
malnutrition 
admitted to the 









collected in three 
separate phases 
(each lasting 9 
days): 
1. Within 48 
hours of 
admission 
2. During early 
rehabilitation 




• Fecal fat* 






















* In 72 hour stool 
collection (measured 
as total grams and as 
% of dietary fat 
intake). 
 
** To assess fat 
excretion as a % of 
dose administered. 
Also assessed 
proportion of 13C in 
triglyceride (TG) and 
fatty acid (FA) 
fractions to distinguish 
Mean fecal fat (SD): 
• Phase 1: 2.4 g/day (3.6) 
or 5.9% (9.4) of dietary 
lipid intake 
• Phase 2: 1.7 (0.9) g/day, 
or 3.3% (2.4) of intake  
• Phase 3: 0.9 (0.6) g/day, 
or 1.4% (0.7) of intake 
• Differences between 
phases were not 
statistically significant. 
 
Total excretion of 13C in 
stool also varied widely 
across patients (0%-44%) 
and did not differ between 
study phases.  
 
Correlation between fecal 
fat and 13C (r=0.48; p<0.05) 
was observed.  
 
Lack of lipid digestion and 
absorption were assessed 
by measuring TG and FA 
fractions, respectively. 
Mean 13C TG recovery (SD) 
(% of administered dose), 
number of patients excreting 
TG: 
• Phase 1: 0.7% (1.6), n=3 
• Phase 2: 0.9% (2.8), n=1  
• Phase 3: no recovery 
from any subjects, 
differences between 
phases were NS 
 
13C FA fraction in stool 
Mean fecal fat 
was not elevated 
compared to 
published norms 
[191, 192] during 
any study phase.  
 
There was wide 
variation in fecal 
fat at 
presentation, and 
wide variations in 
stool 13C across 
subjects. Authors 
indicate that this 




studies on healthy 
children from the 
UK demonstrated 
average excretion 
of 6% [190]. 
 
The majority of 
excreted 13C was 
in the form of FA 
rather than TG. 
Authors 
interpreted this to 
reflect failure of 
lipid absorption in 




form (FA and TG) 
Statistical methods 
might be 
inappropriate for a 
small sample. 
 





SBBO; this might 
have affected GCA 
testing. 
Appendix 7. Evidence table of all studies included in the review.
 Reference and 
Study Outcomes of 
Diagnostic Interest 
Location and 
Target Population  
Design and 
Sample Size  Biomarker Results Conclusion Comments 
excretion caused by 
impaired digestion 
(presence of TG) vs. 
poor absorption 
(presence of FA). 
 
*** To assess bile salt 
deconjugation in the 
bowel caused by 
SBBO; conducted 
after the TG 
assessment and a 3 
day washout period. 
 
**** Expressed as a 
percentage of 
absorbed label (dose 
administered - label 
recovered in stool) to 
assess oxidation for 






Mean 13C FA recovery (SD): 
• Phase 1: 6.0% (7.3)  
• Phase 2: 4.8% (3.7)  
• Phase 3: 3.3% (3.8),  
differences between 
phases were NS 
  
Mean FA values were ~9x 
(NS), 5x (p<0.001), and 3x 
(p<0.05) higher than mean 
TG values in Phases 1, 2, 
and 3, respectively. 
  
Following administration of 
labeled TP, absorbed 13C 
label by breath analysis was 
~5% (range 0%-21.2%) and 
similar across study phases.  
 
Following the administration 
of labeled GCA, there was 
either no or minimal 
recovery of 13C in stool and 
13CO2 on breath (as % of 
dose administered) in all 
phases.  
was found in 
decreasing values 








did not differ 
significantly.  
 
Fecal fat was 
correlated with 
concentrations of 
13C in stool.  
There was no 
evidence of 

















that this breath 
test has not been 
widely used, but 
that healthy UK 
children have 
breath excretion 
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values from 15%-
43% [190], 
compared to a 
mean of 5% and 
range 0%-21% in 
this cohort; the 
latter findings 
were more similar 








Nichols B et al. 
 
Contribution of 
villous atrophy to 
reduced intestinal 











maltase and villous 
atrophy and other 
mucosal intestinal 
markers indicative 
of loss of 
enterocytes and 
enterocytic function.  
 













age 3.6 mo, SD 
1.0) with HAZ and 













n=24 cases  
 














• Maltase activity  























Mean villous atrophy score 
(SD): 
• Cases: 2.6 (0.8) 
• Controls: 1.2 (0.5), 
p=0.006) 
 
WAZ score was correlated 
with villous atrophy (r=0.65, 
p- value not reported).  
 
13/25 [sic] cases and 0/5 
controls had subnormal 
(defined as <94 U/g protein) 
of maltase activity; mean 
maltase was 34% lower 
among cases (p=0.11). 
Maltase activity did not 
appear to decrease with 
WAZ score (further details 
not provided). 
 
However, in sub-analyses 
among those samples with 
an adequate β-actin, a 
housekeeping gene 
message, (n=10 cases, n=9 





atrophy than the 
younger controls. 
 
Among the subset 
tested for mRNA 
messages, 
maltase activity 
as well as the 
mRNA 
abundances for 

























they mocked up ex 
vivo mucosal 
biopsies in these 
controls, resections 




compared to cases’ 
samples derived 
from mucosal 
biopsies. While this 
probably doesn’t 
affect histology, it 
might affect 
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* Mucosal atrophy 
was scored on a scale 
of 1 (absence of 
atrophy compared to 
an organ donor) to 4 
(similar to children 
with active CD). 
 
Histology among 




expressed as a mean 
percent of controls' (SD) 
included: 
• Villous length (reciprocal 
of atrophy score): 38.9 
(41.6), p=0.004 
• Maltase activity: 37.1 
(23.2), p=0.001 
• MGA mRNA: 45.1 (36.4), 
p=0.016 
• Villin mRNA: 52.5 (22.6), 
p=0.003 
• SGLT mRNA: 66.6 (23.1), 
p=0.057 
• β-actin: 88.2 (15.8), 
p=0.189 
 
Both villous length and 
maltase activity in a subset 
of cases were less than 
40% of control values.  
 
MGA, villin, and SGLT 
mRNA abundances were 
correlated with villous 
atrophy score (r=0.73), 
(r=0.76), and (r=0.54), 
respectively (p-values not 
reported)60.  
 
MGA mRNA abundance 







that these are the 
first results that 
directly support 
the hypothesis 
that reductions in 
maltase activity 
are due to villous 
atrophy. This 












will bring in more 
diverse populations 
of cells; only some 
of them might have 
transcripts of 
interest. However, 
the bias is likely in 
a direction that 
would reduce effect 
size. 
 
It was unclear if 
control inclusion 
criteria included 
absence of atrophy 





might not have 
adequately taken 
into account the 




Subsets of subjects 
were investigated 
for various tests. 
For example, 10 
cases had mRNA 
analyses based on 
β-actin adequacy. 
Another instance of 
                                                          
60 Villin and SGLT1 were assessed as a ratio with housekeeper gene β-actin. 
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selected testing 
was the subset of 
22 and 15 cases 
that had WAZ 












CA et al. 
 
Anthelmintic 
treatment of rural 
Bangladeshi 





L:M as a marker of 
intestinal 
permeability, and α 
1-antichymotrypsin 
as a marker of 
inflammation and 










2-5 yr olds from 
poor rural villages, 
sampled randomly 






















* Randomized at 







• Albumin  







Among 93 subjects 
with L:M at baseline:  
• 46 received 
treatment 
• 47 received placebo 
 
Among 66 subjects 
with repeated L:M 
testing: 
• 34 received 
treatment 
• 32 received placebo 
 
Mean L:M61 at baseline: 
• Treatment: 0.22 
• Placebo: 0.25 
 
Seasonal variation in L:M 
was observed, with highest 
values following the 
monsoon season.  
 
Within-subject L:M analysis 
showed no significant 
association with intestinal 
helminthiasis and no 
significant improvement in 
treatment or placebo groups 
over 1 yr. L:M was generally 
not associated with 
giardiasis (with the 
exception of one group at 
one study interval). 
 
L:M was inversely 
correlated with ∆HAZ and 
∆WAZ scores at some of 
the follow-up intervals (r=-
0.22, p<0.02 and r=-0.21, 
L:M ratios were 






L:M values did not 
change 
significantly over 

















data were lost, so 
analysis began 
with samples taken 
at month 2. 
 
The relationship 





                                                          
61 Geometric mean. 
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p<0.05, respectively, at 12 
mo follow-up visit).  
 
Mean serum ACT, albumin 
and total protein were within 
normal ranges and were not 
associated with growth 
parameters. ACT and 
albumin concentrations did 
not significantly change with 
treatment, whereas total 




in these markers 
was a decrease in 
















Panter-Brick C et al. 
 
Pathways leading to 
early growth 
faltering: An 










ratio (Lactose:Cr) as 





3-18 mo olds in 
two cohorts: 
1. All children in 















n=48 in squatter 
cohort  
 










Mean62 Lactose:Cr (CI): 
• Squatter: 0.14 (0.12, 
0.16) 
• Middle Class: 0.08 (0.07, 
0.10) 
• Statistically significant 
difference between the 2 
groups among the 6-12 
mo olds (p=0.007) and 
18-24 mo olds (p=0.002), 
but not among 12-18 mo 
olds.  
• For both SES groups, 
Lactose:Cr values 
decreased with increasing 
age (p<0.001). 
 
HAZ, WAZ, WHZ, and 
∆WAZ scores were strongly 
associated with mean 
Lactose:Cr (p<0.001 each) 
Authors speculate 
that Lactose:Cr 










that impact the 
nutritional status 
of children with 
lower socio-





to control for 






not be as accurate 





compared to L:M, 
requiring only spot 
urine collection and 
no substrate 
                                                          
62 Geometric mean. 
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IgG as markers of 
immunostimulation. 
The latter were also 
assessed for their 
relationship to 
nutritional status.  
as was ∆HAZ score 
(p=0.004); ∆WHZ score was 
not. The strength and 
magnitude of association 
between ∆WAZ score and 
Lactose:Cr was most 
pronounced among the 
wealthier cohort and there 
was no association between 
∆HAZ score and Lactose:Cr 










L:M was not 
assessed in this 
study; direct 
comparison of the 





inversely related to 
Lactose:Cr, testing 
for associations of 
other measured 
blood markers 






Perin NM et al. 
 
Intestinal absorption 
of D-xylose in 
children infected 




D-xylose as a 
marker of intestinal 
absorption among 
HIV-infected 






18 mo-14 yr old 
HIV-infected 
children with GI 
and non-GI 
symptoms of HIV 
infection recruited 
from a pediatric 






Prevalence of an abnormal 
D-xylose result was 7.7%.  
 
Mean D-xylose (SD, range): 
42.8mg/dL (14.4mg/dL, 16-
73 mg/dL)  
 
D-xylose was not 
associated with age. 
 
Of the 8 children with 
abnormal results, 1 had 
diarrhea. Of 19 with 
diarrhea, 1 had an abnormal 
result. 
 
Of those with abnormal 
results, 50% had 
Cryptosporidium infection. 
Of the 33 subjects with 
Cryptosporidium infection, 4 











mg/dL was defined 
as indicative of 
malabsorption. 
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intestine biopsy in 




6 mo-5 yr old 
inpatients from an 
urban setting who 
underwent biopsy 
as part of a work-
up for PD. 
 
There was a high 
proportion of 
children with 







biopsies, site and 





(62 tested):  
• Villous height 












• Brush border 
height  
• Stereological 











measures were similar to 
those by micrometer and 





enterocyte brush border, 
and enterocyte nucleus 
height correlations:  
• WAZ score: r=0.25 
(p=0.038), r=0.26 
(p=0.03), and r=0.24, 
(p=0.05), respectively  
• WHZ score: r=0.29 
(p=0.02), r=0.27 (p=0.03), 
and r=0.16 (p=0.19), 
respectively 
• HAZ score: r=0.16 (0.18), 
r=0.23 (p=0.06), r=0.23 
(0.06)  
 
There was no correlation 
between mucosal surface 





with WAZ and 
WHZ scores, but 
not with HAZ 
score. However, 











Poddar U et al.  
Chandigarh, India 
 







Duodenal biopsy of those 





Authors did not 
report the biopsy 
findings in the TS 
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best for diagnosing 






in controls with 
giardiasis, TS, and 
SBBO 
6.9 yr) presenting 
with symptoms 
consistent with CD 




for CD were of 
interest for this 
review. 
• 22 with 
giardiasis  
• 1 with TS 
• 5 with SBBO 
inflammation of lamina 
propria; there was no 




or SBBO patients. 
2002 
 
Poddar U et al. 
 
Celiac disease in 
India: Are they true 




xylose, and fecal fat 
in children with 
symptoms of CD but 
normal mucosal 
biopsy results  
Chandigarh, India 
 
18 mo-14 yr olds 
with PD, FTT, or 







on biopsy were of 















* In 72-hour stool 
collection. 
 
** Not specified 
whether from urine or 





38% had chronic 
inflammatory cell infiltrates 
in the lamina propria.  
 
55% had abnormal D-xylose 
concentrations. 
 
20% had abnormal fecal fat 
test. 
 
No results beyond 
proportion positive were 







biopsy, more than 
one-third had PD. 
 
D-xylose and 
fecal fat might not 




between fecal fat, 
D-xylose and 
biopsy results were 
not reported. 
 
While 38% of 
controls had PD, 
results for the 
markers studied 
were not stratified 
by PD for this 
group.  
 
Seven children with 
biopsies consistent 
with CD did not 
respond to gluten-
free diet and were 
excluded from the 
study.  
 
Cut-off points used 
to define abnormal 
D-xylose tests 
were not provided. 
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2000 
 
Quadro L et al. 
 
Retinol and retinol-





L:M as a marker of 
small intestinal 
permeability, and its 
correlation with 




favela in Fortaleza, 
Brazil 
  
1-9 yr olds with 
mild malnutrition 
selected from a 
large cohort of 
children from an 
urban slum. They 
were recruited at 
birth and followed 
longitudinally. 
 
19 (63%) had 
some degree of 
vitamin A 
deficiency—all of 
these had mild 
deficiency, except 









 Urine Tests: 
• Lactulose63 
• Mannitol 






80% of subjects had 
abnormal L:M, defined as 
>=0.030.  
 
Serum retinol was:  
• Inversely correlated with 
L:M (r=0.46, p=0.012) 
• Directly correlated with 
mannitol (r=0.66, p<0.01)  
• Not correlated with 
lactulose (data not 
reported) 
Children with low 







The L:M normal 
cutoff was defined 
lower than for most 
other L:M studies, 
as 0.030. The 
authors reference 
several studies 
regarding use of 
this cut point. 
                                                          
63 Lactulose and mannitol results were expressed as % of dose administered. 
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2004 
 
Rabbani GH et al. 
 
Green banana and 
pectin improve small 
intestinal 
permeability and 





L:M as a marker of 
intestinal 
permeability among 
infants with PD who 
are treated with 
green banana, 





5-12 mo old males 
admitted to the 
hospital of the 
International  
Centre for  
Diarrhoeal Disease 
Research with PD 





























Mean L:M65 (SD) by 
treatment group, pre- and 
post-treatment:  
• Banana: pre=0.50 (0.14), 
post=0.21 (0.12), p<0.01 
• Pectin: pre=0.54 (0.17), 
post=0.23 (0.09), p<0.01 
• Placebo: pre=0.41 (0.11), 
post=0.45 (0.13), p>0.6 
 
Lactulose and mannitol 
excretion did not differ 
between groups at baseline.  
 
Lactulose excretion was not 
significantly reduced after 
intervention in the placebo 
group. Mean (SD): 
• Pre-treatment: 1.45 (0.12) 
• Post-treatment: 1.35 
(0.15) 
 
Both treatment groups had 





increased in all groups 
compared to their pre-
treatment values, but only 
significantly so in the 
banana and pectin groups 
(p<0.05).  
 
Mean mannitol % excretion 
(SD), pre- vs. post-
treatment:  
• Banana: 1.82 (0.13) vs. 
L:M values were 
high at baseline 
among the study 
population of 
inpatient young 
children with PD. 
Mean L:M 
significantly 
improved with the 
green banana or 
pectin intervention 
but were still 
above normal 
range following 7 
days of treatment. 
The 
improvements in 
L:M were driven 
by both mannitol 
and lactulose, 
with the latter 








of green banana 
in reducing 
diarrheal fluid loss 








                                                          
64 Lactulose and mannitol results were expressed as % of dose administered. 
65 Type of mean not specified. 
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3.21 (0.16) 
• Pectin: 1.91 (0.12) vs. 3.2 
(0.18) 
• Placebo: 2.10 (0.11) vs. 
2.33 (0.18) 
 
The banana and pectin 
groups stopped having 
diarrhea more often 
compared to controls (e.g. 
p<0.01 by day 4). Among 
the banana and pectin 
groups, stool reductions 
were associated with 
percent change in L:M 
before and after treatment 
(R2=0.84 for pectin and 
R2=0.86 for banana; p<0.05 
for each). 
short-chain fatty 
acids in the colon, 
stimulating 
colonic salt and 
water absorption. 
Pectin is thought 




suggest that short 














Rabbani GH et al. 
 
Increased nitrite and 
nitrate 
concentrations in 
sera and urine of 
patients with cholera 
or shigellosis 
 
To assess and 
compare nitric oxide 
as a marker of 
intestinal 
inflammation among 




2-6 yr olds with 
cholera or 
shigellosis 




recruited from the 
healthy attendants 
of patients or from 
children of hospital 
staff. 
 






• 24 with cholera 
















• Nitrite (NO2) 
• Nitrate (NO3) 







* Nitric oxide (NO) is 
an unstable free 
radical that is 
In children with shigellosis, 
median serum NO was ~8x 
higher at baseline than in 
controls and significantly 
differed from convalescent 
concentrations (p<0.01). 
Concentrations declined by 
52% of baseline during the 
recovery period but did not 
return to values found in the 
controls (measure of 
statistical significance not 
reported).  
 
In children with cholera, 
median serum NO 
concentrations at baseline 
NO as measured 
by both serum 








to 7-10 days after 
hospitalization in 
both cholera and 
shigellosis.  
 
Median serum NO 
concentrations in 
Some values 
reported in table 
format conflict with 
the text; columns of 
data appear to be 
transposed. 
 
Assessment for NO 
correlation with 
fecal leukocyte 
counts was not 
reported, nor was 
the correlation 
between urinary 
NO and total blood 
WBC. 
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or shigellosis or 
healthy controls. 
Evaluated to assess 
nitric oxide 
production during 
infection of small 
bowel without 
inflammatory lesion 








cases: 3.8 (1.2) 
• Cholera cases: 
4.2 (1.4)  





7-10 days of 
treatment). 
 
converted to nitrite 
and nitrate. Urine NO2 
+ NO3 were 
expressed as a ratio 
with urine creatinine in 
order to account for 
differences in urine 
concentration. 
 
were ~4x higher than in 
control subjects. Recovery 
concentrations decreased 
52% from baseline (p<0.01); 
convalescent values did not 
differ from the values in 
controls (p<0.4).  
 
Median urinary NO ratios 
were similar among those 
with Shigella and V. 
cholerae infection, both 
upon admission and 
discharge. Initial values 
were ~2x higher than upon 
discharge (p<0.05 and 0.01, 
respectively). Control 
median NO was of an 
intermediate concentration 
between cases’ admission 
and discharge median 
concentrations; the 
difference between control 
and case admission values 
was NS. 
 
Mean blood WBC counts 
(SD): 
• Shigellosis: 19.6 (3.3)  
• Cholera: 8.3 (2.8) 
• Controls: 7.1 (1.8) 
 
Mean fecal WBC/high 
power field (SD): 
• Shigellosis: 38 (17) 
• Cholera: 5 (2) 
• Controls: 3 (1)  
 
Serum NO correlated with 
blood WBC count in 
shigellosis cases at baseline 
(r2=0.92, p<0.01), but only 
cholera patients 







were much higher 











total blood WBC 
in shigellosis 
cases.   
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to a slight degree upon 
discharge (r2=0.26, no p-
value reported) and there 
was no correlation among 
the cholera cases. Serum 
NO correlated with stool 
volume at presentation 
(r2=0.85, statistically 
significant per authors, p-
value not reported).  
2009 
 
Ritchie BK et al. 
 
13C-sucrose breath 






Sucrose breath test 
(SBT) as a marker 
of small bowel 
mucosal damage vis 
a vis sucrase 




































cases with AD 
 
n=25 controls: 







(32 Aboriginal cases 
and controls tested) 
• C-reactive protein 
(CRP) 










20/32 (63%) of Aboriginal 
children had abnormal L:R 
ratios. 
 
Mean66 L:R (CI): 
• Diarrhea cases: 31.8 
(24.9, 40.7)  
• Aboriginal controls 
without diarrhea: 11.4 




SBT Mean (CI): 
• Diarrhea cases: 1.9% 
(0.9, 3.0), p<0.0001 
compared to non-
Aboriginal controls and 
p=0.004 compared to 
Aboriginal controls 
• Aboriginal controls: 4.1% 
(3.0, 5.2), p=0.032 
compared to non-
Aboriginal controls 
• Non-Aboriginal controls: 
6.1% (4.8, 7.3) 
Significant differences were 
observed between all three 
groups.  
SBT values were 
significantly lower 





















clinically silent TE 






ratios were defined 
as >16; no 
reference or 
derivation was 
provided for this 
cut-point.  
 







was based on data 
for Aboriginal 
cases and controls 
combined; stratified 
analysis was not 
reported and could 
be of interest 
considering the 






                                                          
66 Geometric mean. 
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SBT results were not 
associated with wasting or 
with patient age or 
breastfeeding status. 
 
SBT and L:R were inversely 
correlated (r=0.67; CI: 0.42, 
0.62; p<0.0001). L:R 
explained 45% of the 
variance in SBT; diarrhea 
explained 28% of variance. 
 
SBT was associated with 
increased MCV, relative risk 
(CI)=3.9 (2.8, 5.0). SBT was 
not associated with 
hemoglobin or CRP. 
correlated with 
L:R.  
MCV, CRP, and 
hemoglobin with 
SBT after adjusting 
for potentially 
confounding 










A longitudinal study 




L:M as a marker of 
gut mucosal 
integrity and urinary 
neopterin excretion 
as a marker of cell-
mediated immunity 




1, 6, and 14 wk old 









• L:M  
• Neopterin  
Mean68 L:M (CI): 
• HIV-infected subjects: 
• 1 wk: 0.12 (0.06, 0.27)  
• 6 wk: 0.24 (0.15, 0.38) 
• 14 wk: 0.24 (0.14, 
0.44) 
• Uninfected subjects:  
• 1 wk: 0.13 (0.09, 0.19) 
• 6 wk: 0.08 (0.06, 0.11) 
• 14 wk: 0.09 ( 0.07, 
0.13) 
 
HIV-infection by 14 wk of 
age was significantly 
associated with increased 
L:M. 
 
A non-significant, positive 
trend in neopterin excretion 
was observed among HIV-
L:M was generally 
normal (compared 




















between L:M and 
neopterin was not 
reported. 
                                                          
67 Lactulose and mannitol results were expressed in mg. 
68 Geometric mean. 
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without HIV infection infected infants.  Higher neopterin 
excretion by HIV-
infected infants 
was observed but 












timing for improving 
biochemical and 








serum α-1 acid 
glycoprotein, and C-
reactive protein as 
markers of 
inflammation among 

































either on the day 
of 







• L:M  




• C-reactive protein 
(CRP) 
• α-1 acid 
glycoprotein (AGP) 
 
49 subjects received 
urine testing: 
• Group 1: n=25 
• Group 2: n=24  
 
 
Blood and urine were 




• Group 1:  
• Day 0: ~1.8 
• Day 3: ~2.4  
• Group 2:  
• Day 0: ~1.2 
• Day 3: ~0.7 
 
There were no differences 
in mean L:M between 
groups or within groups 
between days 0 and 3, 
although there was a 
significant difference in 
paired analysis within 
individuals at the two time 
points (data not presented, 
and direction, magnitude 
and degree of significance 
not reported). 
  
Lactulose and mannitol 
excretion were assessed 
only in the paired analysis. 
Lactulose excretion 
decreased between days 0 
and 3 (magnitude of effect 
and degree of significance 
not reported), while mannitol 
excretion showed no 
change.  
Mean L:M ratios 
were very high 
(~10x) (at 
baseline and at 
day 3 in both 
groups) compared 
to other studies in 





that this could 
have been due to 
the severity of 








not result in 
significant 
improvement in 
L:M, neopterin, or 
AGP regardless 
of timing of 
vitamin A 
administration.  
Urine testing could 
only be conducted 
in the laboratory on 
certain days; hence 
only a subset of 
subjects underwent 
those tests.  
 




WBCs and AGP, 




compared to group 
1 at baseline. 
Authors note that 
these parameters 
suggest that Group 
2 patients might 
have been more ill 
at baseline. For the 
subset of 49 
patients 
undergoing urine 
testing, the mean72 
L:M and neopterin 
concentrations 
                                                          
69 For lactulose, mannitol, and neopterin results, excretion measurement was not specified. 
70 Geometric mean. 
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Mean71 neopterin and AGP 
concentrations did not differ 
between groups or within 
groups on the different 
study days or in the paired 
analysis. When initial CRP 
(~2x higher in Group 2 
compared to Group 1, 
p<0.004) was taken into 
account, mean CRP on day 
3 did not differ between the 
2 groups. However in the 
paired analysis, CRP 
concentrations were 
significantly different 




were lower among 
Group 2 than 
Group 1 subjects 
(NS). However, 
baseline 
differences in acute 
phase and vitamin 
A markers at 
baseline were not 
reported separately 
for these 49 
subjects. 
 
Data for lactulose 
and mannitol 





of these molecules 
expressed as ratios 
with creatinine was 
not explained.  
 
Authors suggest 
that their 3-day 
testing period 
(based on their 
previous work in a 
different setting 
[207] might have 
been too short to 
identify effect as 
demonstrated by 
McCullough et al. 
at 10 days after 
presentation [208]. 
                                                                                                                                                                                                                                                                                               
72 Geometric mean. 
71 Geometric mean. 
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2006 
 








school children and 
hospital patients in 




Stool lactoferrin as a 
marker of intestinal 
inflammation among 
hospitalized patients 









diarrhea or other 
GI complaints as 





n=26 <5 yr old: 
• 22 hospital-
based subjects 




16/22 patients and 0/4 
students were lactoferrin 
positive. 
 
While examination of 
lactoferrin association with 
history of diarrhea or with 
Cryptosporidium infection 
was not reported, only 3/22 
and 16/22 hospitalized 
patients and 2/4 and 3/4 
school children were 
positive for Cryptosporidium 
and had a history of 













not found among 
school-recruited 
children, most of 
whom did have a 
history of 
diarrhea. Two of 




Among the entire 
study cohort of all 
ages, lactoferrin 




status (influence of 





frequently found to 
be positive among 
those infected with 
Cryptosporidium; 
statistical testing 
was not reported. 
 
Lactoferrin results 




dilution and was 
considered 
negative if there 




were breastfed and 















Iron (absorption test) 
Mean73 iron absorption from 
ferrous (Fe) sulfate and Fe 
fumarate:  
• Uninfected children: 
Iron absorption 
from Fe fumarate 
was significantly 
lower than from 
Data on iron 
absorption among 
2-5 yr olds are 
limited, making 
                                                          
73 Geometric mean. 
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among children with 
iron deficiency 
anemia with and 
without H. pylori 
infection 
apparently healthy 
children from a 
periurban setting, 
screened for iron 
deficiency and H. 
pylori. 
n=13 cases 
infected with H. 
pylori 
 
n=12 controls not 
infected with H. 
pylori 
15.6% and 5.4%, 
(p<0.001) 
• Infected children before 
treatment: 19.7% and 
5.3%, (p<0.0001)  
• Infected children after 
treatment: 22.5% and 
6.4%, (p<0.0001)  
• H. pylori treatment did not 
significantly affect 






Results do not 
support the 















Sheng XY et al. 
 
Major variables of 
zinc homeostasis in 
Chinese toddlers 
 
Differences in zinc 
absorption in 
healthy toddlers with 
a high prevalence of 
zinc deficiency.  




19-25 mo olds 
recruited from a 
remote small town 
and 2 surrounding 
rural villages.  
 
48% of children 




zinc intake was 
low.  
 














Zinc excretion to 
measure fractional 
absorption of zinc 
(FAZ) and total 
absorbed zinc (TAZ) 
following radiolabeled 
zinc administration  
  
Mean (SD): 
• FAZ: 0.35 (0.12) 
• AZ (mg/d): 0.63 (0.24) 
• EFZ (mg/d): 0.67 (0.23) 
 
The quantity of absorbed 
zinc was lower than 
physiologic requirements. 
 
There was no statistically 
significant difference in any 
laboratory value between 
the town and village groups. 
 
Zinc absorption was ~80% 
of estimated physiologic 
requirement and equivalent 
to the amount of 
endogenous zinc excreted 
via the intestine; it was 
expected that absorbed zinc 
would exceed excreted zinc 
[144, 187, 194, 195]. 
Zinc absorption 
was lower than 
physiologic 
requirements and 
EFZ was higher 
than expected. 
 
The authors note 
that the results 
are difficult to 
explain and 
specifically state 





prevalent in the 
population and 
therefore could 






Sherwani K et al. 
 
Aligarh, India  
 
1-12 yr olds (mean 






method not specified: 
Histopathology 
Six patients had partial 
villous atrophy and non-






The 6 children with 
partial villous 
atrophy were 
thought to have 
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Sample Size  Biomarker Results Conclusion Comments 
Prevalence of iron 
deficiency anemia in 
chronic diarrhoea 
and celiac disease - 
A western UP 
experience 
 
Duodenal biopsy in 
patients with PD  
an urban setting 
with PD recruited 
from pediatric 
outpatient and 




up were subjects 
of interest for this 
review. 
of patients who 
did not have CD, 
but did not identify 
PD etiology in the 
remainder who 
did not have CD. 











mixture in acute and 
persistent diarrhea 
in infants and its 
impact on nutritional 
status 
 
Blood cell and 
albumin markers 
among infants with 
acute, persistent or 
no diarrhea, and 
effects on these 





vitamin A, zinc and 
other 
micronutrients) 
among subjects with 











5/6 PD cases and 
10/14 AD cases 
had some degree 
of malnutrition.  
 
Infants with PD 
had significantly 
lower vitamin A 
and zinc stores 
compared to 
controls. Those 
with AD had 
significantly lower 






• 6 with PD 











• Complete blood 
count and 
differential 


















Mean baseline hemoglobin 
was significantly lower in 
infants with AD and PD 
(p<0.05 for each group) 
than in controls  
 
Mean MCV and MCH were 
lower in those with AD 
(p<0.025 and p<0.01, 
respectively) and PD 
(p<0.01 for both markers) 
compared to controls.  
 
Mean lymphocyte counts 
among PD cases were low 
compared to those of 
controls (p<0.01). 
 
Other markers did not vary 
significantly at baseline. 
However, among infants 
with PD, mean albumin was 
abnormally low, although it 
was not significantly 
different compared to 
controls or those with AD. 
Mean albumin (g/dL) (SE): 
• PD: 2.9 (0.27)  
• AD: 3.29 (0.25)  
• Controls: 3.37 (0.21) 
Albumin and 
many hematologic 





those with PD, 
compared to 
those without 














were not specified. 
 





for PD cases (n=6). 
Controls were 
reported to have 
been matched to 
cases, yet there 
were half the 
number of controls 
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Design and 





lymphocyte counts and 
albumin increased in both 
diarrhea groups to 
concentrations on par with 
control baseline 
concentrations (albeit 
increases were NS except 
within the PD group). MCH 
improved to concentrations 
on par with the control 
group only among the 
infants with AD.  
2003 
 
Tassara O et al. 
 
Gastrointestinal 
diseases in children 










0-12 yr old 
(median 9 mo) 
HIV-infected 
children treated in 
hospital. A high 

















changes were observed on 
endoscopy in the 
esophagus, stomach or 
duodenum in 2 subjects.  
 
Biopsies of esophagus, 
stomach or duodenum 
showed inflammatory 
changes of varying degree 













in the digestive 
system were not 












Thurnham DI et al. 
 
Innate immunity, gut 
integrity, and 
vitamin A in 
Gambian and Indian 
Orissa State, India 
 
Subjects were 











• 31 received 






subjects, L:M was 
assessed at baseline, 
discharge from 
Mean L:M was ~3-fold 
higher among hospitalized 
compared to clinic patients 
at baseline. Within the 
allocation groups, mean 
baseline L:M did not differ 
for either the hospitalized or 
clinic subjects. 
Mean L:M values, 
including post-
intervention 
values, were 2-5 
times higher than 
those observed in 
the UK [209]. 
 
Precise numerical 
values were not 
reported, rather 
L:M results were 
portrayed in figures 
with units 
expressed in mg, 
making it difficult to 
Appendix 7. Evidence table of all studies included in the review.
 Reference and 
Study Outcomes of 
Diagnostic Interest 
Location and 
Target Population  
Design and 
Sample Size  Biomarker Results Conclusion Comments 
infants 
 
L:M as a marker of 
intestinal integrity 
among children 










not specified  
 
1 
• 32 received 
vitamin A at 
discharge (up to 
day 5) 










receive vitamin A 
weekly for 8 wk 
or placebo.  
 
 
* Number of 
subjects in each 
treatment group 




hospital, and 10 or 30 
days after discharge. 
 
For clinic-based 
subjects, L:M was 
assessed at baseline, 
4, and 8 wk. 
 
Among the hospital cohort, 
mean L:M declined 
significantly in the two 
vitamin A groups compared 
to the placebo group, and 
remained lower at day 30 
among the treatment 
groups, but the difference 
was no longer significant 
compared to the placebo 
group. 
 
Among the clinic cohort, 
mean L:M reduction was 
accelerated in vitamin A-
supplemented children. 
However, mean L:M did not 
significantly differ between 
treatment groups at any 
time point.  
 
The rate of decline in L:M 
was most steep among the 
vitamin A-treated 
hospitalized patients, in 
whom the mean L:M value 
decreased by 63% over 30 
days, followed by placebo-
treated hospitalized 
patients, with a decrease of 
38% over 30 days. Mean 
L:M decreased by 57% in 
the vitamin A-treated clinic 
patients, while there was no 
change in L:M among the 
clinic placebo group. 
L:M reduction was 
accelerated 








in either the clinic 





results to those of 
other studies.  
 
Information on 





The article also 
reported re-
analyzed data from 
a 1991 report from 
The Gambia [209]. 
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2009  
 





trial of rifaximin, a 
nonabsorbable 
antibiotic, in the 













rifaximin or placebo  
Limela, Malawi 
 
All 3-5 yr olds from 















It was presumed 
that if SBBO is 










• Sucrose (SUC) 
• Sucralose (SCL) 




ratio (SCL:L)  
 
 
Subjects were tested 
before and after 
treatment. 
At enrollment: 
• Mean mannitol (SD):  
• Treatment: 9.57 (5.24)  
• Placebo: 10.29 (6.62) 
• Mean lactulose (SD): 
• Treatment: 0.30 (0.18) 
• Placebo: 0.34 (0.25) 
• Mean SUC (SD):  
• Treatment: 0.062 
(0.04)  
• Placebo: 0.074 (0.058) 
• Mean SCL (SD):  
• Treatment: 0.51 (0.29)  
• Placebo: 0.58 (0.53) 
• Mean L:M75 (SD): 
• Treatment: 0.18 (0.12) 
• Placebo: 0.17 (0.09) 
• Mean SUC:L (SD): 
• Treatment: 0.50 (0.34) 
• Placebo: 0.64 (0.90) 
• Mean SCL:L (SD): 
• Treatment: 0.42 (0.32) 
• Placebo: 0.39 (0.23) 
• For both groups 
combined:  
• 76% had L:M >0.10 
• 34% had L:M >0.20 
 
No significant post- 
intervention differences 
were observed in any 
fractional sugar excretion or 
dual sugar test, including 




There was a high 
proportion with 
elevated L:M 
















SCL excretion in 
this population 
was similar to that 





lower (0.8) and 
driven by 
lactulose [210]. 
SCL:L might be a 
better marker of 
colonic 
permeability [211-









testing, in particular 
for SCL excretion, 
might account for 
some differences in 
values compared 
to other studies.  
 
This was the first 
use of SCL for site-
specific absorption 
testing in a 
developing country 
setting.  
                                                          
74 Lactulose, mannitol, SUC, and SCL results were expressed as % of dose administered. 
75 Type of mean for sugar ratios not specified. 
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Few data exist on 
SUC excretion. 
Results in this trial 
are similar to 











[210, 212].  
2008 
 
Vieira MM et al. 
 
Carotenoids, retinol, 
and intestinal barrier 









markers of intestinal 
inflammation, and 





2 mo-9 yr olds 




eligible if HAZ 



























48.5% had abnormal L:M.  
 
L:M and excretion of each 
sugar separately did not 
vary with retinol 
concentration. 
 
L:M was associated with 
levels of common dietary 
carotenoids, primarily driven 
by lactulose. However, the 
association was not always 
statistically significant, and 
the direction of association 
varied depending on 
precursor.  
 
40% of stool samples were 
positive for lactoferrin. 
 
Almost half of 
subjects had 
increased L:M, 













that these retinol 
precursors might 
be more sensitive 
predictors of 
L:M threshold for 
abnormal values 
was defined as 
>0.0864 [214]. Cut-














between L:M and 
lactoferrin or fecal 
                                                          
76 Lactulose and mannitol results were expressed as % of dose administered. 
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children with varying 
vitamin A status  
1% of stool samples were 
positive for fecal leukocytes. 
 
30% of stool samples were 
positive for parasites but 
this had no impact on L:M 
results, lactoferrin, or acute 










leukocytes as well 
as those between 
retinol or 
carotenoids and 
lactoferrin or fecal 
leukocytes were 





















L:M and plasma 
immunoglobulins 







enrolled in a 
glutamine trial 
 
West Kiang region, 
Gambia 
 
4-10 mo olds from 
a rural area 
followed during the 
5-month rainy 









amino acids was 
orally 
administered 
twice daily during 
























Mean77 L:M (CI):  
• Baseline:  
• Glutamine group: 0.33 
(0.25, 0.43) 
• Placebo group: 0.33 
(0.26, 0.41) 
• Post-intervention: 
• Glutamine group: 0.29 
(0.23, 0.35) 
• Placebo group: 0.26 
(0.21, 0.32) 
 
Mean excretion of lactulose 
(CI):  
• Baseline:  
• Glutamine group: 0.21 
(0.16, 0.28) 
• Placebo group: 0.20 
(0.15, 0.26) 
• Post-intervention: 
• Glutamine group: 0.17 
(0.13, 0.21) 
• Placebo group: 0.14 
L:M values were 
elevated in this 
population, with 
no significant 
change after the 
intervention.  
 







either at baseline 










between L:M and 
growth parameters, 
immuno-globulins, 
and acute phase 
proteins were not 
reported. 
                                                          
77 Geometric mean 
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 (0.11, 0.18) 
 
Mean excretion of mannitol 
(CI):  
• Baseline:  
• Glutamine group: 2.65 
(2.02, 3.48) 
• Placebo group: 2.50 
(1.87, 3.36) 
• Post-intervention: 
• Glutamine group: 2.48 
(1.99, 3.11) 
• Placebo group: 2.14 
(1.62, 2.82) 
 
L:M values did not differ 
significantly between 
treatment groups before or 
following intervention. 
However, a repeated 
measures ANOVA showed 
that during supplementation, 
L:M values were borderline 
elevated among the 
glutamine-supplemented 
group relative to the placebo 
group (p=0.05), counter to 
expectation. 
 
Neither ACT, CRP, albumin, 
nor immunoglobulins IgA, 
IgG, or IgM differed 
significantly between 
treatment and placebo 
groups, either at baseline or 
at the end of 
supplementation. 
 
Mean levels of IgA and IgG 
increased during the study 
(p <0.001), while IgM levels 
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Design and 
Sample Size  Biomarker Results Conclusion Comments 
did not. Concentrations of 
each of these 
immunoglobulins did not 
differ between treatment 
and placebo groups. 
 
Plasma albumin, ACT, 
and CRP values showed no 
change over the course of 
the study. 
 
Proportions of children with 
elevated CRP ranged from 
30-41% at different 
collection time points. The 
glutamine intervention had 
no effect on proportion of 
children with elevated CRP. 
 
Treatment and placebo 
groups experienced 
decreases in WAZ, HAZ, 
and MUAC coinciding with 
the rainy season; however, 
there was no significant 
difference observed 
between the groups for any 
of these parameters.  
 
Treatment and placebo 
groups did not differ in 
morbidity indices (i.e. 
percentage of time reported 




Willumsen JF et al. 
 
Subclinical mastitis 

















There was no significant 
association between L:M 
and subclinical mastitis as 




mastitis was not 
associated with 
magnitude of L:M. 
 
Actual L:M values 
were not reported 
but are found in a 
companion study, 
also included in 
this review [119]. 
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 Reference and 
Study Outcomes of 
Diagnostic Interest 
Location and 
Target Population  
Design and 




L:M as a marker of 
infant intestinal 




infants followed up 




clinic via a vitamin 
A supplementation 




n=104 mothers  
 
n=108 infants (4 
pairs of twins), 
(26 were HIV-
infected by 3 mo 
of age) 
The study group in 
Willumsen, et al. 
represents a 
subsample of the 
study population 








permeability test in 
children with 














0-36 mo olds with 
watery diarrhea 
admitted to oral 







• 15 with C. 
parvum alone 
• 7 with rotavirus 
alone 
• 7 with bacteria 













convalescent (at day 
20) L:M ratios were 
assessed. 
Mean78 L:M (SE) at day 1, 
day 20: 
• Rotavirus only: 0.67 
(0.38), 0.19 (0.09) 
• Cryptosporidium only: 0.76 
(0.43), 0.28 (0.14) 
• Bacterial infection: ranged 
from 0.2-0.87, 0.11-0.99 
• Unknown etiology: 0.26 
(0.12), 0.29 (0.18) 
 
Mean L:M ratios 
significantly differed 
between the unknown 
etiology and both the 
rotavirus (p< 0.01) and 
Cryptosporidium groups 
(p<0.05) at baseline, but 
not at day 20.  
 
Mean L:M ratios decreased 
between baseline and day 




Among the group of 
subjects with enteric 
bacterial infections, the 
















Mean L:M did not 
change 
significantly 
among those with 
diarrhea of 
unknown 








                                                          
78 Arithmetic mean. 
Appendix 7. Evidence table of all studies included in the review.
 Reference and 
Study Outcomes of 
Diagnostic Interest 
Location and 
Target Population  
Design and 
Sample Size  Biomarker Results Conclusion Comments 
causative agents identified 
and mean L:M ratios 
(baseline, day 20) were: 
Campylobacter jejuni and 
rotavirus infection (0.86, 
0.18), C. jejuni and 
Cryptosporidium infection 
(0.87, 0.53), Salmonella sp. 
(0.2, 0.11), C. jejuni (0.69, 
0.99), and Aeromonas sp. 
(0.38, 0.11). The L:M ratios 
of this group of seven 
infants were not included in 
the statistical analyses. 
similar to those 






Notes: Some studies included subjects ≥5 yr of age. Where these studies provided data separately for children <5 yr, we present results for only those subjects. Where these 
studies did not stratify results by age, but did report the number of children <5 yr included in the study, we provide a breakdown of under-5s. 
All studies reporting lactulose:rhamnose ratio results presented values multiplied by a factor of 100 for ease of reporting. 
Further details on L:M studies can be found in Table 14.  
Abbreviations: AD=acute diarrhea, ALT=alanine aminotransferase, AST=aspartate aminotransferase, CBC=complete blood count, CD=celiac disease, CI=95% confidence interval, 
Cr=creatinine, ∆=change in, EED=environmental enteric dysfunction, FTT=failure to thrive, GI=gastrointestinal, HAZ=height-for-age Z-(score), HDL=high density lipoproteins, 
HIV=human immunodeficiency virus, HLA=human leukocyte antigen, IEL=intraepithelial lymphocytes, IgA=immunoglobulin A, IgE=immunoglobulin E, IgG=immunoglobulin G, 
IgM=immunoglobulin M, IL=interleukin, IFN=interferon, LDL=low density lipoproteins, L:M=lactulose:mannitol ratio, mo=month(s), NS=not statistically significant, PD=persistent 
diarrhea, RCT=randomized controlled trial, SBBO=small bowel bacterial overgrowth, SD=standard deviation, SE=standard error, SES=socioeconomic status, Tc-99m=technetium 
99, T3=triiodothyronine, T4 = thyroxine, TE=tropical enteropathy, TGF=transforming growth factor, TNF=tumor necrosis factor, TS=tropical sprue, WAZ=weight-for-age Z-(score), 
WBC=white blood cell count, WFA=weight-for-age, WHZ=weight-for-height Z-(score), wk=week(s), yr=year(s) 
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